Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Classification of current anticancer immunotherapies</title><author><name sortKey="Galluzzi, Lorenzo" sort="Galluzzi, Lorenzo" uniqKey="Galluzzi L" first="Lorenzo" last="Galluzzi">Lorenzo Galluzzi</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Vacchelli, Erika" sort="Vacchelli, Erika" uniqKey="Vacchelli E" first="Erika" last="Vacchelli">Erika Vacchelli</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Pedro, Jose Manuel Bravo San" sort="Pedro, Jose Manuel Bravo San" uniqKey="Pedro J" first="José-Manuel Bravo-San" last="Pedro">José-Manuel Bravo-San Pedro</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Buque, Aitziber" sort="Buque, Aitziber" uniqKey="Buque A" first="Aitziber" last="Buqué">Aitziber Buqué</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Senovilla, Laura" sort="Senovilla, Laura" uniqKey="Senovilla L" first="Laura" last="Senovilla">Laura Senovilla</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Baracco, Elisa Elena" sort="Baracco, Elisa Elena" uniqKey="Baracco E" first="Elisa Elena" last="Baracco">Elisa Elena Baracco</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A5"> Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France</nlm:aff></affiliation></author><author><name sortKey="Bloy, Norma" sort="Bloy, Norma" uniqKey="Bloy N" first="Norma" last="Bloy">Norma Bloy</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A5"> Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France</nlm:aff></affiliation></author><author><name sortKey="Castoldi, Francesca" sort="Castoldi, Francesca" uniqKey="Castoldi F" first="Francesca" last="Castoldi">Francesca Castoldi</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A5"> Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France</nlm:aff></affiliation><affiliation><nlm:aff id="A6"> Sotio a.c., Prague, Czech Republic</nlm:aff></affiliation></author><author><name sortKey="Abastado, Jean Pierre" sort="Abastado, Jean Pierre" uniqKey="Abastado J" first="Jean-Pierre" last="Abastado">Jean-Pierre Abastado</name><affiliation><nlm:aff id="A7"> Pole d'innovation thérapeutique en oncologie, Institut de Recherches Internationales Servier, Suresnes, France</nlm:aff></affiliation></author><author><name sortKey="Agostinis, Patrizia" sort="Agostinis, Patrizia" uniqKey="Agostinis P" first="Patrizia" last="Agostinis">Patrizia Agostinis</name><affiliation><nlm:aff id="A8"> Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Apte, Ron N" sort="Apte, Ron N" uniqKey="Apte R" first="Ron N." last="Apte">Ron N. Apte</name><affiliation><nlm:aff id="A9"> The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel</nlm:aff></affiliation></author><author><name sortKey="Aranda, Fernando" sort="Aranda, Fernando" uniqKey="Aranda F" first="Fernando" last="Aranda">Fernando Aranda</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A10"> Group of Immune receptors of the Innate and Adaptive System, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Ayyoub, Maha" sort="Ayyoub, Maha" uniqKey="Ayyoub M" first="Maha" last="Ayyoub">Maha Ayyoub</name><affiliation><nlm:aff id="A11"> INSERM, U1102, Saint Herblain, France</nlm:aff></affiliation><affiliation><nlm:aff id="A12"> Institut de Cancérologie de l'Ouest, Saint Herblain, France</nlm:aff></affiliation></author><author><name sortKey="Beckhove, Philipp" sort="Beckhove, Philipp" uniqKey="Beckhove P" first="Philipp" last="Beckhove">Philipp Beckhove</name><affiliation><nlm:aff id="A13"> Translational Immunology Division, German Cancer Research Center, Heidelberg, Germany</nlm:aff></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation><nlm:aff id="A14"> Equipe 11, Centre Léon Bérard (CLR), Lyon, France</nlm:aff></affiliation><affiliation><nlm:aff id="A15"> Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France</nlm:aff></affiliation></author><author><name sortKey="Bracci, Laura" sort="Bracci, Laura" uniqKey="Bracci L" first="Laura" last="Bracci">Laura Bracci</name><affiliation><nlm:aff id="A16"> Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy</nlm:aff></affiliation></author><author><name sortKey="Caignard, Anne" sort="Caignard, Anne" uniqKey="Caignard A" first="Anne" last="Caignard">Anne Caignard</name><affiliation><nlm:aff id="A17"> INSERM, U1160, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A18"> Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Castelli, Chiara" sort="Castelli, Chiara" uniqKey="Castelli C" first="Chiara" last="Castelli">Chiara Castelli</name><affiliation><nlm:aff id="A19"> Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy</nlm:aff></affiliation></author><author><name sortKey="Cavallo, Federica" sort="Cavallo, Federica" uniqKey="Cavallo F" first="Federica" last="Cavallo">Federica Cavallo</name><affiliation><nlm:aff id="A20"> Molecular Biotechnology Center, Dept. of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy</nlm:aff></affiliation></author><author><name sortKey="Celis, Estaban" sort="Celis, Estaban" uniqKey="Celis E" first="Estaban" last="Celis">Estaban Celis</name><affiliation><nlm:aff id="A21"> Cancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Cerundolo, Vincenzo" sort="Cerundolo, Vincenzo" uniqKey="Cerundolo V" first="Vincenzo" last="Cerundolo">Vincenzo Cerundolo</name><affiliation><nlm:aff id="A22"> MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK</nlm:aff></affiliation></author><author><name sortKey="Clayton, Aled" sort="Clayton, Aled" uniqKey="Clayton A" first="Aled" last="Clayton">Aled Clayton</name><affiliation><nlm:aff id="A23"> Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK</nlm:aff></affiliation><affiliation><nlm:aff id="A24"> Velindre Cancer Centre, Cardiff, UK</nlm:aff></affiliation></author><author><name sortKey="Colombo, Mario P" sort="Colombo, Mario P" uniqKey="Colombo M" first="Mario P." last="Colombo">Mario P. Colombo</name><affiliation><nlm:aff id="A19"> Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy</nlm:aff></affiliation></author><author><name sortKey="Coussens, Lisa" sort="Coussens, Lisa" uniqKey="Coussens L" first="Lisa" last="Coussens">Lisa Coussens</name><affiliation><nlm:aff id="A25"> Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA</nlm:aff></affiliation></author><author><name sortKey="Dhodapkar, Madhav V" sort="Dhodapkar, Madhav V" uniqKey="Dhodapkar M" first="Madhav V." last="Dhodapkar">Madhav V. Dhodapkar</name><affiliation><nlm:aff id="A26"> Sect. of Hematology and Immunobiology, Yale Cancer Center, Yale University, New Haven, CT, USA</nlm:aff></affiliation></author><author><name sortKey="Eggermont, Alexander M" sort="Eggermont, Alexander M" uniqKey="Eggermont A" first="Alexander M." last="Eggermont">Alexander M. Eggermont</name><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Fearon, Douglas T" sort="Fearon, Douglas T" uniqKey="Fearon D" first="Douglas T." last="Fearon">Douglas T. Fearon</name><affiliation><nlm:aff id="A27"> Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Fridman, Wolf H" sort="Fridman, Wolf H" uniqKey="Fridman W" first="Wolf H." last="Fridman">Wolf H. Fridman</name><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A28"> Université Pierre et Marie Curie/Paris VI, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A29"> Equipe 13, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Fu Kova, Jitka" sort="Fu Kova, Jitka" uniqKey="Fu Kova J" first="Jitka" last="Fu Ková">Jitka Fu Ková</name><affiliation><nlm:aff id="A6"> Sotio a.c., Prague, Czech Republic</nlm:aff></affiliation><affiliation><nlm:aff id="A30"> Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic</nlm:aff></affiliation></author><author><name sortKey="Gabrilovich, Dmitry I" sort="Gabrilovich, Dmitry I" uniqKey="Gabrilovich D" first="Dmitry I." last="Gabrilovich">Dmitry I. Gabrilovich</name><affiliation><nlm:aff id="A31"> Dept. of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Galon, Jerome" sort="Galon, Jerome" uniqKey="Galon J" first="Jérôme" last="Galon">Jérôme Galon</name><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A28"> Université Pierre et Marie Curie/Paris VI, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A32"> Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Garg, Abhishek" sort="Garg, Abhishek" uniqKey="Garg A" first="Abhishek" last="Garg">Abhishek Garg</name><affiliation><nlm:aff id="A8"> Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Ghiringhelli, Francois" sort="Ghiringhelli, Francois" uniqKey="Ghiringhelli F" first="François" last="Ghiringhelli">François Ghiringhelli</name><affiliation><nlm:aff id="A33"> INSERM, UMR866, Dijon, France</nlm:aff></affiliation><affiliation><nlm:aff id="A34"> Centre Georges François Leclerc, Dijon, France</nlm:aff></affiliation><affiliation><nlm:aff id="A35"> Université de Bourgogne, Dijon, France</nlm:aff></affiliation></author><author><name sortKey="Giaccone, Giuseppe" sort="Giaccone, Giuseppe" uniqKey="Giaccone G" first="Giuseppe" last="Giaccone">Giuseppe Giaccone</name><affiliation><nlm:aff id="A36"> Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A37"> Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</nlm:aff></affiliation></author><author><name sortKey="Gilboa, Eli" sort="Gilboa, Eli" uniqKey="Gilboa E" first="Eli" last="Gilboa">Eli Gilboa</name><affiliation><nlm:aff id="A38"> Dept. of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA</nlm:aff></affiliation></author><author><name sortKey="Gnjatic, Sacha" sort="Gnjatic, Sacha" uniqKey="Gnjatic S" first="Sacha" last="Gnjatic">Sacha Gnjatic</name><affiliation><nlm:aff id="A39"> Sect. of Hematology/Oncology, Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Hoos, Axel" sort="Hoos, Axel" uniqKey="Hoos A" first="Axel" last="Hoos">Axel Hoos</name><affiliation><nlm:aff id="A40"> Glaxo Smith Kline, Cancer Immunotherapy Consortium, Collegeville, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Hosmalin, Anne" sort="Hosmalin, Anne" uniqKey="Hosmalin A" first="Anne" last="Hosmalin">Anne Hosmalin</name><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A41"> INSERM, U1016, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A42"> CNRS, UMR8104, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A43"> Hôpital Cochin, AP-HP, Paris, France</nlm:aff></affiliation></author><author><name sortKey="J Ger, Dirk" sort="J Ger, Dirk" uniqKey="J Ger D" first="Dirk" last="J Ger">Dirk J Ger</name><affiliation><nlm:aff id="A44"> National Center for Tumor Diseases, University Medical Center Heidelberg, Heidelberg, Germany</nlm:aff></affiliation></author><author><name sortKey="Kalinski, Pawel" sort="Kalinski, Pawel" uniqKey="Kalinski P" first="Pawel" last="Kalinski">Pawel Kalinski</name><affiliation><nlm:aff id="A45"> Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A46"> University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A47"> Dept. of Immunology and Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="K Rre, Klas" sort="K Rre, Klas" uniqKey="K Rre K" first="Klas" last="K Rre">Klas K Rre</name><affiliation><nlm:aff id="A48"> Dept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Kepp, Oliver" sort="Kepp, Oliver" uniqKey="Kepp O" first="Oliver" last="Kepp">Oliver Kepp</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A49"> Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Kiessling, Rolf" sort="Kiessling, Rolf" uniqKey="Kiessling R" first="Rolf" last="Kiessling">Rolf Kiessling</name><affiliation><nlm:aff id="A50"> Dept. of Oncology, Karolinska Institute Hospital, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name><affiliation><nlm:aff id="A51"> University of Pittsburgh Cancer Institute Laboratory, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Klein, Eva" sort="Klein, Eva" uniqKey="Klein E" first="Eva" last="Klein">Eva Klein</name><affiliation><nlm:aff id="A48"> Dept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Knuth, Alexander" sort="Knuth, Alexander" uniqKey="Knuth A" first="Alexander" last="Knuth">Alexander Knuth</name><affiliation><nlm:aff id="A52"> National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar</nlm:aff></affiliation></author><author><name sortKey="Lewis, Claire E" sort="Lewis, Claire E" uniqKey="Lewis C" first="Claire E." last="Lewis">Claire E. Lewis</name><affiliation><nlm:aff id="A53"> Academic Unit of Inflammation and Tumour Targeting, Dept. of Oncology, University of Sheffield Medical School, Sheffield, UK</nlm:aff></affiliation></author><author><name sortKey="Liblau, Roland" sort="Liblau, Roland" uniqKey="Liblau R" first="Roland" last="Liblau">Roland Liblau</name><affiliation><nlm:aff id="A54"> INSERM, UMR1043, Toulouse, France</nlm:aff></affiliation><affiliation><nlm:aff id="A55"> CNRS, UMR5282, Toulouse, France</nlm:aff></affiliation><affiliation><nlm:aff id="A56"> Laboratoire d'Immunologie, CHU Toulouse, Université Toulouse II, Toulouse, France</nlm:aff></affiliation></author><author><name sortKey="Lotze, Michael T" sort="Lotze, Michael T" uniqKey="Lotze M" first="Michael T." last="Lotze">Michael T. Lotze</name><affiliation><nlm:aff id="A45"> Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A46"> University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Lugli, Enrico" sort="Lugli, Enrico" uniqKey="Lugli E" first="Enrico" last="Lugli">Enrico Lugli</name><affiliation><nlm:aff id="A57"> Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy</nlm:aff></affiliation></author><author><name sortKey="Mach, Jean Pierre" sort="Mach, Jean Pierre" uniqKey="Mach J" first="Jean-Pierre" last="Mach">Jean-Pierre Mach</name><affiliation><nlm:aff id="A58"> Dept. of Biochemistry, University of Lausanne, Epalinges, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Mattei, Fabrizio" sort="Mattei, Fabrizio" uniqKey="Mattei F" first="Fabrizio" last="Mattei">Fabrizio Mattei</name><affiliation><nlm:aff id="A16"> Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy</nlm:aff></affiliation></author><author><name sortKey="Mavilio, Domenico" sort="Mavilio, Domenico" uniqKey="Mavilio D" first="Domenico" last="Mavilio">Domenico Mavilio</name><affiliation><nlm:aff id="A57"> Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy</nlm:aff></affiliation><affiliation><nlm:aff id="A59"> Dept. of Medical Biotechnologies and Translational Medicine, University of Milan, Rozzano, Italy</nlm:aff></affiliation></author><author><name sortKey="Melero, Ignacio" sort="Melero, Ignacio" uniqKey="Melero I" first="Ignacio" last="Melero">Ignacio Melero</name><affiliation><nlm:aff id="A60"> Dept. of Immunology, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain</nlm:aff></affiliation><affiliation><nlm:aff id="A61"> Dept. of Oncology, Clínica Universidad de Navarra, Pamplona, Spain</nlm:aff></affiliation></author><author><name sortKey="Melief, Cornelis J" sort="Melief, Cornelis J" uniqKey="Melief C" first="Cornelis J." last="Melief">Cornelis J. Melief</name><affiliation><nlm:aff id="A62"> ISA Therapeutics, Leiden, The Netherlands</nlm:aff></affiliation><affiliation><nlm:aff id="A63"> Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Mittendorf, Elizabeth A" sort="Mittendorf, Elizabeth A" uniqKey="Mittendorf E" first="Elizabeth A." last="Mittendorf">Elizabeth A. Mittendorf</name><affiliation><nlm:aff id="A64"> Research Dept. of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA</nlm:aff></affiliation></author><author><name sortKey="Moretta, Lorenzo" sort="Moretta, Lorenzo" uniqKey="Moretta L" first="Lorenzo" last="Moretta">Lorenzo Moretta</name><affiliation><nlm:aff id="A65"> Istituto Giannina Gaslini, Genova, Italy</nlm:aff></affiliation></author><author><name sortKey="Odunsi, Adekunke" sort="Odunsi, Adekunke" uniqKey="Odunsi A" first="Adekunke" last="Odunsi">Adekunke Odunsi</name><affiliation><nlm:aff id="A66"> Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Okada, Hideho" sort="Okada, Hideho" uniqKey="Okada H" first="Hideho" last="Okada">Hideho Okada</name><affiliation><nlm:aff id="A67"> Dept. of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA</nlm:aff></affiliation></author><author><name sortKey="Palucka, Anna Karolina" sort="Palucka, Anna Karolina" uniqKey="Palucka A" first="Anna Karolina" last="Palucka">Anna Karolina Palucka</name><affiliation><nlm:aff id="A68"> The Jackson Laboratory for Genomics Medicine, Farmington, CT, USA</nlm:aff></affiliation></author><author><name sortKey="Peter, Marcus E" sort="Peter, Marcus E" uniqKey="Peter M" first="Marcus E." last="Peter">Marcus E. Peter</name><affiliation><nlm:aff id="A69"> Div. of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Pienta, Kenneth J" sort="Pienta, Kenneth J" uniqKey="Pienta K" first="Kenneth J." last="Pienta">Kenneth J. Pienta</name><affiliation><nlm:aff id="A70"> The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA</nlm:aff></affiliation></author><author><name sortKey="Porgador, Angel" sort="Porgador, Angel" uniqKey="Porgador A" first="Angel" last="Porgador">Angel Porgador</name><affiliation><nlm:aff id="A9"> The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel</nlm:aff></affiliation></author><author><name sortKey="Prendergast, George C" sort="Prendergast, George C" uniqKey="Prendergast G" first="George C." last="Prendergast">George C. Prendergast</name><affiliation><nlm:aff id="A71"> Lankenau Institute for Medical Research, Wynnewood, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A72"> Dept. of Pathology, Anatomy and Cell Biology, Sidney Kimmel Medical College, Philadelphia, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A73"> Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Rabinovich, Gabriel A" sort="Rabinovich, Gabriel A" uniqKey="Rabinovich G" first="Gabriel A." last="Rabinovich">Gabriel A. Rabinovich</name><affiliation><nlm:aff id="A74"> Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina</nlm:aff></affiliation></author><author><name sortKey="Restifo, Nicholas P" sort="Restifo, Nicholas P" uniqKey="Restifo N" first="Nicholas P." last="Restifo">Nicholas P. Restifo</name><affiliation><nlm:aff id="A75"> National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA</nlm:aff></affiliation></author><author><name sortKey="Rizvi, Naiyer" sort="Rizvi, Naiyer" uniqKey="Rizvi N" first="Naiyer" last="Rizvi">Naiyer Rizvi</name><affiliation><nlm:aff id="A76"> Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Sautes Fridman, Catherine" sort="Sautes Fridman, Catherine" uniqKey="Sautes Fridman C" first="Catherine" last="Sautès-Fridman">Catherine Sautès-Fridman</name><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A28"> Université Pierre et Marie Curie/Paris VI, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A29"> Equipe 13, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Schreiber, Hans" sort="Schreiber, Hans" uniqKey="Schreiber H" first="Hans" last="Schreiber">Hans Schreiber</name><affiliation><nlm:aff id="A77"> Dept. of Pathology, The Cancer Research Center, The University of Chicago, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Seliger, Barbara" sort="Seliger, Barbara" uniqKey="Seliger B" first="Barbara" last="Seliger">Barbara Seliger</name><affiliation><nlm:aff id="A78"> Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany</nlm:aff></affiliation></author><author><name sortKey="Shiku, Hiroshi" sort="Shiku, Hiroshi" uniqKey="Shiku H" first="Hiroshi" last="Shiku">Hiroshi Shiku</name><affiliation><nlm:aff id="A79"> Dept. of Immuno-GeneTherapy, Mie University Graduate School of Medicine, Tsu, Japan</nlm:aff></affiliation></author><author><name sortKey="Silva Santos, Bruno" sort="Silva Santos, Bruno" uniqKey="Silva Santos B" first="Bruno" last="Silva-Santos">Bruno Silva-Santos</name><affiliation><nlm:aff id="A80"> Instituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal</nlm:aff></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name><affiliation><nlm:aff id="A81"> Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="A82"> School of Medicine, University of Queensland, Herston, Queensland, Australia</nlm:aff></affiliation></author><author><name sortKey="Speiser, Daniel E" sort="Speiser, Daniel E" uniqKey="Speiser D" first="Daniel E." last="Speiser">Daniel E. Speiser</name><affiliation><nlm:aff id="A83"> Dept. of Oncology, University of Lausanne, Lausanne, Switzerland</nlm:aff></affiliation><affiliation><nlm:aff id="A84"> Ludwig Cancer Research Center, Lausanne, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Spisek, Radek" sort="Spisek, Radek" uniqKey="Spisek R" first="Radek" last="Spisek">Radek Spisek</name><affiliation><nlm:aff id="A6"> Sotio a.c., Prague, Czech Republic</nlm:aff></affiliation><affiliation><nlm:aff id="A30"> Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic</nlm:aff></affiliation></author><author><name sortKey="Srivastava, Pramod K" sort="Srivastava, Pramod K" uniqKey="Srivastava P" first="Pramod K." last="Srivastava">Pramod K. Srivastava</name><affiliation><nlm:aff id="A85"> Dept. of Immunology, University of Connecticut School of Medicine, Farmington, CT, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A86"> Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA</nlm:aff></affiliation></author><author><name sortKey="Talmadge, James E" sort="Talmadge, James E" uniqKey="Talmadge J" first="James E." last="Talmadge">James E. Talmadge</name><affiliation><nlm:aff id="A87"> Laboratory of Transplantation Immunology, Dept. of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA</nlm:aff></affiliation></author><author><name sortKey="Tartour, Eric" sort="Tartour, Eric" uniqKey="Tartour E" first="Eric" last="Tartour">Eric Tartour</name><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A88"> INSERM, U970, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A89"> Paris-Cardiovascular Research Center (PARCC), Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A90"> Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Van Der Burg, Sjoerd H" sort="Van Der Burg, Sjoerd H" uniqKey="Van Der Burg S" first="Sjoerd H." last="Van Der Burg">Sjoerd H. Van Der Burg</name><affiliation><nlm:aff id="A91"> Dept. of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Van Den Eynde, Benoit J" sort="Van Den Eynde, Benoit J" uniqKey="Van Den Eynde B" first="Benoît J." last="Van Den Eynde">Benoît J. Van Den Eynde</name><affiliation><nlm:aff id="A92"> Ludwig Institute for Cancer Research, Brussels, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="A93"> de Duve Institute, Brussels, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="A94"> Université Catholique de Louvain, Brussels, Belgium</nlm:aff></affiliation></author><author><name sortKey="Vile, Richard" sort="Vile, Richard" uniqKey="Vile R" first="Richard" last="Vile">Richard Vile</name><affiliation><nlm:aff id="A95"> Dept. of Molecular Medicine and Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA</nlm:aff></affiliation></author><author><name sortKey="Wagner, Hermann" sort="Wagner, Hermann" uniqKey="Wagner H" first="Hermann" last="Wagner">Hermann Wagner</name><affiliation><nlm:aff id="A96"> Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Munich, Germany</nlm:aff></affiliation></author><author><name sortKey="Weber, Jeffrey S" sort="Weber, Jeffrey S" uniqKey="Weber J" first="Jeffrey S." last="Weber">Jeffrey S. Weber</name><affiliation><nlm:aff id="A97"> Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, FL, USA</nlm:aff></affiliation></author><author><name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name><affiliation><nlm:aff id="A46"> University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A98"> University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D." last="Wolchok">Jedd D. Wolchok</name><affiliation><nlm:aff id="A99"> Dept. of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A100"> Weill Cornell Medical College, New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A101"> INSERM, U1015, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A102"> Centre d'Investigation Clinique Biothérapie 507 (CICBT507), Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Zou, Weiping" sort="Zou, Weiping" uniqKey="Zou W" first="Weiping" last="Zou">Weiping Zou</name><affiliation><nlm:aff id="A103"> University of Michigan, School of Medicine, Ann Arbor, MI, USA</nlm:aff></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A49"> Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A104"> Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25537519</idno><idno type="pmc">4350348</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350348</idno><idno type="RBID">PMC:4350348</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">002F59</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002F59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Classification of current anticancer immunotherapies</title><author><name sortKey="Galluzzi, Lorenzo" sort="Galluzzi, Lorenzo" uniqKey="Galluzzi L" first="Lorenzo" last="Galluzzi">Lorenzo Galluzzi</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Vacchelli, Erika" sort="Vacchelli, Erika" uniqKey="Vacchelli E" first="Erika" last="Vacchelli">Erika Vacchelli</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Pedro, Jose Manuel Bravo San" sort="Pedro, Jose Manuel Bravo San" uniqKey="Pedro J" first="José-Manuel Bravo-San" last="Pedro">José-Manuel Bravo-San Pedro</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Buque, Aitziber" sort="Buque, Aitziber" uniqKey="Buque A" first="Aitziber" last="Buqué">Aitziber Buqué</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Senovilla, Laura" sort="Senovilla, Laura" uniqKey="Senovilla L" first="Laura" last="Senovilla">Laura Senovilla</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Baracco, Elisa Elena" sort="Baracco, Elisa Elena" uniqKey="Baracco E" first="Elisa Elena" last="Baracco">Elisa Elena Baracco</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A5"> Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France</nlm:aff></affiliation></author><author><name sortKey="Bloy, Norma" sort="Bloy, Norma" uniqKey="Bloy N" first="Norma" last="Bloy">Norma Bloy</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A5"> Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France</nlm:aff></affiliation></author><author><name sortKey="Castoldi, Francesca" sort="Castoldi, Francesca" uniqKey="Castoldi F" first="Francesca" last="Castoldi">Francesca Castoldi</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A5"> Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France</nlm:aff></affiliation><affiliation><nlm:aff id="A6"> Sotio a.c., Prague, Czech Republic</nlm:aff></affiliation></author><author><name sortKey="Abastado, Jean Pierre" sort="Abastado, Jean Pierre" uniqKey="Abastado J" first="Jean-Pierre" last="Abastado">Jean-Pierre Abastado</name><affiliation><nlm:aff id="A7"> Pole d'innovation thérapeutique en oncologie, Institut de Recherches Internationales Servier, Suresnes, France</nlm:aff></affiliation></author><author><name sortKey="Agostinis, Patrizia" sort="Agostinis, Patrizia" uniqKey="Agostinis P" first="Patrizia" last="Agostinis">Patrizia Agostinis</name><affiliation><nlm:aff id="A8"> Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Apte, Ron N" sort="Apte, Ron N" uniqKey="Apte R" first="Ron N." last="Apte">Ron N. Apte</name><affiliation><nlm:aff id="A9"> The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel</nlm:aff></affiliation></author><author><name sortKey="Aranda, Fernando" sort="Aranda, Fernando" uniqKey="Aranda F" first="Fernando" last="Aranda">Fernando Aranda</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A10"> Group of Immune receptors of the Innate and Adaptive System, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Ayyoub, Maha" sort="Ayyoub, Maha" uniqKey="Ayyoub M" first="Maha" last="Ayyoub">Maha Ayyoub</name><affiliation><nlm:aff id="A11"> INSERM, U1102, Saint Herblain, France</nlm:aff></affiliation><affiliation><nlm:aff id="A12"> Institut de Cancérologie de l'Ouest, Saint Herblain, France</nlm:aff></affiliation></author><author><name sortKey="Beckhove, Philipp" sort="Beckhove, Philipp" uniqKey="Beckhove P" first="Philipp" last="Beckhove">Philipp Beckhove</name><affiliation><nlm:aff id="A13"> Translational Immunology Division, German Cancer Research Center, Heidelberg, Germany</nlm:aff></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation><nlm:aff id="A14"> Equipe 11, Centre Léon Bérard (CLR), Lyon, France</nlm:aff></affiliation><affiliation><nlm:aff id="A15"> Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France</nlm:aff></affiliation></author><author><name sortKey="Bracci, Laura" sort="Bracci, Laura" uniqKey="Bracci L" first="Laura" last="Bracci">Laura Bracci</name><affiliation><nlm:aff id="A16"> Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy</nlm:aff></affiliation></author><author><name sortKey="Caignard, Anne" sort="Caignard, Anne" uniqKey="Caignard A" first="Anne" last="Caignard">Anne Caignard</name><affiliation><nlm:aff id="A17"> INSERM, U1160, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A18"> Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Castelli, Chiara" sort="Castelli, Chiara" uniqKey="Castelli C" first="Chiara" last="Castelli">Chiara Castelli</name><affiliation><nlm:aff id="A19"> Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy</nlm:aff></affiliation></author><author><name sortKey="Cavallo, Federica" sort="Cavallo, Federica" uniqKey="Cavallo F" first="Federica" last="Cavallo">Federica Cavallo</name><affiliation><nlm:aff id="A20"> Molecular Biotechnology Center, Dept. of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy</nlm:aff></affiliation></author><author><name sortKey="Celis, Estaban" sort="Celis, Estaban" uniqKey="Celis E" first="Estaban" last="Celis">Estaban Celis</name><affiliation><nlm:aff id="A21"> Cancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Cerundolo, Vincenzo" sort="Cerundolo, Vincenzo" uniqKey="Cerundolo V" first="Vincenzo" last="Cerundolo">Vincenzo Cerundolo</name><affiliation><nlm:aff id="A22"> MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK</nlm:aff></affiliation></author><author><name sortKey="Clayton, Aled" sort="Clayton, Aled" uniqKey="Clayton A" first="Aled" last="Clayton">Aled Clayton</name><affiliation><nlm:aff id="A23"> Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK</nlm:aff></affiliation><affiliation><nlm:aff id="A24"> Velindre Cancer Centre, Cardiff, UK</nlm:aff></affiliation></author><author><name sortKey="Colombo, Mario P" sort="Colombo, Mario P" uniqKey="Colombo M" first="Mario P." last="Colombo">Mario P. Colombo</name><affiliation><nlm:aff id="A19"> Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy</nlm:aff></affiliation></author><author><name sortKey="Coussens, Lisa" sort="Coussens, Lisa" uniqKey="Coussens L" first="Lisa" last="Coussens">Lisa Coussens</name><affiliation><nlm:aff id="A25"> Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA</nlm:aff></affiliation></author><author><name sortKey="Dhodapkar, Madhav V" sort="Dhodapkar, Madhav V" uniqKey="Dhodapkar M" first="Madhav V." last="Dhodapkar">Madhav V. Dhodapkar</name><affiliation><nlm:aff id="A26"> Sect. of Hematology and Immunobiology, Yale Cancer Center, Yale University, New Haven, CT, USA</nlm:aff></affiliation></author><author><name sortKey="Eggermont, Alexander M" sort="Eggermont, Alexander M" uniqKey="Eggermont A" first="Alexander M." last="Eggermont">Alexander M. Eggermont</name><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Fearon, Douglas T" sort="Fearon, Douglas T" uniqKey="Fearon D" first="Douglas T." last="Fearon">Douglas T. Fearon</name><affiliation><nlm:aff id="A27"> Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Fridman, Wolf H" sort="Fridman, Wolf H" uniqKey="Fridman W" first="Wolf H." last="Fridman">Wolf H. Fridman</name><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A28"> Université Pierre et Marie Curie/Paris VI, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A29"> Equipe 13, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Fu Kova, Jitka" sort="Fu Kova, Jitka" uniqKey="Fu Kova J" first="Jitka" last="Fu Ková">Jitka Fu Ková</name><affiliation><nlm:aff id="A6"> Sotio a.c., Prague, Czech Republic</nlm:aff></affiliation><affiliation><nlm:aff id="A30"> Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic</nlm:aff></affiliation></author><author><name sortKey="Gabrilovich, Dmitry I" sort="Gabrilovich, Dmitry I" uniqKey="Gabrilovich D" first="Dmitry I." last="Gabrilovich">Dmitry I. Gabrilovich</name><affiliation><nlm:aff id="A31"> Dept. of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Galon, Jerome" sort="Galon, Jerome" uniqKey="Galon J" first="Jérôme" last="Galon">Jérôme Galon</name><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A28"> Université Pierre et Marie Curie/Paris VI, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A32"> Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Garg, Abhishek" sort="Garg, Abhishek" uniqKey="Garg A" first="Abhishek" last="Garg">Abhishek Garg</name><affiliation><nlm:aff id="A8"> Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium</nlm:aff></affiliation></author><author><name sortKey="Ghiringhelli, Francois" sort="Ghiringhelli, Francois" uniqKey="Ghiringhelli F" first="François" last="Ghiringhelli">François Ghiringhelli</name><affiliation><nlm:aff id="A33"> INSERM, UMR866, Dijon, France</nlm:aff></affiliation><affiliation><nlm:aff id="A34"> Centre Georges François Leclerc, Dijon, France</nlm:aff></affiliation><affiliation><nlm:aff id="A35"> Université de Bourgogne, Dijon, France</nlm:aff></affiliation></author><author><name sortKey="Giaccone, Giuseppe" sort="Giaccone, Giuseppe" uniqKey="Giaccone G" first="Giuseppe" last="Giaccone">Giuseppe Giaccone</name><affiliation><nlm:aff id="A36"> Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A37"> Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</nlm:aff></affiliation></author><author><name sortKey="Gilboa, Eli" sort="Gilboa, Eli" uniqKey="Gilboa E" first="Eli" last="Gilboa">Eli Gilboa</name><affiliation><nlm:aff id="A38"> Dept. of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA</nlm:aff></affiliation></author><author><name sortKey="Gnjatic, Sacha" sort="Gnjatic, Sacha" uniqKey="Gnjatic S" first="Sacha" last="Gnjatic">Sacha Gnjatic</name><affiliation><nlm:aff id="A39"> Sect. of Hematology/Oncology, Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Hoos, Axel" sort="Hoos, Axel" uniqKey="Hoos A" first="Axel" last="Hoos">Axel Hoos</name><affiliation><nlm:aff id="A40"> Glaxo Smith Kline, Cancer Immunotherapy Consortium, Collegeville, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Hosmalin, Anne" sort="Hosmalin, Anne" uniqKey="Hosmalin A" first="Anne" last="Hosmalin">Anne Hosmalin</name><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A41"> INSERM, U1016, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A42"> CNRS, UMR8104, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A43"> Hôpital Cochin, AP-HP, Paris, France</nlm:aff></affiliation></author><author><name sortKey="J Ger, Dirk" sort="J Ger, Dirk" uniqKey="J Ger D" first="Dirk" last="J Ger">Dirk J Ger</name><affiliation><nlm:aff id="A44"> National Center for Tumor Diseases, University Medical Center Heidelberg, Heidelberg, Germany</nlm:aff></affiliation></author><author><name sortKey="Kalinski, Pawel" sort="Kalinski, Pawel" uniqKey="Kalinski P" first="Pawel" last="Kalinski">Pawel Kalinski</name><affiliation><nlm:aff id="A45"> Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A46"> University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A47"> Dept. of Immunology and Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="K Rre, Klas" sort="K Rre, Klas" uniqKey="K Rre K" first="Klas" last="K Rre">Klas K Rre</name><affiliation><nlm:aff id="A48"> Dept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Kepp, Oliver" sort="Kepp, Oliver" uniqKey="Kepp O" first="Oliver" last="Kepp">Oliver Kepp</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A49"> Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Kiessling, Rolf" sort="Kiessling, Rolf" uniqKey="Kiessling R" first="Rolf" last="Kiessling">Rolf Kiessling</name><affiliation><nlm:aff id="A50"> Dept. of Oncology, Karolinska Institute Hospital, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name><affiliation><nlm:aff id="A51"> University of Pittsburgh Cancer Institute Laboratory, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Klein, Eva" sort="Klein, Eva" uniqKey="Klein E" first="Eva" last="Klein">Eva Klein</name><affiliation><nlm:aff id="A48"> Dept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden</nlm:aff></affiliation></author><author><name sortKey="Knuth, Alexander" sort="Knuth, Alexander" uniqKey="Knuth A" first="Alexander" last="Knuth">Alexander Knuth</name><affiliation><nlm:aff id="A52"> National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar</nlm:aff></affiliation></author><author><name sortKey="Lewis, Claire E" sort="Lewis, Claire E" uniqKey="Lewis C" first="Claire E." last="Lewis">Claire E. Lewis</name><affiliation><nlm:aff id="A53"> Academic Unit of Inflammation and Tumour Targeting, Dept. of Oncology, University of Sheffield Medical School, Sheffield, UK</nlm:aff></affiliation></author><author><name sortKey="Liblau, Roland" sort="Liblau, Roland" uniqKey="Liblau R" first="Roland" last="Liblau">Roland Liblau</name><affiliation><nlm:aff id="A54"> INSERM, UMR1043, Toulouse, France</nlm:aff></affiliation><affiliation><nlm:aff id="A55"> CNRS, UMR5282, Toulouse, France</nlm:aff></affiliation><affiliation><nlm:aff id="A56"> Laboratoire d'Immunologie, CHU Toulouse, Université Toulouse II, Toulouse, France</nlm:aff></affiliation></author><author><name sortKey="Lotze, Michael T" sort="Lotze, Michael T" uniqKey="Lotze M" first="Michael T." last="Lotze">Michael T. Lotze</name><affiliation><nlm:aff id="A45"> Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A46"> University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Lugli, Enrico" sort="Lugli, Enrico" uniqKey="Lugli E" first="Enrico" last="Lugli">Enrico Lugli</name><affiliation><nlm:aff id="A57"> Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy</nlm:aff></affiliation></author><author><name sortKey="Mach, Jean Pierre" sort="Mach, Jean Pierre" uniqKey="Mach J" first="Jean-Pierre" last="Mach">Jean-Pierre Mach</name><affiliation><nlm:aff id="A58"> Dept. of Biochemistry, University of Lausanne, Epalinges, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Mattei, Fabrizio" sort="Mattei, Fabrizio" uniqKey="Mattei F" first="Fabrizio" last="Mattei">Fabrizio Mattei</name><affiliation><nlm:aff id="A16"> Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy</nlm:aff></affiliation></author><author><name sortKey="Mavilio, Domenico" sort="Mavilio, Domenico" uniqKey="Mavilio D" first="Domenico" last="Mavilio">Domenico Mavilio</name><affiliation><nlm:aff id="A57"> Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy</nlm:aff></affiliation><affiliation><nlm:aff id="A59"> Dept. of Medical Biotechnologies and Translational Medicine, University of Milan, Rozzano, Italy</nlm:aff></affiliation></author><author><name sortKey="Melero, Ignacio" sort="Melero, Ignacio" uniqKey="Melero I" first="Ignacio" last="Melero">Ignacio Melero</name><affiliation><nlm:aff id="A60"> Dept. of Immunology, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain</nlm:aff></affiliation><affiliation><nlm:aff id="A61"> Dept. of Oncology, Clínica Universidad de Navarra, Pamplona, Spain</nlm:aff></affiliation></author><author><name sortKey="Melief, Cornelis J" sort="Melief, Cornelis J" uniqKey="Melief C" first="Cornelis J." last="Melief">Cornelis J. Melief</name><affiliation><nlm:aff id="A62"> ISA Therapeutics, Leiden, The Netherlands</nlm:aff></affiliation><affiliation><nlm:aff id="A63"> Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Mittendorf, Elizabeth A" sort="Mittendorf, Elizabeth A" uniqKey="Mittendorf E" first="Elizabeth A." last="Mittendorf">Elizabeth A. Mittendorf</name><affiliation><nlm:aff id="A64"> Research Dept. of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA</nlm:aff></affiliation></author><author><name sortKey="Moretta, Lorenzo" sort="Moretta, Lorenzo" uniqKey="Moretta L" first="Lorenzo" last="Moretta">Lorenzo Moretta</name><affiliation><nlm:aff id="A65"> Istituto Giannina Gaslini, Genova, Italy</nlm:aff></affiliation></author><author><name sortKey="Odunsi, Adekunke" sort="Odunsi, Adekunke" uniqKey="Odunsi A" first="Adekunke" last="Odunsi">Adekunke Odunsi</name><affiliation><nlm:aff id="A66"> Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Okada, Hideho" sort="Okada, Hideho" uniqKey="Okada H" first="Hideho" last="Okada">Hideho Okada</name><affiliation><nlm:aff id="A67"> Dept. of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA</nlm:aff></affiliation></author><author><name sortKey="Palucka, Anna Karolina" sort="Palucka, Anna Karolina" uniqKey="Palucka A" first="Anna Karolina" last="Palucka">Anna Karolina Palucka</name><affiliation><nlm:aff id="A68"> The Jackson Laboratory for Genomics Medicine, Farmington, CT, USA</nlm:aff></affiliation></author><author><name sortKey="Peter, Marcus E" sort="Peter, Marcus E" uniqKey="Peter M" first="Marcus E." last="Peter">Marcus E. Peter</name><affiliation><nlm:aff id="A69"> Div. of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Pienta, Kenneth J" sort="Pienta, Kenneth J" uniqKey="Pienta K" first="Kenneth J." last="Pienta">Kenneth J. Pienta</name><affiliation><nlm:aff id="A70"> The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA</nlm:aff></affiliation></author><author><name sortKey="Porgador, Angel" sort="Porgador, Angel" uniqKey="Porgador A" first="Angel" last="Porgador">Angel Porgador</name><affiliation><nlm:aff id="A9"> The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel</nlm:aff></affiliation></author><author><name sortKey="Prendergast, George C" sort="Prendergast, George C" uniqKey="Prendergast G" first="George C." last="Prendergast">George C. Prendergast</name><affiliation><nlm:aff id="A71"> Lankenau Institute for Medical Research, Wynnewood, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A72"> Dept. of Pathology, Anatomy and Cell Biology, Sidney Kimmel Medical College, Philadelphia, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A73"> Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Rabinovich, Gabriel A" sort="Rabinovich, Gabriel A" uniqKey="Rabinovich G" first="Gabriel A." last="Rabinovich">Gabriel A. Rabinovich</name><affiliation><nlm:aff id="A74"> Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina</nlm:aff></affiliation></author><author><name sortKey="Restifo, Nicholas P" sort="Restifo, Nicholas P" uniqKey="Restifo N" first="Nicholas P." last="Restifo">Nicholas P. Restifo</name><affiliation><nlm:aff id="A75"> National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA</nlm:aff></affiliation></author><author><name sortKey="Rizvi, Naiyer" sort="Rizvi, Naiyer" uniqKey="Rizvi N" first="Naiyer" last="Rizvi">Naiyer Rizvi</name><affiliation><nlm:aff id="A76"> Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Sautes Fridman, Catherine" sort="Sautes Fridman, Catherine" uniqKey="Sautes Fridman C" first="Catherine" last="Sautès-Fridman">Catherine Sautès-Fridman</name><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A28"> Université Pierre et Marie Curie/Paris VI, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A29"> Equipe 13, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Schreiber, Hans" sort="Schreiber, Hans" uniqKey="Schreiber H" first="Hans" last="Schreiber">Hans Schreiber</name><affiliation><nlm:aff id="A77"> Dept. of Pathology, The Cancer Research Center, The University of Chicago, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Seliger, Barbara" sort="Seliger, Barbara" uniqKey="Seliger B" first="Barbara" last="Seliger">Barbara Seliger</name><affiliation><nlm:aff id="A78"> Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany</nlm:aff></affiliation></author><author><name sortKey="Shiku, Hiroshi" sort="Shiku, Hiroshi" uniqKey="Shiku H" first="Hiroshi" last="Shiku">Hiroshi Shiku</name><affiliation><nlm:aff id="A79"> Dept. of Immuno-GeneTherapy, Mie University Graduate School of Medicine, Tsu, Japan</nlm:aff></affiliation></author><author><name sortKey="Silva Santos, Bruno" sort="Silva Santos, Bruno" uniqKey="Silva Santos B" first="Bruno" last="Silva-Santos">Bruno Silva-Santos</name><affiliation><nlm:aff id="A80"> Instituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal</nlm:aff></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name><affiliation><nlm:aff id="A81"> Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="A82"> School of Medicine, University of Queensland, Herston, Queensland, Australia</nlm:aff></affiliation></author><author><name sortKey="Speiser, Daniel E" sort="Speiser, Daniel E" uniqKey="Speiser D" first="Daniel E." last="Speiser">Daniel E. Speiser</name><affiliation><nlm:aff id="A83"> Dept. of Oncology, University of Lausanne, Lausanne, Switzerland</nlm:aff></affiliation><affiliation><nlm:aff id="A84"> Ludwig Cancer Research Center, Lausanne, Switzerland</nlm:aff></affiliation></author><author><name sortKey="Spisek, Radek" sort="Spisek, Radek" uniqKey="Spisek R" first="Radek" last="Spisek">Radek Spisek</name><affiliation><nlm:aff id="A6"> Sotio a.c., Prague, Czech Republic</nlm:aff></affiliation><affiliation><nlm:aff id="A30"> Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic</nlm:aff></affiliation></author><author><name sortKey="Srivastava, Pramod K" sort="Srivastava, Pramod K" uniqKey="Srivastava P" first="Pramod K." last="Srivastava">Pramod K. Srivastava</name><affiliation><nlm:aff id="A85"> Dept. of Immunology, University of Connecticut School of Medicine, Farmington, CT, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A86"> Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA</nlm:aff></affiliation></author><author><name sortKey="Talmadge, James E" sort="Talmadge, James E" uniqKey="Talmadge J" first="James E." last="Talmadge">James E. Talmadge</name><affiliation><nlm:aff id="A87"> Laboratory of Transplantation Immunology, Dept. of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA</nlm:aff></affiliation></author><author><name sortKey="Tartour, Eric" sort="Tartour, Eric" uniqKey="Tartour E" first="Eric" last="Tartour">Eric Tartour</name><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A88"> INSERM, U970, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A89"> Paris-Cardiovascular Research Center (PARCC), Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A90"> Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Van Der Burg, Sjoerd H" sort="Van Der Burg, Sjoerd H" uniqKey="Van Der Burg S" first="Sjoerd H." last="Van Der Burg">Sjoerd H. Van Der Burg</name><affiliation><nlm:aff id="A91"> Dept. of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Van Den Eynde, Benoit J" sort="Van Den Eynde, Benoit J" uniqKey="Van Den Eynde B" first="Benoît J." last="Van Den Eynde">Benoît J. Van Den Eynde</name><affiliation><nlm:aff id="A92"> Ludwig Institute for Cancer Research, Brussels, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="A93"> de Duve Institute, Brussels, Belgium</nlm:aff></affiliation><affiliation><nlm:aff id="A94"> Université Catholique de Louvain, Brussels, Belgium</nlm:aff></affiliation></author><author><name sortKey="Vile, Richard" sort="Vile, Richard" uniqKey="Vile R" first="Richard" last="Vile">Richard Vile</name><affiliation><nlm:aff id="A95"> Dept. of Molecular Medicine and Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA</nlm:aff></affiliation></author><author><name sortKey="Wagner, Hermann" sort="Wagner, Hermann" uniqKey="Wagner H" first="Hermann" last="Wagner">Hermann Wagner</name><affiliation><nlm:aff id="A96"> Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Munich, Germany</nlm:aff></affiliation></author><author><name sortKey="Weber, Jeffrey S" sort="Weber, Jeffrey S" uniqKey="Weber J" first="Jeffrey S." last="Weber">Jeffrey S. Weber</name><affiliation><nlm:aff id="A97"> Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, FL, USA</nlm:aff></affiliation></author><author><name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name><affiliation><nlm:aff id="A46"> University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A98"> University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</nlm:aff></affiliation></author><author><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D." last="Wolchok">Jedd D. Wolchok</name><affiliation><nlm:aff id="A99"> Dept. of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A100"> Weill Cornell Medical College, New York, NY, USA</nlm:aff></affiliation></author><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation><nlm:aff id="A3"> Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A101"> INSERM, U1015, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A102"> Centre d'Investigation Clinique Biothérapie 507 (CICBT507), Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation></author><author><name sortKey="Zou, Weiping" sort="Zou, Weiping" uniqKey="Zou W" first="Weiping" last="Zou">Weiping Zou</name><affiliation><nlm:aff id="A103"> University of Michigan, School of Medicine, Ann Arbor, MI, USA</nlm:aff></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation><nlm:aff id="A1"> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A2"> INSERM, U1138, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A4"> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</nlm:aff></affiliation><affiliation><nlm:aff id="A49"> Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France</nlm:aff></affiliation><affiliation><nlm:aff id="A104"> Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France</nlm:aff></affiliation></author></analytic><series><title level="j">Oncotarget</title><idno type="eISSN">1949-2553</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into “passive” and “active” based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Dean, M" uniqKey="Dean M">M Dean</name></author><author><name sortKey="Fojo, T" uniqKey="Fojo T">T Fojo</name></author><author><name sortKey="Bates, S" uniqKey="Bates S">S Bates</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Visvader, Je" uniqKey="Visvader J">JE Visvader</name></author><author><name sortKey="Lindeman, Gj" uniqKey="Lindeman G">GJ Lindeman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beck, B" uniqKey="Beck B">B Beck</name></author><author><name sortKey="Blanpain, C" uniqKey="Blanpain C">C Blanpain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mueller, Mm" uniqKey="Mueller M">MM Mueller</name></author><author><name sortKey="Fusenig, Ne" uniqKey="Fusenig N">NE Fusenig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Albini, A" uniqKey="Albini A">A Albini</name></author><author><name sortKey="Sporn, Mb" uniqKey="Sporn M">MB Sporn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holzel, M" uniqKey="Holzel M">M Holzel</name></author><author><name sortKey="Bovier, A" uniqKey="Bovier A">A Bovier</name></author><author><name sortKey="Tuting, T" uniqKey="Tuting T">T Tuting</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wellen, Ke" uniqKey="Wellen K">KE Wellen</name></author><author><name sortKey="Thompson, Cb" uniqKey="Thompson C">CB Thompson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Vander Heiden, Mg" uniqKey="Vander Heiden M">MG Vander Heiden</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Green, Dr" uniqKey="Green D">DR Green</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Solimini, Nl" uniqKey="Solimini N">NL Solimini</name></author><author><name sortKey="Luo, J" uniqKey="Luo J">J Luo</name></author><author><name sortKey="Elledge, Sj" uniqKey="Elledge S">SJ Elledge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Luo, J" uniqKey="Luo J">J Luo</name></author><author><name sortKey="Solimini, Nl" uniqKey="Solimini N">NL Solimini</name></author><author><name sortKey="Elledge, Sj" uniqKey="Elledge S">SJ Elledge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Bravo San Pedro, Jm" uniqKey="Bravo San Pedro J">JM Bravo-San Pedro</name></author><author><name sortKey="Vitale, I" uniqKey="Vitale I">I Vitale</name></author><author><name sortKey="Aaronson, Sa" uniqKey="Aaronson S">SA Aaronson</name></author><author><name sortKey="Abrams, Jm" uniqKey="Abrams J">JM Abrams</name></author><author><name sortKey="Adam, D" uniqKey="Adam D">D Adam</name></author><author><name sortKey="Alnemri, Es" uniqKey="Alnemri E">ES Alnemri</name></author><author><name sortKey="Altucci, L" uniqKey="Altucci L">L Altucci</name></author><author><name sortKey="Andrews, D" uniqKey="Andrews D">D Andrews</name></author><author><name sortKey="Annicchiarico Petruzzelli, M" uniqKey="Annicchiarico Petruzzelli M">M Annicchiarico-Petruzzelli</name></author><author><name sortKey="Baehrecke, Eh" uniqKey="Baehrecke E">EH Baehrecke</name></author><author><name sortKey="Bazan, Ng" uniqKey="Bazan N">NG Bazan</name></author><author><name sortKey="Bertrand, Mj" uniqKey="Bertrand M">MJ Bertrand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Krautwald, S" uniqKey="Krautwald S">S Krautwald</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Linkermann, A" uniqKey="Linkermann A">A Linkermann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vanden Berghe, T" uniqKey="Vanden Berghe T">T Vanden Berghe</name></author><author><name sortKey="Linkermann, A" uniqKey="Linkermann A">A Linkermann</name></author><author><name sortKey="Jouan Lanhouet, S" uniqKey="Jouan Lanhouet S">S Jouan-Lanhouet</name></author><author><name sortKey="Walczak, H" uniqKey="Walczak H">H Walczak</name></author><author><name sortKey="Vandenabeele, P" uniqKey="Vandenabeele P">P Vandenabeele</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schreiber, Rd" uniqKey="Schreiber R">RD Schreiber</name></author><author><name sortKey="Old, Lj" uniqKey="Old L">LJ Old</name></author><author><name sortKey="Smyth, Mj" uniqKey="Smyth M">MJ Smyth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Tesniere, A" uniqKey="Tesniere A">A Tesniere</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carmeliet, P" uniqKey="Carmeliet P">P Carmeliet</name></author><author><name sortKey="Jain, Rk" uniqKey="Jain R">RK Jain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Albini, A" uniqKey="Albini A">A Albini</name></author><author><name sortKey="Tosetti, F" uniqKey="Tosetti F">F Tosetti</name></author><author><name sortKey="Li, Vw" uniqKey="Li V">VW Li</name></author><author><name sortKey="Noonan, Dm" uniqKey="Noonan D">DM Noonan</name></author><author><name sortKey="Li, Ww" uniqKey="Li W">WW Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lake, Ra" uniqKey="Lake R">RA Lake</name></author><author><name sortKey="Robinson, Bw" uniqKey="Robinson B">BW Robinson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Aj" uniqKey="Muller A">AJ Muller</name></author><author><name sortKey="Scherle, Pa" uniqKey="Scherle P">PA Scherle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Melero, I" uniqKey="Melero I">I Melero</name></author><author><name sortKey="Hervas Stubbs, S" uniqKey="Hervas Stubbs S">S Hervas-Stubbs</name></author><author><name sortKey="Glennie, M" uniqKey="Glennie M">M Glennie</name></author><author><name sortKey="Pardoll, Dm" uniqKey="Pardoll D">DM Pardoll</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Humphries, C" uniqKey="Humphries C">C Humphries</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maus, Mv" uniqKey="Maus M">MV Maus</name></author><author><name sortKey="Fraietta, Ja" uniqKey="Fraietta J">JA Fraietta</name></author><author><name sortKey="Levine, Bl" uniqKey="Levine B">BL Levine</name></author><author><name sortKey="Kalos, M" uniqKey="Kalos M">M Kalos</name></author><author><name sortKey="Zhao, Y" uniqKey="Zhao Y">Y Zhao</name></author><author><name sortKey="June, Ch" uniqKey="June C">CH June</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sharma, P" uniqKey="Sharma P">P Sharma</name></author><author><name sortKey="Wagner, K" uniqKey="Wagner K">K Wagner</name></author><author><name sortKey="Wolchok, Jd" uniqKey="Wolchok J">JD Wolchok</name></author><author><name sortKey="Allison, Jp" uniqKey="Allison J">JP Allison</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vanneman, M" uniqKey="Vanneman M">M Vanneman</name></author><author><name sortKey="Dranoff, G" uniqKey="Dranoff G">G Dranoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pardoll, Dm" uniqKey="Pardoll D">DM Pardoll</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Palucka, K" uniqKey="Palucka K">K Palucka</name></author><author><name sortKey="Banchereau, J" uniqKey="Banchereau J">J Banchereau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kershaw, Mh" uniqKey="Kershaw M">MH Kershaw</name></author><author><name sortKey="Westwood, Ja" uniqKey="Westwood J">JA Westwood</name></author><author><name sortKey="Darcy, Pk" uniqKey="Darcy P">PK Darcy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coulie, Pg" uniqKey="Coulie P">PG Coulie</name></author><author><name sortKey="Van Den Eynde, Bj" uniqKey="Van Den Eynde B">BJ Van den Eynde</name></author><author><name sortKey="Van Der Bruggen, P" uniqKey="Van Der Bruggen P">P van der Bruggen</name></author><author><name sortKey="Boon, T" uniqKey="Boon T">T Boon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lichty, Bd" uniqKey="Lichty B">BD Lichty</name></author><author><name sortKey="Breitbach, Cj" uniqKey="Breitbach C">CJ Breitbach</name></author><author><name sortKey="Stojdl, Df" uniqKey="Stojdl D">DF Stojdl</name></author><author><name sortKey="Bell, Jc" uniqKey="Bell J">JC Bell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rice, J" uniqKey="Rice J">J Rice</name></author><author><name sortKey="Ottensmeier, Ch" uniqKey="Ottensmeier C">CH Ottensmeier</name></author><author><name sortKey="Stevenson, Fk" uniqKey="Stevenson F">FK Stevenson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Couzin Frankel, J" uniqKey="Couzin Frankel J">J Couzin-Frankel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Prada, N" uniqKey="Prada N">N Prada</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lesterhuis, Wj" uniqKey="Lesterhuis W">WJ Lesterhuis</name></author><author><name sortKey="Haanen, Jb" uniqKey="Haanen J">JB Haanen</name></author><author><name sortKey="Punt, Cj" uniqKey="Punt C">CJ Punt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weiner, Lm" uniqKey="Weiner L">LM Weiner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strebhardt, K" uniqKey="Strebhardt K">K Strebhardt</name></author><author><name sortKey="Ullrich, A" uniqKey="Ullrich A">A Ullrich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Melief, Cj" uniqKey="Melief C">CJ Melief</name></author><author><name sortKey="Van Der Burg, Sh" uniqKey="Van Der Burg S">SH van der Burg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dronca, Rs" uniqKey="Dronca R">RS Dronca</name></author><author><name sortKey="Dong, H" uniqKey="Dong H">H Dong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Westin, Jr" uniqKey="Westin J">JR Westin</name></author><author><name sortKey="Chu, F" uniqKey="Chu F">F Chu</name></author><author><name sortKey="Zhang, M" uniqKey="Zhang M">M Zhang</name></author><author><name sortKey="Fayad, Le" uniqKey="Fayad L">LE Fayad</name></author><author><name sortKey="Kwak, Lw" uniqKey="Kwak L">LW Kwak</name></author><author><name sortKey="Fowler, N" uniqKey="Fowler N">N Fowler</name></author><author><name sortKey="Romaguera, J" uniqKey="Romaguera J">J Romaguera</name></author><author><name sortKey="Hagemeister, F" uniqKey="Hagemeister F">F Hagemeister</name></author><author><name sortKey="Fanale, M" uniqKey="Fanale M">M Fanale</name></author><author><name sortKey="Samaniego, F" uniqKey="Samaniego F">F Samaniego</name></author><author><name sortKey="Feng, L" uniqKey="Feng L">L Feng</name></author><author><name sortKey="Baladandayuthapani, V" uniqKey="Baladandayuthapani V">V Baladandayuthapani</name></author><author><name sortKey="Wang, Z" uniqKey="Wang Z">Z Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lipson, Ej" uniqKey="Lipson E">EJ Lipson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alkan, Ss" uniqKey="Alkan S">SS Alkan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weiner, Lm" uniqKey="Weiner L">LM Weiner</name></author><author><name sortKey="Surana, R" uniqKey="Surana R">R Surana</name></author><author><name sortKey="Wang, S" uniqKey="Wang S">S Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zucman Rossi, J" uniqKey="Zucman Rossi J">J Zucman-Rossi</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weiner, Lm" uniqKey="Weiner L">LM Weiner</name></author><author><name sortKey="Belldegrun, As" uniqKey="Belldegrun A">AS Belldegrun</name></author><author><name sortKey="Crawford, J" uniqKey="Crawford J">J Crawford</name></author><author><name sortKey="Tolcher, Aw" uniqKey="Tolcher A">AW Tolcher</name></author><author><name sortKey="Lockbaum, P" uniqKey="Lockbaum P">P Lockbaum</name></author><author><name sortKey="Arends, Rh" uniqKey="Arends R">RH Arends</name></author><author><name sortKey="Navale, L" uniqKey="Navale L">L Navale</name></author><author><name sortKey="Amado, Rg" uniqKey="Amado R">RG Amado</name></author><author><name sortKey="Schwab, G" uniqKey="Schwab G">G Schwab</name></author><author><name sortKey="Figlin, Ra" uniqKey="Figlin R">RA Figlin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ming Lim, C" uniqKey="Ming Lim C">C Ming Lim</name></author><author><name sortKey="Stephenson, R" uniqKey="Stephenson R">R Stephenson</name></author><author><name sortKey="Salazar, Am" uniqKey="Salazar A">AM Salazar</name></author><author><name sortKey="Ferris, Rl" uniqKey="Ferris R">RL Ferris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaplan Lefko, Pj" uniqKey="Kaplan Lefko P">PJ Kaplan-Lefko</name></author><author><name sortKey="Graves, Jd" uniqKey="Graves J">JD Graves</name></author><author><name sortKey="Zoog, Sj" uniqKey="Zoog S">SJ Zoog</name></author><author><name sortKey="Pan, Y" uniqKey="Pan Y">Y Pan</name></author><author><name sortKey="Wall, J" uniqKey="Wall J">J Wall</name></author><author><name sortKey="Branstetter, Dg" uniqKey="Branstetter D">DG Branstetter</name></author><author><name sortKey="Moriguchi, J" uniqKey="Moriguchi J">J Moriguchi</name></author><author><name sortKey="Coxon, A" uniqKey="Coxon A">A Coxon</name></author><author><name sortKey="Huard, Jn" uniqKey="Huard J">JN Huard</name></author><author><name sortKey="Xu, R" uniqKey="Xu R">R Xu</name></author><author><name sortKey="Peach, Ml" uniqKey="Peach M">ML Peach</name></author><author><name sortKey="Juan, G" uniqKey="Juan G">G Juan</name></author><author><name sortKey="Kaufman, S" uniqKey="Kaufman S">S Kaufman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrara, N" uniqKey="Ferrara N">N Ferrara</name></author><author><name sortKey="Hillan, Kj" uniqKey="Hillan K">KJ Hillan</name></author><author><name sortKey="Gerber, Hp" uniqKey="Gerber H">HP Gerber</name></author><author><name sortKey="Novotny, W" uniqKey="Novotny W">W Novotny</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Michielsen, Aj" uniqKey="Michielsen A">AJ Michielsen</name></author><author><name sortKey="Ryan, Ej" uniqKey="Ryan E">EJ Ryan</name></author><author><name sortKey="O Sullivan, Jn" uniqKey="O Sullivan J">JN O'Sullivan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cavallo, F" uniqKey="Cavallo F">F Cavallo</name></author><author><name sortKey="Calogero, Ra" uniqKey="Calogero R">RA Calogero</name></author><author><name sortKey="Forni, G" uniqKey="Forni G">G Forni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De La Motte Rouge, T" uniqKey="De La Motte Rouge T">T de La Motte Rouge</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Olaussen, Ka" uniqKey="Olaussen K">KA Olaussen</name></author><author><name sortKey="Zermati, Y" uniqKey="Zermati Y">Y Zermati</name></author><author><name sortKey="Tasdemir, E" uniqKey="Tasdemir E">E Tasdemir</name></author><author><name sortKey="Robert, T" uniqKey="Robert T">T Robert</name></author><author><name sortKey="Ripoche, H" uniqKey="Ripoche H">H Ripoche</name></author><author><name sortKey="Lazar, V" uniqKey="Lazar V">V Lazar</name></author><author><name sortKey="Dessen, P" uniqKey="Dessen P">P Dessen</name></author><author><name sortKey="Harper, F" uniqKey="Harper F">F Harper</name></author><author><name sortKey="Pierron, G" uniqKey="Pierron G">G Pierron</name></author><author><name sortKey="Pinna, G" uniqKey="Pinna G">G Pinna</name></author><author><name sortKey="Araujo, N" uniqKey="Araujo N">N Araujo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Forero Torres, A" uniqKey="Forero Torres A">A Forero-Torres</name></author><author><name sortKey="Infante, Jr" uniqKey="Infante J">JR Infante</name></author><author><name sortKey="Waterhouse, D" uniqKey="Waterhouse D">D Waterhouse</name></author><author><name sortKey="Wong, L" uniqKey="Wong L">L Wong</name></author><author><name sortKey="Vickers, S" uniqKey="Vickers S">S Vickers</name></author><author><name sortKey="Arrowsmith, E" uniqKey="Arrowsmith E">E Arrowsmith</name></author><author><name sortKey="He, Ar" uniqKey="He A">AR He</name></author><author><name sortKey="Hart, L" uniqKey="Hart L">L Hart</name></author><author><name sortKey="Trent, D" uniqKey="Trent D">D Trent</name></author><author><name sortKey="Wade, J" uniqKey="Wade J">J Wade</name></author><author><name sortKey="Jin, X" uniqKey="Jin X">X Jin</name></author><author><name sortKey="Wang, Q" uniqKey="Wang Q">Q Wang</name></author><author><name sortKey="Austin, T" uniqKey="Austin T">T Austin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hughes, B" uniqKey="Hughes B">B Hughes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leal, M" uniqKey="Leal M">M Leal</name></author><author><name sortKey="Sapra, P" uniqKey="Sapra P">P Sapra</name></author><author><name sortKey="Hurvitz, Sa" uniqKey="Hurvitz S">SA Hurvitz</name></author><author><name sortKey="Senter, P" uniqKey="Senter P">P Senter</name></author><author><name sortKey="Wahl, A" uniqKey="Wahl A">A Wahl</name></author><author><name sortKey="Schutten, M" uniqKey="Schutten M">M Schutten</name></author><author><name sortKey="Shah, Dk" uniqKey="Shah D">DK Shah</name></author><author><name sortKey="Haddish Berhane, N" uniqKey="Haddish Berhane N">N Haddish-Berhane</name></author><author><name sortKey="Kabbarah, O" uniqKey="Kabbarah O">O Kabbarah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hubert, P" uniqKey="Hubert P">P Hubert</name></author><author><name sortKey="Amigorena, S" uniqKey="Amigorena S">S Amigorena</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Houot, R" uniqKey="Houot R">R Houot</name></author><author><name sortKey="Kohrt, H" uniqKey="Kohrt H">H Kohrt</name></author><author><name sortKey="Levy, R" uniqKey="Levy R">R Levy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kute, T" uniqKey="Kute T">T Kute</name></author><author><name sortKey="Stehle Jr, Jr" uniqKey="Stehle Jr J">JR Stehle Jr</name></author><author><name sortKey="Ornelles, D" uniqKey="Ornelles D">D Ornelles</name></author><author><name sortKey="Walker, N" uniqKey="Walker N">N Walker</name></author><author><name sortKey="Delbono, O" uniqKey="Delbono O">O Delbono</name></author><author><name sortKey="Vaughn, Jp" uniqKey="Vaughn J">JP Vaughn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Winiarska, M" uniqKey="Winiarska M">M Winiarska</name></author><author><name sortKey="Glodkowska Mrowka, E" uniqKey="Glodkowska Mrowka E">E Glodkowska-Mrowka</name></author><author><name sortKey="Bil, J" uniqKey="Bil J">J Bil</name></author><author><name sortKey="Golab, J" uniqKey="Golab J">J Golab</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zipfel, Pf" uniqKey="Zipfel P">PF Zipfel</name></author><author><name sortKey="Skerka, C" uniqKey="Skerka C">C Skerka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scott, Sd" uniqKey="Scott S">SD Scott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jones, B" uniqKey="Jones B">B Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Armeanu Ebinger, S" uniqKey="Armeanu Ebinger S">S Armeanu-Ebinger</name></author><author><name sortKey="Hoh, A" uniqKey="Hoh A">A Hoh</name></author><author><name sortKey="Wenz, J" uniqKey="Wenz J">J Wenz</name></author><author><name sortKey="Fuchs, J" uniqKey="Fuchs J">J Fuchs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Topp, Ms" uniqKey="Topp M">MS Topp</name></author><author><name sortKey="Gokbuget, N" uniqKey="Gokbuget N">N Gokbuget</name></author><author><name sortKey="Zugmaier, G" uniqKey="Zugmaier G">G Zugmaier</name></author><author><name sortKey="Degenhard, E" uniqKey="Degenhard E">E Degenhard</name></author><author><name sortKey="Goebeler, Me" uniqKey="Goebeler M">ME Goebeler</name></author><author><name sortKey="Klinger, M" uniqKey="Klinger M">M Klinger</name></author><author><name sortKey="Neumann, Sa" uniqKey="Neumann S">SA Neumann</name></author><author><name sortKey="Horst, Ha" uniqKey="Horst H">HA Horst</name></author><author><name sortKey="Raff, T" uniqKey="Raff T">T Raff</name></author><author><name sortKey="Viardot, A" uniqKey="Viardot A">A Viardot</name></author><author><name sortKey="Stelljes, M" uniqKey="Stelljes M">M Stelljes</name></author><author><name sortKey="Schaich, M" uniqKey="Schaich M">M Schaich</name></author><author><name sortKey="Kohne Volland, R" uniqKey="Kohne Volland R">R Kohne-Volland</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walter, Rb" uniqKey="Walter R">RB Walter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choi, Bd" uniqKey="Choi B">BD Choi</name></author><author><name sortKey="Gedeon, Pc" uniqKey="Gedeon P">PC Gedeon</name></author><author><name sortKey="Sanchez Perez, L" uniqKey="Sanchez Perez L">L Sanchez-Perez</name></author><author><name sortKey="Bigner, Dd" uniqKey="Bigner D">DD Bigner</name></author><author><name sortKey="Sampson, Jh" uniqKey="Sampson J">JH Sampson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choi, Bd" uniqKey="Choi B">BD Choi</name></author><author><name sortKey="Pastan, I" uniqKey="Pastan I">I Pastan</name></author><author><name sortKey="Bigner, Dd" uniqKey="Bigner D">DD Bigner</name></author><author><name sortKey="Sampson, Jh" uniqKey="Sampson J">JH Sampson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoffman, Lm" uniqKey="Hoffman L">LM Hoffman</name></author><author><name sortKey="Gore, L" uniqKey="Gore L">L Gore</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kawaguchi, Y" uniqKey="Kawaguchi Y">Y Kawaguchi</name></author><author><name sortKey="Kono, K" uniqKey="Kono K">K Kono</name></author><author><name sortKey="Mimura, K" uniqKey="Mimura K">K Mimura</name></author><author><name sortKey="Sugai, H" uniqKey="Sugai H">H Sugai</name></author><author><name sortKey="Akaike, H" uniqKey="Akaike H">H Akaike</name></author><author><name sortKey="Fujii, H" uniqKey="Fujii H">H Fujii</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Srivastava, Rm" uniqKey="Srivastava R">RM Srivastava</name></author><author><name sortKey="Lee, Sc" uniqKey="Lee S">SC Lee</name></author><author><name sortKey="Andrade Filho, Pa" uniqKey="Andrade Filho P">PA Andrade Filho</name></author><author><name sortKey="Lord, Ca" uniqKey="Lord C">CA Lord</name></author><author><name sortKey="Jie, Hb" uniqKey="Jie H">HB Jie</name></author><author><name sortKey="Davidson, Hc" uniqKey="Davidson H">HC Davidson</name></author><author><name sortKey="Lopez Albaitero, A" uniqKey="Lopez Albaitero A">A Lopez-Albaitero</name></author><author><name sortKey="Gibson, Sp" uniqKey="Gibson S">SP Gibson</name></author><author><name sortKey="Gooding, We" uniqKey="Gooding W">WE Gooding</name></author><author><name sortKey="Ferrone, S" uniqKey="Ferrone S">S Ferrone</name></author><author><name sortKey="Ferris, Rl" uniqKey="Ferris R">RL Ferris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Derer, S" uniqKey="Derer S">S Derer</name></author><author><name sortKey="Lohse, S" uniqKey="Lohse S">S Lohse</name></author><author><name sortKey="Valerius, T" uniqKey="Valerius T">T Valerius</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mansfield, As" uniqKey="Mansfield A">AS Mansfield</name></author><author><name sortKey="Nevala, Wk" uniqKey="Nevala W">WK Nevala</name></author><author><name sortKey="Lieser, Ea" uniqKey="Lieser E">EA Lieser</name></author><author><name sortKey="Leontovich, Aa" uniqKey="Leontovich A">AA Leontovich</name></author><author><name sortKey="Markovic, Sn" uniqKey="Markovic S">SN Markovic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Manzoni, M" uniqKey="Manzoni M">M Manzoni</name></author><author><name sortKey="Rovati, B" uniqKey="Rovati B">B Rovati</name></author><author><name sortKey="Ronzoni, M" uniqKey="Ronzoni M">M Ronzoni</name></author><author><name sortKey="Loupakis, F" uniqKey="Loupakis F">F Loupakis</name></author><author><name sortKey="Mariucci, S" uniqKey="Mariucci S">S Mariucci</name></author><author><name sortKey="Ricci, V" uniqKey="Ricci V">V Ricci</name></author><author><name sortKey="Gattoni, E" uniqKey="Gattoni E">E Gattoni</name></author><author><name sortKey="Salvatore, L" uniqKey="Salvatore L">L Salvatore</name></author><author><name sortKey="Tinelli, C" uniqKey="Tinelli C">C Tinelli</name></author><author><name sortKey="Villa, E" uniqKey="Villa E">E Villa</name></author><author><name sortKey="Danova, M" uniqKey="Danova M">M Danova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hodi, Fs" uniqKey="Hodi F">FS Hodi</name></author><author><name sortKey="Lawrence, D" uniqKey="Lawrence D">D Lawrence</name></author><author><name sortKey="Lezcano, C" uniqKey="Lezcano C">C Lezcano</name></author><author><name sortKey="Wu, X" uniqKey="Wu X">X Wu</name></author><author><name sortKey="Zhou, J" uniqKey="Zhou J">J Zhou</name></author><author><name sortKey="Sasada, T" uniqKey="Sasada T">T Sasada</name></author><author><name sortKey="Zeng, W" uniqKey="Zeng W">W Zeng</name></author><author><name sortKey="Giobbie Hurder, A" uniqKey="Giobbie Hurder A">A Giobbie-Hurder</name></author><author><name sortKey="Atkins, Mb" uniqKey="Atkins M">MB Atkins</name></author><author><name sortKey="Ibrahim, N" uniqKey="Ibrahim N">N Ibrahim</name></author><author><name sortKey="Friedlander, P" uniqKey="Friedlander P">P Friedlander</name></author><author><name sortKey="Flaherty, Kt" uniqKey="Flaherty K">KT Flaherty</name></author><author><name sortKey="Murphy, Gf" uniqKey="Murphy G">GF Murphy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Terme, M" uniqKey="Terme M">M Terme</name></author><author><name sortKey="Pernot, S" uniqKey="Pernot S">S Pernot</name></author><author><name sortKey="Marcheteau, E" uniqKey="Marcheteau E">E Marcheteau</name></author><author><name sortKey="Sandoval, F" uniqKey="Sandoval F">F Sandoval</name></author><author><name sortKey="Benhamouda, N" uniqKey="Benhamouda N">N Benhamouda</name></author><author><name sortKey="Colussi, O" uniqKey="Colussi O">O Colussi</name></author><author><name sortKey="Dubreuil, O" uniqKey="Dubreuil O">O Dubreuil</name></author><author><name sortKey="Carpentier, Af" uniqKey="Carpentier A">AF Carpentier</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Taieb, J" uniqKey="Taieb J">J Taieb</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mellor, Jd" uniqKey="Mellor J">JD Mellor</name></author><author><name sortKey="Brown, Mp" uniqKey="Brown M">MP Brown</name></author><author><name sortKey="Irving, Hr" uniqKey="Irving H">HR Irving</name></author><author><name sortKey="Zalcberg, Jr" uniqKey="Zalcberg J">JR Zalcberg</name></author><author><name sortKey="Dobrovic, A" uniqKey="Dobrovic A">A Dobrovic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Restifo, Np" uniqKey="Restifo N">NP Restifo</name></author><author><name sortKey="Dudley, Me" uniqKey="Dudley M">ME Dudley</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lerret, Nm" uniqKey="Lerret N">NM Lerret</name></author><author><name sortKey="Marzo, Al" uniqKey="Marzo A">AL Marzo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jenq, Rr" uniqKey="Jenq R">RR Jenq</name></author><author><name sortKey="Van Den Brink, Mr" uniqKey="Van Den Brink M">MR van den Brink</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Senovilla, L" uniqKey="Senovilla L">L Senovilla</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Vitale, I" uniqKey="Vitale I">I Vitale</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Fucikova, J" uniqKey="Fucikova J">J Fucikova</name></author><author><name sortKey="Cremer, I" uniqKey="Cremer I">I Cremer</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ueno, H" uniqKey="Ueno H">H Ueno</name></author><author><name sortKey="Palucka, Ak" uniqKey="Palucka A">AK Palucka</name></author><author><name sortKey="Banchereau, J" uniqKey="Banchereau J">J Banchereau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Palucka, K" uniqKey="Palucka K">K Palucka</name></author><author><name sortKey="Banchereau, J" uniqKey="Banchereau J">J Banchereau</name></author><author><name sortKey="Mellman, I" uniqKey="Mellman I">I Mellman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dudley, Me" uniqKey="Dudley M">ME Dudley</name></author><author><name sortKey="Wunderlich, Jr" uniqKey="Wunderlich J">JR Wunderlich</name></author><author><name sortKey="Yang, Jc" uniqKey="Yang J">JC Yang</name></author><author><name sortKey="Sherry, Rm" uniqKey="Sherry R">RM Sherry</name></author><author><name sortKey="Topalian, Sl" uniqKey="Topalian S">SL Topalian</name></author><author><name sortKey="Restifo, Np" uniqKey="Restifo N">NP Restifo</name></author><author><name sortKey="Royal, Re" uniqKey="Royal R">RE Royal</name></author><author><name sortKey="Kammula, U" uniqKey="Kammula U">U Kammula</name></author><author><name sortKey="White, De" uniqKey="White D">DE White</name></author><author><name sortKey="Mavroukakis, Sa" uniqKey="Mavroukakis S">SA Mavroukakis</name></author><author><name sortKey="Rogers, Lj" uniqKey="Rogers L">LJ Rogers</name></author><author><name sortKey="Gracia, Gj" uniqKey="Gracia G">GJ Gracia</name></author><author><name sortKey="Jones, Sa" uniqKey="Jones S">SA Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Lugli, E" uniqKey="Lugli E">E Lugli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Merhavi Shoham, E" uniqKey="Merhavi Shoham E">E Merhavi-Shoham</name></author><author><name sortKey="Haga Friedman, A" uniqKey="Haga Friedman A">A Haga-Friedman</name></author><author><name sortKey="Cohen, Cj" uniqKey="Cohen C">CJ Cohen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, K" uniqKey="Liu K">K Liu</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, J" uniqKey="Zhou J">J Zhou</name></author><author><name sortKey="Shen, X" uniqKey="Shen X">X Shen</name></author><author><name sortKey="Huang, J" uniqKey="Huang J">J Huang</name></author><author><name sortKey="Hodes, Rj" uniqKey="Hodes R">RJ Hodes</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author><author><name sortKey="Robbins, Pf" uniqKey="Robbins P">PF Robbins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kalbasi, A" uniqKey="Kalbasi A">A Kalbasi</name></author><author><name sortKey="Shrimali, Rk" uniqKey="Shrimali R">RK Shrimali</name></author><author><name sortKey="Chinnasamy, D" uniqKey="Chinnasamy D">D Chinnasamy</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hinrichs, Cs" uniqKey="Hinrichs C">CS Hinrichs</name></author><author><name sortKey="Borman, Za" uniqKey="Borman Z">ZA Borman</name></author><author><name sortKey="Gattinoni, L" uniqKey="Gattinoni L">L Gattinoni</name></author><author><name sortKey="Yu, Z" uniqKey="Yu Z">Z Yu</name></author><author><name sortKey="Burns, Wr" uniqKey="Burns W">WR Burns</name></author><author><name sortKey="Huang, J" uniqKey="Huang J">J Huang</name></author><author><name sortKey="Klebanoff, Ca" uniqKey="Klebanoff C">CA Klebanoff</name></author><author><name sortKey="Johnson, La" uniqKey="Johnson L">LA Johnson</name></author><author><name sortKey="Kerkar, Sp" uniqKey="Kerkar S">SP Kerkar</name></author><author><name sortKey="Yang, S" uniqKey="Yang S">S Yang</name></author><author><name sortKey="Muranski, P" uniqKey="Muranski P">P Muranski</name></author><author><name sortKey="Palmer, Dc" uniqKey="Palmer D">DC Palmer</name></author><author><name sortKey="Scott, Cd" uniqKey="Scott C">CD Scott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bellone, M" uniqKey="Bellone M">M Bellone</name></author><author><name sortKey="Calcinotto, A" uniqKey="Calcinotto A">A Calcinotto</name></author><author><name sortKey="Corti, A" uniqKey="Corti A">A Corti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kershaw, Mh" uniqKey="Kershaw M">MH Kershaw</name></author><author><name sortKey="Teng, Mw" uniqKey="Teng M">MW Teng</name></author><author><name sortKey="Smyth, Mj" uniqKey="Smyth M">MJ Smyth</name></author><author><name sortKey="Darcy, Pk" uniqKey="Darcy P">PK Darcy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ray, S" uniqKey="Ray S">S Ray</name></author><author><name sortKey="Chhabra, A" uniqKey="Chhabra A">A Chhabra</name></author><author><name sortKey="Chakraborty, Ng" uniqKey="Chakraborty N">NG Chakraborty</name></author><author><name sortKey="Hegde, U" uniqKey="Hegde U">U Hegde</name></author><author><name sortKey="Dorsky, Di" uniqKey="Dorsky D">DI Dorsky</name></author><author><name sortKey="Chodon, T" uniqKey="Chodon T">T Chodon</name></author><author><name sortKey="Von Euw, E" uniqKey="Von Euw E">E von Euw</name></author><author><name sortKey="Comin Anduix, B" uniqKey="Comin Anduix B">B Comin-Anduix</name></author><author><name sortKey="Koya, Rc" uniqKey="Koya R">RC Koya</name></author><author><name sortKey="Ribas, A" uniqKey="Ribas A">A Ribas</name></author><author><name sortKey="Economou, Js" uniqKey="Economou J">JS Economou</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author><author><name sortKey="Mukherji, B" uniqKey="Mukherji B">B Mukherji</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sadelain, M" uniqKey="Sadelain M">M Sadelain</name></author><author><name sortKey="Riviere, I" uniqKey="Riviere I">I Riviere</name></author><author><name sortKey="Brentjens, R" uniqKey="Brentjens R">R Brentjens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Robbins, Pf" uniqKey="Robbins P">PF Robbins</name></author><author><name sortKey="Morgan, Ra" uniqKey="Morgan R">RA Morgan</name></author><author><name sortKey="Feldman, Sa" uniqKey="Feldman S">SA Feldman</name></author><author><name sortKey="Yang, Jc" uniqKey="Yang J">JC Yang</name></author><author><name sortKey="Sherry, Rm" uniqKey="Sherry R">RM Sherry</name></author><author><name sortKey="Dudley, Me" uniqKey="Dudley M">ME Dudley</name></author><author><name sortKey="Wunderlich, Jr" uniqKey="Wunderlich J">JR Wunderlich</name></author><author><name sortKey="Nahvi, Av" uniqKey="Nahvi A">AV Nahvi</name></author><author><name sortKey="Helman, Lj" uniqKey="Helman L">LJ Helman</name></author><author><name sortKey="Mackall, Cl" uniqKey="Mackall C">CL Mackall</name></author><author><name sortKey="Kammula, Us" uniqKey="Kammula U">US Kammula</name></author><author><name sortKey="Hughes, Ms" uniqKey="Hughes M">MS Hughes</name></author><author><name sortKey="Restifo, Np" uniqKey="Restifo N">NP Restifo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dotti, G" uniqKey="Dotti G">G Dotti</name></author><author><name sortKey="Gottschalk, S" uniqKey="Gottschalk S">S Gottschalk</name></author><author><name sortKey="Savoldo, B" uniqKey="Savoldo B">B Savoldo</name></author><author><name sortKey="Brenner, Mk" uniqKey="Brenner M">MK Brenner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Porter, Dl" uniqKey="Porter D">DL Porter</name></author><author><name sortKey="Levine, Bl" uniqKey="Levine B">BL Levine</name></author><author><name sortKey="Kalos, M" uniqKey="Kalos M">M Kalos</name></author><author><name sortKey="Bagg, A" uniqKey="Bagg A">A Bagg</name></author><author><name sortKey="June, Ch" uniqKey="June C">CH June</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kochenderfer, Jn" uniqKey="Kochenderfer J">JN Kochenderfer</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Long, Ah" uniqKey="Long A">AH Long</name></author><author><name sortKey="Haso, Wm" uniqKey="Haso W">WM Haso</name></author><author><name sortKey="Orentas, Rj" uniqKey="Orentas R">RJ Orentas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spear, P" uniqKey="Spear P">P Spear</name></author><author><name sortKey="Barber, A" uniqKey="Barber A">A Barber</name></author><author><name sortKey="Sentman, Cl" uniqKey="Sentman C">CL Sentman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Badoual, C" uniqKey="Badoual C">C Badoual</name></author><author><name sortKey="Bastier, Pl" uniqKey="Bastier P">PL Bastier</name></author><author><name sortKey="Roussel, H" uniqKey="Roussel H">H Roussel</name></author><author><name sortKey="Mandavit, M" uniqKey="Mandavit M">M Mandavit</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boissel, L" uniqKey="Boissel L">L Boissel</name></author><author><name sortKey="Betancur Boissel, M" uniqKey="Betancur Boissel M">M Betancur-Boissel</name></author><author><name sortKey="Lu, W" uniqKey="Lu W">W Lu</name></author><author><name sortKey="Krause, Ds" uniqKey="Krause D">DS Krause</name></author><author><name sortKey="Van Etten, Ra" uniqKey="Van Etten R">RA Van Etten</name></author><author><name sortKey="Wels, Ws" uniqKey="Wels W">WS Wels</name></author><author><name sortKey="Klingemann, H" uniqKey="Klingemann H">H Klingemann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brentjens, Rj" uniqKey="Brentjens R">RJ Brentjens</name></author><author><name sortKey="Riviere, I" uniqKey="Riviere I">I Riviere</name></author><author><name sortKey="Park, Jh" uniqKey="Park J">JH Park</name></author><author><name sortKey="Davila, Ml" uniqKey="Davila M">ML Davila</name></author><author><name sortKey="Wang, X" uniqKey="Wang X">X Wang</name></author><author><name sortKey="Stefanski, J" uniqKey="Stefanski J">J Stefanski</name></author><author><name sortKey="Taylor, C" uniqKey="Taylor C">C Taylor</name></author><author><name sortKey="Yeh, R" uniqKey="Yeh R">R Yeh</name></author><author><name sortKey="Bartido, S" uniqKey="Bartido S">S Bartido</name></author><author><name sortKey="Borquez Ojeda, O" uniqKey="Borquez Ojeda O">O Borquez-Ojeda</name></author><author><name sortKey="Olszewska, M" uniqKey="Olszewska M">M Olszewska</name></author><author><name sortKey="Bernal, Y" uniqKey="Bernal Y">Y Bernal</name></author><author><name sortKey="Pegram, H" uniqKey="Pegram H">H Pegram</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kalos, M" uniqKey="Kalos M">M Kalos</name></author><author><name sortKey="Levine, Bl" uniqKey="Levine B">BL Levine</name></author><author><name sortKey="Porter, Dl" uniqKey="Porter D">DL Porter</name></author><author><name sortKey="Katz, S" uniqKey="Katz S">S Katz</name></author><author><name sortKey="Grupp, Sa" uniqKey="Grupp S">SA Grupp</name></author><author><name sortKey="Bagg, A" uniqKey="Bagg A">A Bagg</name></author><author><name sortKey="June, Ch" uniqKey="June C">CH June</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brentjens, Rj" uniqKey="Brentjens R">RJ Brentjens</name></author><author><name sortKey="Davila, Ml" uniqKey="Davila M">ML Davila</name></author><author><name sortKey="Riviere, I" uniqKey="Riviere I">I Riviere</name></author><author><name sortKey="Park, J" uniqKey="Park J">J Park</name></author><author><name sortKey="Wang, X" uniqKey="Wang X">X Wang</name></author><author><name sortKey="Cowell, Lg" uniqKey="Cowell L">LG Cowell</name></author><author><name sortKey="Bartido, S" uniqKey="Bartido S">S Bartido</name></author><author><name sortKey="Stefanski, J" uniqKey="Stefanski J">J Stefanski</name></author><author><name sortKey="Taylor, C" uniqKey="Taylor C">C Taylor</name></author><author><name sortKey="Olszewska, M" uniqKey="Olszewska M">M Olszewska</name></author><author><name sortKey="Borquez Ojeda, O" uniqKey="Borquez Ojeda O">O Borquez-Ojeda</name></author><author><name sortKey="Qu, J" uniqKey="Qu J">J Qu</name></author><author><name sortKey="Wasielewska, T" uniqKey="Wasielewska T">T Wasielewska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Louis, Cu" uniqKey="Louis C">CU Louis</name></author><author><name sortKey="Savoldo, B" uniqKey="Savoldo B">B Savoldo</name></author><author><name sortKey="Dotti, G" uniqKey="Dotti G">G Dotti</name></author><author><name sortKey="Pule, M" uniqKey="Pule M">M Pule</name></author><author><name sortKey="Yvon, E" uniqKey="Yvon E">E Yvon</name></author><author><name sortKey="Myers, Gd" uniqKey="Myers G">GD Myers</name></author><author><name sortKey="Rossig, C" uniqKey="Rossig C">C Rossig</name></author><author><name sortKey="Russell, Hv" uniqKey="Russell H">HV Russell</name></author><author><name sortKey="Diouf, O" uniqKey="Diouf O">O Diouf</name></author><author><name sortKey="Liu, E" uniqKey="Liu E">E Liu</name></author><author><name sortKey="Liu, H" uniqKey="Liu H">H Liu</name></author><author><name sortKey="Wu, Mf" uniqKey="Wu M">MF Wu</name></author><author><name sortKey="Gee, Ap" uniqKey="Gee A">AP Gee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beatty, Gl" uniqKey="Beatty G">GL Beatty</name></author><author><name sortKey="Haas, Ar" uniqKey="Haas A">AR Haas</name></author><author><name sortKey="Maus, Mv" uniqKey="Maus M">MV Maus</name></author><author><name sortKey="Torigian, Da" uniqKey="Torigian D">DA Torigian</name></author><author><name sortKey="Soulen, Mc" uniqKey="Soulen M">MC Soulen</name></author><author><name sortKey="Plesa, G" uniqKey="Plesa G">G Plesa</name></author><author><name sortKey="Chew, A" uniqKey="Chew A">A Chew</name></author><author><name sortKey="Zhao, Y" uniqKey="Zhao Y">Y Zhao</name></author><author><name sortKey="Levine, Bl" uniqKey="Levine B">BL Levine</name></author><author><name sortKey="Albelda, Sm" uniqKey="Albelda S">SM Albelda</name></author><author><name sortKey="Kalos, M" uniqKey="Kalos M">M Kalos</name></author><author><name sortKey="June, Ch" uniqKey="June C">CH June</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pegram, Hj" uniqKey="Pegram H">HJ Pegram</name></author><author><name sortKey="Jackson, Jt" uniqKey="Jackson J">JT Jackson</name></author><author><name sortKey="Smyth, Mj" uniqKey="Smyth M">MJ Smyth</name></author><author><name sortKey="Kershaw, Mh" uniqKey="Kershaw M">MH Kershaw</name></author><author><name sortKey="Darcy, Pk" uniqKey="Darcy P">PK Darcy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ruggeri, L" uniqKey="Ruggeri L">L Ruggeri</name></author><author><name sortKey="Capanni, M" uniqKey="Capanni M">M Capanni</name></author><author><name sortKey="Urbani, E" uniqKey="Urbani E">E Urbani</name></author><author><name sortKey="Perruccio, K" uniqKey="Perruccio K">K Perruccio</name></author><author><name sortKey="Shlomchik, Wd" uniqKey="Shlomchik W">WD Shlomchik</name></author><author><name sortKey="Tosti, A" uniqKey="Tosti A">A Tosti</name></author><author><name sortKey="Posati, S" uniqKey="Posati S">S Posati</name></author><author><name sortKey="Rogaia, D" uniqKey="Rogaia D">D Rogaia</name></author><author><name sortKey="Frassoni, F" uniqKey="Frassoni F">F Frassoni</name></author><author><name sortKey="Aversa, F" uniqKey="Aversa F">F Aversa</name></author><author><name sortKey="Martelli, Mf" uniqKey="Martelli M">MF Martelli</name></author><author><name sortKey="Velardi, A" uniqKey="Velardi A">A Velardi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Okada, K" uniqKey="Okada K">K Okada</name></author><author><name sortKey="Nannmark, U" uniqKey="Nannmark U">U Nannmark</name></author><author><name sortKey="Vujanovic, Nl" uniqKey="Vujanovic N">NL Vujanovic</name></author><author><name sortKey="Watkins, S" uniqKey="Watkins S">S Watkins</name></author><author><name sortKey="Basse, P" uniqKey="Basse P">P Basse</name></author><author><name sortKey="Herberman, Rb" uniqKey="Herberman R">RB Herberman</name></author><author><name sortKey="Whiteside, Tl" uniqKey="Whiteside T">TL Whiteside</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Besser, Mj" uniqKey="Besser M">MJ Besser</name></author><author><name sortKey="Shoham, T" uniqKey="Shoham T">T Shoham</name></author><author><name sortKey="Harari Steinberg, O" uniqKey="Harari Steinberg O">O Harari-Steinberg</name></author><author><name sortKey="Zabari, N" uniqKey="Zabari N">N Zabari</name></author><author><name sortKey="Ortenberg, R" uniqKey="Ortenberg R">R Ortenberg</name></author><author><name sortKey="Yakirevitch, A" uniqKey="Yakirevitch A">A Yakirevitch</name></author><author><name sortKey="Nagler, A" uniqKey="Nagler A">A Nagler</name></author><author><name sortKey="Loewenthal, R" uniqKey="Loewenthal R">R Loewenthal</name></author><author><name sortKey="Schachter, J" uniqKey="Schachter J">J Schachter</name></author><author><name sortKey="Markel, G" uniqKey="Markel G">G Markel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Terme, M" uniqKey="Terme M">M Terme</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mattarollo, Sr" uniqKey="Mattarollo S">SR Mattarollo</name></author><author><name sortKey="Smyth, Mj" uniqKey="Smyth M">MJ Smyth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lister, J" uniqKey="Lister J">J Lister</name></author><author><name sortKey="Rybka, Wb" uniqKey="Rybka W">WB Rybka</name></author><author><name sortKey="Donnenberg, Ad" uniqKey="Donnenberg A">AD Donnenberg</name></author><author><name sortKey="Demagalhaes Silverman, M" uniqKey="Demagalhaes Silverman M">M deMagalhaes-Silverman</name></author><author><name sortKey="Pincus, Sm" uniqKey="Pincus S">SM Pincus</name></author><author><name sortKey="Bloom, Ej" uniqKey="Bloom E">EJ Bloom</name></author><author><name sortKey="Elder, Em" uniqKey="Elder E">EM Elder</name></author><author><name sortKey="Ball, Ed" uniqKey="Ball E">ED Ball</name></author><author><name sortKey="Whiteside, Tl" uniqKey="Whiteside T">TL Whiteside</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Parkhurst, Mr" uniqKey="Parkhurst M">MR Parkhurst</name></author><author><name sortKey="Riley, Jp" uniqKey="Riley J">JP Riley</name></author><author><name sortKey="Dudley, Me" uniqKey="Dudley M">ME Dudley</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iliopoulou, Eg" uniqKey="Iliopoulou E">EG Iliopoulou</name></author><author><name sortKey="Kountourakis, P" uniqKey="Kountourakis P">P Kountourakis</name></author><author><name sortKey="Karamouzis, Mv" uniqKey="Karamouzis M">MV Karamouzis</name></author><author><name sortKey="Doufexis, D" uniqKey="Doufexis D">D Doufexis</name></author><author><name sortKey="Ardavanis, A" uniqKey="Ardavanis A">A Ardavanis</name></author><author><name sortKey="Baxevanis, Cn" uniqKey="Baxevanis C">CN Baxevanis</name></author><author><name sortKey="Rigatos, G" uniqKey="Rigatos G">G Rigatos</name></author><author><name sortKey="Papamichail, M" uniqKey="Papamichail M">M Papamichail</name></author><author><name sortKey="Perez, Sa" uniqKey="Perez S">SA Perez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, Q" uniqKey="Li Q">Q Li</name></author><author><name sortKey="Lao, X" uniqKey="Lao X">X Lao</name></author><author><name sortKey="Pan, Q" uniqKey="Pan Q">Q Pan</name></author><author><name sortKey="Ning, N" uniqKey="Ning N">N Ning</name></author><author><name sortKey="Yet, J" uniqKey="Yet J">J Yet</name></author><author><name sortKey="Xu, Y" uniqKey="Xu Y">Y Xu</name></author><author><name sortKey="Li, S" uniqKey="Li S">S Li</name></author><author><name sortKey="Chang, Ae" uniqKey="Chang A">AE Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Visser, Ke" uniqKey="De Visser K">KE de Visser</name></author><author><name sortKey="Korets, Lv" uniqKey="Korets L">LV Korets</name></author><author><name sortKey="Coussens, Lm" uniqKey="Coussens L">LM Coussens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schioppa, T" uniqKey="Schioppa T">T Schioppa</name></author><author><name sortKey="Moore, R" uniqKey="Moore R">R Moore</name></author><author><name sortKey="Thompson, Rg" uniqKey="Thompson R">RG Thompson</name></author><author><name sortKey="Rosser, Ec" uniqKey="Rosser E">EC Rosser</name></author><author><name sortKey="Kulbe, H" uniqKey="Kulbe H">H Kulbe</name></author><author><name sortKey="Nedospasov, S" uniqKey="Nedospasov S">S Nedospasov</name></author><author><name sortKey="Mauri, C" uniqKey="Mauri C">C Mauri</name></author><author><name sortKey="Coussens, Lm" uniqKey="Coussens L">LM Coussens</name></author><author><name sortKey="Balkwill, Fr" uniqKey="Balkwill F">FR Balkwill</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senovilla, L" uniqKey="Senovilla L">L Senovilla</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Ma, Y" uniqKey="Ma Y">Y Ma</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fremd, C" uniqKey="Fremd C">C Fremd</name></author><author><name sortKey="Schuetz, F" uniqKey="Schuetz F">F Schuetz</name></author><author><name sortKey="Sohn, C" uniqKey="Sohn C">C Sohn</name></author><author><name sortKey="Beckhove, P" uniqKey="Beckhove P">P Beckhove</name></author><author><name sortKey="Domschke, C" uniqKey="Domschke C">C Domschke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mignot, G" uniqKey="Mignot G">G Mignot</name></author><author><name sortKey="Ullrich, E" uniqKey="Ullrich E">E Ullrich</name></author><author><name sortKey="Bonmort, M" uniqKey="Bonmort M">M Bonmort</name></author><author><name sortKey="Menard, C" uniqKey="Menard C">C Menard</name></author><author><name sortKey="Apetoh, L" uniqKey="Apetoh L">L Apetoh</name></author><author><name sortKey="Taieb, J" uniqKey="Taieb J">J Taieb</name></author><author><name sortKey="Bosisio, D" uniqKey="Bosisio D">D Bosisio</name></author><author><name sortKey="Sozzani, S" uniqKey="Sozzani S">S Sozzani</name></author><author><name sortKey="Ferrantini, M" uniqKey="Ferrantini M">M Ferrantini</name></author><author><name sortKey="Schmitz, J" uniqKey="Schmitz J">J Schmitz</name></author><author><name sortKey="Mack, M" uniqKey="Mack M">M Mack</name></author><author><name sortKey="Ryffel, B" uniqKey="Ryffel B">B Ryffel</name></author><author><name sortKey="Bulfone Paus, S" uniqKey="Bulfone Paus S">S Bulfone-Paus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ullrich, E" uniqKey="Ullrich E">E Ullrich</name></author><author><name sortKey="Bonmort, M" uniqKey="Bonmort M">M Bonmort</name></author><author><name sortKey="Mignot, G" uniqKey="Mignot G">G Mignot</name></author><author><name sortKey="Jacobs, B" uniqKey="Jacobs B">B Jacobs</name></author><author><name sortKey="Bosisio, D" uniqKey="Bosisio D">D Bosisio</name></author><author><name sortKey="Sozzani, S" uniqKey="Sozzani S">S Sozzani</name></author><author><name sortKey="Jalil, A" uniqKey="Jalil A">A Jalil</name></author><author><name sortKey="Louache, F" uniqKey="Louache F">F Louache</name></author><author><name sortKey="Bulanova, E" uniqKey="Bulanova E">E Bulanova</name></author><author><name sortKey="Geissman, F" uniqKey="Geissman F">F Geissman</name></author><author><name sortKey="Ryffel, B" uniqKey="Ryffel B">B Ryffel</name></author><author><name sortKey="Chaput, N" uniqKey="Chaput N">N Chaput</name></author><author><name sortKey="Bulfone Paus, S" uniqKey="Bulfone Paus S">S Bulfone-Paus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Besser, Mj" uniqKey="Besser M">MJ Besser</name></author><author><name sortKey="Shapira Frommer, R" uniqKey="Shapira Frommer R">R Shapira-Frommer</name></author><author><name sortKey="Itzhaki, O" uniqKey="Itzhaki O">O Itzhaki</name></author><author><name sortKey="Treves, Aj" uniqKey="Treves A">AJ Treves</name></author><author><name sortKey="Zippel, Db" uniqKey="Zippel D">DB Zippel</name></author><author><name sortKey="Levy, D" uniqKey="Levy D">D Levy</name></author><author><name sortKey="Kubi, A" uniqKey="Kubi A">A Kubi</name></author><author><name sortKey="Shoshani, N" uniqKey="Shoshani N">N Shoshani</name></author><author><name sortKey="Zikich, D" uniqKey="Zikich D">D Zikich</name></author><author><name sortKey="Ohayon, Y" uniqKey="Ohayon Y">Y Ohayon</name></author><author><name sortKey="Ohayon, D" uniqKey="Ohayon D">D Ohayon</name></author><author><name sortKey="Shalmon, B" uniqKey="Shalmon B">B Shalmon</name></author><author><name sortKey="Markel, G" uniqKey="Markel G">G Markel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Santegoets, Sj" uniqKey="Santegoets S">SJ Santegoets</name></author><author><name sortKey="Turksma, Aw" uniqKey="Turksma A">AW Turksma</name></author><author><name sortKey="Powell Jr, Dj" uniqKey="Powell Jr D">DJ Powell Jr</name></author><author><name sortKey="Hooijberg, E" uniqKey="Hooijberg E">E Hooijberg</name></author><author><name sortKey="De Gruijl, Td" uniqKey="De Gruijl T">TD de Gruijl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singh, H" uniqKey="Singh H">H Singh</name></author><author><name sortKey="Figliola, Mj" uniqKey="Figliola M">MJ Figliola</name></author><author><name sortKey="Dawson, Mj" uniqKey="Dawson M">MJ Dawson</name></author><author><name sortKey="Huls, H" uniqKey="Huls H">H Huls</name></author><author><name sortKey="Olivares, S" uniqKey="Olivares S">S Olivares</name></author><author><name sortKey="Switzer, K" uniqKey="Switzer K">K Switzer</name></author><author><name sortKey="Mi, T" uniqKey="Mi T">T Mi</name></author><author><name sortKey="Maiti, S" uniqKey="Maiti S">S Maiti</name></author><author><name sortKey="Kebriaei, P" uniqKey="Kebriaei P">P Kebriaei</name></author><author><name sortKey="Lee, Da" uniqKey="Lee D">DA Lee</name></author><author><name sortKey="Champlin, Re" uniqKey="Champlin R">RE Champlin</name></author><author><name sortKey="Cooper, Lj" uniqKey="Cooper L">LJ Cooper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russell, Sj" uniqKey="Russell S">SJ Russell</name></author><author><name sortKey="Peng, Kw" uniqKey="Peng K">KW Peng</name></author><author><name sortKey="Bell, Jc" uniqKey="Bell J">JC Bell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vaha Koskela, Mj" uniqKey="Vaha Koskela M">MJ Vaha-Koskela</name></author><author><name sortKey="Heikkila, Je" uniqKey="Heikkila J">JE Heikkila</name></author><author><name sortKey="Hinkkanen, Ae" uniqKey="Hinkkanen A">AE Hinkkanen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Makela, Ar" uniqKey="Makela A">AR Makela</name></author><author><name sortKey="Matilainen, H" uniqKey="Matilainen H">H Matilainen</name></author><author><name sortKey="White, Dj" uniqKey="White D">DJ White</name></author><author><name sortKey="Ruoslahti, E" uniqKey="Ruoslahti E">E Ruoslahti</name></author><author><name sortKey="Oker Blom, C" uniqKey="Oker Blom C">C Oker-Blom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singh, P" uniqKey="Singh P">P Singh</name></author><author><name sortKey="Destito, G" uniqKey="Destito G">G Destito</name></author><author><name sortKey="Schneemann, A" uniqKey="Schneemann A">A Schneemann</name></author><author><name sortKey="Manchester, M" uniqKey="Manchester M">M Manchester</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Brenner, C" uniqKey="Brenner C">C Brenner</name></author><author><name sortKey="Morselli, E" uniqKey="Morselli E">E Morselli</name></author><author><name sortKey="Touat, Z" uniqKey="Touat Z">Z Touat</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boisgerault, N" uniqKey="Boisgerault N">N Boisgerault</name></author><author><name sortKey="Guillerme, Jb" uniqKey="Guillerme J">JB Guillerme</name></author><author><name sortKey="Pouliquen, D" uniqKey="Pouliquen D">D Pouliquen</name></author><author><name sortKey="Mesel Lemoine, M" uniqKey="Mesel Lemoine M">M Mesel-Lemoine</name></author><author><name sortKey="Achard, C" uniqKey="Achard C">C Achard</name></author><author><name sortKey="Combredet, C" uniqKey="Combredet C">C Combredet</name></author><author><name sortKey="Fonteneau, Jf" uniqKey="Fonteneau J">JF Fonteneau</name></author><author><name sortKey="Tangy, F" uniqKey="Tangy F">F Tangy</name></author><author><name sortKey="Gregoire, M" uniqKey="Gregoire M">M Gregoire</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wildner, O" uniqKey="Wildner O">O Wildner</name></author><author><name sortKey="Blaese, Rm" uniqKey="Blaese R">RM Blaese</name></author><author><name sortKey="Morris, Jc" uniqKey="Morris J">JC Morris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tseng, Jc" uniqKey="Tseng J">JC Tseng</name></author><author><name sortKey="Zanzonico, Pb" uniqKey="Zanzonico P">PB Zanzonico</name></author><author><name sortKey="Levin, B" uniqKey="Levin B">B Levin</name></author><author><name sortKey="Finn, R" uniqKey="Finn R">R Finn</name></author><author><name sortKey="Larson, Sm" uniqKey="Larson S">SM Larson</name></author><author><name sortKey="Meruelo, D" uniqKey="Meruelo D">D Meruelo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Foloppe, J" uniqKey="Foloppe J">J Foloppe</name></author><author><name sortKey="Kintz, J" uniqKey="Kintz J">J Kintz</name></author><author><name sortKey="Futin, N" uniqKey="Futin N">N Futin</name></author><author><name sortKey="Findeli, A" uniqKey="Findeli A">A Findeli</name></author><author><name sortKey="Cordier, P" uniqKey="Cordier P">P Cordier</name></author><author><name sortKey="Schlesinger, Y" uniqKey="Schlesinger Y">Y Schlesinger</name></author><author><name sortKey="Hoffmann, C" uniqKey="Hoffmann C">C Hoffmann</name></author><author><name sortKey="Tosch, C" uniqKey="Tosch C">C Tosch</name></author><author><name sortKey="Balloul, Jm" uniqKey="Balloul J">JM Balloul</name></author><author><name sortKey="Erbs, P" uniqKey="Erbs P">P Erbs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Deisseroth, A" uniqKey="Deisseroth A">A Deisseroth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leveille, S" uniqKey="Leveille S">S Leveille</name></author><author><name sortKey="Samuel, S" uniqKey="Samuel S">S Samuel</name></author><author><name sortKey="Goulet, Ml" uniqKey="Goulet M">ML Goulet</name></author><author><name sortKey="Hiscott, J" uniqKey="Hiscott J">J Hiscott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lampe, J" uniqKey="Lampe J">J Lampe</name></author><author><name sortKey="Bossow, S" uniqKey="Bossow S">S Bossow</name></author><author><name sortKey="Weiland, T" uniqKey="Weiland T">T Weiland</name></author><author><name sortKey="Smirnow, I" uniqKey="Smirnow I">I Smirnow</name></author><author><name sortKey="Lehmann, R" uniqKey="Lehmann R">R Lehmann</name></author><author><name sortKey="Neubert, W" uniqKey="Neubert W">W Neubert</name></author><author><name sortKey="Bitzer, M" uniqKey="Bitzer M">M Bitzer</name></author><author><name sortKey="Lauer, Um" uniqKey="Lauer U">UM Lauer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shinoura, N" uniqKey="Shinoura N">N Shinoura</name></author><author><name sortKey="Yoshida, Y" uniqKey="Yoshida Y">Y Yoshida</name></author><author><name sortKey="Asai, A" uniqKey="Asai A">A Asai</name></author><author><name sortKey="Kirino, T" uniqKey="Kirino T">T Kirino</name></author><author><name sortKey="Hamada, H" uniqKey="Hamada H">H Hamada</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, L" uniqKey="Zhao L">L Zhao</name></author><author><name sortKey="Dong, A" uniqKey="Dong A">A Dong</name></author><author><name sortKey="Gu, J" uniqKey="Gu J">J Gu</name></author><author><name sortKey="Liu, Z" uniqKey="Liu Z">Z Liu</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Zhang, W" uniqKey="Zhang W">W Zhang</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author><author><name sortKey="He, L" uniqKey="He L">L He</name></author><author><name sortKey="Qian, C" uniqKey="Qian C">C Qian</name></author><author><name sortKey="Qian, Q" uniqKey="Qian Q">Q Qian</name></author><author><name sortKey="Liu, X" uniqKey="Liu X">X Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, W" uniqKey="Zhu W">W Zhu</name></author><author><name sortKey="Zhang, H" uniqKey="Zhang H">H Zhang</name></author><author><name sortKey="Shi, Y" uniqKey="Shi Y">Y Shi</name></author><author><name sortKey="Song, M" uniqKey="Song M">M Song</name></author><author><name sortKey="Zhu, B" uniqKey="Zhu B">B Zhu</name></author><author><name sortKey="Wei, L" uniqKey="Wei L">L Wei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jiang, G" uniqKey="Jiang G">G Jiang</name></author><author><name sortKey="Li, J" uniqKey="Li J">J Li</name></author><author><name sortKey="Zeng, Z" uniqKey="Zeng Z">Z Zeng</name></author><author><name sortKey="Xian, L" uniqKey="Xian L">L Xian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shen, W" uniqKey="Shen W">W Shen</name></author><author><name sortKey="Tu, Jk" uniqKey="Tu J">JK Tu</name></author><author><name sortKey="Wang, Xh" uniqKey="Wang X">XH Wang</name></author><author><name sortKey="Fu, Zx" uniqKey="Fu Z">ZX Fu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liang, M" uniqKey="Liang M">M Liang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raty, Jk" uniqKey="Raty J">JK Raty</name></author><author><name sortKey="Pikkarainen, Jt" uniqKey="Pikkarainen J">JT Pikkarainen</name></author><author><name sortKey="Wirth, T" uniqKey="Wirth T">T Wirth</name></author><author><name sortKey="Yla Herttuala, S" uniqKey="Yla Herttuala S">S Yla-Herttuala</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alvarez Breckenridge, Ca" uniqKey="Alvarez Breckenridge C">CA Alvarez-Breckenridge</name></author><author><name sortKey="Yu, J" uniqKey="Yu J">J Yu</name></author><author><name sortKey="Caligiuri, Ma" uniqKey="Caligiuri M">MA Caligiuri</name></author><author><name sortKey="Chiocca, Ea" uniqKey="Chiocca E">EA Chiocca</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bernt, Km" uniqKey="Bernt K">KM Bernt</name></author><author><name sortKey="Ni, S" uniqKey="Ni S">S Ni</name></author><author><name sortKey="Gaggar, A" uniqKey="Gaggar A">A Gaggar</name></author><author><name sortKey="Li, Zy" uniqKey="Li Z">ZY Li</name></author><author><name sortKey="Shayakhmetov, Dm" uniqKey="Shayakhmetov D">DM Shayakhmetov</name></author><author><name sortKey="Lieber, A" uniqKey="Lieber A">A Lieber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Underhill, Dm" uniqKey="Underhill D">DM Underhill</name></author><author><name sortKey="Ozinsky, A" uniqKey="Ozinsky A">A Ozinsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ikeda, K" uniqKey="Ikeda K">K Ikeda</name></author><author><name sortKey="Wakimoto, H" uniqKey="Wakimoto H">H Wakimoto</name></author><author><name sortKey="Ichikawa, T" uniqKey="Ichikawa T">T Ichikawa</name></author><author><name sortKey="Jhung, S" uniqKey="Jhung S">S Jhung</name></author><author><name sortKey="Hochberg, Fh" uniqKey="Hochberg F">FH Hochberg</name></author><author><name sortKey="Louis, Dn" uniqKey="Louis D">DN Louis</name></author><author><name sortKey="Chiocca, Ea" uniqKey="Chiocca E">EA Chiocca</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pensiero, Mn" uniqKey="Pensiero M">MN Pensiero</name></author><author><name sortKey="Wysocki, Ca" uniqKey="Wysocki C">CA Wysocki</name></author><author><name sortKey="Nader, K" uniqKey="Nader K">K Nader</name></author><author><name sortKey="Kikuchi, Ge" uniqKey="Kikuchi G">GE Kikuchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fisher, Kd" uniqKey="Fisher K">KD Fisher</name></author><author><name sortKey="Stallwood, Y" uniqKey="Stallwood Y">Y Stallwood</name></author><author><name sortKey="Green, Nk" uniqKey="Green N">NK Green</name></author><author><name sortKey="Ulbrich, K" uniqKey="Ulbrich K">K Ulbrich</name></author><author><name sortKey="Mautner, V" uniqKey="Mautner V">V Mautner</name></author><author><name sortKey="Seymour, Lw" uniqKey="Seymour L">LW Seymour</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Massari, I" uniqKey="Massari I">I Massari</name></author><author><name sortKey="Donnini, A" uniqKey="Donnini A">A Donnini</name></author><author><name sortKey="Argentati, K" uniqKey="Argentati K">K Argentati</name></author><author><name sortKey="Straino, S" uniqKey="Straino S">S Straino</name></author><author><name sortKey="Mangoni, A" uniqKey="Mangoni A">A Mangoni</name></author><author><name sortKey="Gaetano, C" uniqKey="Gaetano C">C Gaetano</name></author><author><name sortKey="Viticchi, C" uniqKey="Viticchi C">C Viticchi</name></author><author><name sortKey="Capogrossi, M" uniqKey="Capogrossi M">M Capogrossi</name></author><author><name sortKey="Provinciali, M" uniqKey="Provinciali M">M Provinciali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Diaconu, I" uniqKey="Diaconu I">I Diaconu</name></author><author><name sortKey="Cerullo, V" uniqKey="Cerullo V">V Cerullo</name></author><author><name sortKey="Hirvinen, Ml" uniqKey="Hirvinen M">ML Hirvinen</name></author><author><name sortKey="Escutenaire, S" uniqKey="Escutenaire S">S Escutenaire</name></author><author><name sortKey="Ugolini, M" uniqKey="Ugolini M">M Ugolini</name></author><author><name sortKey="Pesonen, Sk" uniqKey="Pesonen S">SK Pesonen</name></author><author><name sortKey="Bramante, S" uniqKey="Bramante S">S Bramante</name></author><author><name sortKey="Parviainen, S" uniqKey="Parviainen S">S Parviainen</name></author><author><name sortKey="Kanerva, A" uniqKey="Kanerva A">A Kanerva</name></author><author><name sortKey="Loskog, As" uniqKey="Loskog A">AS Loskog</name></author><author><name sortKey="Eliopoulos, Ag" uniqKey="Eliopoulos A">AG Eliopoulos</name></author><author><name sortKey="Pesonen, S" uniqKey="Pesonen S">S Pesonen</name></author><author><name sortKey="Hemminki, A" uniqKey="Hemminki A">A Hemminki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pesonen, S" uniqKey="Pesonen S">S Pesonen</name></author><author><name sortKey="Diaconu, I" uniqKey="Diaconu I">I Diaconu</name></author><author><name sortKey="Kangasniemi, L" uniqKey="Kangasniemi L">L Kangasniemi</name></author><author><name sortKey="Ranki, T" uniqKey="Ranki T">T Ranki</name></author><author><name sortKey="Kanerva, A" uniqKey="Kanerva A">A Kanerva</name></author><author><name sortKey="Pesonen, Sk" uniqKey="Pesonen S">SK Pesonen</name></author><author><name sortKey="Gerdemann, U" uniqKey="Gerdemann U">U Gerdemann</name></author><author><name sortKey="Leen, Am" uniqKey="Leen A">AM Leen</name></author><author><name sortKey="Kairemo, K" uniqKey="Kairemo K">K Kairemo</name></author><author><name sortKey="Oksanen, M" uniqKey="Oksanen M">M Oksanen</name></author><author><name sortKey="Haavisto, E" uniqKey="Haavisto E">E Haavisto</name></author><author><name sortKey="Holm, Sl" uniqKey="Holm S">SL Holm</name></author><author><name sortKey="Karioja Kallio, A" uniqKey="Karioja Kallio A">A Karioja-Kallio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gomes, Em" uniqKey="Gomes E">EM Gomes</name></author><author><name sortKey="Rodrigues, Ms" uniqKey="Rodrigues M">MS Rodrigues</name></author><author><name sortKey="Phadke, Ap" uniqKey="Phadke A">AP Phadke</name></author><author><name sortKey="Butcher, Ld" uniqKey="Butcher L">LD Butcher</name></author><author><name sortKey="Starling, C" uniqKey="Starling C">C Starling</name></author><author><name sortKey="Chen, S" uniqKey="Chen S">S Chen</name></author><author><name sortKey="Chang, D" uniqKey="Chang D">D Chang</name></author><author><name sortKey="Hernandez Alcoceba, R" uniqKey="Hernandez Alcoceba R">R Hernandez-Alcoceba</name></author><author><name sortKey="Newman, Jt" uniqKey="Newman J">JT Newman</name></author><author><name sortKey="Stone, Mj" uniqKey="Stone M">MJ Stone</name></author><author><name sortKey="Tong, Aw" uniqKey="Tong A">AW Tong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choi, Ik" uniqKey="Choi I">IK Choi</name></author><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author><author><name sortKey="Oh, E" uniqKey="Oh E">E Oh</name></author><author><name sortKey="Kim, J" uniqKey="Kim J">J Kim</name></author><author><name sortKey="Yun, Co" uniqKey="Yun C">CO Yun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heo, J" uniqKey="Heo J">J Heo</name></author><author><name sortKey="Reid, T" uniqKey="Reid T">T Reid</name></author><author><name sortKey="Ruo, L" uniqKey="Ruo L">L Ruo</name></author><author><name sortKey="Breitbach, Cj" uniqKey="Breitbach C">CJ Breitbach</name></author><author><name sortKey="Rose, S" uniqKey="Rose S">S Rose</name></author><author><name sortKey="Bloomston, M" uniqKey="Bloomston M">M Bloomston</name></author><author><name sortKey="Cho, M" uniqKey="Cho M">M Cho</name></author><author><name sortKey="Lim, Hy" uniqKey="Lim H">HY Lim</name></author><author><name sortKey="Chung, Hc" uniqKey="Chung H">HC Chung</name></author><author><name sortKey="Kim, Cw" uniqKey="Kim C">CW Kim</name></author><author><name sortKey="Burke, J" uniqKey="Burke J">J Burke</name></author><author><name sortKey="Lencioni, R" uniqKey="Lencioni R">R Lencioni</name></author><author><name sortKey="Hickman, T" uniqKey="Hickman T">T Hickman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kanerva, A" uniqKey="Kanerva A">A Kanerva</name></author><author><name sortKey="Nokisalmi, P" uniqKey="Nokisalmi P">P Nokisalmi</name></author><author><name sortKey="Diaconu, I" uniqKey="Diaconu I">I Diaconu</name></author><author><name sortKey="Koski, A" uniqKey="Koski A">A Koski</name></author><author><name sortKey="Cerullo, V" uniqKey="Cerullo V">V Cerullo</name></author><author><name sortKey="Liikanen, I" uniqKey="Liikanen I">I Liikanen</name></author><author><name sortKey="Tahtinen, S" uniqKey="Tahtinen S">S Tahtinen</name></author><author><name sortKey="Oksanen, M" uniqKey="Oksanen M">M Oksanen</name></author><author><name sortKey="Heiskanen, R" uniqKey="Heiskanen R">R Heiskanen</name></author><author><name sortKey="Pesonen, S" uniqKey="Pesonen S">S Pesonen</name></author><author><name sortKey="Joensuu, T" uniqKey="Joensuu T">T Joensuu</name></author><author><name sortKey="Alanko, T" uniqKey="Alanko T">T Alanko</name></author><author><name sortKey="Partanen, K" uniqKey="Partanen K">K Partanen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Egilmez, Nk" uniqKey="Egilmez N">NK Egilmez</name></author><author><name sortKey="Harden, Jl" uniqKey="Harden J">JL Harden</name></author><author><name sortKey="Rowswell Turner, Rb" uniqKey="Rowswell Turner R">RB Rowswell-Turner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, J" uniqKey="Li J">J Li</name></author><author><name sortKey="O Malley, M" uniqKey="O Malley M">M O'Malley</name></author><author><name sortKey="Sampath, P" uniqKey="Sampath P">P Sampath</name></author><author><name sortKey="Kalinski, P" uniqKey="Kalinski P">P Kalinski</name></author><author><name sortKey="Bartlett, Dl" uniqKey="Bartlett D">DL Bartlett</name></author><author><name sortKey="Thorne, Sh" uniqKey="Thorne S">SH Thorne</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Banchereau, J" uniqKey="Banchereau J">J Banchereau</name></author><author><name sortKey="Palucka, Ak" uniqKey="Palucka A">AK Palucka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coosemans, A" uniqKey="Coosemans A">A Coosemans</name></author><author><name sortKey="Vergote, I" uniqKey="Vergote I">I Vergote</name></author><author><name sortKey="Van Gool, Sw" uniqKey="Van Gool S">SW Van Gool</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Merad, M" uniqKey="Merad M">M Merad</name></author><author><name sortKey="Sathe, P" uniqKey="Sathe P">P Sathe</name></author><author><name sortKey="Helft, J" uniqKey="Helft J">J Helft</name></author><author><name sortKey="Miller, J" uniqKey="Miller J">J Miller</name></author><author><name sortKey="Mortha, A" uniqKey="Mortha A">A Mortha</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bonifaz, L" uniqKey="Bonifaz L">L Bonifaz</name></author><author><name sortKey="Bonnyay, D" uniqKey="Bonnyay D">D Bonnyay</name></author><author><name sortKey="Mahnke, K" uniqKey="Mahnke K">K Mahnke</name></author><author><name sortKey="Rivera, M" uniqKey="Rivera M">M Rivera</name></author><author><name sortKey="Nussenzweig, Mc" uniqKey="Nussenzweig M">MC Nussenzweig</name></author><author><name sortKey="Steinman, Rm" uniqKey="Steinman R">RM Steinman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hawiger, D" uniqKey="Hawiger D">D Hawiger</name></author><author><name sortKey="Inaba, K" uniqKey="Inaba K">K Inaba</name></author><author><name sortKey="Dorsett, Y" uniqKey="Dorsett Y">Y Dorsett</name></author><author><name sortKey="Guo, M" uniqKey="Guo M">M Guo</name></author><author><name sortKey="Mahnke, K" uniqKey="Mahnke K">K Mahnke</name></author><author><name sortKey="Rivera, M" uniqKey="Rivera M">M Rivera</name></author><author><name sortKey="Ravetch, Jv" uniqKey="Ravetch J">JV Ravetch</name></author><author><name sortKey="Steinman, Rm" uniqKey="Steinman R">RM Steinman</name></author><author><name sortKey="Nussenzweig, Mc" uniqKey="Nussenzweig M">MC Nussenzweig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Linette, Gp" uniqKey="Linette G">GP Linette</name></author><author><name sortKey="Carreno, Bm" uniqKey="Carreno B">BM Carreno</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mayordomo, Ji" uniqKey="Mayordomo J">JI Mayordomo</name></author><author><name sortKey="Zorina, T" uniqKey="Zorina T">T Zorina</name></author><author><name sortKey="Storkus, Wj" uniqKey="Storkus W">WJ Storkus</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Celluzzi, C" uniqKey="Celluzzi C">C Celluzzi</name></author><author><name sortKey="Falo, Ld" uniqKey="Falo L">LD Falo</name></author><author><name sortKey="Melief, Cj" uniqKey="Melief C">CJ Melief</name></author><author><name sortKey="Ildstad, St" uniqKey="Ildstad S">ST Ildstad</name></author><author><name sortKey="Kast, Wm" uniqKey="Kast W">WM Kast</name></author><author><name sortKey="Deleo, Ab" uniqKey="Deleo A">AB Deleo</name></author><author><name sortKey="Lotze, Mt" uniqKey="Lotze M">MT Lotze</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Mayordomo, Ji" uniqKey="Mayordomo J">JI Mayordomo</name></author><author><name sortKey="Tjandrawan, T" uniqKey="Tjandrawan T">T Tjandrawan</name></author><author><name sortKey="Deleo, Ab" uniqKey="Deleo A">AB DeLeo</name></author><author><name sortKey="Clarke, Mr" uniqKey="Clarke M">MR Clarke</name></author><author><name sortKey="Lotze, Mt" uniqKey="Lotze M">MT Lotze</name></author><author><name sortKey="Storkus, Wj" uniqKey="Storkus W">WJ Storkus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fernandez, Nc" uniqKey="Fernandez N">NC Fernandez</name></author><author><name sortKey="Lozier, A" uniqKey="Lozier A">A Lozier</name></author><author><name sortKey="Flament, C" uniqKey="Flament C">C Flament</name></author><author><name sortKey="Ricciardi Castagnoli, P" uniqKey="Ricciardi Castagnoli P">P Ricciardi-Castagnoli</name></author><author><name sortKey="Bellet, D" uniqKey="Bellet D">D Bellet</name></author><author><name sortKey="Suter, M" uniqKey="Suter M">M Suter</name></author><author><name sortKey="Perricaudet, M" uniqKey="Perricaudet M">M Perricaudet</name></author><author><name sortKey="Tursz, T" uniqKey="Tursz T">T Tursz</name></author><author><name sortKey="Maraskovsky, E" uniqKey="Maraskovsky E">E Maraskovsky</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Okada, H" uniqKey="Okada H">H Okada</name></author><author><name sortKey="Kalinski, P" uniqKey="Kalinski P">P Kalinski</name></author><author><name sortKey="Ueda, R" uniqKey="Ueda R">R Ueda</name></author><author><name sortKey="Hoji, A" uniqKey="Hoji A">A Hoji</name></author><author><name sortKey="Kohanbash, G" uniqKey="Kohanbash G">G Kohanbash</name></author><author><name sortKey="Donegan, Te" uniqKey="Donegan T">TE Donegan</name></author><author><name sortKey="Mintz, Ah" uniqKey="Mintz A">AH Mintz</name></author><author><name sortKey="Engh, Ja" uniqKey="Engh J">JA Engh</name></author><author><name sortKey="Bartlett, Dl" uniqKey="Bartlett D">DL Bartlett</name></author><author><name sortKey="Brown, Ck" uniqKey="Brown C">CK Brown</name></author><author><name sortKey="Zeh, H" uniqKey="Zeh H">H Zeh</name></author><author><name sortKey="Holtzman, Mp" uniqKey="Holtzman M">MP Holtzman</name></author><author><name sortKey="Reinhart, Ta" uniqKey="Reinhart T">TA Reinhart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeis, M" uniqKey="Zeis M">M Zeis</name></author><author><name sortKey="Siegel, S" uniqKey="Siegel S">S Siegel</name></author><author><name sortKey="Wagner, A" uniqKey="Wagner A">A Wagner</name></author><author><name sortKey="Schmitz, M" uniqKey="Schmitz M">M Schmitz</name></author><author><name sortKey="Marget, M" uniqKey="Marget M">M Marget</name></author><author><name sortKey="Kuhl Burmeister, R" uniqKey="Kuhl Burmeister R">R Kuhl-Burmeister</name></author><author><name sortKey="Adamzik, I" uniqKey="Adamzik I">I Adamzik</name></author><author><name sortKey="Kabelitz, D" uniqKey="Kabelitz D">D Kabelitz</name></author><author><name sortKey="Dreger, P" uniqKey="Dreger P">P Dreger</name></author><author><name sortKey="Schmitz, N" uniqKey="Schmitz N">N Schmitz</name></author><author><name sortKey="Heiser, A" uniqKey="Heiser A">A Heiser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Antonia, Sj" uniqKey="Antonia S">SJ Antonia</name></author><author><name sortKey="Mirza, N" uniqKey="Mirza N">N Mirza</name></author><author><name sortKey="Fricke, I" uniqKey="Fricke I">I Fricke</name></author><author><name sortKey="Chiappori, A" uniqKey="Chiappori A">A Chiappori</name></author><author><name sortKey="Thompson, P" uniqKey="Thompson P">P Thompson</name></author><author><name sortKey="Williams, N" uniqKey="Williams N">N Williams</name></author><author><name sortKey="Bepler, G" uniqKey="Bepler G">G Bepler</name></author><author><name sortKey="Simon, G" uniqKey="Simon G">G Simon</name></author><author><name sortKey="Janssen, W" uniqKey="Janssen W">W Janssen</name></author><author><name sortKey="Lee, Jh" uniqKey="Lee J">JH Lee</name></author><author><name sortKey="Menander, K" uniqKey="Menander K">K Menander</name></author><author><name sortKey="Chada, S" uniqKey="Chada S">S Chada</name></author><author><name sortKey="Gabrilovich, Di" uniqKey="Gabrilovich D">DI Gabrilovich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Irvine, As" uniqKey="Irvine A">AS Irvine</name></author><author><name sortKey="Trinder, Pk" uniqKey="Trinder P">PK Trinder</name></author><author><name sortKey="Laughton, Dl" uniqKey="Laughton D">DL Laughton</name></author><author><name sortKey="Ketteringham, H" uniqKey="Ketteringham H">H Ketteringham</name></author><author><name sortKey="Mcdermott, Rh" uniqKey="Mcdermott R">RH McDermott</name></author><author><name sortKey="Reid, Sc" uniqKey="Reid S">SC Reid</name></author><author><name sortKey="Haines, Am" uniqKey="Haines A">AM Haines</name></author><author><name sortKey="Amir, A" uniqKey="Amir A">A Amir</name></author><author><name sortKey="Husain, R" uniqKey="Husain R">R Husain</name></author><author><name sortKey="Doshi, R" uniqKey="Doshi R">R Doshi</name></author><author><name sortKey="Young, Ls" uniqKey="Young L">LS Young</name></author><author><name sortKey="Mountain, A" uniqKey="Mountain A">A Mountain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Manickan, E" uniqKey="Manickan E">E Manickan</name></author><author><name sortKey="Kanangat, S" uniqKey="Kanangat S">S Kanangat</name></author><author><name sortKey="Rouse, Rj" uniqKey="Rouse R">RJ Rouse</name></author><author><name sortKey="Yu, Z" uniqKey="Yu Z">Z Yu</name></author><author><name sortKey="Rouse, Bt" uniqKey="Rouse B">BT Rouse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blalock, Lt" uniqKey="Blalock L">LT Blalock</name></author><author><name sortKey="Landsberg, J" uniqKey="Landsberg J">J Landsberg</name></author><author><name sortKey="Messmer, M" uniqKey="Messmer M">M Messmer</name></author><author><name sortKey="Shi, J" uniqKey="Shi J">J Shi</name></author><author><name sortKey="Pardee, Ad" uniqKey="Pardee A">AD Pardee</name></author><author><name sortKey="Haskell, R" uniqKey="Haskell R">R Haskell</name></author><author><name sortKey="Vujanovic, L" uniqKey="Vujanovic L">L Vujanovic</name></author><author><name sortKey="Kirkwood, Jm" uniqKey="Kirkwood J">JM Kirkwood</name></author><author><name sortKey="Butterfield, Lh" uniqKey="Butterfield L">LH Butterfield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fields, Rc" uniqKey="Fields R">RC Fields</name></author><author><name sortKey="Shimizu, K" uniqKey="Shimizu K">K Shimizu</name></author><author><name sortKey="Mule, Jj" uniqKey="Mule J">JJ Mule</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kokhaei, P" uniqKey="Kokhaei P">P Kokhaei</name></author><author><name sortKey="Rezvany, Mr" uniqKey="Rezvany M">MR Rezvany</name></author><author><name sortKey="Virving, L" uniqKey="Virving L">L Virving</name></author><author><name sortKey="Choudhury, A" uniqKey="Choudhury A">A Choudhury</name></author><author><name sortKey="Rabbani, H" uniqKey="Rabbani H">H Rabbani</name></author><author><name sortKey="Osterborg, A" uniqKey="Osterborg A">A Osterborg</name></author><author><name sortKey="Mellstedt, H" uniqKey="Mellstedt H">H Mellstedt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Albert, Ml" uniqKey="Albert M">ML Albert</name></author><author><name sortKey="Sauter, B" uniqKey="Sauter B">B Sauter</name></author><author><name sortKey="Bhardwaj, N" uniqKey="Bhardwaj N">N Bhardwaj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kandalaft, Le" uniqKey="Kandalaft L">LE Kandalaft</name></author><author><name sortKey="Powell, Dj" uniqKey="Powell D">DJ Powell</name></author><author><name sortKey="Chiang, Cl" uniqKey="Chiang C">CL Chiang</name></author><author><name sortKey="Tanyi, J" uniqKey="Tanyi J">J Tanyi</name></author><author><name sortKey="Kim, S" uniqKey="Kim S">S Kim</name></author><author><name sortKey="Bosch, M" uniqKey="Bosch M">M Bosch</name></author><author><name sortKey="Montone, K" uniqKey="Montone K">K Montone</name></author><author><name sortKey="Mick, R" uniqKey="Mick R">R Mick</name></author><author><name sortKey="Levine, Bl" uniqKey="Levine B">BL Levine</name></author><author><name sortKey="Torigian, Da" uniqKey="Torigian D">DA Torigian</name></author><author><name sortKey="June, Ch" uniqKey="June C">CH June</name></author><author><name sortKey="Coukos, G" uniqKey="Coukos G">G Coukos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fucikova, J" uniqKey="Fucikova J">J Fucikova</name></author><author><name sortKey="Rozkova, D" uniqKey="Rozkova D">D Rozkova</name></author><author><name sortKey="Ulcova, H" uniqKey="Ulcova H">H Ulcova</name></author><author><name sortKey="Budinsky, V" uniqKey="Budinsky V">V Budinsky</name></author><author><name sortKey="Sochorova, K" uniqKey="Sochorova K">K Sochorova</name></author><author><name sortKey="Pokorna, K" uniqKey="Pokorna K">K Pokorna</name></author><author><name sortKey="Bartunkova, J" uniqKey="Bartunkova J">J Bartunkova</name></author><author><name sortKey="Spisek, R" uniqKey="Spisek R">R Spisek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fucikova, J" uniqKey="Fucikova J">J Fucikova</name></author><author><name sortKey="Kralikova, P" uniqKey="Kralikova P">P Kralikova</name></author><author><name sortKey="Fialova, A" uniqKey="Fialova A">A Fialova</name></author><author><name sortKey="Brtnicky, T" uniqKey="Brtnicky T">T Brtnicky</name></author><author><name sortKey="Rob, L" uniqKey="Rob L">L Rob</name></author><author><name sortKey="Bartunkova, J" uniqKey="Bartunkova J">J Bartunkova</name></author><author><name sortKey="Spisek, R" uniqKey="Spisek R">R Spisek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boczkowski, D" uniqKey="Boczkowski D">D Boczkowski</name></author><author><name sortKey="Nair, Sk" uniqKey="Nair S">SK Nair</name></author><author><name sortKey="Nam, Jh" uniqKey="Nam J">JH Nam</name></author><author><name sortKey="Lyerly, Hk" uniqKey="Lyerly H">HK Lyerly</name></author><author><name sortKey="Gilboa, E" uniqKey="Gilboa E">E Gilboa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boczkowski, D" uniqKey="Boczkowski D">D Boczkowski</name></author><author><name sortKey="Nair, Sk" uniqKey="Nair S">SK Nair</name></author><author><name sortKey="Snyder, D" uniqKey="Snyder D">D Snyder</name></author><author><name sortKey="Gilboa, E" uniqKey="Gilboa E">E Gilboa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ashley, Dm" uniqKey="Ashley D">DM Ashley</name></author><author><name sortKey="Faiola, B" uniqKey="Faiola B">B Faiola</name></author><author><name sortKey="Nair, S" uniqKey="Nair S">S Nair</name></author><author><name sortKey="Hale, Lp" uniqKey="Hale L">LP Hale</name></author><author><name sortKey="Bigner, Dd" uniqKey="Bigner D">DD Bigner</name></author><author><name sortKey="Gilboa, E" uniqKey="Gilboa E">E Gilboa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garg, Nk" uniqKey="Garg N">NK Garg</name></author><author><name sortKey="Dwivedi, P" uniqKey="Dwivedi P">P Dwivedi</name></author><author><name sortKey="Prabha, P" uniqKey="Prabha P">P Prabha</name></author><author><name sortKey="Tyagi, Rk" uniqKey="Tyagi R">RK Tyagi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schmidt, T" uniqKey="Schmidt T">T Schmidt</name></author><author><name sortKey="Ziske, C" uniqKey="Ziske C">C Ziske</name></author><author><name sortKey="Marten, A" uniqKey="Marten A">A Marten</name></author><author><name sortKey="Endres, S" uniqKey="Endres S">S Endres</name></author><author><name sortKey="Tiemann, K" uniqKey="Tiemann K">K Tiemann</name></author><author><name sortKey="Schmitz, V" uniqKey="Schmitz V">V Schmitz</name></author><author><name sortKey="Gorschluter, M" uniqKey="Gorschluter M">M Gorschluter</name></author><author><name sortKey="Schneider, C" uniqKey="Schneider C">C Schneider</name></author><author><name sortKey="Sauerbruch, T" uniqKey="Sauerbruch T">T Sauerbruch</name></author><author><name sortKey="Schmidt Wolf, Ig" uniqKey="Schmidt Wolf I">IG Schmidt-Wolf</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Celluzzi, Cm" uniqKey="Celluzzi C">CM Celluzzi</name></author><author><name sortKey="Falo, Ld" uniqKey="Falo L">LD Falo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Saffold, S" uniqKey="Saffold S">S Saffold</name></author><author><name sortKey="Cao, X" uniqKey="Cao X">X Cao</name></author><author><name sortKey="Krauss, J" uniqKey="Krauss J">J Krauss</name></author><author><name sortKey="Chen, W" uniqKey="Chen W">W Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Orentas, Rj" uniqKey="Orentas R">RJ Orentas</name></author><author><name sortKey="Schauer, D" uniqKey="Schauer D">D Schauer</name></author><author><name sortKey="Bin, Q" uniqKey="Bin Q">Q Bin</name></author><author><name sortKey="Johnson, Bd" uniqKey="Johnson B">BD Johnson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koido, S" uniqKey="Koido S">S Koido</name></author><author><name sortKey="Homma, S" uniqKey="Homma S">S Homma</name></author><author><name sortKey="Okamoto, M" uniqKey="Okamoto M">M Okamoto</name></author><author><name sortKey="Namiki, Y" uniqKey="Namiki Y">Y Namiki</name></author><author><name sortKey="Kan, S" uniqKey="Kan S">S Kan</name></author><author><name sortKey="Takakura, K" uniqKey="Takakura K">K Takakura</name></author><author><name sortKey="Kajihara, M" uniqKey="Kajihara M">M Kajihara</name></author><author><name sortKey="Uchiyama, K" uniqKey="Uchiyama K">K Uchiyama</name></author><author><name sortKey="Hara, E" uniqKey="Hara E">E Hara</name></author><author><name sortKey="Ohkusa, T" uniqKey="Ohkusa T">T Ohkusa</name></author><author><name sortKey="Gong, J" uniqKey="Gong J">J Gong</name></author><author><name sortKey="Tajiri, H" uniqKey="Tajiri H">H Tajiri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koido, S" uniqKey="Koido S">S Koido</name></author><author><name sortKey="Homma, S" uniqKey="Homma S">S Homma</name></author><author><name sortKey="Okamoto, M" uniqKey="Okamoto M">M Okamoto</name></author><author><name sortKey="Namiki, Y" uniqKey="Namiki Y">Y Namiki</name></author><author><name sortKey="Takakura, K" uniqKey="Takakura K">K Takakura</name></author><author><name sortKey="Uchiyama, K" uniqKey="Uchiyama K">K Uchiyama</name></author><author><name sortKey="Kajihara, M" uniqKey="Kajihara M">M Kajihara</name></author><author><name sortKey="Arihiro, S" uniqKey="Arihiro S">S Arihiro</name></author><author><name sortKey="Imazu, H" uniqKey="Imazu H">H Imazu</name></author><author><name sortKey="Arakawa, H" uniqKey="Arakawa H">H Arakawa</name></author><author><name sortKey="Kan, S" uniqKey="Kan S">S Kan</name></author><author><name sortKey="Komita, H" uniqKey="Komita H">H Komita</name></author><author><name sortKey="Ito, M" uniqKey="Ito M">M Ito</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koido, S" uniqKey="Koido S">S Koido</name></author><author><name sortKey="Homma, S" uniqKey="Homma S">S Homma</name></author><author><name sortKey="Okamoto, M" uniqKey="Okamoto M">M Okamoto</name></author><author><name sortKey="Namiki, Y" uniqKey="Namiki Y">Y Namiki</name></author><author><name sortKey="Takakura, K" uniqKey="Takakura K">K Takakura</name></author><author><name sortKey="Uchiyama, K" uniqKey="Uchiyama K">K Uchiyama</name></author><author><name sortKey="Kajihara, M" uniqKey="Kajihara M">M Kajihara</name></author><author><name sortKey="Arihiro, S" uniqKey="Arihiro S">S Arihiro</name></author><author><name sortKey="Imazu, H" uniqKey="Imazu H">H Imazu</name></author><author><name sortKey="Arakawa, H" uniqKey="Arakawa H">H Arakawa</name></author><author><name sortKey="Kan, S" uniqKey="Kan S">S Kan</name></author><author><name sortKey="Komita, H" uniqKey="Komita H">H Komita</name></author><author><name sortKey="Kamata, Y" uniqKey="Kamata Y">Y Kamata</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bonifaz, Lc" uniqKey="Bonifaz L">LC Bonifaz</name></author><author><name sortKey="Bonnyay, Dp" uniqKey="Bonnyay D">DP Bonnyay</name></author><author><name sortKey="Charalambous, A" uniqKey="Charalambous A">A Charalambous</name></author><author><name sortKey="Darguste, Di" uniqKey="Darguste D">DI Darguste</name></author><author><name sortKey="Fujii, S" uniqKey="Fujii S">S Fujii</name></author><author><name sortKey="Soares, H" uniqKey="Soares H">H Soares</name></author><author><name sortKey="Brimnes, Mk" uniqKey="Brimnes M">MK Brimnes</name></author><author><name sortKey="Moltedo, B" uniqKey="Moltedo B">B Moltedo</name></author><author><name sortKey="Moran, Tm" uniqKey="Moran T">TM Moran</name></author><author><name sortKey="Steinman, Rm" uniqKey="Steinman R">RM Steinman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berraondo, P" uniqKey="Berraondo P">P Berraondo</name></author><author><name sortKey="Nouze, C" uniqKey="Nouze C">C Nouze</name></author><author><name sortKey="Preville, X" uniqKey="Preville X">X Preville</name></author><author><name sortKey="Ladant, D" uniqKey="Ladant D">D Ladant</name></author><author><name sortKey="Leclerc, C" uniqKey="Leclerc C">C Leclerc</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Klechevsky, E" uniqKey="Klechevsky E">E Klechevsky</name></author><author><name sortKey="Flamar, Al" uniqKey="Flamar A">AL Flamar</name></author><author><name sortKey="Cao, Y" uniqKey="Cao Y">Y Cao</name></author><author><name sortKey="Blanck, Jp" uniqKey="Blanck J">JP Blanck</name></author><author><name sortKey="Liu, M" uniqKey="Liu M">M Liu</name></author><author><name sortKey="O Bar, A" uniqKey="O Bar A">A O'Bar</name></author><author><name sortKey="Agouna Deciat, O" uniqKey="Agouna Deciat O">O Agouna-Deciat</name></author><author><name sortKey="Klucar, P" uniqKey="Klucar P">P Klucar</name></author><author><name sortKey="Thompson Snipes, L" uniqKey="Thompson Snipes L">L Thompson-Snipes</name></author><author><name sortKey="Zurawski, S" uniqKey="Zurawski S">S Zurawski</name></author><author><name sortKey="Reiter, Y" uniqKey="Reiter Y">Y Reiter</name></author><author><name sortKey="Palucka, Ak" uniqKey="Palucka A">AK Palucka</name></author><author><name sortKey="Zurawski, G" uniqKey="Zurawski G">G Zurawski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schreibelt, G" uniqKey="Schreibelt G">G Schreibelt</name></author><author><name sortKey="Klinkenberg, Lj" uniqKey="Klinkenberg L">LJ Klinkenberg</name></author><author><name sortKey="Cruz, Lj" uniqKey="Cruz L">LJ Cruz</name></author><author><name sortKey="Tacken, Pj" uniqKey="Tacken P">PJ Tacken</name></author><author><name sortKey="Tel, J" uniqKey="Tel J">J Tel</name></author><author><name sortKey="Kreutz, M" uniqKey="Kreutz M">M Kreutz</name></author><author><name sortKey="Adema, Gj" uniqKey="Adema G">GJ Adema</name></author><author><name sortKey="Brown, Gd" uniqKey="Brown G">GD Brown</name></author><author><name sortKey="Figdor, Cg" uniqKey="Figdor C">CG Figdor</name></author><author><name sortKey="De Vries, Ij" uniqKey="De Vries I">IJ de Vries</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tacken, Pj" uniqKey="Tacken P">PJ Tacken</name></author><author><name sortKey="Ginter, W" uniqKey="Ginter W">W Ginter</name></author><author><name sortKey="Berod, L" uniqKey="Berod L">L Berod</name></author><author><name sortKey="Cruz, Lj" uniqKey="Cruz L">LJ Cruz</name></author><author><name sortKey="Joosten, B" uniqKey="Joosten B">B Joosten</name></author><author><name sortKey="Sparwasser, T" uniqKey="Sparwasser T">T Sparwasser</name></author><author><name sortKey="Figdor, Cg" uniqKey="Figdor C">CG Figdor</name></author><author><name sortKey="Cambi, A" uniqKey="Cambi A">A Cambi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tacken, Pj" uniqKey="Tacken P">PJ Tacken</name></author><author><name sortKey="Zeelenberg, Is" uniqKey="Zeelenberg I">IS Zeelenberg</name></author><author><name sortKey="Cruz, Lj" uniqKey="Cruz L">LJ Cruz</name></author><author><name sortKey="Van Hout Kuijer, Ma" uniqKey="Van Hout Kuijer M">MA van Hout-Kuijer</name></author><author><name sortKey="Van De Glind, G" uniqKey="Van De Glind G">G van de Glind</name></author><author><name sortKey="Fokkink, Rg" uniqKey="Fokkink R">RG Fokkink</name></author><author><name sortKey="Lambeck, Aj" uniqKey="Lambeck A">AJ Lambeck</name></author><author><name sortKey="Figdor, Cg" uniqKey="Figdor C">CG Figdor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, B" uniqKey="Wang B">B Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcia Vallejo, Jj" uniqKey="Garcia Vallejo J">JJ Garcia-Vallejo</name></author><author><name sortKey="Unger, Ww" uniqKey="Unger W">WW Unger</name></author><author><name sortKey="Kalay, H" uniqKey="Kalay H">H Kalay</name></author><author><name sortKey="Van Kooyk, Y" uniqKey="Van Kooyk Y">Y van Kooyk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Regnault, A" uniqKey="Regnault A">A Regnault</name></author><author><name sortKey="Lozier, A" uniqKey="Lozier A">A Lozier</name></author><author><name sortKey="Wolfers, J" uniqKey="Wolfers J">J Wolfers</name></author><author><name sortKey="Flament, C" uniqKey="Flament C">C Flament</name></author><author><name sortKey="Tenza, D" uniqKey="Tenza D">D Tenza</name></author><author><name sortKey="Ricciardi Castagnoli, P" uniqKey="Ricciardi Castagnoli P">P Ricciardi-Castagnoli</name></author><author><name sortKey="Raposo, G" uniqKey="Raposo G">G Raposo</name></author><author><name sortKey="Amigorena, S" uniqKey="Amigorena S">S Amigorena</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Viaud, S" uniqKey="Viaud S">S Viaud</name></author><author><name sortKey="Thery, C" uniqKey="Thery C">C Thery</name></author><author><name sortKey="Ploix, S" uniqKey="Ploix S">S Ploix</name></author><author><name sortKey="Tursz, T" uniqKey="Tursz T">T Tursz</name></author><author><name sortKey="Lapierre, V" uniqKey="Lapierre V">V Lapierre</name></author><author><name sortKey="Lantz, O" uniqKey="Lantz O">O Lantz</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Chaput, N" uniqKey="Chaput N">N Chaput</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munich, S" uniqKey="Munich S">S Munich</name></author><author><name sortKey="Sobo Vujanovic, A" uniqKey="Sobo Vujanovic A">A Sobo-Vujanovic</name></author><author><name sortKey="Buchser, Wj" uniqKey="Buchser W">WJ Buchser</name></author><author><name sortKey="Beer Stolz, D" uniqKey="Beer Stolz D">D Beer-Stolz</name></author><author><name sortKey="Vujanovic, Nl" uniqKey="Vujanovic N">NL Vujanovic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Satoh, Y" uniqKey="Satoh Y">Y Satoh</name></author><author><name sortKey="Esche, C" uniqKey="Esche C">C Esche</name></author><author><name sortKey="Gambotto, A" uniqKey="Gambotto A">A Gambotto</name></author><author><name sortKey="Shurin, Gv" uniqKey="Shurin G">GV Shurin</name></author><author><name sortKey="Yurkovetsky, Zr" uniqKey="Yurkovetsky Z">ZR Yurkovetsky</name></author><author><name sortKey="Robbins, Pd" uniqKey="Robbins P">PD Robbins</name></author><author><name sortKey="Watkins, Sc" uniqKey="Watkins S">SC Watkins</name></author><author><name sortKey="Todo, S" uniqKey="Todo S">S Todo</name></author><author><name sortKey="Herberman, Rb" uniqKey="Herberman R">RB Herberman</name></author><author><name sortKey="Lotze, Mt" uniqKey="Lotze M">MT Lotze</name></author><author><name sortKey="Shurin, Mr" uniqKey="Shurin M">MR Shurin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nishioka, Y" uniqKey="Nishioka Y">Y Nishioka</name></author><author><name sortKey="Hirao, M" uniqKey="Hirao M">M Hirao</name></author><author><name sortKey="Robbins, Pd" uniqKey="Robbins P">PD Robbins</name></author><author><name sortKey="Lotze, Mt" uniqKey="Lotze M">MT Lotze</name></author><author><name sortKey="Tahara, H" uniqKey="Tahara H">H Tahara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Endo, H" uniqKey="Endo H">H Endo</name></author><author><name sortKey="Saito, T" uniqKey="Saito T">T Saito</name></author><author><name sortKey="Kenjo, A" uniqKey="Kenjo A">A Kenjo</name></author><author><name sortKey="Hoshino, M" uniqKey="Hoshino M">M Hoshino</name></author><author><name sortKey="Terashima, M" uniqKey="Terashima M">M Terashima</name></author><author><name sortKey="Sato, T" uniqKey="Sato T">T Sato</name></author><author><name sortKey="Anazawa, T" uniqKey="Anazawa T">T Anazawa</name></author><author><name sortKey="Kimura, T" uniqKey="Kimura T">T Kimura</name></author><author><name sortKey="Tsuchiya, T" uniqKey="Tsuchiya T">T Tsuchiya</name></author><author><name sortKey="Irisawa, A" uniqKey="Irisawa A">A Irisawa</name></author><author><name sortKey="Ohira, H" uniqKey="Ohira H">H Ohira</name></author><author><name sortKey="Hikichi, T" uniqKey="Hikichi T">T Hikichi</name></author><author><name sortKey="Takagi, T" uniqKey="Takagi T">T Takagi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="You, Cx" uniqKey="You C">CX You</name></author><author><name sortKey="Shi, M" uniqKey="Shi M">M Shi</name></author><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Cao, M" uniqKey="Cao M">M Cao</name></author><author><name sortKey="Luo, R" uniqKey="Luo R">R Luo</name></author><author><name sortKey="Hermonat, Pl" uniqKey="Hermonat P">PL Hermonat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bol, Kf" uniqKey="Bol K">KF Bol</name></author><author><name sortKey="Tel, J" uniqKey="Tel J">J Tel</name></author><author><name sortKey="De Vries, Ij" uniqKey="De Vries I">IJ de Vries</name></author><author><name sortKey="Figdor, Cg" uniqKey="Figdor C">CG Figdor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harfuddin, Z" uniqKey="Harfuddin Z">Z Harfuddin</name></author><author><name sortKey="Kwajah, S" uniqKey="Kwajah S">S Kwajah</name></author><author><name sortKey="Chong Nyi Sim, A" uniqKey="Chong Nyi Sim A">A Chong Nyi Sim</name></author><author><name sortKey="Macary, Pa" uniqKey="Macary P">PA Macary</name></author><author><name sortKey="Schwarz, H" uniqKey="Schwarz H">H Schwarz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tacken, Pj" uniqKey="Tacken P">PJ Tacken</name></author><author><name sortKey="De Vries, Ij" uniqKey="De Vries I">IJ de Vries</name></author><author><name sortKey="Gijzen, K" uniqKey="Gijzen K">K Gijzen</name></author><author><name sortKey="Joosten, B" uniqKey="Joosten B">B Joosten</name></author><author><name sortKey="Wu, D" uniqKey="Wu D">D Wu</name></author><author><name sortKey="Rother, Rp" uniqKey="Rother R">RP Rother</name></author><author><name sortKey="Faas, Sj" uniqKey="Faas S">SJ Faas</name></author><author><name sortKey="Punt, Cj" uniqKey="Punt C">CJ Punt</name></author><author><name sortKey="Torensma, R" uniqKey="Torensma R">R Torensma</name></author><author><name sortKey="Adema, Gj" uniqKey="Adema G">GJ Adema</name></author><author><name sortKey="Figdor, Cg" uniqKey="Figdor C">CG Figdor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haicheur, N" uniqKey="Haicheur N">N Haicheur</name></author><author><name sortKey="Bismuth, E" uniqKey="Bismuth E">E Bismuth</name></author><author><name sortKey="Bosset, S" uniqKey="Bosset S">S Bosset</name></author><author><name sortKey="Adotevi, O" uniqKey="Adotevi O">O Adotevi</name></author><author><name sortKey="Warnier, G" uniqKey="Warnier G">G Warnier</name></author><author><name sortKey="Lacabanne, V" uniqKey="Lacabanne V">V Lacabanne</name></author><author><name sortKey="Regnault, A" uniqKey="Regnault A">A Regnault</name></author><author><name sortKey="Desaymard, C" uniqKey="Desaymard C">C Desaymard</name></author><author><name sortKey="Amigorena, S" uniqKey="Amigorena S">S Amigorena</name></author><author><name sortKey="Ricciardi Castagnoli, P" uniqKey="Ricciardi Castagnoli P">P Ricciardi-Castagnoli</name></author><author><name sortKey="Goud, B" uniqKey="Goud B">B Goud</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Johannes, L" uniqKey="Johannes L">L Johannes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Broekhoven, Cl" uniqKey="Van Broekhoven C">CL van Broekhoven</name></author><author><name sortKey="Parish, Cr" uniqKey="Parish C">CR Parish</name></author><author><name sortKey="Demangel, C" uniqKey="Demangel C">C Demangel</name></author><author><name sortKey="Britton, Wj" uniqKey="Britton W">WJ Britton</name></author><author><name sortKey="Altin, Jg" uniqKey="Altin J">JG Altin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Badiee, A" uniqKey="Badiee A">A Badiee</name></author><author><name sortKey="Davies, N" uniqKey="Davies N">N Davies</name></author><author><name sortKey="Mcdonald, K" uniqKey="Mcdonald K">K McDonald</name></author><author><name sortKey="Radford, K" uniqKey="Radford K">K Radford</name></author><author><name sortKey="Michiue, H" uniqKey="Michiue H">H Michiue</name></author><author><name sortKey="Hart, D" uniqKey="Hart D">D Hart</name></author><author><name sortKey="Kato, M" uniqKey="Kato M">M Kato</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, L" uniqKey="Yang L">L Yang</name></author><author><name sortKey="Yang, H" uniqKey="Yang H">H Yang</name></author><author><name sortKey="Rideout, K" uniqKey="Rideout K">K Rideout</name></author><author><name sortKey="Cho, T" uniqKey="Cho T">T Cho</name></author><author><name sortKey="Joo, Ki" uniqKey="Joo K">KI Joo</name></author><author><name sortKey="Ziegler, L" uniqKey="Ziegler L">L Ziegler</name></author><author><name sortKey="Elliot, A" uniqKey="Elliot A">A Elliot</name></author><author><name sortKey="Walls, A" uniqKey="Walls A">A Walls</name></author><author><name sortKey="Yu, D" uniqKey="Yu D">D Yu</name></author><author><name sortKey="Baltimore, D" uniqKey="Baltimore D">D Baltimore</name></author><author><name sortKey="Wang, P" uniqKey="Wang P">P Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hangalapura, Bn" uniqKey="Hangalapura B">BN Hangalapura</name></author><author><name sortKey="Oosterhoff, D" uniqKey="Oosterhoff D">D Oosterhoff</name></author><author><name sortKey="De Groot, J" uniqKey="De Groot J">J de Groot</name></author><author><name sortKey="Boon, L" uniqKey="Boon L">L Boon</name></author><author><name sortKey="Tuting, T" uniqKey="Tuting T">T Tuting</name></author><author><name sortKey="Van Den Eertwegh, Aj" uniqKey="Van Den Eertwegh A">AJ van den Eertwegh</name></author><author><name sortKey="Gerritsen, Wr" uniqKey="Gerritsen W">WR Gerritsen</name></author><author><name sortKey="Van Beusechem, Vw" uniqKey="Van Beusechem V">VW van Beusechem</name></author><author><name sortKey="Pereboev, A" uniqKey="Pereboev A">A Pereboev</name></author><author><name sortKey="Curiel, Dt" uniqKey="Curiel D">DT Curiel</name></author><author><name sortKey="Scheper, Rj" uniqKey="Scheper R">RJ Scheper</name></author><author><name sortKey="De Gruijl, Td" uniqKey="De Gruijl T">TD de Gruijl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Korokhov, N" uniqKey="Korokhov N">N Korokhov</name></author><author><name sortKey="De Gruijl, Td" uniqKey="De Gruijl T">TD de Gruijl</name></author><author><name sortKey="Aldrich, Wa" uniqKey="Aldrich W">WA Aldrich</name></author><author><name sortKey="Triozzi, Pl" uniqKey="Triozzi P">PL Triozzi</name></author><author><name sortKey="Banerjee, Pt" uniqKey="Banerjee P">PT Banerjee</name></author><author><name sortKey="Gillies, Sd" uniqKey="Gillies S">SD Gillies</name></author><author><name sortKey="Curiel, Tj" uniqKey="Curiel T">TJ Curiel</name></author><author><name sortKey="Douglas, Jt" uniqKey="Douglas J">JT Douglas</name></author><author><name sortKey="Scheper, Rj" uniqKey="Scheper R">RJ Scheper</name></author><author><name sortKey="Curiel, Dt" uniqKey="Curiel D">DT Curiel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kantoff, Pw" uniqKey="Kantoff P">PW Kantoff</name></author><author><name sortKey="Higano, Cs" uniqKey="Higano C">CS Higano</name></author><author><name sortKey="Shore, Nd" uniqKey="Shore N">ND Shore</name></author><author><name sortKey="Berger, Er" uniqKey="Berger E">ER Berger</name></author><author><name sortKey="Small, Ej" uniqKey="Small E">EJ Small</name></author><author><name sortKey="Penson, Df" uniqKey="Penson D">DF Penson</name></author><author><name sortKey="Redfern, Ch" uniqKey="Redfern C">CH Redfern</name></author><author><name sortKey="Ferrari, Ac" uniqKey="Ferrari A">AC Ferrari</name></author><author><name sortKey="Dreicer, R" uniqKey="Dreicer R">R Dreicer</name></author><author><name sortKey="Sims, Rb" uniqKey="Sims R">RB Sims</name></author><author><name sortKey="Xu, Y" uniqKey="Xu Y">Y Xu</name></author><author><name sortKey="Frohlich, Mw" uniqKey="Frohlich M">MW Frohlich</name></author><author><name sortKey="Schellhammer, Pf" uniqKey="Schellhammer P">PF Schellhammer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Higano, Cs" uniqKey="Higano C">CS Higano</name></author><author><name sortKey="Small, Ej" uniqKey="Small E">EJ Small</name></author><author><name sortKey="Schellhammer, P" uniqKey="Schellhammer P">P Schellhammer</name></author><author><name sortKey="Yasothan, U" uniqKey="Yasothan U">U Yasothan</name></author><author><name sortKey="Gubernick, S" uniqKey="Gubernick S">S Gubernick</name></author><author><name sortKey="Kirkpatrick, P" uniqKey="Kirkpatrick P">P Kirkpatrick</name></author><author><name sortKey="Kantoff, Pw" uniqKey="Kantoff P">PW Kantoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Palucka, K" uniqKey="Palucka K">K Palucka</name></author><author><name sortKey="Banchereau, J" uniqKey="Banchereau J">J Banchereau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lakomy, D" uniqKey="Lakomy D">D Lakomy</name></author><author><name sortKey="Janikashvili, N" uniqKey="Janikashvili N">N Janikashvili</name></author><author><name sortKey="Fraszczak, J" uniqKey="Fraszczak J">J Fraszczak</name></author><author><name sortKey="Trad, M" uniqKey="Trad M">M Trad</name></author><author><name sortKey="Audia, S" uniqKey="Audia S">S Audia</name></author><author><name sortKey="Samson, M" uniqKey="Samson M">M Samson</name></author><author><name sortKey="Ciudad, M" uniqKey="Ciudad M">M Ciudad</name></author><author><name sortKey="Vinit, J" uniqKey="Vinit J">J Vinit</name></author><author><name sortKey="Vergely, C" uniqKey="Vergely C">C Vergely</name></author><author><name sortKey="Caillot, D" uniqKey="Caillot D">D Caillot</name></author><author><name sortKey="Foucher, P" uniqKey="Foucher P">P Foucher</name></author><author><name sortKey="Lagrost, L" uniqKey="Lagrost L">L Lagrost</name></author><author><name sortKey="Chouaib, S" uniqKey="Chouaib S">S Chouaib</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Figdor, Cg" uniqKey="Figdor C">CG Figdor</name></author><author><name sortKey="De Vries, Ij" uniqKey="De Vries I">IJ de Vries</name></author><author><name sortKey="Lesterhuis, Wj" uniqKey="Lesterhuis W">WJ Lesterhuis</name></author><author><name sortKey="Melief, Cj" uniqKey="Melief C">CJ Melief</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gilboa, E" uniqKey="Gilboa E">E Gilboa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senovilla, L" uniqKey="Senovilla L">L Senovilla</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Garcia, P" uniqKey="Garcia P">P Garcia</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aranda, F" uniqKey="Aranda F">F Aranda</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aruga, A" uniqKey="Aruga A">A Aruga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ricupito, A" uniqKey="Ricupito A">A Ricupito</name></author><author><name sortKey="Grioni, M" uniqKey="Grioni M">M Grioni</name></author><author><name sortKey="Calcinotto, A" uniqKey="Calcinotto A">A Calcinotto</name></author><author><name sortKey="Bellone, M" uniqKey="Bellone M">M Bellone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hailemichael, Y" uniqKey="Hailemichael Y">Y Hailemichael</name></author><author><name sortKey="Overwijk, Ww" uniqKey="Overwijk W">WW Overwijk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bijker, Ms" uniqKey="Bijker M">MS Bijker</name></author><author><name sortKey="Melief, Cj" uniqKey="Melief C">CJ Melief</name></author><author><name sortKey="Offringa, R" uniqKey="Offringa R">R Offringa</name></author><author><name sortKey="Van Der Burg, Sh" uniqKey="Van Der Burg S">SH van der Burg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yaddanapudi, K" uniqKey="Yaddanapudi K">K Yaddanapudi</name></author><author><name sortKey="Mitchell, Ra" uniqKey="Mitchell R">RA Mitchell</name></author><author><name sortKey="Eaton, Jw" uniqKey="Eaton J">JW Eaton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Valmori, D" uniqKey="Valmori D">D Valmori</name></author><author><name sortKey="Souleimanian, Ne" uniqKey="Souleimanian N">NE Souleimanian</name></author><author><name sortKey="Tosello, V" uniqKey="Tosello V">V Tosello</name></author><author><name sortKey="Bhardwaj, N" uniqKey="Bhardwaj N">N Bhardwaj</name></author><author><name sortKey="Adams, S" uniqKey="Adams S">S Adams</name></author><author><name sortKey="O Neill, D" uniqKey="O Neill D">D O'Neill</name></author><author><name sortKey="Pavlick, A" uniqKey="Pavlick A">A Pavlick</name></author><author><name sortKey="Escalon, Jb" uniqKey="Escalon J">JB Escalon</name></author><author><name sortKey="Cruz, Cm" uniqKey="Cruz C">CM Cruz</name></author><author><name sortKey="Angiulli, A" uniqKey="Angiulli A">A Angiulli</name></author><author><name sortKey="Angiulli, F" uniqKey="Angiulli F">F Angiulli</name></author><author><name sortKey="Mears, G" uniqKey="Mears G">G Mears</name></author><author><name sortKey="Vogel, Sm" uniqKey="Vogel S">SM Vogel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Melero, I" uniqKey="Melero I">I Melero</name></author><author><name sortKey="Gaudernack, G" uniqKey="Gaudernack G">G Gaudernack</name></author><author><name sortKey="Gerritsen, W" uniqKey="Gerritsen W">W Gerritsen</name></author><author><name sortKey="Huber, C" uniqKey="Huber C">C Huber</name></author><author><name sortKey="Parmiani, G" uniqKey="Parmiani G">G Parmiani</name></author><author><name sortKey="Scholl, S" uniqKey="Scholl S">S Scholl</name></author><author><name sortKey="Thatcher, N" uniqKey="Thatcher N">N Thatcher</name></author><author><name sortKey="Wagstaff, J" uniqKey="Wagstaff J">J Wagstaff</name></author><author><name sortKey="Zielinski, C" uniqKey="Zielinski C">C Zielinski</name></author><author><name sortKey="Faulkner, I" uniqKey="Faulkner I">I Faulkner</name></author><author><name sortKey="Mellstedt, H" uniqKey="Mellstedt H">H Mellstedt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Binder, Dc" uniqKey="Binder D">DC Binder</name></author><author><name sortKey="Schreiber, H" uniqKey="Schreiber H">H Schreiber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bijker, Ms" uniqKey="Bijker M">MS Bijker</name></author><author><name sortKey="Van Den Eeden, Sj" uniqKey="Van Den Eeden S">SJ van den Eeden</name></author><author><name sortKey="Franken, Kl" uniqKey="Franken K">KL Franken</name></author><author><name sortKey="Melief, Cj" uniqKey="Melief C">CJ Melief</name></author><author><name sortKey="Offringa, R" uniqKey="Offringa R">R Offringa</name></author><author><name sortKey="Van Der Burg, Sh" uniqKey="Van Der Burg S">SH van der Burg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zom, Gg" uniqKey="Zom G">GG Zom</name></author><author><name sortKey="Khan, S" uniqKey="Khan S">S Khan</name></author><author><name sortKey="Britten, Cm" uniqKey="Britten C">CM Britten</name></author><author><name sortKey="Sommandas, V" uniqKey="Sommandas V">V Sommandas</name></author><author><name sortKey="Camps, Mg" uniqKey="Camps M">MG Camps</name></author><author><name sortKey="Loof, Nm" uniqKey="Loof N">NM Loof</name></author><author><name sortKey="Budden, Cf" uniqKey="Budden C">CF Budden</name></author><author><name sortKey="Meeuwenoord, Nj" uniqKey="Meeuwenoord N">NJ Meeuwenoord</name></author><author><name sortKey="Filippov, Dv" uniqKey="Filippov D">DV Filippov</name></author><author><name sortKey="Van Der Marel, Ga" uniqKey="Van Der Marel G">GA van der Marel</name></author><author><name sortKey="Overkleeft, Hs" uniqKey="Overkleeft H">HS Overkleeft</name></author><author><name sortKey="Melief, Cj" uniqKey="Melief C">CJ Melief</name></author><author><name sortKey="Ossendorp, F" uniqKey="Ossendorp F">F Ossendorp</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hailemichael, Y" uniqKey="Hailemichael Y">Y Hailemichael</name></author><author><name sortKey="Dai, Z" uniqKey="Dai Z">Z Dai</name></author><author><name sortKey="Jaffarzad, N" uniqKey="Jaffarzad N">N Jaffarzad</name></author><author><name sortKey="Ye, Y" uniqKey="Ye Y">Y Ye</name></author><author><name sortKey="Medina, Ma" uniqKey="Medina M">MA Medina</name></author><author><name sortKey="Huang, Xf" uniqKey="Huang X">XF Huang</name></author><author><name sortKey="Dorta Estremera, Sm" uniqKey="Dorta Estremera S">SM Dorta-Estremera</name></author><author><name sortKey="Greeley, Nr" uniqKey="Greeley N">NR Greeley</name></author><author><name sortKey="Nitti, G" uniqKey="Nitti G">G Nitti</name></author><author><name sortKey="Peng, W" uniqKey="Peng W">W Peng</name></author><author><name sortKey="Liu, C" uniqKey="Liu C">C Liu</name></author><author><name sortKey="Lou, Y" uniqKey="Lou Y">Y Lou</name></author><author><name sortKey="Wang, Z" uniqKey="Wang Z">Z Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ciocca, Dr" uniqKey="Ciocca D">DR Ciocca</name></author><author><name sortKey="Cayado Gutierrez, N" uniqKey="Cayado Gutierrez N">N Cayado-Gutierrez</name></author><author><name sortKey="Maccioni, M" uniqKey="Maccioni M">M Maccioni</name></author><author><name sortKey="Cuello Carrion, Fd" uniqKey="Cuello Carrion F">FD Cuello-Carrion</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fioretti, D" uniqKey="Fioretti D">D Fioretti</name></author><author><name sortKey="Iurescia, S" uniqKey="Iurescia S">S Iurescia</name></author><author><name sortKey="Fazio, Vm" uniqKey="Fazio V">VM Fazio</name></author><author><name sortKey="Rinaldi, M" uniqKey="Rinaldi M">M Rinaldi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Ma" uniqKey="Liu M">MA Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stevenson, Fk" uniqKey="Stevenson F">FK Stevenson</name></author><author><name sortKey="Ottensmeier, Ch" uniqKey="Ottensmeier C">CH Ottensmeier</name></author><author><name sortKey="Rice, J" uniqKey="Rice J">J Rice</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, Q" uniqKey="Zhou Q">Q Zhou</name></author><author><name sortKey="Buchholz, Cj" uniqKey="Buchholz C">CJ Buchholz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shirota, H" uniqKey="Shirota H">H Shirota</name></author><author><name sortKey="Petrenko, L" uniqKey="Petrenko L">L Petrenko</name></author><author><name sortKey="Hong, C" uniqKey="Hong C">C Hong</name></author><author><name sortKey="Klinman, Dm" uniqKey="Klinman D">DM Klinman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heath, Wr" uniqKey="Heath W">WR Heath</name></author><author><name sortKey="Belz, Gt" uniqKey="Belz G">GT Belz</name></author><author><name sortKey="Behrens, Gm" uniqKey="Behrens G">GM Behrens</name></author><author><name sortKey="Smith, Cm" uniqKey="Smith C">CM Smith</name></author><author><name sortKey="Forehan, Sp" uniqKey="Forehan S">SP Forehan</name></author><author><name sortKey="Parish, Ia" uniqKey="Parish I">IA Parish</name></author><author><name sortKey="Davey, Gm" uniqKey="Davey G">GM Davey</name></author><author><name sortKey="Wilson, Ns" uniqKey="Wilson N">NS Wilson</name></author><author><name sortKey="Carbone, Fr" uniqKey="Carbone F">FR Carbone</name></author><author><name sortKey="Villadangos, Ja" uniqKey="Villadangos J">JA Villadangos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pol, Jg" uniqKey="Pol J">JG Pol</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Bridle, Bw" uniqKey="Bridle B">BW Bridle</name></author><author><name sortKey="Stephenson, Kb" uniqKey="Stephenson K">KB Stephenson</name></author><author><name sortKey="Resseguier, J" uniqKey="Resseguier J">J Resseguier</name></author><author><name sortKey="Hanson, S" uniqKey="Hanson S">S Hanson</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author><author><name sortKey="Kazdhan, N" uniqKey="Kazdhan N">N Kazdhan</name></author><author><name sortKey="Bramson, Jl" uniqKey="Bramson J">JL Bramson</name></author><author><name sortKey="Stojdl, Df" uniqKey="Stojdl D">DF Stojdl</name></author><author><name sortKey="Wan, Y" uniqKey="Wan Y">Y Wan</name></author><author><name sortKey="Lichty, Bd" uniqKey="Lichty B">BD Lichty</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bridle, Bw" uniqKey="Bridle B">BW Bridle</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author><author><name sortKey="Lemay, Cg" uniqKey="Lemay C">CG Lemay</name></author><author><name sortKey="Diallo, Js" uniqKey="Diallo J">JS Diallo</name></author><author><name sortKey="Pol, J" uniqKey="Pol J">J Pol</name></author><author><name sortKey="Nguyen, A" uniqKey="Nguyen A">A Nguyen</name></author><author><name sortKey="Capretta, A" uniqKey="Capretta A">A Capretta</name></author><author><name sortKey="He, R" uniqKey="He R">R He</name></author><author><name sortKey="Bramson, Jl" uniqKey="Bramson J">JL Bramson</name></author><author><name sortKey="Bell, Jc" uniqKey="Bell J">JC Bell</name></author><author><name sortKey="Lichty, Bd" uniqKey="Lichty B">BD Lichty</name></author><author><name sortKey="Wan, Y" uniqKey="Wan Y">Y Wan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bridle, Bw" uniqKey="Bridle B">BW Bridle</name></author><author><name sortKey="Clouthier, D" uniqKey="Clouthier D">D Clouthier</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Pol, J" uniqKey="Pol J">J Pol</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author><author><name sortKey="Lichty, Bd" uniqKey="Lichty B">BD Lichty</name></author><author><name sortKey="Bramson, Jl" uniqKey="Bramson J">JL Bramson</name></author><author><name sortKey="Wan, Y" uniqKey="Wan Y">Y Wan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bolhassani, A" uniqKey="Bolhassani A">A Bolhassani</name></author><author><name sortKey="Zahedifard, F" uniqKey="Zahedifard F">F Zahedifard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gardlik, R" uniqKey="Gardlik R">R Gardlik</name></author><author><name sortKey="Fruehauf, Jh" uniqKey="Fruehauf J">JH Fruehauf</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moreno, M" uniqKey="Moreno M">M Moreno</name></author><author><name sortKey="Kramer, Mg" uniqKey="Kramer M">MG Kramer</name></author><author><name sortKey="Yim, L" uniqKey="Yim L">L Yim</name></author><author><name sortKey="Chabalgoity, Ja" uniqKey="Chabalgoity J">JA Chabalgoity</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Toussaint, B" uniqKey="Toussaint B">B Toussaint</name></author><author><name sortKey="Chauchet, X" uniqKey="Chauchet X">X Chauchet</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author><author><name sortKey="Polack, B" uniqKey="Polack B">B Polack</name></author><author><name sortKey="Le Gouellec, A" uniqKey="Le Gouellec A">A Le Gouellec</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wood, C" uniqKey="Wood C">C Wood</name></author><author><name sortKey="Srivastava, P" uniqKey="Srivastava P">P Srivastava</name></author><author><name sortKey="Bukowski, R" uniqKey="Bukowski R">R Bukowski</name></author><author><name sortKey="Lacombe, L" uniqKey="Lacombe L">L Lacombe</name></author><author><name sortKey="Gorelov, Ai" uniqKey="Gorelov A">AI Gorelov</name></author><author><name sortKey="Gorelov, S" uniqKey="Gorelov S">S Gorelov</name></author><author><name sortKey="Mulders, P" uniqKey="Mulders P">P Mulders</name></author><author><name sortKey="Zielinski, H" uniqKey="Zielinski H">H Zielinski</name></author><author><name sortKey="Hoos, A" uniqKey="Hoos A">A Hoos</name></author><author><name sortKey="Teofilovici, F" uniqKey="Teofilovici F">F Teofilovici</name></author><author><name sortKey="Isakov, L" uniqKey="Isakov L">L Isakov</name></author><author><name sortKey="Flanigan, R" uniqKey="Flanigan R">R Flanigan</name></author><author><name sortKey="Figlin, R" uniqKey="Figlin R">R Figlin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kenter, Gg" uniqKey="Kenter G">GG Kenter</name></author><author><name sortKey="Welters, Mj" uniqKey="Welters M">MJ Welters</name></author><author><name sortKey="Valentijn, Ar" uniqKey="Valentijn A">AR Valentijn</name></author><author><name sortKey="Lowik, Mj" uniqKey="Lowik M">MJ Lowik</name></author><author><name sortKey="Berends Van Der Meer, Dm" uniqKey="Berends Van Der Meer D">DM Berends-van der Meer</name></author><author><name sortKey="Vloon, Ap" uniqKey="Vloon A">AP Vloon</name></author><author><name sortKey="Essahsah, F" uniqKey="Essahsah F">F Essahsah</name></author><author><name sortKey="Fathers, Lm" uniqKey="Fathers L">LM Fathers</name></author><author><name sortKey="Offringa, R" uniqKey="Offringa R">R Offringa</name></author><author><name sortKey="Drijfhout, Jw" uniqKey="Drijfhout J">JW Drijfhout</name></author><author><name sortKey="Wafelman, Ar" uniqKey="Wafelman A">AR Wafelman</name></author><author><name sortKey="Oostendorp, J" uniqKey="Oostendorp J">J Oostendorp</name></author><author><name sortKey="Fleuren, Gj" uniqKey="Fleuren G">GJ Fleuren</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walter, S" uniqKey="Walter S">S Walter</name></author><author><name sortKey="Weinschenk, T" uniqKey="Weinschenk T">T Weinschenk</name></author><author><name sortKey="Stenzl, A" uniqKey="Stenzl A">A Stenzl</name></author><author><name sortKey="Zdrojowy, R" uniqKey="Zdrojowy R">R Zdrojowy</name></author><author><name sortKey="Pluzanska, A" uniqKey="Pluzanska A">A Pluzanska</name></author><author><name sortKey="Szczylik, C" uniqKey="Szczylik C">C Szczylik</name></author><author><name sortKey="Staehler, M" uniqKey="Staehler M">M Staehler</name></author><author><name sortKey="Brugger, W" uniqKey="Brugger W">W Brugger</name></author><author><name sortKey="Dietrich, Py" uniqKey="Dietrich P">PY Dietrich</name></author><author><name sortKey="Mendrzyk, R" uniqKey="Mendrzyk R">R Mendrzyk</name></author><author><name sortKey="Hilf, N" uniqKey="Hilf N">N Hilf</name></author><author><name sortKey="Schoor, O" uniqKey="Schoor O">O Schoor</name></author><author><name sortKey="Fritsche, J" uniqKey="Fritsche J">J Fritsche</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Davis, Bs" uniqKey="Davis B">BS Davis</name></author><author><name sortKey="Chang, Gj" uniqKey="Chang G">GJ Chang</name></author><author><name sortKey="Cropp, B" uniqKey="Cropp B">B Cropp</name></author><author><name sortKey="Roehrig, Jt" uniqKey="Roehrig J">JT Roehrig</name></author><author><name sortKey="Martin, Da" uniqKey="Martin D">DA Martin</name></author><author><name sortKey="Mitchell, Cj" uniqKey="Mitchell C">CJ Mitchell</name></author><author><name sortKey="Bowen, R" uniqKey="Bowen R">R Bowen</name></author><author><name sortKey="Bunning, Ml" uniqKey="Bunning M">ML Bunning</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Anderson, Ed" uniqKey="Anderson E">ED Anderson</name></author><author><name sortKey="Mourich, Dv" uniqKey="Mourich D">DV Mourich</name></author><author><name sortKey="Leong, Ja" uniqKey="Leong J">JA Leong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Anderson, Ed" uniqKey="Anderson E">ED Anderson</name></author><author><name sortKey="Mourich, Dv" uniqKey="Mourich D">DV Mourich</name></author><author><name sortKey="Fahrenkrug, Sc" uniqKey="Fahrenkrug S">SC Fahrenkrug</name></author><author><name sortKey="Lapatra, S" uniqKey="Lapatra S">S LaPatra</name></author><author><name sortKey="Shepherd, J" uniqKey="Shepherd J">J Shepherd</name></author><author><name sortKey="Leong, Ja" uniqKey="Leong J">JA Leong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bergman, Pj" uniqKey="Bergman P">PJ Bergman</name></author><author><name sortKey="Mcknight, J" uniqKey="Mcknight J">J McKnight</name></author><author><name sortKey="Novosad, A" uniqKey="Novosad A">A Novosad</name></author><author><name sortKey="Charney, S" uniqKey="Charney S">S Charney</name></author><author><name sortKey="Farrelly, J" uniqKey="Farrelly J">J Farrelly</name></author><author><name sortKey="Craft, D" uniqKey="Craft D">D Craft</name></author><author><name sortKey="Wulderk, M" uniqKey="Wulderk M">M Wulderk</name></author><author><name sortKey="Jeffers, Y" uniqKey="Jeffers Y">Y Jeffers</name></author><author><name sortKey="Sadelain, M" uniqKey="Sadelain M">M Sadelain</name></author><author><name sortKey="Hohenhaus, Ae" uniqKey="Hohenhaus A">AE Hohenhaus</name></author><author><name sortKey="Segal, N" uniqKey="Segal N">N Segal</name></author><author><name sortKey="Gregor, P" uniqKey="Gregor P">P Gregor</name></author><author><name sortKey="Engelhorn, M" uniqKey="Engelhorn M">M Engelhorn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tato, Cm" uniqKey="Tato C">CM Tato</name></author><author><name sortKey="Cua, Dj" uniqKey="Cua D">DJ Cua</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tato, Cm" uniqKey="Tato C">CM Tato</name></author><author><name sortKey="Cua, Dj" uniqKey="Cua D">DJ Cua</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tato, Cm" uniqKey="Tato C">CM Tato</name></author><author><name sortKey="Cua, Dj" uniqKey="Cua D">DJ Cua</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tato, Cm" uniqKey="Tato C">CM Tato</name></author><author><name sortKey="Cua, Dj" uniqKey="Cua D">DJ Cua</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Papatriantafyllou, M" uniqKey="Papatriantafyllou M">M Papatriantafyllou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, P" uniqKey="Chen P">P Chen</name></author><author><name sortKey="Balachandran, S" uniqKey="Balachandran S">S Balachandran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahmadzadeh, M" uniqKey="Ahmadzadeh M">M Ahmadzadeh</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cesana, Gc" uniqKey="Cesana G">GC Cesana</name></author><author><name sortKey="Deraffele, G" uniqKey="Deraffele G">G DeRaffele</name></author><author><name sortKey="Cohen, S" uniqKey="Cohen S">S Cohen</name></author><author><name sortKey="Moroziewicz, D" uniqKey="Moroziewicz D">D Moroziewicz</name></author><author><name sortKey="Mitcham, J" uniqKey="Mitcham J">J Mitcham</name></author><author><name sortKey="Stoutenburg, J" uniqKey="Stoutenburg J">J Stoutenburg</name></author><author><name sortKey="Cheung, K" uniqKey="Cheung K">K Cheung</name></author><author><name sortKey="Hesdorffer, C" uniqKey="Hesdorffer C">C Hesdorffer</name></author><author><name sortKey="Kim Schulze, S" uniqKey="Kim Schulze S">S Kim-Schulze</name></author><author><name sortKey="Kaufman, Hl" uniqKey="Kaufman H">HL Kaufman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sim, Gc" uniqKey="Sim G">GC Sim</name></author><author><name sortKey="Martin Orozco, N" uniqKey="Martin Orozco N">N Martin-Orozco</name></author><author><name sortKey="Jin, L" uniqKey="Jin L">L Jin</name></author><author><name sortKey="Yang, Y" uniqKey="Yang Y">Y Yang</name></author><author><name sortKey="Wu, S" uniqKey="Wu S">S Wu</name></author><author><name sortKey="Washington, E" uniqKey="Washington E">E Washington</name></author><author><name sortKey="Sanders, D" uniqKey="Sanders D">D Sanders</name></author><author><name sortKey="Lacey, C" uniqKey="Lacey C">C Lacey</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author><author><name sortKey="Vence, L" uniqKey="Vence L">L Vence</name></author><author><name sortKey="Hwu, P" uniqKey="Hwu P">P Hwu</name></author><author><name sortKey="Radvanyi, L" uniqKey="Radvanyi L">L Radvanyi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Camisaschi, C" uniqKey="Camisaschi C">C Camisaschi</name></author><author><name sortKey="Filipazzi, P" uniqKey="Filipazzi P">P Filipazzi</name></author><author><name sortKey="Tazzari, M" uniqKey="Tazzari M">M Tazzari</name></author><author><name sortKey="Casati, C" uniqKey="Casati C">C Casati</name></author><author><name sortKey="Beretta, V" uniqKey="Beretta V">V Beretta</name></author><author><name sortKey="Pilla, L" uniqKey="Pilla L">L Pilla</name></author><author><name sortKey="Patuzzo, R" uniqKey="Patuzzo R">R Patuzzo</name></author><author><name sortKey="Maurichi, A" uniqKey="Maurichi A">A Maurichi</name></author><author><name sortKey="Cova, A" uniqKey="Cova A">A Cova</name></author><author><name sortKey="Maio, M" uniqKey="Maio M">M Maio</name></author><author><name sortKey="Chiarion Sileni, V" uniqKey="Chiarion Sileni V">V Chiarion-Sileni</name></author><author><name sortKey="Tragni, G" uniqKey="Tragni G">G Tragni</name></author><author><name sortKey="Santinami, M" uniqKey="Santinami M">M Santinami</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tomov, B" uniqKey="Tomov B">B Tomov</name></author><author><name sortKey="Popov, D" uniqKey="Popov D">D Popov</name></author><author><name sortKey="Tomova, R" uniqKey="Tomova R">R Tomova</name></author><author><name sortKey="Vladov, N" uniqKey="Vladov N">N Vladov</name></author><author><name sortKey="Den Otter, W" uniqKey="Den Otter W">W Den Otter</name></author><author><name sortKey="Krastev, Z" uniqKey="Krastev Z">Z Krastev</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Robertson, Mj" uniqKey="Robertson M">MJ Robertson</name></author><author><name sortKey="Kline, J" uniqKey="Kline J">J Kline</name></author><author><name sortKey="Struemper, H" uniqKey="Struemper H">H Struemper</name></author><author><name sortKey="Koch, Km" uniqKey="Koch K">KM Koch</name></author><author><name sortKey="Bauman, Jw" uniqKey="Bauman J">JW Bauman</name></author><author><name sortKey="Gardner, Os" uniqKey="Gardner O">OS Gardner</name></author><author><name sortKey="Murray, Sc" uniqKey="Murray S">SC Murray</name></author><author><name sortKey="Germaschewski, F" uniqKey="Germaschewski F">F Germaschewski</name></author><author><name sortKey="Weisenbach, J" uniqKey="Weisenbach J">J Weisenbach</name></author><author><name sortKey="Jonak, Z" uniqKey="Jonak Z">Z Jonak</name></author><author><name sortKey="Toso, Jf" uniqKey="Toso J">JF Toso</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gorin, Nc" uniqKey="Gorin N">NC Gorin</name></author><author><name sortKey="Isnard, F" uniqKey="Isnard F">F Isnard</name></author><author><name sortKey="Garderet, L" uniqKey="Garderet L">L Garderet</name></author><author><name sortKey="Ikhlef, S" uniqKey="Ikhlef S">S Ikhlef</name></author><author><name sortKey="Corm, S" uniqKey="Corm S">S Corm</name></author><author><name sortKey="Quesnel, B" uniqKey="Quesnel B">B Quesnel</name></author><author><name sortKey="Legrand, O" uniqKey="Legrand O">O Legrand</name></author><author><name sortKey="Cachanado, M" uniqKey="Cachanado M">M Cachanado</name></author><author><name sortKey="Rousseau, A" uniqKey="Rousseau A">A Rousseau</name></author><author><name sortKey="Laporte, Jp" uniqKey="Laporte J">JP Laporte</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheung, Iy" uniqKey="Cheung I">IY Cheung</name></author><author><name sortKey="Hsu, K" uniqKey="Hsu K">K Hsu</name></author><author><name sortKey="Cheung, Nk" uniqKey="Cheung N">NK Cheung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheung, Nk" uniqKey="Cheung N">NK Cheung</name></author><author><name sortKey="Guo, H" uniqKey="Guo H">H Guo</name></author><author><name sortKey="Hu, J" uniqKey="Hu J">J Hu</name></author><author><name sortKey="Tassev, Dv" uniqKey="Tassev D">DV Tassev</name></author><author><name sortKey="Cheung, Iy" uniqKey="Cheung I">IY Cheung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coker, Sa" uniqKey="Coker S">SA Coker</name></author><author><name sortKey="Dandamudi, Ub" uniqKey="Dandamudi U">UB Dandamudi</name></author><author><name sortKey="Beelen, Ap" uniqKey="Beelen A">AP Beelen</name></author><author><name sortKey="Crosby, Na" uniqKey="Crosby N">NA Crosby</name></author><author><name sortKey="Fisher, Jl" uniqKey="Fisher J">JL Fisher</name></author><author><name sortKey="Obrocea, M" uniqKey="Obrocea M">M Obrocea</name></author><author><name sortKey="Ernstoff, Ms" uniqKey="Ernstoff M">MS Ernstoff</name></author><author><name sortKey="Lewis, Ld" uniqKey="Lewis L">LD Lewis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="West, Ee" uniqKey="West E">EE West</name></author><author><name sortKey="Jin, Ht" uniqKey="Jin H">HT Jin</name></author><author><name sortKey="Rasheed, Au" uniqKey="Rasheed A">AU Rasheed</name></author><author><name sortKey="Penaloza Macmaster, P" uniqKey="Penaloza Macmaster P">P Penaloza-Macmaster</name></author><author><name sortKey="Ha, Sj" uniqKey="Ha S">SJ Ha</name></author><author><name sortKey="Tan, Wg" uniqKey="Tan W">WG Tan</name></author><author><name sortKey="Youngblood, B" uniqKey="Youngblood B">B Youngblood</name></author><author><name sortKey="Freeman, Gj" uniqKey="Freeman G">GJ Freeman</name></author><author><name sortKey="Smith, Ka" uniqKey="Smith K">KA Smith</name></author><author><name sortKey="Ahmed, R" uniqKey="Ahmed R">R Ahmed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Omori, R" uniqKey="Omori R">R Omori</name></author><author><name sortKey="Eguchi, J" uniqKey="Eguchi J">J Eguchi</name></author><author><name sortKey="Hiroishi, K" uniqKey="Hiroishi K">K Hiroishi</name></author><author><name sortKey="Ishii, S" uniqKey="Ishii S">S Ishii</name></author><author><name sortKey="Hiraide, A" uniqKey="Hiraide A">A Hiraide</name></author><author><name sortKey="Sakaki, M" uniqKey="Sakaki M">M Sakaki</name></author><author><name sortKey="Doi, H" uniqKey="Doi H">H Doi</name></author><author><name sortKey="Kajiwara, A" uniqKey="Kajiwara A">A Kajiwara</name></author><author><name sortKey="Ito, T" uniqKey="Ito T">T Ito</name></author><author><name sortKey="Kogo, M" uniqKey="Kogo M">M Kogo</name></author><author><name sortKey="Imawari, M" uniqKey="Imawari M">M Imawari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prieto, Pa" uniqKey="Prieto P">PA Prieto</name></author><author><name sortKey="Yang, Jc" uniqKey="Yang J">JC Yang</name></author><author><name sortKey="Sherry, Rm" uniqKey="Sherry R">RM Sherry</name></author><author><name sortKey="Hughes, Ms" uniqKey="Hughes M">MS Hughes</name></author><author><name sortKey="Kammula, Us" uniqKey="Kammula U">US Kammula</name></author><author><name sortKey="White, De" uniqKey="White D">DE White</name></author><author><name sortKey="Levy, Cl" uniqKey="Levy C">CL Levy</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author><author><name sortKey="Phan, Gq" uniqKey="Phan G">GQ Phan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arellano, M" uniqKey="Arellano M">M Arellano</name></author><author><name sortKey="Lonial, S" uniqKey="Lonial S">S Lonial</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Demirer, T" uniqKey="Demirer T">T Demirer</name></author><author><name sortKey="Ayli, M" uniqKey="Ayli M">M Ayli</name></author><author><name sortKey="Ozcan, M" uniqKey="Ozcan M">M Ozcan</name></author><author><name sortKey="Gunel, N" uniqKey="Gunel N">N Gunel</name></author><author><name sortKey="Haznedar, R" uniqKey="Haznedar R">R Haznedar</name></author><author><name sortKey="Dagli, M" uniqKey="Dagli M">M Dagli</name></author><author><name sortKey="Fen, T" uniqKey="Fen T">T Fen</name></author><author><name sortKey="Genc, Y" uniqKey="Genc Y">Y Genc</name></author><author><name sortKey="Dincer, S" uniqKey="Dincer S">S Dincer</name></author><author><name sortKey="Arslan, O" uniqKey="Arslan O">O Arslan</name></author><author><name sortKey="Gurman, G" uniqKey="Gurman G">G Gurman</name></author><author><name sortKey="Demirer, S" uniqKey="Demirer S">S Demirer</name></author><author><name sortKey="Ozet, G" uniqKey="Ozet G">G Ozet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Kk" uniqKey="Chan K">KK Chan</name></author><author><name sortKey="Siu, E" uniqKey="Siu E">E Siu</name></author><author><name sortKey="Krahn, Md" uniqKey="Krahn M">MD Krahn</name></author><author><name sortKey="Imrie, K" uniqKey="Imrie K">K Imrie</name></author><author><name sortKey="Alibhai, Sm" uniqKey="Alibhai S">SM Alibhai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pabst, T" uniqKey="Pabst T">T Pabst</name></author><author><name sortKey="Vellenga, E" uniqKey="Vellenga E">E Vellenga</name></author><author><name sortKey="Van Putten, W" uniqKey="Van Putten W">W van Putten</name></author><author><name sortKey="Schouten, Hc" uniqKey="Schouten H">HC Schouten</name></author><author><name sortKey="Graux, C" uniqKey="Graux C">C Graux</name></author><author><name sortKey="Vekemans, Mc" uniqKey="Vekemans M">MC Vekemans</name></author><author><name sortKey="Biemond, B" uniqKey="Biemond B">B Biemond</name></author><author><name sortKey="Sonneveld, P" uniqKey="Sonneveld P">P Sonneveld</name></author><author><name sortKey="Passweg, J" uniqKey="Passweg J">J Passweg</name></author><author><name sortKey="Verdonck, L" uniqKey="Verdonck L">L Verdonck</name></author><author><name sortKey="Legdeur, Mc" uniqKey="Legdeur M">MC Legdeur</name></author><author><name sortKey="Theobald, M" uniqKey="Theobald M">M Theobald</name></author><author><name sortKey="Jacky, E" uniqKey="Jacky E">E Jacky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hodi, Fs" uniqKey="Hodi F">FS Hodi</name></author><author><name sortKey="Lee, S" uniqKey="Lee S">S Lee</name></author><author><name sortKey="Mcdermott, Df" uniqKey="Mcdermott D">DF McDermott</name></author><author><name sortKey="Rao, Un" uniqKey="Rao U">UN Rao</name></author><author><name sortKey="Butterfield, Lh" uniqKey="Butterfield L">LH Butterfield</name></author><author><name sortKey="Tarhini, Aa" uniqKey="Tarhini A">AA Tarhini</name></author><author><name sortKey="Leming, P" uniqKey="Leming P">P Leming</name></author><author><name sortKey="Puzanov, I" uniqKey="Puzanov I">I Puzanov</name></author><author><name sortKey="Shin, D" uniqKey="Shin D">D Shin</name></author><author><name sortKey="Kirkwood, Jm" uniqKey="Kirkwood J">JM Kirkwood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deroose, Jp" uniqKey="Deroose J">JP Deroose</name></author><author><name sortKey="Eggermont, Am" uniqKey="Eggermont A">AM Eggermont</name></author><author><name sortKey="Van Geel, An" uniqKey="Van Geel A">AN van Geel</name></author><author><name sortKey="De Wilt, Jh" uniqKey="De Wilt J">JH de Wilt</name></author><author><name sortKey="Burger, Jw" uniqKey="Burger J">JW Burger</name></author><author><name sortKey="Verhoef, C" uniqKey="Verhoef C">C Verhoef</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eggermont, Am" uniqKey="Eggermont A">AM Eggermont</name></author><author><name sortKey="Schraffordt Koops, H" uniqKey="Schraffordt Koops H">H Schraffordt Koops</name></author><author><name sortKey="Lienard, D" uniqKey="Lienard D">D Lienard</name></author><author><name sortKey="Kroon, Bb" uniqKey="Kroon B">BB Kroon</name></author><author><name sortKey="Van Geel, An" uniqKey="Van Geel A">AN van Geel</name></author><author><name sortKey="Hoekstra, Hj" uniqKey="Hoekstra H">HJ Hoekstra</name></author><author><name sortKey="Lejeune, Fj" uniqKey="Lejeune F">FJ Lejeune</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deroose, Jp" uniqKey="Deroose J">JP Deroose</name></author><author><name sortKey="Eggermont, Am" uniqKey="Eggermont A">AM Eggermont</name></author><author><name sortKey="Van Geel, An" uniqKey="Van Geel A">AN van Geel</name></author><author><name sortKey="Burger, Jw" uniqKey="Burger J">JW Burger</name></author><author><name sortKey="Den Bakker, Ma" uniqKey="Den Bakker M">MA den Bakker</name></author><author><name sortKey="De Wilt, Jh" uniqKey="De Wilt J">JH de Wilt</name></author><author><name sortKey="Verhoef, C" uniqKey="Verhoef C">C Verhoef</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Horssen, R" uniqKey="Van Horssen R">R van Horssen</name></author><author><name sortKey="Ten Hagen, Tl" uniqKey="Ten Hagen T">TL Ten Hagen</name></author><author><name sortKey="Eggermont, Am" uniqKey="Eggermont A">AM Eggermont</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Melero, I" uniqKey="Melero I">I Melero</name></author><author><name sortKey="Grimaldi, Am" uniqKey="Grimaldi A">AM Grimaldi</name></author><author><name sortKey="Perez Gracia, Jl" uniqKey="Perez Gracia J">JL Perez-Gracia</name></author><author><name sortKey="Ascierto, Pa" uniqKey="Ascierto P">PA Ascierto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chawla, A" uniqKey="Chawla A">A Chawla</name></author><author><name sortKey="Philips, Av" uniqKey="Philips A">AV Philips</name></author><author><name sortKey="Alatrash, G" uniqKey="Alatrash G">G Alatrash</name></author><author><name sortKey="Mittendorf, E" uniqKey="Mittendorf E">E Mittendorf</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nowak, Ak" uniqKey="Nowak A">AK Nowak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walker, Ls" uniqKey="Walker L">LS Walker</name></author><author><name sortKey="Sansom, Dm" uniqKey="Sansom D">DM Sansom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Waitz, R" uniqKey="Waitz R">R Waitz</name></author><author><name sortKey="Fasso, M" uniqKey="Fasso M">M Fasso</name></author><author><name sortKey="Allison, Jp" uniqKey="Allison J">JP Allison</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munir, S" uniqKey="Munir S">S Munir</name></author><author><name sortKey="Andersen, Gh" uniqKey="Andersen G">GH Andersen</name></author><author><name sortKey="Svane, Im" uniqKey="Svane I">IM Svane</name></author><author><name sortKey="Andersen, Mh" uniqKey="Andersen M">MH Andersen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fife, Bt" uniqKey="Fife B">BT Fife</name></author><author><name sortKey="Pauken, Ke" uniqKey="Pauken K">KE Pauken</name></author><author><name sortKey="Eagar, Tn" uniqKey="Eagar T">TN Eagar</name></author><author><name sortKey="Obu, T" uniqKey="Obu T">T Obu</name></author><author><name sortKey="Wu, J" uniqKey="Wu J">J Wu</name></author><author><name sortKey="Tang, Q" uniqKey="Tang Q">Q Tang</name></author><author><name sortKey="Azuma, M" uniqKey="Azuma M">M Azuma</name></author><author><name sortKey="Krummel, Mf" uniqKey="Krummel M">MF Krummel</name></author><author><name sortKey="Bluestone, Ja" uniqKey="Bluestone J">JA Bluestone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raulet, Dh" uniqKey="Raulet D">DH Raulet</name></author><author><name sortKey="Guerra, N" uniqKey="Guerra N">N Guerra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joncker, Nt" uniqKey="Joncker N">NT Joncker</name></author><author><name sortKey="Raulet, Dh" uniqKey="Raulet D">DH Raulet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Long, Eo" uniqKey="Long E">EO Long</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schalper, Ka" uniqKey="Schalper K">KA Schalper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Curiel, Tj" uniqKey="Curiel T">TJ Curiel</name></author><author><name sortKey="Wei, S" uniqKey="Wei S">S Wei</name></author><author><name sortKey="Dong, H" uniqKey="Dong H">H Dong</name></author><author><name sortKey="Alvarez, X" uniqKey="Alvarez X">X Alvarez</name></author><author><name sortKey="Cheng, P" uniqKey="Cheng P">P Cheng</name></author><author><name sortKey="Mottram, P" uniqKey="Mottram P">P Mottram</name></author><author><name sortKey="Krzysiek, R" uniqKey="Krzysiek R">R Krzysiek</name></author><author><name sortKey="Knutson, Kl" uniqKey="Knutson K">KL Knutson</name></author><author><name sortKey="Daniel, B" uniqKey="Daniel B">B Daniel</name></author><author><name sortKey="Zimmermann, Mc" uniqKey="Zimmermann M">MC Zimmermann</name></author><author><name sortKey="David, O" uniqKey="David O">O David</name></author><author><name sortKey="Burow, M" uniqKey="Burow M">M Burow</name></author><author><name sortKey="Gordon, A" uniqKey="Gordon A">A Gordon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zou, W" uniqKey="Zou W">W Zou</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Melero, I" uniqKey="Melero I">I Melero</name></author><author><name sortKey="Hirschhorn Cymerman, D" uniqKey="Hirschhorn Cymerman D">D Hirschhorn-Cymerman</name></author><author><name sortKey="Morales Kastresana, A" uniqKey="Morales Kastresana A">A Morales-Kastresana</name></author><author><name sortKey="Sanmamed, Mf" uniqKey="Sanmamed M">MF Sanmamed</name></author><author><name sortKey="Wolchok, Jd" uniqKey="Wolchok J">JD Wolchok</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adler, Aj" uniqKey="Adler A">AJ Adler</name></author><author><name sortKey="Vella, At" uniqKey="Vella A">AT Vella</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Withers, Dr" uniqKey="Withers D">DR Withers</name></author><author><name sortKey="Gaspal, Fm" uniqKey="Gaspal F">FM Gaspal</name></author><author><name sortKey="Bekiaris, V" uniqKey="Bekiaris V">V Bekiaris</name></author><author><name sortKey="Mcconnell, Fm" uniqKey="Mcconnell F">FM McConnell</name></author><author><name sortKey="Kim, M" uniqKey="Kim M">M Kim</name></author><author><name sortKey="Anderson, G" uniqKey="Anderson G">G Anderson</name></author><author><name sortKey="Lane, Pj" uniqKey="Lane P">PJ Lane</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Croft, M" uniqKey="Croft M">M Croft</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sugamura, K" uniqKey="Sugamura K">K Sugamura</name></author><author><name sortKey="Ishii, N" uniqKey="Ishii N">N Ishii</name></author><author><name sortKey="Weinberg, Ad" uniqKey="Weinberg A">AD Weinberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hombach, Aa" uniqKey="Hombach A">AA Hombach</name></author><author><name sortKey="Heiders, J" uniqKey="Heiders J">J Heiders</name></author><author><name sortKey="Foppe, M" uniqKey="Foppe M">M Foppe</name></author><author><name sortKey="Chmielewski, M" uniqKey="Chmielewski M">M Chmielewski</name></author><author><name sortKey="Abken, H" uniqKey="Abken H">H Abken</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Melero, I" uniqKey="Melero I">I Melero</name></author><author><name sortKey="Shuford, Ww" uniqKey="Shuford W">WW Shuford</name></author><author><name sortKey="Newby, Sa" uniqKey="Newby S">SA Newby</name></author><author><name sortKey="Aruffo, A" uniqKey="Aruffo A">A Aruffo</name></author><author><name sortKey="Ledbetter, Ja" uniqKey="Ledbetter J">JA Ledbetter</name></author><author><name sortKey="Hellstrom, Ke" uniqKey="Hellstrom K">KE Hellstrom</name></author><author><name sortKey="Mittler, Rs" uniqKey="Mittler R">RS Mittler</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ye, Q" uniqKey="Ye Q">Q Ye</name></author><author><name sortKey="Song, Dg" uniqKey="Song D">DG Song</name></author><author><name sortKey="Powell Jr, Dj" uniqKey="Powell Jr D">DJ Powell Jr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shevach, Em" uniqKey="Shevach E">EM Shevach</name></author><author><name sortKey="Stephens, Gl" uniqKey="Stephens G">GL Stephens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shimizu, J" uniqKey="Shimizu J">J Shimizu</name></author><author><name sortKey="Yamazaki, S" uniqKey="Yamazaki S">S Yamazaki</name></author><author><name sortKey="Takahashi, T" uniqKey="Takahashi T">T Takahashi</name></author><author><name sortKey="Ishida, Y" uniqKey="Ishida Y">Y Ishida</name></author><author><name sortKey="Sakaguchi, S" uniqKey="Sakaguchi S">S Sakaguchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chacon, Ja" uniqKey="Chacon J">JA Chacon</name></author><author><name sortKey="Pilon Thomas, S" uniqKey="Pilon Thomas S">S Pilon-Thomas</name></author><author><name sortKey="Sarnaik, Aa" uniqKey="Sarnaik A">AA Sarnaik</name></author><author><name sortKey="Radvanyi, Lg" uniqKey="Radvanyi L">LG Radvanyi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schnurr, M" uniqKey="Schnurr M">M Schnurr</name></author><author><name sortKey="Duewell, P" uniqKey="Duewell P">P Duewell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pickup, M" uniqKey="Pickup M">M Pickup</name></author><author><name sortKey="Novitskiy, S" uniqKey="Novitskiy S">S Novitskiy</name></author><author><name sortKey="Moses, Hl" uniqKey="Moses H">HL Moses</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peng, W" uniqKey="Peng W">W Peng</name></author><author><name sortKey="Lizee, G" uniqKey="Lizee G">G Lizee</name></author><author><name sortKey="Hwu, P" uniqKey="Hwu P">P Hwu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reck, M" uniqKey="Reck M">M Reck</name></author><author><name sortKey="Bondarenko, I" uniqKey="Bondarenko I">I Bondarenko</name></author><author><name sortKey="Luft, A" uniqKey="Luft A">A Luft</name></author><author><name sortKey="Serwatowski, P" uniqKey="Serwatowski P">P Serwatowski</name></author><author><name sortKey="Barlesi, F" uniqKey="Barlesi F">F Barlesi</name></author><author><name sortKey="Chacko, R" uniqKey="Chacko R">R Chacko</name></author><author><name sortKey="Sebastian, M" uniqKey="Sebastian M">M Sebastian</name></author><author><name sortKey="Lu, H" uniqKey="Lu H">H Lu</name></author><author><name sortKey="Cuillerot, Jm" uniqKey="Cuillerot J">JM Cuillerot</name></author><author><name sortKey="Lynch, Tj" uniqKey="Lynch T">TJ Lynch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mavilio, D" uniqKey="Mavilio D">D Mavilio</name></author><author><name sortKey="Lugli, E" uniqKey="Lugli E">E Lugli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wolchok, Jd" uniqKey="Wolchok J">JD Wolchok</name></author><author><name sortKey="Kluger, H" uniqKey="Kluger H">H Kluger</name></author><author><name sortKey="Callahan, Mk" uniqKey="Callahan M">MK Callahan</name></author><author><name sortKey="Postow, Ma" uniqKey="Postow M">MA Postow</name></author><author><name sortKey="Rizvi, Na" uniqKey="Rizvi N">NA Rizvi</name></author><author><name sortKey="Lesokhin, Am" uniqKey="Lesokhin A">AM Lesokhin</name></author><author><name sortKey="Segal, Nh" uniqKey="Segal N">NH Segal</name></author><author><name sortKey="Ariyan, Ce" uniqKey="Ariyan C">CE Ariyan</name></author><author><name sortKey="Gordon, Ra" uniqKey="Gordon R">RA Gordon</name></author><author><name sortKey="Reed, K" uniqKey="Reed K">K Reed</name></author><author><name sortKey="Burke, Mm" uniqKey="Burke M">MM Burke</name></author><author><name sortKey="Caldwell, A" uniqKey="Caldwell A">A Caldwell</name></author><author><name sortKey="Kronenberg, Sa" uniqKey="Kronenberg S">SA Kronenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lipson, Ej" uniqKey="Lipson E">EJ Lipson</name></author><author><name sortKey="Sharfman, Wh" uniqKey="Sharfman W">WH Sharfman</name></author><author><name sortKey="Drake, Cg" uniqKey="Drake C">CG Drake</name></author><author><name sortKey="Wollner, I" uniqKey="Wollner I">I Wollner</name></author><author><name sortKey="Taube, Jm" uniqKey="Taube J">JM Taube</name></author><author><name sortKey="Anders, Ra" uniqKey="Anders R">RA Anders</name></author><author><name sortKey="Xu, H" uniqKey="Xu H">H Xu</name></author><author><name sortKey="Yao, S" uniqKey="Yao S">S Yao</name></author><author><name sortKey="Pons, A" uniqKey="Pons A">A Pons</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author><author><name sortKey="Pardoll, Dm" uniqKey="Pardoll D">DM Pardoll</name></author><author><name sortKey="Brahmer, Jr" uniqKey="Brahmer J">JR Brahmer</name></author><author><name sortKey="Topalian, Sl" uniqKey="Topalian S">SL Topalian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamid, O" uniqKey="Hamid O">O Hamid</name></author><author><name sortKey="Robert, C" uniqKey="Robert C">C Robert</name></author><author><name sortKey="Daud, A" uniqKey="Daud A">A Daud</name></author><author><name sortKey="Hodi, Fs" uniqKey="Hodi F">FS Hodi</name></author><author><name sortKey="Hwu, Wj" uniqKey="Hwu W">WJ Hwu</name></author><author><name sortKey="Kefford, R" uniqKey="Kefford R">R Kefford</name></author><author><name sortKey="Wolchok, Jd" uniqKey="Wolchok J">JD Wolchok</name></author><author><name sortKey="Hersey, P" uniqKey="Hersey P">P Hersey</name></author><author><name sortKey="Joseph, Rw" uniqKey="Joseph R">RW Joseph</name></author><author><name sortKey="Weber, Js" uniqKey="Weber J">JS Weber</name></author><author><name sortKey="Dronca, R" uniqKey="Dronca R">R Dronca</name></author><author><name sortKey="Gangadhar, Tc" uniqKey="Gangadhar T">TC Gangadhar</name></author><author><name sortKey="Patnaik, A" uniqKey="Patnaik A">A Patnaik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cooper, Za" uniqKey="Cooper Z">ZA Cooper</name></author><author><name sortKey="Frederick, Dt" uniqKey="Frederick D">DT Frederick</name></author><author><name sortKey="Ahmed, Z" uniqKey="Ahmed Z">Z Ahmed</name></author><author><name sortKey="Wargo, Ja" uniqKey="Wargo J">JA Wargo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hodi, Fs" uniqKey="Hodi F">FS Hodi</name></author><author><name sortKey="O Day, Sj" uniqKey="O Day S">SJ O'Day</name></author><author><name sortKey="Mcdermott, Df" uniqKey="Mcdermott D">DF McDermott</name></author><author><name sortKey="Weber, Rw" uniqKey="Weber R">RW Weber</name></author><author><name sortKey="Sosman, Ja" uniqKey="Sosman J">JA Sosman</name></author><author><name sortKey="Haanen, Jb" uniqKey="Haanen J">JB Haanen</name></author><author><name sortKey="Gonzalez, R" uniqKey="Gonzalez R">R Gonzalez</name></author><author><name sortKey="Robert, C" uniqKey="Robert C">C Robert</name></author><author><name sortKey="Schadendorf, D" uniqKey="Schadendorf D">D Schadendorf</name></author><author><name sortKey="Hassel, Jc" uniqKey="Hassel J">JC Hassel</name></author><author><name sortKey="Akerley, W" uniqKey="Akerley W">W Akerley</name></author><author><name sortKey="Van Den Eertwegh, Aj" uniqKey="Van Den Eertwegh A">AJ van den Eertwegh</name></author><author><name sortKey="Lutzky, J" uniqKey="Lutzky J">J Lutzky</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Erdmann, Mk" uniqKey="Erdmann M">MK Erdmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wolchok, Jd" uniqKey="Wolchok J">JD Wolchok</name></author><author><name sortKey="Neyns, B" uniqKey="Neyns B">B Neyns</name></author><author><name sortKey="Linette, G" uniqKey="Linette G">G Linette</name></author><author><name sortKey="Negrier, S" uniqKey="Negrier S">S Negrier</name></author><author><name sortKey="Lutzky, J" uniqKey="Lutzky J">J Lutzky</name></author><author><name sortKey="Thomas, L" uniqKey="Thomas L">L Thomas</name></author><author><name sortKey="Waterfield, W" uniqKey="Waterfield W">W Waterfield</name></author><author><name sortKey="Schadendorf, D" uniqKey="Schadendorf D">D Schadendorf</name></author><author><name sortKey="Smylie, M" uniqKey="Smylie M">M Smylie</name></author><author><name sortKey="Guthrie, T" uniqKey="Guthrie T">T Guthrie</name></author><author><name sortKey="Grob, Jj" uniqKey="Grob J">JJ Grob</name></author><author><name sortKey="Chesney, J" uniqKey="Chesney J">J Chesney</name></author><author><name sortKey="Chin, K" uniqKey="Chin K">K Chin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sondak, Vk" uniqKey="Sondak V">VK Sondak</name></author><author><name sortKey="Smalley, Ks" uniqKey="Smalley K">KS Smalley</name></author><author><name sortKey="Kudchadkar, R" uniqKey="Kudchadkar R">R Kudchadkar</name></author><author><name sortKey="Grippon, S" uniqKey="Grippon S">S Grippon</name></author><author><name sortKey="Kirkpatrick, P" uniqKey="Kirkpatrick P">P Kirkpatrick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tumeh, Pc" uniqKey="Tumeh P">PC Tumeh</name></author><author><name sortKey="Harview, Cl" uniqKey="Harview C">CL Harview</name></author><author><name sortKey="Yearley, Jh" uniqKey="Yearley J">JH Yearley</name></author><author><name sortKey="Shintaku, Ip" uniqKey="Shintaku I">IP Shintaku</name></author><author><name sortKey="Taylor, Ej" uniqKey="Taylor E">EJ Taylor</name></author><author><name sortKey="Robert, L" uniqKey="Robert L">L Robert</name></author><author><name sortKey="Chmielowski, B" uniqKey="Chmielowski B">B Chmielowski</name></author><author><name sortKey="Spasic, M" uniqKey="Spasic M">M Spasic</name></author><author><name sortKey="Henry, G" uniqKey="Henry G">G Henry</name></author><author><name sortKey="Ciobanu, V" uniqKey="Ciobanu V">V Ciobanu</name></author><author><name sortKey="West, An" uniqKey="West A">AN West</name></author><author><name sortKey="Carmona, M" uniqKey="Carmona M">M Carmona</name></author><author><name sortKey="Kivork, C" uniqKey="Kivork C">C Kivork</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Poole, Rm" uniqKey="Poole R">RM Poole</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Robert, C" uniqKey="Robert C">C Robert</name></author><author><name sortKey="Ribas, A" uniqKey="Ribas A">A Ribas</name></author><author><name sortKey="Wolchok, Jd" uniqKey="Wolchok J">JD Wolchok</name></author><author><name sortKey="Hodi, Fs" uniqKey="Hodi F">FS Hodi</name></author><author><name sortKey="Hamid, O" uniqKey="Hamid O">O Hamid</name></author><author><name sortKey="Kefford, R" uniqKey="Kefford R">R Kefford</name></author><author><name sortKey="Weber, Js" uniqKey="Weber J">JS Weber</name></author><author><name sortKey="Joshua, Am" uniqKey="Joshua A">AM Joshua</name></author><author><name sortKey="Hwu, Wj" uniqKey="Hwu W">WJ Hwu</name></author><author><name sortKey="Gangadhar, Tc" uniqKey="Gangadhar T">TC Gangadhar</name></author><author><name sortKey="Patnaik, A" uniqKey="Patnaik A">A Patnaik</name></author><author><name sortKey="Dronca, R" uniqKey="Dronca R">R Dronca</name></author><author><name sortKey="Zarour, H" uniqKey="Zarour H">H Zarour</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bagcchi, S" uniqKey="Bagcchi S">S Bagcchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deeks, Ed" uniqKey="Deeks E">ED Deeks</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Robert, C" uniqKey="Robert C">C Robert</name></author><author><name sortKey="Long, Gv" uniqKey="Long G">GV Long</name></author><author><name sortKey="Brady, B" uniqKey="Brady B">B Brady</name></author><author><name sortKey="Dutriaux, C" uniqKey="Dutriaux C">C Dutriaux</name></author><author><name sortKey="Maio, M" uniqKey="Maio M">M Maio</name></author><author><name sortKey="Mortier, L" uniqKey="Mortier L">L Mortier</name></author><author><name sortKey="Hassel, Jc" uniqKey="Hassel J">JC Hassel</name></author><author><name sortKey="Rutkowski, P" uniqKey="Rutkowski P">P Rutkowski</name></author><author><name sortKey="Mcneil, C" uniqKey="Mcneil C">C McNeil</name></author><author><name sortKey="Kalinka Warzocha, E" uniqKey="Kalinka Warzocha E">E Kalinka-Warzocha</name></author><author><name sortKey="Savage, Kj" uniqKey="Savage K">KJ Savage</name></author><author><name sortKey="Hernberg, Mm" uniqKey="Hernberg M">MM Hernberg</name></author><author><name sortKey="Lebbe, C" uniqKey="Lebbe C">C Lebbe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aranda, F" uniqKey="Aranda F">F Aranda</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ansell, Sm" uniqKey="Ansell S">SM Ansell</name></author><author><name sortKey="Lesokhin, Am" uniqKey="Lesokhin A">AM Lesokhin</name></author><author><name sortKey="Borrello, I" uniqKey="Borrello I">I Borrello</name></author><author><name sortKey="Halwani, A" uniqKey="Halwani A">A Halwani</name></author><author><name sortKey="Scott, Ec" uniqKey="Scott E">EC Scott</name></author><author><name sortKey="Gutierrez, M" uniqKey="Gutierrez M">M Gutierrez</name></author><author><name sortKey="Schuster, Sj" uniqKey="Schuster S">SJ Schuster</name></author><author><name sortKey="Millenson, Mm" uniqKey="Millenson M">MM Millenson</name></author><author><name sortKey="Cattry, D" uniqKey="Cattry D">D Cattry</name></author><author><name sortKey="Freeman, Gj" uniqKey="Freeman G">GJ Freeman</name></author><author><name sortKey="Rodig, Sj" uniqKey="Rodig S">SJ Rodig</name></author><author><name sortKey="Chapuy, B" uniqKey="Chapuy B">B Chapuy</name></author><author><name sortKey="Ligon, Ah" uniqKey="Ligon A">AH Ligon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dai, M" uniqKey="Dai M">M Dai</name></author><author><name sortKey="Yip, Yy" uniqKey="Yip Y">YY Yip</name></author><author><name sortKey="Hellstrom, I" uniqKey="Hellstrom I">I Hellstrom</name></author><author><name sortKey="Hellstrom, Ke" uniqKey="Hellstrom K">KE Hellstrom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wei, H" uniqKey="Wei H">H Wei</name></author><author><name sortKey="Zhao, L" uniqKey="Zhao L">L Zhao</name></author><author><name sortKey="Hellstrom, I" uniqKey="Hellstrom I">I Hellstrom</name></author><author><name sortKey="Hellstrom, Ke" uniqKey="Hellstrom K">KE Hellstrom</name></author><author><name sortKey="Guo, Y" uniqKey="Guo Y">Y Guo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kohrt, He" uniqKey="Kohrt H">HE Kohrt</name></author><author><name sortKey="Colevas, Ad" uniqKey="Colevas A">AD Colevas</name></author><author><name sortKey="Houot, R" uniqKey="Houot R">R Houot</name></author><author><name sortKey="Weiskopf, K" uniqKey="Weiskopf K">K Weiskopf</name></author><author><name sortKey="Goldstein, Mj" uniqKey="Goldstein M">MJ Goldstein</name></author><author><name sortKey="Lund, P" uniqKey="Lund P">P Lund</name></author><author><name sortKey="Mueller, A" uniqKey="Mueller A">A Mueller</name></author><author><name sortKey="Sagiv Barfi, I" uniqKey="Sagiv Barfi I">I Sagiv-Barfi</name></author><author><name sortKey="Marabelle, A" uniqKey="Marabelle A">A Marabelle</name></author><author><name sortKey="Lira, R" uniqKey="Lira R">R Lira</name></author><author><name sortKey="Troutner, E" uniqKey="Troutner E">E Troutner</name></author><author><name sortKey="Richards, L" uniqKey="Richards L">L Richards</name></author><author><name sortKey="Rajapaska, A" uniqKey="Rajapaska A">A Rajapaska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kohrt, He" uniqKey="Kohrt H">HE Kohrt</name></author><author><name sortKey="Houot, R" uniqKey="Houot R">R Houot</name></author><author><name sortKey="Weiskopf, K" uniqKey="Weiskopf K">K Weiskopf</name></author><author><name sortKey="Goldstein, Mj" uniqKey="Goldstein M">MJ Goldstein</name></author><author><name sortKey="Scheeren, F" uniqKey="Scheeren F">F Scheeren</name></author><author><name sortKey="Czerwinski, D" uniqKey="Czerwinski D">D Czerwinski</name></author><author><name sortKey="Colevas, Ad" uniqKey="Colevas A">AD Colevas</name></author><author><name sortKey="Weng, Wk" uniqKey="Weng W">WK Weng</name></author><author><name sortKey="Clarke, Mf" uniqKey="Clarke M">MF Clarke</name></author><author><name sortKey="Carlson, Rw" uniqKey="Carlson R">RW Carlson</name></author><author><name sortKey="Stockdale, Fe" uniqKey="Stockdale F">FE Stockdale</name></author><author><name sortKey="Mollick, Ja" uniqKey="Mollick J">JA Mollick</name></author><author><name sortKey="Chen, L" uniqKey="Chen L">L Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Snyder, A" uniqKey="Snyder A">A Snyder</name></author><author><name sortKey="Makarov, V" uniqKey="Makarov V">V Makarov</name></author><author><name sortKey="Merghoub, T" uniqKey="Merghoub T">T Merghoub</name></author><author><name sortKey="Yuan, J" uniqKey="Yuan J">J Yuan</name></author><author><name sortKey="Zaretsky, Jm" uniqKey="Zaretsky J">JM Zaretsky</name></author><author><name sortKey="Desrichard, A" uniqKey="Desrichard A">A Desrichard</name></author><author><name sortKey="Walsh, La" uniqKey="Walsh L">LA Walsh</name></author><author><name sortKey="Postow, Ma" uniqKey="Postow M">MA Postow</name></author><author><name sortKey="Wong, P" uniqKey="Wong P">P Wong</name></author><author><name sortKey="Ho, Ts" uniqKey="Ho T">TS Ho</name></author><author><name sortKey="Hollmann, Tj" uniqKey="Hollmann T">TJ Hollmann</name></author><author><name sortKey="Bruggeman, C" uniqKey="Bruggeman C">C Bruggeman</name></author><author><name sortKey="Kannan, K" uniqKey="Kannan K">K Kannan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Aranda, F" uniqKey="Aranda F">F Aranda</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Kennedy, Ep" uniqKey="Kennedy E">EP Kennedy</name></author><author><name sortKey="Platten, M" uniqKey="Platten M">M Platten</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yoshida, R" uniqKey="Yoshida R">R Yoshida</name></author><author><name sortKey="Hayaishi, O" uniqKey="Hayaishi O">O Hayaishi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pfefferkorn, Er" uniqKey="Pfefferkorn E">ER Pfefferkorn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munn, Dh" uniqKey="Munn D">DH Munn</name></author><author><name sortKey="Zhou, M" uniqKey="Zhou M">M Zhou</name></author><author><name sortKey="Attwood, Jt" uniqKey="Attwood J">JT Attwood</name></author><author><name sortKey="Bondarev, I" uniqKey="Bondarev I">I Bondarev</name></author><author><name sortKey="Conway, Sj" uniqKey="Conway S">SJ Conway</name></author><author><name sortKey="Marshall, B" uniqKey="Marshall B">B Marshall</name></author><author><name sortKey="Brown, C" uniqKey="Brown C">C Brown</name></author><author><name sortKey="Mellor, Al" uniqKey="Mellor A">AL Mellor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Uyttenhove, C" uniqKey="Uyttenhove C">C Uyttenhove</name></author><author><name sortKey="Pilotte, L" uniqKey="Pilotte L">L Pilotte</name></author><author><name sortKey="Theate, I" uniqKey="Theate I">I Theate</name></author><author><name sortKey="Stroobant, V" uniqKey="Stroobant V">V Stroobant</name></author><author><name sortKey="Colau, D" uniqKey="Colau D">D Colau</name></author><author><name sortKey="Parmentier, N" uniqKey="Parmentier N">N Parmentier</name></author><author><name sortKey="Boon, T" uniqKey="Boon T">T Boon</name></author><author><name sortKey="Van Den Eynde, Bj" uniqKey="Van Den Eynde B">BJ Van den Eynde</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munn, Dh" uniqKey="Munn D">DH Munn</name></author><author><name sortKey="Sharma, Md" uniqKey="Sharma M">MD Sharma</name></author><author><name sortKey="Baban, B" uniqKey="Baban B">B Baban</name></author><author><name sortKey="Harding, Hp" uniqKey="Harding H">HP Harding</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Ron, D" uniqKey="Ron D">D Ron</name></author><author><name sortKey="Mellor, Al" uniqKey="Mellor A">AL Mellor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munn, Dh" uniqKey="Munn D">DH Munn</name></author><author><name sortKey="Sharma, Md" uniqKey="Sharma M">MD Sharma</name></author><author><name sortKey="Hou, D" uniqKey="Hou D">D Hou</name></author><author><name sortKey="Baban, B" uniqKey="Baban B">B Baban</name></author><author><name sortKey="Lee, Jr" uniqKey="Lee J">JR Lee</name></author><author><name sortKey="Antonia, Sj" uniqKey="Antonia S">SJ Antonia</name></author><author><name sortKey="Messina, Jl" uniqKey="Messina J">JL Messina</name></author><author><name sortKey="Chandler, P" uniqKey="Chandler P">P Chandler</name></author><author><name sortKey="Koni, Pa" uniqKey="Koni P">PA Koni</name></author><author><name sortKey="Mellor, Al" uniqKey="Mellor A">AL Mellor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Aj" uniqKey="Muller A">AJ Muller</name></author><author><name sortKey="Sharma, Md" uniqKey="Sharma M">MD Sharma</name></author><author><name sortKey="Chandler, Pr" uniqKey="Chandler P">PR Chandler</name></author><author><name sortKey="Duhadaway, Jb" uniqKey="Duhadaway J">JB Duhadaway</name></author><author><name sortKey="Everhart, Me" uniqKey="Everhart M">ME Everhart</name></author><author><name sortKey="Johnson, Ba" uniqKey="Johnson B">BA Johnson</name></author><author><name sortKey="Kahler, Dj" uniqKey="Kahler D">DJ Kahler</name></author><author><name sortKey="Pihkala, J" uniqKey="Pihkala J">J Pihkala</name></author><author><name sortKey="Soler, Ap" uniqKey="Soler A">AP Soler</name></author><author><name sortKey="Munn, Dh" uniqKey="Munn D">DH Munn</name></author><author><name sortKey="Prendergast, Gc" uniqKey="Prendergast G">GC Prendergast</name></author><author><name sortKey="Mellor, Al" uniqKey="Mellor A">AL Mellor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, C" uniqKey="Smith C">C Smith</name></author><author><name sortKey="Chang, My" uniqKey="Chang M">MY Chang</name></author><author><name sortKey="Parker, Kh" uniqKey="Parker K">KH Parker</name></author><author><name sortKey="Beury, Dw" uniqKey="Beury D">DW Beury</name></author><author><name sortKey="Duhadaway, Jb" uniqKey="Duhadaway J">JB DuHadaway</name></author><author><name sortKey="Flick, He" uniqKey="Flick H">HE Flick</name></author><author><name sortKey="Boulden, J" uniqKey="Boulden J">J Boulden</name></author><author><name sortKey="Sutanto Ward, E" uniqKey="Sutanto Ward E">E Sutanto-Ward</name></author><author><name sortKey="Soler, Ap" uniqKey="Soler A">AP Soler</name></author><author><name sortKey="Laury Kleintop, Ld" uniqKey="Laury Kleintop L">LD Laury-Kleintop</name></author><author><name sortKey="Mandik Nayak, L" uniqKey="Mandik Nayak L">L Mandik-Nayak</name></author><author><name sortKey="Metz, R" uniqKey="Metz R">R Metz</name></author><author><name sortKey="Ostrand Rosenberg, S" uniqKey="Ostrand Rosenberg S">S Ostrand-Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abe, Bt" uniqKey="Abe B">BT Abe</name></author><author><name sortKey="Macian, F" uniqKey="Macian F">F Macian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Bravo San Pedro, Jm" uniqKey="Bravo San Pedro J">JM Bravo-San Pedro</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Creelan, Bc" uniqKey="Creelan B">BC Creelan</name></author><author><name sortKey="Antonia, S" uniqKey="Antonia S">S Antonia</name></author><author><name sortKey="Bepler, G" uniqKey="Bepler G">G Bepler</name></author><author><name sortKey="Garrett, Tj" uniqKey="Garrett T">TJ Garrett</name></author><author><name sortKey="Simon, Gr" uniqKey="Simon G">GR Simon</name></author><author><name sortKey="Soliman, Hh" uniqKey="Soliman H">HH Soliman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mezrich, Jd" uniqKey="Mezrich J">JD Mezrich</name></author><author><name sortKey="Fechner, Jh" uniqKey="Fechner J">JH Fechner</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Johnson, Bp" uniqKey="Johnson B">BP Johnson</name></author><author><name sortKey="Burlingham, Wj" uniqKey="Burlingham W">WJ Burlingham</name></author><author><name sortKey="Bradfield, Ca" uniqKey="Bradfield C">CA Bradfield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Favre, D" uniqKey="Favre D">D Favre</name></author><author><name sortKey="Mold, J" uniqKey="Mold J">J Mold</name></author><author><name sortKey="Hunt, Pw" uniqKey="Hunt P">PW Hunt</name></author><author><name sortKey="Kanwar, B" uniqKey="Kanwar B">B Kanwar</name></author><author><name sortKey="Loke, P" uniqKey="Loke P">P Loke</name></author><author><name sortKey="Seu, L" uniqKey="Seu L">L Seu</name></author><author><name sortKey="Barbour, Jd" uniqKey="Barbour J">JD Barbour</name></author><author><name sortKey="Lowe, Mm" uniqKey="Lowe M">MM Lowe</name></author><author><name sortKey="Jayawardene, A" uniqKey="Jayawardene A">A Jayawardene</name></author><author><name sortKey="Aweeka, F" uniqKey="Aweeka F">F Aweeka</name></author><author><name sortKey="Huang, Y" uniqKey="Huang Y">Y Huang</name></author><author><name sortKey="Douek, Dc" uniqKey="Douek D">DC Douek</name></author><author><name sortKey="Brenchley, Jm" uniqKey="Brenchley J">JM Brenchley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gandhi, R" uniqKey="Gandhi R">R Gandhi</name></author><author><name sortKey="Kumar, D" uniqKey="Kumar D">D Kumar</name></author><author><name sortKey="Burns, Ej" uniqKey="Burns E">EJ Burns</name></author><author><name sortKey="Nadeau, M" uniqKey="Nadeau M">M Nadeau</name></author><author><name sortKey="Dake, B" uniqKey="Dake B">B Dake</name></author><author><name sortKey="Laroni, A" uniqKey="Laroni A">A Laroni</name></author><author><name sortKey="Kozoriz, D" uniqKey="Kozoriz D">D Kozoriz</name></author><author><name sortKey="Weiner, Hl" uniqKey="Weiner H">HL Weiner</name></author><author><name sortKey="Quintana, Fj" uniqKey="Quintana F">FJ Quintana</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Platten, M" uniqKey="Platten M">M Platten</name></author><author><name sortKey="Ho, Pp" uniqKey="Ho P">PP Ho</name></author><author><name sortKey="Youssef, S" uniqKey="Youssef S">S Youssef</name></author><author><name sortKey="Fontoura, P" uniqKey="Fontoura P">P Fontoura</name></author><author><name sortKey="Garren, H" uniqKey="Garren H">H Garren</name></author><author><name sortKey="Hur, Em" uniqKey="Hur E">EM Hur</name></author><author><name sortKey="Gupta, R" uniqKey="Gupta R">R Gupta</name></author><author><name sortKey="Lee, Ly" uniqKey="Lee L">LY Lee</name></author><author><name sortKey="Kidd, Ba" uniqKey="Kidd B">BA Kidd</name></author><author><name sortKey="Robinson, Wh" uniqKey="Robinson W">WH Robinson</name></author><author><name sortKey="Sobel, Ra" uniqKey="Sobel R">RA Sobel</name></author><author><name sortKey="Selley, Ml" uniqKey="Selley M">ML Selley</name></author><author><name sortKey="Steinman, L" uniqKey="Steinman L">L Steinman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hayashi, T" uniqKey="Hayashi T">T Hayashi</name></author><author><name sortKey="Mo, Jh" uniqKey="Mo J">JH Mo</name></author><author><name sortKey="Gong, X" uniqKey="Gong X">X Gong</name></author><author><name sortKey="Rossetto, C" uniqKey="Rossetto C">C Rossetto</name></author><author><name sortKey="Jang, A" uniqKey="Jang A">A Jang</name></author><author><name sortKey="Beck, L" uniqKey="Beck L">L Beck</name></author><author><name sortKey="Elliott, Gi" uniqKey="Elliott G">GI Elliott</name></author><author><name sortKey="Kufareva, I" uniqKey="Kufareva I">I Kufareva</name></author><author><name sortKey="Abagyan, R" uniqKey="Abagyan R">R Abagyan</name></author><author><name sortKey="Broide, Dh" uniqKey="Broide D">DH Broide</name></author><author><name sortKey="Lee, J" uniqKey="Lee J">J Lee</name></author><author><name sortKey="Raz, E" uniqKey="Raz E">E Raz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mellor, Al" uniqKey="Mellor A">AL Mellor</name></author><author><name sortKey="Baban, B" uniqKey="Baban B">B Baban</name></author><author><name sortKey="Chandler, P" uniqKey="Chandler P">P Chandler</name></author><author><name sortKey="Marshall, B" uniqKey="Marshall B">B Marshall</name></author><author><name sortKey="Jhaver, K" uniqKey="Jhaver K">K Jhaver</name></author><author><name sortKey="Hansen, A" uniqKey="Hansen A">A Hansen</name></author><author><name sortKey="Koni, Pa" uniqKey="Koni P">PA Koni</name></author><author><name sortKey="Iwashima, M" uniqKey="Iwashima M">M Iwashima</name></author><author><name sortKey="Munn, Dh" uniqKey="Munn D">DH Munn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hwu, P" uniqKey="Hwu P">P Hwu</name></author><author><name sortKey="Du, Mx" uniqKey="Du M">MX Du</name></author><author><name sortKey="Lapointe, R" uniqKey="Lapointe R">R Lapointe</name></author><author><name sortKey="Do, M" uniqKey="Do M">M Do</name></author><author><name sortKey="Taylor, Mw" uniqKey="Taylor M">MW Taylor</name></author><author><name sortKey="Young, Ha" uniqKey="Young H">HA Young</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munn, Dh" uniqKey="Munn D">DH Munn</name></author><author><name sortKey="Sharma, Md" uniqKey="Sharma M">MD Sharma</name></author><author><name sortKey="Lee, Jr" uniqKey="Lee J">JR Lee</name></author><author><name sortKey="Jhaver, Kg" uniqKey="Jhaver K">KG Jhaver</name></author><author><name sortKey="Johnson, Ts" uniqKey="Johnson T">TS Johnson</name></author><author><name sortKey="Keskin, Db" uniqKey="Keskin D">DB Keskin</name></author><author><name sortKey="Marshall, B" uniqKey="Marshall B">B Marshall</name></author><author><name sortKey="Chandler, P" uniqKey="Chandler P">P Chandler</name></author><author><name sortKey="Antonia, Sj" uniqKey="Antonia S">SJ Antonia</name></author><author><name sortKey="Burgess, R" uniqKey="Burgess R">R Burgess</name></author><author><name sortKey="Slingluff, Cl" uniqKey="Slingluff C">CL Slingluff</name></author><author><name sortKey="Mellor, Al" uniqKey="Mellor A">AL Mellor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fallarino, F" uniqKey="Fallarino F">F Fallarino</name></author><author><name sortKey="Orabona, C" uniqKey="Orabona C">C Orabona</name></author><author><name sortKey="Vacca, C" uniqKey="Vacca C">C Vacca</name></author><author><name sortKey="Bianchi, R" uniqKey="Bianchi R">R Bianchi</name></author><author><name sortKey="Gizzi, S" uniqKey="Gizzi S">S Gizzi</name></author><author><name sortKey="Asselin Paturel, C" uniqKey="Asselin Paturel C">C Asselin-Paturel</name></author><author><name sortKey="Fioretti, Mc" uniqKey="Fioretti M">MC Fioretti</name></author><author><name sortKey="Trinchieri, G" uniqKey="Trinchieri G">G Trinchieri</name></author><author><name sortKey="Grohmann, U" uniqKey="Grohmann U">U Grohmann</name></author><author><name sortKey="Puccetti, P" uniqKey="Puccetti P">P Puccetti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fallarino, F" uniqKey="Fallarino F">F Fallarino</name></author><author><name sortKey="Asselin Paturel, C" uniqKey="Asselin Paturel C">C Asselin-Paturel</name></author><author><name sortKey="Vacca, C" uniqKey="Vacca C">C Vacca</name></author><author><name sortKey="Bianchi, R" uniqKey="Bianchi R">R Bianchi</name></author><author><name sortKey="Gizzi, S" uniqKey="Gizzi S">S Gizzi</name></author><author><name sortKey="Fioretti, Mc" uniqKey="Fioretti M">MC Fioretti</name></author><author><name sortKey="Trinchieri, G" uniqKey="Trinchieri G">G Trinchieri</name></author><author><name sortKey="Grohmann, U" uniqKey="Grohmann U">U Grohmann</name></author><author><name sortKey="Puccetti, P" uniqKey="Puccetti P">P Puccetti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Conrad, C" uniqKey="Conrad C">C Conrad</name></author><author><name sortKey="Gilliet, M" uniqKey="Gilliet M">M Gilliet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sisirak, V" uniqKey="Sisirak V">V Sisirak</name></author><author><name sortKey="Faget, J" uniqKey="Faget J">J Faget</name></author><author><name sortKey="Vey, N" uniqKey="Vey N">N Vey</name></author><author><name sortKey="Blay, Jy" uniqKey="Blay J">JY Blay</name></author><author><name sortKey="Menetrier Caux, C" uniqKey="Menetrier Caux C">C Menetrier-Caux</name></author><author><name sortKey="Caux, C" uniqKey="Caux C">C Caux</name></author><author><name sortKey="Bendriss Vermare, N" uniqKey="Bendriss Vermare N">N Bendriss-Vermare</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Aj" uniqKey="Muller A">AJ Muller</name></author><author><name sortKey="Duhadaway, Jb" uniqKey="Duhadaway J">JB DuHadaway</name></author><author><name sortKey="Donover, Ps" uniqKey="Donover P">PS Donover</name></author><author><name sortKey="Sutanto Ward, E" uniqKey="Sutanto Ward E">E Sutanto-Ward</name></author><author><name sortKey="Prendergast, Gc" uniqKey="Prendergast G">GC Prendergast</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Manuel, Er" uniqKey="Manuel E">ER Manuel</name></author><author><name sortKey="Diamond, Dj" uniqKey="Diamond D">DJ Diamond</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zheng, X" uniqKey="Zheng X">X Zheng</name></author><author><name sortKey="Koropatnick, J" uniqKey="Koropatnick J">J Koropatnick</name></author><author><name sortKey="Chen, D" uniqKey="Chen D">D Chen</name></author><author><name sortKey="Velenosi, T" uniqKey="Velenosi T">T Velenosi</name></author><author><name sortKey="Ling, H" uniqKey="Ling H">H Ling</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Jiang, N" uniqKey="Jiang N">N Jiang</name></author><author><name sortKey="Navarro, B" uniqKey="Navarro B">B Navarro</name></author><author><name sortKey="Ichim, Te" uniqKey="Ichim T">TE Ichim</name></author><author><name sortKey="Urquhart, B" uniqKey="Urquhart B">B Urquhart</name></author><author><name sortKey="Min, W" uniqKey="Min W">W Min</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blache, Ca" uniqKey="Blache C">CA Blache</name></author><author><name sortKey="Manuel, Er" uniqKey="Manuel E">ER Manuel</name></author><author><name sortKey="Kaltcheva, Ti" uniqKey="Kaltcheva T">TI Kaltcheva</name></author><author><name sortKey="Wong, An" uniqKey="Wong A">AN Wong</name></author><author><name sortKey="Ellenhorn, Jd" uniqKey="Ellenhorn J">JD Ellenhorn</name></author><author><name sortKey="Blazar, Br" uniqKey="Blazar B">BR Blazar</name></author><author><name sortKey="Diamond, Dj" uniqKey="Diamond D">DJ Diamond</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iversen, Tz" uniqKey="Iversen T">TZ Iversen</name></author><author><name sortKey="Engell Noerregaard, L" uniqKey="Engell Noerregaard L">L Engell-Noerregaard</name></author><author><name sortKey="Ellebaek, E" uniqKey="Ellebaek E">E Ellebaek</name></author><author><name sortKey="Andersen, R" uniqKey="Andersen R">R Andersen</name></author><author><name sortKey="Larsen, Sk" uniqKey="Larsen S">SK Larsen</name></author><author><name sortKey="Bjoern, J" uniqKey="Bjoern J">J Bjoern</name></author><author><name sortKey="Zeyher, C" uniqKey="Zeyher C">C Zeyher</name></author><author><name sortKey="Gouttefangeas, C" uniqKey="Gouttefangeas C">C Gouttefangeas</name></author><author><name sortKey="Thomsen, Bm" uniqKey="Thomsen B">BM Thomsen</name></author><author><name sortKey="Holm, B" uniqKey="Holm B">B Holm</name></author><author><name sortKey="Thor Straten, P" uniqKey="Thor Straten P">P Thor Straten</name></author><author><name sortKey="Mellemgaard, A" uniqKey="Mellemgaard A">A Mellemgaard</name></author><author><name sortKey="Andersen, Mh" uniqKey="Andersen M">MH Andersen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soliman, Hh" uniqKey="Soliman H">HH Soliman</name></author><author><name sortKey="Minton, Se" uniqKey="Minton S">SE Minton</name></author><author><name sortKey="Ismail Khan, R" uniqKey="Ismail Khan R">R Ismail-Khan</name></author><author><name sortKey="Han, Hs" uniqKey="Han H">HS Han</name></author><author><name sortKey="Vahanian, Nn" uniqKey="Vahanian N">NN Vahanian</name></author><author><name sortKey="Ramsey, Wj" uniqKey="Ramsey W">WJ Ramsey</name></author><author><name sortKey="Kennedy, E" uniqKey="Kennedy E">E Kennedy</name></author><author><name sortKey="Link, Cj" uniqKey="Link C">CJ Link</name></author><author><name sortKey="Sullivan, D" uniqKey="Sullivan D">D Sullivan</name></author><author><name sortKey="Antonia, Sj" uniqKey="Antonia S">SJ Antonia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jackson, E" uniqKey="Jackson E">E Jackson</name></author><author><name sortKey="Dees, Ec" uniqKey="Dees E">EC Dees</name></author><author><name sortKey="Kauh, Js" uniqKey="Kauh J">JS Kauh</name></author><author><name sortKey="Harvey, Rd" uniqKey="Harvey R">RD Harvey</name></author><author><name sortKey="Neuger, A" uniqKey="Neuger A">A Neuger</name></author><author><name sortKey="Lush, R" uniqKey="Lush R">R Lush</name></author><author><name sortKey="Antonia, Sj" uniqKey="Antonia S">SJ Antonia</name></author><author><name sortKey="Minton, Se" uniqKey="Minton S">SE Minton</name></author><author><name sortKey="Ismail Khan, R" uniqKey="Ismail Khan R">R Ismail-Khan</name></author><author><name sortKey="Han, Hs" uniqKey="Han H">HS Han</name></author><author><name sortKey="Vahanian, Nn" uniqKey="Vahanian N">NN Vahanian</name></author><author><name sortKey="Ramsey, Wj" uniqKey="Ramsey W">WJ Ramsey</name></author><author><name sortKey="Link, Cj" uniqKey="Link C">CJ Link</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soliman, Hh" uniqKey="Soliman H">HH Soliman</name></author><author><name sortKey="Antonia, Sj" uniqKey="Antonia S">SJ Antonia</name></author><author><name sortKey="Sullivan, D" uniqKey="Sullivan D">D Sullivan</name></author><author><name sortKey="Vanahanian, N" uniqKey="Vanahanian N">N Vanahanian</name></author><author><name sortKey="Link, Cj" uniqKey="Link C">CJ Link</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beatty, Gl" uniqKey="Beatty G">GL Beatty</name></author><author><name sortKey="O Dwyer, Pj" uniqKey="O Dwyer P">PJ O'Dwyer</name></author><author><name sortKey="Clark, J" uniqKey="Clark J">J Clark</name></author><author><name sortKey="Shi, Jg" uniqKey="Shi J">JG Shi</name></author><author><name sortKey="Newton, Rc" uniqKey="Newton R">RC Newton</name></author><author><name sortKey="Schaub, R" uniqKey="Schaub R">R Schaub</name></author><author><name sortKey="Maleski, J" uniqKey="Maleski J">J Maleski</name></author><author><name sortKey="Leopold, L" uniqKey="Leopold L">L Leopold</name></author><author><name sortKey="Gajewski, T" uniqKey="Gajewski T">T Gajewski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gibney, Gt" uniqKey="Gibney G">GT Gibney</name></author><author><name sortKey="Hamid, O" uniqKey="Hamid O">O Hamid</name></author><author><name sortKey="Gangadhar, Tc" uniqKey="Gangadhar T">TC Gangadhar</name></author><author><name sortKey="Lutzky, J" uniqKey="Lutzky J">J Lutzky</name></author><author><name sortKey="Olszanski, Aj" uniqKey="Olszanski A">AJ Olszanski</name></author><author><name sortKey="Gajewski, T" uniqKey="Gajewski T">T Gajewski</name></author><author><name sortKey="Chmielowski, B" uniqKey="Chmielowski B">B Chmielowski</name></author><author><name sortKey="Boasberg, Pd" uniqKey="Boasberg P">PD Boasberg</name></author><author><name sortKey="Zhao, Y" uniqKey="Zhao Y">Y Zhao</name></author><author><name sortKey="Newton, Rc" uniqKey="Newton R">RC Newton</name></author><author><name sortKey="Scherle, Pa" uniqKey="Scherle P">PA Scherle</name></author><author><name sortKey="Bowman, J" uniqKey="Bowman J">J Bowman</name></author><author><name sortKey="Maleski, J" uniqKey="Maleski J">J Maleski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Newton, Rc" uniqKey="Newton R">RC Newton</name></author><author><name sortKey="Scherle, Pa" uniqKey="Scherle P">PA Scherle</name></author><author><name sortKey="Bowman, K" uniqKey="Bowman K">K Bowman</name></author><author><name sortKey="Liu, X" uniqKey="Liu X">X Liu</name></author><author><name sortKey="Beatty, Gl" uniqKey="Beatty G">GL Beatty</name></author><author><name sortKey="O Dwyer, Pj" uniqKey="O Dwyer P">PJ O'Dwyer</name></author><author><name sortKey="Gajewski, T" uniqKey="Gajewski T">T Gajewski</name></author><author><name sortKey="Bowman, J" uniqKey="Bowman J">J Bowman</name></author><author><name sortKey="Schaub, R" uniqKey="Schaub R">R Schaub</name></author><author><name sortKey="Leopold, L" uniqKey="Leopold L">L Leopold</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aymeric, L" uniqKey="Aymeric L">L Aymeric</name></author><author><name sortKey="Apetoh, L" uniqKey="Apetoh L">L Apetoh</name></author><author><name sortKey="Ghiringhelli, F" uniqKey="Ghiringhelli F">F Ghiringhelli</name></author><author><name sortKey="Tesniere, A" uniqKey="Tesniere A">A Tesniere</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Smyth, Mj" uniqKey="Smyth M">MJ Smyth</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cauwels, A" uniqKey="Cauwels A">A Cauwels</name></author><author><name sortKey="Rogge, E" uniqKey="Rogge E">E Rogge</name></author><author><name sortKey="Vandendriessche, B" uniqKey="Vandendriessche B">B Vandendriessche</name></author><author><name sortKey="Shiva, S" uniqKey="Shiva S">S Shiva</name></author><author><name sortKey="Brouckaert, P" uniqKey="Brouckaert P">P Brouckaert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ma, Y" uniqKey="Ma Y">Y Ma</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Yang, H" uniqKey="Yang H">H Yang</name></author><author><name sortKey="Catani, Jp" uniqKey="Catani J">JP Catani</name></author><author><name sortKey="Hannani, D" uniqKey="Hannani D">D Hannani</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Sukkurwala, Aq" uniqKey="Sukkurwala A">AQ Sukkurwala</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Elliott, Mr" uniqKey="Elliott M">MR Elliott</name></author><author><name sortKey="Chekeni, Fb" uniqKey="Chekeni F">FB Chekeni</name></author><author><name sortKey="Trampont, Pc" uniqKey="Trampont P">PC Trampont</name></author><author><name sortKey="Lazarowski, Er" uniqKey="Lazarowski E">ER Lazarowski</name></author><author><name sortKey="Kadl, A" uniqKey="Kadl A">A Kadl</name></author><author><name sortKey="Walk, Sf" uniqKey="Walk S">SF Walk</name></author><author><name sortKey="Park, D" uniqKey="Park D">D Park</name></author><author><name sortKey="Woodson, Ri" uniqKey="Woodson R">RI Woodson</name></author><author><name sortKey="Ostankovich, M" uniqKey="Ostankovich M">M Ostankovich</name></author><author><name sortKey="Sharma, P" uniqKey="Sharma P">P Sharma</name></author><author><name sortKey="Lysiak, Jj" uniqKey="Lysiak J">JJ Lysiak</name></author><author><name sortKey="Harden, Tk" uniqKey="Harden T">TK Harden</name></author><author><name sortKey="Leitinger, N" uniqKey="Leitinger N">N Leitinger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamaguchi, H" uniqKey="Yamaguchi H">H Yamaguchi</name></author><author><name sortKey="Maruyama, T" uniqKey="Maruyama T">T Maruyama</name></author><author><name sortKey="Urade, Y" uniqKey="Urade Y">Y Urade</name></author><author><name sortKey="Nagata, S" uniqKey="Nagata S">S Nagata</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sorrentino, R" uniqKey="Sorrentino R">R Sorrentino</name></author><author><name sortKey="Pinto, A" uniqKey="Pinto A">A Pinto</name></author><author><name sortKey="Morello, S" uniqKey="Morello S">S Morello</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deaglio, S" uniqKey="Deaglio S">S Deaglio</name></author><author><name sortKey="Dwyer, Km" uniqKey="Dwyer K">KM Dwyer</name></author><author><name sortKey="Gao, W" uniqKey="Gao W">W Gao</name></author><author><name sortKey="Friedman, D" uniqKey="Friedman D">D Friedman</name></author><author><name sortKey="Usheva, A" uniqKey="Usheva A">A Usheva</name></author><author><name sortKey="Erat, A" uniqKey="Erat A">A Erat</name></author><author><name sortKey="Chen, Jf" uniqKey="Chen J">JF Chen</name></author><author><name sortKey="Enjyoji, K" uniqKey="Enjyoji K">K Enjyoji</name></author><author><name sortKey="Linden, J" uniqKey="Linden J">J Linden</name></author><author><name sortKey="Oukka, M" uniqKey="Oukka M">M Oukka</name></author><author><name sortKey="Kuchroo, Vk" uniqKey="Kuchroo V">VK Kuchroo</name></author><author><name sortKey="Strom, Tb" uniqKey="Strom T">TB Strom</name></author><author><name sortKey="Robson, Sc" uniqKey="Robson S">SC Robson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Sukkurwala, Aq" uniqKey="Sukkurwala A">AQ Sukkurwala</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Shen, S" uniqKey="Shen S">S Shen</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Antonioli, L" uniqKey="Antonioli L">L Antonioli</name></author><author><name sortKey="Pacher, P" uniqKey="Pacher P">P Pacher</name></author><author><name sortKey="Vizi, Es" uniqKey="Vizi E">ES Vizi</name></author><author><name sortKey="Hasko, G" uniqKey="Hasko G">G Hasko</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bastid, J" uniqKey="Bastid J">J Bastid</name></author><author><name sortKey="Cottalorda Regairaz, A" uniqKey="Cottalorda Regairaz A">A Cottalorda-Regairaz</name></author><author><name sortKey="Alberici, G" uniqKey="Alberici G">G Alberici</name></author><author><name sortKey="Bonnefoy, N" uniqKey="Bonnefoy N">N Bonnefoy</name></author><author><name sortKey="Eliaou, Jf" uniqKey="Eliaou J">JF Eliaou</name></author><author><name sortKey="Bensussan, A" uniqKey="Bensussan A">A Bensussan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Salmi, M" uniqKey="Salmi M">M Salmi</name></author><author><name sortKey="Jalkanen, S" uniqKey="Jalkanen S">S Jalkanen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, B" uniqKey="Zhang B">B Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aliagas, E" uniqKey="Aliagas E">E Aliagas</name></author><author><name sortKey="Vidal, A" uniqKey="Vidal A">A Vidal</name></author><author><name sortKey="Texido, L" uniqKey="Texido L">L Texido</name></author><author><name sortKey="Ponce, J" uniqKey="Ponce J">J Ponce</name></author><author><name sortKey="Condom, E" uniqKey="Condom E">E Condom</name></author><author><name sortKey="Martin Satue, M" uniqKey="Martin Satue M">M Martin-Satue</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clayton, A" uniqKey="Clayton A">A Clayton</name></author><author><name sortKey="Al Taei, S" uniqKey="Al Taei S">S Al-Taei</name></author><author><name sortKey="Webber, J" uniqKey="Webber J">J Webber</name></author><author><name sortKey="Mason, Md" uniqKey="Mason M">MD Mason</name></author><author><name sortKey="Tabi, Z" uniqKey="Tabi Z">Z Tabi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Young, A" uniqKey="Young A">A Young</name></author><author><name sortKey="Mittal, D" uniqKey="Mittal D">D Mittal</name></author><author><name sortKey="Stagg, J" uniqKey="Stagg J">J Stagg</name></author><author><name sortKey="Smyth, Mj" uniqKey="Smyth M">MJ Smyth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Metz, R" uniqKey="Metz R">R Metz</name></author><author><name sortKey="Smith, C" uniqKey="Smith C">C Smith</name></author><author><name sortKey="Duhadaway, Jb" uniqKey="Duhadaway J">JB DuHadaway</name></author><author><name sortKey="Chandler, P" uniqKey="Chandler P">P Chandler</name></author><author><name sortKey="Baban, B" uniqKey="Baban B">B Baban</name></author><author><name sortKey="Merlo, Lm" uniqKey="Merlo L">LM Merlo</name></author><author><name sortKey="Pigott, E" uniqKey="Pigott E">E Pigott</name></author><author><name sortKey="Keough, Mp" uniqKey="Keough M">MP Keough</name></author><author><name sortKey="Rust, S" uniqKey="Rust S">S Rust</name></author><author><name sortKey="Mellor, Al" uniqKey="Mellor A">AL Mellor</name></author><author><name sortKey="Mandik Nayak, L" uniqKey="Mandik Nayak L">L Mandik-Nayak</name></author><author><name sortKey="Muller, Aj" uniqKey="Muller A">AJ Muller</name></author><author><name sortKey="Prendergast, Gc" uniqKey="Prendergast G">GC Prendergast</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prendergast, Gc" uniqKey="Prendergast G">GC Prendergast</name></author><author><name sortKey="Smith, C" uniqKey="Smith C">C Smith</name></author><author><name sortKey="Thomas, S" uniqKey="Thomas S">S Thomas</name></author><author><name sortKey="Mandik Nayak, L" uniqKey="Mandik Nayak L">L Mandik-Nayak</name></author><author><name sortKey="Laury Kleintop, L" uniqKey="Laury Kleintop L">L Laury-Kleintop</name></author><author><name sortKey="Metz, R" uniqKey="Metz R">R Metz</name></author><author><name sortKey="Muller, Aj" uniqKey="Muller A">AJ Muller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Palm, Nw" uniqKey="Palm N">NW Palm</name></author><author><name sortKey="Medzhitov, R" uniqKey="Medzhitov R">R Medzhitov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Delgado, M" uniqKey="Delgado M">M Delgado</name></author><author><name sortKey="Singh, S" uniqKey="Singh S">S Singh</name></author><author><name sortKey="De Haro, S" uniqKey="De Haro S">S De Haro</name></author><author><name sortKey="Master, S" uniqKey="Master S">S Master</name></author><author><name sortKey="Ponpuak, M" uniqKey="Ponpuak M">M Ponpuak</name></author><author><name sortKey="Dinkins, C" uniqKey="Dinkins C">C Dinkins</name></author><author><name sortKey="Ornatowski, W" uniqKey="Ornatowski W">W Ornatowski</name></author><author><name sortKey="Vergne, I" uniqKey="Vergne I">I Vergne</name></author><author><name sortKey="Deretic, V" uniqKey="Deretic V">V Deretic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kawai, T" uniqKey="Kawai T">T Kawai</name></author><author><name sortKey="Akira, S" uniqKey="Akira S">S Akira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hennessy, Ej" uniqKey="Hennessy E">EJ Hennessy</name></author><author><name sortKey="Parker, Ae" uniqKey="Parker A">AE Parker</name></author><author><name sortKey="O Neill, La" uniqKey="O Neill L">LA O'Neill</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saleh, M" uniqKey="Saleh M">M Saleh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Franchi, L" uniqKey="Franchi L">L Franchi</name></author><author><name sortKey="Warner, N" uniqKey="Warner N">N Warner</name></author><author><name sortKey="Viani, K" uniqKey="Viani K">K Viani</name></author><author><name sortKey="Nunez, G" uniqKey="Nunez G">G Nunez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garg, Ad" uniqKey="Garg A">AD Garg</name></author><author><name sortKey="Martin, S" uniqKey="Martin S">S Martin</name></author><author><name sortKey="Golab, J" uniqKey="Golab J">J Golab</name></author><author><name sortKey="Agostinis, P" uniqKey="Agostinis P">P Agostinis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brenner, C" uniqKey="Brenner C">C Brenner</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spel, L" uniqKey="Spel L">L Spel</name></author><author><name sortKey="Boelens, Jj" uniqKey="Boelens J">JJ Boelens</name></author><author><name sortKey="Nierkens, S" uniqKey="Nierkens S">S Nierkens</name></author><author><name sortKey="Boes, M" uniqKey="Boes M">M Boes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yi, Y" uniqKey="Yi Y">Y Yi</name></author><author><name sortKey="Zhou, Z" uniqKey="Zhou Z">Z Zhou</name></author><author><name sortKey="Shu, S" uniqKey="Shu S">S Shu</name></author><author><name sortKey="Fang, Y" uniqKey="Fang Y">Y Fang</name></author><author><name sortKey="Twitty, C" uniqKey="Twitty C">C Twitty</name></author><author><name sortKey="Hilton, Tl" uniqKey="Hilton T">TL Hilton</name></author><author><name sortKey="Aung, S" uniqKey="Aung S">S Aung</name></author><author><name sortKey="Urba, Wj" uniqKey="Urba W">WJ Urba</name></author><author><name sortKey="Fox, Ba" uniqKey="Fox B">BA Fox</name></author><author><name sortKey="Hu, Hm" uniqKey="Hu H">HM Hu</name></author><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fitzgerald, Ka" uniqKey="Fitzgerald K">KA Fitzgerald</name></author><author><name sortKey="Palsson Mcdermott, Em" uniqKey="Palsson Mcdermott E">EM Palsson-McDermott</name></author><author><name sortKey="Bowie, Ag" uniqKey="Bowie A">AG Bowie</name></author><author><name sortKey="Jefferies, Ca" uniqKey="Jefferies C">CA Jefferies</name></author><author><name sortKey="Mansell, As" uniqKey="Mansell A">AS Mansell</name></author><author><name sortKey="Brady, G" uniqKey="Brady G">G Brady</name></author><author><name sortKey="Brint, E" uniqKey="Brint E">E Brint</name></author><author><name sortKey="Dunne, A" uniqKey="Dunne A">A Dunne</name></author><author><name sortKey="Gray, P" uniqKey="Gray P">P Gray</name></author><author><name sortKey="Harte, Mt" uniqKey="Harte M">MT Harte</name></author><author><name sortKey="Mcmurray, D" uniqKey="Mcmurray D">D McMurray</name></author><author><name sortKey="Smith, De" uniqKey="Smith D">DE Smith</name></author><author><name sortKey="Sims, Je" uniqKey="Sims J">JE Sims</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Medzhitov, R" uniqKey="Medzhitov R">R Medzhitov</name></author><author><name sortKey="Preston Hurlburt, P" uniqKey="Preston Hurlburt P">P Preston-Hurlburt</name></author><author><name sortKey="Kopp, E" uniqKey="Kopp E">E Kopp</name></author><author><name sortKey="Stadlen, A" uniqKey="Stadlen A">A Stadlen</name></author><author><name sortKey="Chen, C" uniqKey="Chen C">C Chen</name></author><author><name sortKey="Ghosh, S" uniqKey="Ghosh S">S Ghosh</name></author><author><name sortKey="Janeway, Ca" uniqKey="Janeway C">CA Janeway</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strober, W" uniqKey="Strober W">W Strober</name></author><author><name sortKey="Murray, Pj" uniqKey="Murray P">PJ Murray</name></author><author><name sortKey="Kitani, A" uniqKey="Kitani A">A Kitani</name></author><author><name sortKey="Watanabe, T" uniqKey="Watanabe T">T Watanabe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamamoto, M" uniqKey="Yamamoto M">M Yamamoto</name></author><author><name sortKey="Sato, S" uniqKey="Sato S">S Sato</name></author><author><name sortKey="Hemmi, H" uniqKey="Hemmi H">H Hemmi</name></author><author><name sortKey="Hoshino, K" uniqKey="Hoshino K">K Hoshino</name></author><author><name sortKey="Kaisho, T" uniqKey="Kaisho T">T Kaisho</name></author><author><name sortKey="Sanjo, H" uniqKey="Sanjo H">H Sanjo</name></author><author><name sortKey="Takeuchi, O" uniqKey="Takeuchi O">O Takeuchi</name></author><author><name sortKey="Sugiyama, M" uniqKey="Sugiyama M">M Sugiyama</name></author><author><name sortKey="Okabe, M" uniqKey="Okabe M">M Okabe</name></author><author><name sortKey="Takeda, K" uniqKey="Takeda K">K Takeda</name></author><author><name sortKey="Akira, S" uniqKey="Akira S">S Akira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Honda, K" uniqKey="Honda K">K Honda</name></author><author><name sortKey="Yanai, H" uniqKey="Yanai H">H Yanai</name></author><author><name sortKey="Negishi, H" uniqKey="Negishi H">H Negishi</name></author><author><name sortKey="Asagiri, M" uniqKey="Asagiri M">M Asagiri</name></author><author><name sortKey="Sato, M" uniqKey="Sato M">M Sato</name></author><author><name sortKey="Mizutani, T" uniqKey="Mizutani T">T Mizutani</name></author><author><name sortKey="Shimada, N" uniqKey="Shimada N">N Shimada</name></author><author><name sortKey="Ohba, Y" uniqKey="Ohba Y">Y Ohba</name></author><author><name sortKey="Takaoka, A" uniqKey="Takaoka A">A Takaoka</name></author><author><name sortKey="Yoshida, N" uniqKey="Yoshida N">N Yoshida</name></author><author><name sortKey="Taniguchi, T" uniqKey="Taniguchi T">T Taniguchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brennan, Tv" uniqKey="Brennan T">TV Brennan</name></author><author><name sortKey="Lin, L" uniqKey="Lin L">L Lin</name></author><author><name sortKey="Huang, X" uniqKey="Huang X">X Huang</name></author><author><name sortKey="Cardona, Dm" uniqKey="Cardona D">DM Cardona</name></author><author><name sortKey="Li, Z" uniqKey="Li Z">Z Li</name></author><author><name sortKey="Dredge, K" uniqKey="Dredge K">K Dredge</name></author><author><name sortKey="Chao, Nj" uniqKey="Chao N">NJ Chao</name></author><author><name sortKey="Yang, Y" uniqKey="Yang Y">Y Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Krysko, Dv" uniqKey="Krysko D">DV Krysko</name></author><author><name sortKey="Garg, Ad" uniqKey="Garg A">AD Garg</name></author><author><name sortKey="Kaczmarek, A" uniqKey="Kaczmarek A">A Kaczmarek</name></author><author><name sortKey="Krysko, O" uniqKey="Krysko O">O Krysko</name></author><author><name sortKey="Agostinis, P" uniqKey="Agostinis P">P Agostinis</name></author><author><name sortKey="Vandenabeele, P" uniqKey="Vandenabeele P">P Vandenabeele</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Schlemmer, F" uniqKey="Schlemmer F">F Schlemmer</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Sukkurwala, Aq" uniqKey="Sukkurwala A">AQ Sukkurwala</name></author><author><name sortKey="Menger, L" uniqKey="Menger L">L Menger</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Vitale, I" uniqKey="Vitale I">I Vitale</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Senovilla, L" uniqKey="Senovilla L">L Senovilla</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Smyth, Mj" uniqKey="Smyth M">MJ Smyth</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Demaria, S" uniqKey="Demaria S">S Demaria</name></author><author><name sortKey="Vanpouille Box, C" uniqKey="Vanpouille Box C">C Vanpouille-Box</name></author><author><name sortKey="Formenti, Sc" uniqKey="Formenti S">SC Formenti</name></author><author><name sortKey="Adams, S" uniqKey="Adams S">S Adams</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brito, La" uniqKey="Brito L">LA Brito</name></author><author><name sortKey="O Hagan, Dt" uniqKey="O Hagan D">DT O'Hagan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maisonneuve, C" uniqKey="Maisonneuve C">C Maisonneuve</name></author><author><name sortKey="Bertholet, S" uniqKey="Bertholet S">S Bertholet</name></author><author><name sortKey="Philpott, Dj" uniqKey="Philpott D">DJ Philpott</name></author><author><name sortKey="De Gregorio, E" uniqKey="De Gregorio E">E De Gregorio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Narayan, R" uniqKey="Narayan R">R Narayan</name></author><author><name sortKey="Nguyen, H" uniqKey="Nguyen H">H Nguyen</name></author><author><name sortKey="Bentow, Jj" uniqKey="Bentow J">JJ Bentow</name></author><author><name sortKey="Moy, L" uniqKey="Moy L">L Moy</name></author><author><name sortKey="Lee, Dk" uniqKey="Lee D">DK Lee</name></author><author><name sortKey="Greger, S" uniqKey="Greger S">S Greger</name></author><author><name sortKey="Haskell, J" uniqKey="Haskell J">J Haskell</name></author><author><name sortKey="Vanchinathan, V" uniqKey="Vanchinathan V">V Vanchinathan</name></author><author><name sortKey="Chang, Pl" uniqKey="Chang P">PL Chang</name></author><author><name sortKey="Tsui, S" uniqKey="Tsui S">S Tsui</name></author><author><name sortKey="Konishi, T" uniqKey="Konishi T">T Konishi</name></author><author><name sortKey="Comin Anduix, B" uniqKey="Comin Anduix B">B Comin-Anduix</name></author><author><name sortKey="Dauphine, C" uniqKey="Dauphine C">C Dauphine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoffman, Es" uniqKey="Hoffman E">ES Hoffman</name></author><author><name sortKey="Smith, Re" uniqKey="Smith R">RE Smith</name></author><author><name sortKey="Renaud, Rc" uniqKey="Renaud R">RC Renaud</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paavonen, J" uniqKey="Paavonen J">J Paavonen</name></author><author><name sortKey="Naud, P" uniqKey="Naud P">P Naud</name></author><author><name sortKey="Salmeron, J" uniqKey="Salmeron J">J Salmeron</name></author><author><name sortKey="Wheeler, Cm" uniqKey="Wheeler C">CM Wheeler</name></author><author><name sortKey="Chow, Sn" uniqKey="Chow S">SN Chow</name></author><author><name sortKey="Apter, D" uniqKey="Apter D">D Apter</name></author><author><name sortKey="Kitchener, H" uniqKey="Kitchener H">H Kitchener</name></author><author><name sortKey="Castellsague, X" uniqKey="Castellsague X">X Castellsague</name></author><author><name sortKey="Teixeira, Jc" uniqKey="Teixeira J">JC Teixeira</name></author><author><name sortKey="Skinner, Sr" uniqKey="Skinner S">SR Skinner</name></author><author><name sortKey="Hedrick, J" uniqKey="Hedrick J">J Hedrick</name></author><author><name sortKey="Jaisamrarn, U" uniqKey="Jaisamrarn U">U Jaisamrarn</name></author><author><name sortKey="Limson, G" uniqKey="Limson G">G Limson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Okamoto, H" uniqKey="Okamoto H">H Okamoto</name></author><author><name sortKey="Shoin, S" uniqKey="Shoin S">S Shoin</name></author><author><name sortKey="Koshimura, S" uniqKey="Koshimura S">S Koshimura</name></author><author><name sortKey="Shimizu, R" uniqKey="Shimizu R">R Shimizu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rakoff Nahoum, S" uniqKey="Rakoff Nahoum S">S Rakoff-Nahoum</name></author><author><name sortKey="Medzhitov, R" uniqKey="Medzhitov R">R Medzhitov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ando, K" uniqKey="Ando K">K Ando</name></author><author><name sortKey="Mori, K" uniqKey="Mori K">K Mori</name></author><author><name sortKey="Corradini, N" uniqKey="Corradini N">N Corradini</name></author><author><name sortKey="Redini, F" uniqKey="Redini F">F Redini</name></author><author><name sortKey="Heymann, D" uniqKey="Heymann D">D Heymann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Murray, Jl" uniqKey="Murray J">JL Murray</name></author><author><name sortKey="Kleinerman, Es" uniqKey="Kleinerman E">ES Kleinerman</name></author><author><name sortKey="Cunningham, Je" uniqKey="Cunningham J">JE Cunningham</name></author><author><name sortKey="Tatom, Jr" uniqKey="Tatom J">JR Tatom</name></author><author><name sortKey="Andrejcio, K" uniqKey="Andrejcio K">K Andrejcio</name></author><author><name sortKey="Lepe Zuniga, J" uniqKey="Lepe Zuniga J">J Lepe-Zuniga</name></author><author><name sortKey="Lamki, Lm" uniqKey="Lamki L">LM Lamki</name></author><author><name sortKey="Rosenblum, Mg" uniqKey="Rosenblum M">MG Rosenblum</name></author><author><name sortKey="Frost, H" uniqKey="Frost H">H Frost</name></author><author><name sortKey="Gutterman, Ju" uniqKey="Gutterman J">JU Gutterman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fidler, Ij" uniqKey="Fidler I">IJ Fidler</name></author><author><name sortKey="Fogler, We" uniqKey="Fogler W">WE Fogler</name></author><author><name sortKey="Brownbill, Af" uniqKey="Brownbill A">AF Brownbill</name></author><author><name sortKey="Schumann, G" uniqKey="Schumann G">G Schumann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Tartour, E" uniqKey="Tartour E">E Tartour</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Eggermont, A" uniqKey="Eggermont A">A Eggermont</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Murad, Ym" uniqKey="Murad Y">YM Murad</name></author><author><name sortKey="Clay, Tm" uniqKey="Clay T">TM Clay</name></author><author><name sortKey="Lyerly, Hk" uniqKey="Lyerly H">HK Lyerly</name></author><author><name sortKey="Morse, Ma" uniqKey="Morse M">MA Morse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alexopoulou, L" uniqKey="Alexopoulou L">L Alexopoulou</name></author><author><name sortKey="Holt, Ac" uniqKey="Holt A">AC Holt</name></author><author><name sortKey="Medzhitov, R" uniqKey="Medzhitov R">R Medzhitov</name></author><author><name sortKey="Flavell, Ra" uniqKey="Flavell R">RA Flavell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levy, Hb" uniqKey="Levy H">HB Levy</name></author><author><name sortKey="Baer, G" uniqKey="Baer G">G Baer</name></author><author><name sortKey="Baron, S" uniqKey="Baron S">S Baron</name></author><author><name sortKey="Buckler, Ce" uniqKey="Buckler C">CE Buckler</name></author><author><name sortKey="Gibbs, Cj" uniqKey="Gibbs C">CJ Gibbs</name></author><author><name sortKey="Iadarola, Mj" uniqKey="Iadarola M">MJ Iadarola</name></author><author><name sortKey="London, Wt" uniqKey="London W">WT London</name></author><author><name sortKey="Rice, J" uniqKey="Rice J">J Rice</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hagstrom, J" uniqKey="Hagstrom J">J Hagstrom</name></author><author><name sortKey="Heikkila, A" uniqKey="Heikkila A">A Heikkila</name></author><author><name sortKey="Siironen, P" uniqKey="Siironen P">P Siironen</name></author><author><name sortKey="Louhimo, J" uniqKey="Louhimo J">J Louhimo</name></author><author><name sortKey="Heiskanen, I" uniqKey="Heiskanen I">I Heiskanen</name></author><author><name sortKey="Maenpaa, H" uniqKey="Maenpaa H">H Maenpaa</name></author><author><name sortKey="Arola, J" uniqKey="Arola J">J Arola</name></author><author><name sortKey="Haglund, C" uniqKey="Haglund C">C Haglund</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kauppila, Jh" uniqKey="Kauppila J">JH Kauppila</name></author><author><name sortKey="Mattila, Ae" uniqKey="Mattila A">AE Mattila</name></author><author><name sortKey="Karttunen, Tj" uniqKey="Karttunen T">TJ Karttunen</name></author><author><name sortKey="Salo, T" uniqKey="Salo T">T Salo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kauppila, Jh" uniqKey="Kauppila J">JH Kauppila</name></author><author><name sortKey="Mattila, Ae" uniqKey="Mattila A">AE Mattila</name></author><author><name sortKey="Karttunen, Tj" uniqKey="Karttunen T">TJ Karttunen</name></author><author><name sortKey="Salo, T" uniqKey="Salo T">T Salo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahmed, A" uniqKey="Ahmed A">A Ahmed</name></author><author><name sortKey="Redmond, Hp" uniqKey="Redmond H">HP Redmond</name></author><author><name sortKey="Wang, Jh" uniqKey="Wang J">JH Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Conti, L" uniqKey="Conti L">L Conti</name></author><author><name sortKey="Lanzardo, S" uniqKey="Lanzardo S">S Lanzardo</name></author><author><name sortKey="Arigoni, M" uniqKey="Arigoni M">M Arigoni</name></author><author><name sortKey="Antonazzo, R" uniqKey="Antonazzo R">R Antonazzo</name></author><author><name sortKey="Radaelli, E" uniqKey="Radaelli E">E Radaelli</name></author><author><name sortKey="Cantarella, D" uniqKey="Cantarella D">D Cantarella</name></author><author><name sortKey="Calogero, Ra" uniqKey="Calogero R">RA Calogero</name></author><author><name sortKey="Cavallo, F" uniqKey="Cavallo F">F Cavallo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tye, H" uniqKey="Tye H">H Tye</name></author><author><name sortKey="Kennedy, Cl" uniqKey="Kennedy C">CL Kennedy</name></author><author><name sortKey="Najdovska, M" uniqKey="Najdovska M">M Najdovska</name></author><author><name sortKey="Mcleod, L" uniqKey="Mcleod L">L McLeod</name></author><author><name sortKey="Mccormack, W" uniqKey="Mccormack W">W McCormack</name></author><author><name sortKey="Hughes, N" uniqKey="Hughes N">N Hughes</name></author><author><name sortKey="Dev, A" uniqKey="Dev A">A Dev</name></author><author><name sortKey="Sievert, W" uniqKey="Sievert W">W Sievert</name></author><author><name sortKey="Ooi, Ch" uniqKey="Ooi C">CH Ooi</name></author><author><name sortKey="Ishikawa, To" uniqKey="Ishikawa T">TO Ishikawa</name></author><author><name sortKey="Oshima, H" uniqKey="Oshima H">H Oshima</name></author><author><name sortKey="Bhathal, Ps" uniqKey="Bhathal P">PS Bhathal</name></author><author><name sortKey="Parker, Ae" uniqKey="Parker A">AE Parker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cherfils Vicini, J" uniqKey="Cherfils Vicini J">J Cherfils-Vicini</name></author><author><name sortKey="Platonova, S" uniqKey="Platonova S">S Platonova</name></author><author><name sortKey="Gillard, M" uniqKey="Gillard M">M Gillard</name></author><author><name sortKey="Laurans, L" uniqKey="Laurans L">L Laurans</name></author><author><name sortKey="Validire, P" uniqKey="Validire P">P Validire</name></author><author><name sortKey="Caliandro, R" uniqKey="Caliandro R">R Caliandro</name></author><author><name sortKey="Magdeleinat, P" uniqKey="Magdeleinat P">P Magdeleinat</name></author><author><name sortKey="Mami Chouaib, F" uniqKey="Mami Chouaib F">F Mami-Chouaib</name></author><author><name sortKey="Dieu Nosjean, Mc" uniqKey="Dieu Nosjean M">MC Dieu-Nosjean</name></author><author><name sortKey="Fridman, Wh" uniqKey="Fridman W">WH Fridman</name></author><author><name sortKey="Damotte, D" uniqKey="Damotte D">D Damotte</name></author><author><name sortKey="Sautes Fridman, C" uniqKey="Sautes Fridman C">C Sautes-Fridman</name></author><author><name sortKey="Cremer, I" uniqKey="Cremer I">I Cremer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pasquier, E" uniqKey="Pasquier E">E Pasquier</name></author><author><name sortKey="Kavallaris, M" uniqKey="Kavallaris M">M Kavallaris</name></author><author><name sortKey="Andre, N" uniqKey="Andre N">N Andre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sheng Sow, H" uniqKey="Sheng Sow H">H Sheng Sow</name></author><author><name sortKey="Mattarollo, Sr" uniqKey="Mattarollo S">SR Mattarollo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garg, Ad" uniqKey="Garg A">AD Garg</name></author><author><name sortKey="Krysko, Dv" uniqKey="Krysko D">DV Krysko</name></author><author><name sortKey="Verfaillie, T" uniqKey="Verfaillie T">T Verfaillie</name></author><author><name sortKey="Kaczmarek, A" uniqKey="Kaczmarek A">A Kaczmarek</name></author><author><name sortKey="Ferreira, Gb" uniqKey="Ferreira G">GB Ferreira</name></author><author><name sortKey="Marysael, T" uniqKey="Marysael T">T Marysael</name></author><author><name sortKey="Rubio, N" uniqKey="Rubio N">N Rubio</name></author><author><name sortKey="Firczuk, M" uniqKey="Firczuk M">M Firczuk</name></author><author><name sortKey="Mathieu, C" uniqKey="Mathieu C">C Mathieu</name></author><author><name sortKey="Roebroek, Aj" uniqKey="Roebroek A">AJ Roebroek</name></author><author><name sortKey="Annaert, W" uniqKey="Annaert W">W Annaert</name></author><author><name sortKey="Golab, J" uniqKey="Golab J">J Golab</name></author><author><name sortKey="De Witte, P" uniqKey="De Witte P">P de Witte</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Panaretakis, T" uniqKey="Panaretakis T">T Panaretakis</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Brockmeier, U" uniqKey="Brockmeier U">U Brockmeier</name></author><author><name sortKey="Tesniere, A" uniqKey="Tesniere A">A Tesniere</name></author><author><name sortKey="Bjorklund, Ac" uniqKey="Bjorklund A">AC Bjorklund</name></author><author><name sortKey="Chapman, Dc" uniqKey="Chapman D">DC Chapman</name></author><author><name sortKey="Durchschlag, M" uniqKey="Durchschlag M">M Durchschlag</name></author><author><name sortKey="Joza, N" uniqKey="Joza N">N Joza</name></author><author><name sortKey="Pierron, G" uniqKey="Pierron G">G Pierron</name></author><author><name sortKey="Van Endert, P" uniqKey="Van Endert P">P van Endert</name></author><author><name sortKey="Yuan, J" uniqKey="Yuan J">J Yuan</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Madeo, F" uniqKey="Madeo F">F Madeo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cirone, M" uniqKey="Cirone M">M Cirone</name></author><author><name sortKey="Di Renzo, L" uniqKey="Di Renzo L">L Di Renzo</name></author><author><name sortKey="Lotti, Lv" uniqKey="Lotti L">LV Lotti</name></author><author><name sortKey="Conte, V" uniqKey="Conte V">V Conte</name></author><author><name sortKey="Trivedi, P" uniqKey="Trivedi P">P Trivedi</name></author><author><name sortKey="Santarelli, R" uniqKey="Santarelli R">R Santarelli</name></author><author><name sortKey="Gonnella, R" uniqKey="Gonnella R">R Gonnella</name></author><author><name sortKey="Frati, L" uniqKey="Frati L">L Frati</name></author><author><name sortKey="Faggioni, A" uniqKey="Faggioni A">A Faggioni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Menger, L" uniqKey="Menger L">L Menger</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Ma, Y" uniqKey="Ma Y">Y Ma</name></author><author><name sortKey="Shen, S" uniqKey="Shen S">S Shen</name></author><author><name sortKey="Yamazaki, T" uniqKey="Yamazaki T">T Yamazaki</name></author><author><name sortKey="Sukkurwala, Aq" uniqKey="Sukkurwala A">AQ Sukkurwala</name></author><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Mignot, G" uniqKey="Mignot G">G Mignot</name></author><author><name sortKey="Schlemmer, F" uniqKey="Schlemmer F">F Schlemmer</name></author><author><name sortKey="Sulpice, E" uniqKey="Sulpice E">E Sulpice</name></author><author><name sortKey="Locher, C" uniqKey="Locher C">C Locher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Sukkurwala, Aq" uniqKey="Sukkurwala A">AQ Sukkurwala</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Ma, Y" uniqKey="Ma Y">Y Ma</name></author><author><name sortKey="Pellegatti, P" uniqKey="Pellegatti P">P Pellegatti</name></author><author><name sortKey="Shen, S" uniqKey="Shen S">S Shen</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Scoazec, M" uniqKey="Scoazec M">M Scoazec</name></author><author><name sortKey="Mignot, G" uniqKey="Mignot G">G Mignot</name></author><author><name sortKey="Rello Varona, S" uniqKey="Rello Varona S">S Rello-Varona</name></author><author><name sortKey="Tailler, M" uniqKey="Tailler M">M Tailler</name></author><author><name sortKey="Menger, L" uniqKey="Menger L">L Menger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tesniere, A" uniqKey="Tesniere A">A Tesniere</name></author><author><name sortKey="Schlemmer, F" uniqKey="Schlemmer F">F Schlemmer</name></author><author><name sortKey="Boige, V" uniqKey="Boige V">V Boige</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Ghiringhelli, F" uniqKey="Ghiringhelli F">F Ghiringhelli</name></author><author><name sortKey="Aymeric, L" uniqKey="Aymeric L">L Aymeric</name></author><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Apetoh, L" uniqKey="Apetoh L">L Apetoh</name></author><author><name sortKey="Barault, L" uniqKey="Barault L">L Barault</name></author><author><name sortKey="Mendiboure, J" uniqKey="Mendiboure J">J Mendiboure</name></author><author><name sortKey="Pignon, Jp" uniqKey="Pignon J">JP Pignon</name></author><author><name sortKey="Jooste, V" uniqKey="Jooste V">V Jooste</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ma, Y" uniqKey="Ma Y">Y Ma</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Mattarollo, Sr" uniqKey="Mattarollo S">SR Mattarollo</name></author><author><name sortKey="Yamazaki, T" uniqKey="Yamazaki T">T Yamazaki</name></author><author><name sortKey="Aymeric, L" uniqKey="Aymeric L">L Aymeric</name></author><author><name sortKey="Yang, H" uniqKey="Yang H">H Yang</name></author><author><name sortKey="Portela Catani, Jp" uniqKey="Portela Catani J">JP Portela Catani</name></author><author><name sortKey="Hannani, D" uniqKey="Hannani D">D Hannani</name></author><author><name sortKey="Duret, H" uniqKey="Duret H">H Duret</name></author><author><name sortKey="Steegh, K" uniqKey="Steegh K">K Steegh</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Schlemmer, F" uniqKey="Schlemmer F">F Schlemmer</name></author><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Senovilla, L" uniqKey="Senovilla L">L Senovilla</name></author><author><name sortKey="Vitale, I" uniqKey="Vitale I">I Vitale</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Agostinis, P" uniqKey="Agostinis P">P Agostinis</name></author><author><name sortKey="Apetoh, L" uniqKey="Apetoh L">L Apetoh</name></author><author><name sortKey="Aranda, F" uniqKey="Aranda F">F Aranda</name></author><author><name sortKey="Barnaba, V" uniqKey="Barnaba V">V Barnaba</name></author><author><name sortKey="Bloy, N" uniqKey="Bloy N">N Bloy</name></author><author><name sortKey="Bracci, L" uniqKey="Bracci L">L Bracci</name></author><author><name sortKey="Breckpot, K" uniqKey="Breckpot K">K Breckpot</name></author><author><name sortKey="Brough, D" uniqKey="Brough D">D Brough</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bugaut, H" uniqKey="Bugaut H">H Bugaut</name></author><author><name sortKey="Bruchard, M" uniqKey="Bruchard M">M Bruchard</name></author><author><name sortKey="Berger, H" uniqKey="Berger H">H Berger</name></author><author><name sortKey="Derangere, V" uniqKey="Derangere V">V Derangere</name></author><author><name sortKey="Odoul, L" uniqKey="Odoul L">L Odoul</name></author><author><name sortKey="Euvrard, R" uniqKey="Euvrard R">R Euvrard</name></author><author><name sortKey="Ladoire, S" uniqKey="Ladoire S">S Ladoire</name></author><author><name sortKey="Chalmin, F" uniqKey="Chalmin F">F Chalmin</name></author><author><name sortKey="Vegran, F" uniqKey="Vegran F">F Vegran</name></author><author><name sortKey="Rebe, C" uniqKey="Rebe C">C Rebe</name></author><author><name sortKey="Apetoh, L" uniqKey="Apetoh L">L Apetoh</name></author><author><name sortKey="Ghiringhelli, F" uniqKey="Ghiringhelli F">F Ghiringhelli</name></author><author><name sortKey="Mignot, G" uniqKey="Mignot G">G Mignot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Schlemmer, F" uniqKey="Schlemmer F">F Schlemmer</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Tailler, M" uniqKey="Tailler M">M Tailler</name></author><author><name sortKey="Shen, S" uniqKey="Shen S">S Shen</name></author><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Menger, L" uniqKey="Menger L">L Menger</name></author><author><name sortKey="Gdoura, A" uniqKey="Gdoura A">A Gdoura</name></author><author><name sortKey="Tajeddine, N" uniqKey="Tajeddine N">N Tajeddine</name></author><author><name sortKey="Tesniere, A" uniqKey="Tesniere A">A Tesniere</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schiavoni, G" uniqKey="Schiavoni G">G Schiavoni</name></author><author><name sortKey="Sistigu, A" uniqKey="Sistigu A">A Sistigu</name></author><author><name sortKey="Valentini, M" uniqKey="Valentini M">M Valentini</name></author><author><name sortKey="Mattei, F" uniqKey="Mattei F">F Mattei</name></author><author><name sortKey="Sestili, P" uniqKey="Sestili P">P Sestili</name></author><author><name sortKey="Spadaro, F" uniqKey="Spadaro F">F Spadaro</name></author><author><name sortKey="Sanchez, M" uniqKey="Sanchez M">M Sanchez</name></author><author><name sortKey="Lorenzi, S" uniqKey="Lorenzi S">S Lorenzi</name></author><author><name sortKey="D Urso, Mt" uniqKey="D Urso M">MT D'Urso</name></author><author><name sortKey="Belardelli, F" uniqKey="Belardelli F">F Belardelli</name></author><author><name sortKey="Gabriele, L" uniqKey="Gabriele L">L Gabriele</name></author><author><name sortKey="Proietti, E" uniqKey="Proietti E">E Proietti</name></author><author><name sortKey="Bracci, L" uniqKey="Bracci L">L Bracci</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sistigu, A" uniqKey="Sistigu A">A Sistigu</name></author><author><name sortKey="Yamazaki, T" uniqKey="Yamazaki T">T Yamazaki</name></author><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Chaba, K" uniqKey="Chaba K">K Chaba</name></author><author><name sortKey="Enot, Dp" uniqKey="Enot D">DP Enot</name></author><author><name sortKey="Adam, J" uniqKey="Adam J">J Adam</name></author><author><name sortKey="Vitale, I" uniqKey="Vitale I">I Vitale</name></author><author><name sortKey="Goubar, A" uniqKey="Goubar A">A Goubar</name></author><author><name sortKey="Baracco, Ee" uniqKey="Baracco E">EE Baracco</name></author><author><name sortKey="Remedios, C" uniqKey="Remedios C">C Remedios</name></author><author><name sortKey="Fend, L" uniqKey="Fend L">L Fend</name></author><author><name sortKey="Hannani, D" uniqKey="Hannani D">D Hannani</name></author><author><name sortKey="Aymeric, L" uniqKey="Aymeric L">L Aymeric</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guerriero, Jl" uniqKey="Guerriero J">JL Guerriero</name></author><author><name sortKey="Ditsworth, D" uniqKey="Ditsworth D">D Ditsworth</name></author><author><name sortKey="Fan, Y" uniqKey="Fan Y">Y Fan</name></author><author><name sortKey="Zhao, F" uniqKey="Zhao F">F Zhao</name></author><author><name sortKey="Crawford, Hc" uniqKey="Crawford H">HC Crawford</name></author><author><name sortKey="Zong, Wx" uniqKey="Zong W">WX Zong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Suzuki, Y" uniqKey="Suzuki Y">Y Suzuki</name></author><author><name sortKey="Mimura, K" uniqKey="Mimura K">K Mimura</name></author><author><name sortKey="Yoshimoto, Y" uniqKey="Yoshimoto Y">Y Yoshimoto</name></author><author><name sortKey="Watanabe, M" uniqKey="Watanabe M">M Watanabe</name></author><author><name sortKey="Ohkubo, Y" uniqKey="Ohkubo Y">Y Ohkubo</name></author><author><name sortKey="Izawa, S" uniqKey="Izawa S">S Izawa</name></author><author><name sortKey="Murata, K" uniqKey="Murata K">K Murata</name></author><author><name sortKey="Fujii, H" uniqKey="Fujii H">H Fujii</name></author><author><name sortKey="Nakano, T" uniqKey="Nakano T">T Nakano</name></author><author><name sortKey="Kono, K" uniqKey="Kono K">K Kono</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ko, A" uniqKey="Ko A">A Ko</name></author><author><name sortKey="Kanehisa, A" uniqKey="Kanehisa A">A Kanehisa</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Senovilla, L" uniqKey="Senovilla L">L Senovilla</name></author><author><name sortKey="Chargari, C" uniqKey="Chargari C">C Chargari</name></author><author><name sortKey="Dugue, D" uniqKey="Dugue D">D Dugue</name></author><author><name sortKey="Marino, G" uniqKey="Marino G">G Marino</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Perfettini, Jl" uniqKey="Perfettini J">JL Perfettini</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Deutsch, E" uniqKey="Deutsch E">E Deutsch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gameiro, Sr" uniqKey="Gameiro S">SR Gameiro</name></author><author><name sortKey="Jammeh, Ml" uniqKey="Jammeh M">ML Jammeh</name></author><author><name sortKey="Wattenberg, Mm" uniqKey="Wattenberg M">MM Wattenberg</name></author><author><name sortKey="Tsang, Ky" uniqKey="Tsang K">KY Tsang</name></author><author><name sortKey="Ferrone, S" uniqKey="Ferrone S">S Ferrone</name></author><author><name sortKey="Hodge, Jw" uniqKey="Hodge J">JW Hodge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schildkopf, P" uniqKey="Schildkopf P">P Schildkopf</name></author><author><name sortKey="Frey, B" uniqKey="Frey B">B Frey</name></author><author><name sortKey="Ott, Oj" uniqKey="Ott O">OJ Ott</name></author><author><name sortKey="Rubner, Y" uniqKey="Rubner Y">Y Rubner</name></author><author><name sortKey="Multhoff, G" uniqKey="Multhoff G">G Multhoff</name></author><author><name sortKey="Sauer, R" uniqKey="Sauer R">R Sauer</name></author><author><name sortKey="Fietkau, R" uniqKey="Fietkau R">R Fietkau</name></author><author><name sortKey="Gaipl, Us" uniqKey="Gaipl U">US Gaipl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hasumi, K" uniqKey="Hasumi K">K Hasumi</name></author><author><name sortKey="Aoki, Y" uniqKey="Aoki Y">Y Aoki</name></author><author><name sortKey="Wantanabe, R" uniqKey="Wantanabe R">R Wantanabe</name></author><author><name sortKey="Mann, Dl" uniqKey="Mann D">DL Mann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garg, Ad" uniqKey="Garg A">AD Garg</name></author><author><name sortKey="Krysko, Dv" uniqKey="Krysko D">DV Krysko</name></author><author><name sortKey="Vandenabeele, P" uniqKey="Vandenabeele P">P Vandenabeele</name></author><author><name sortKey="Agostinis, P" uniqKey="Agostinis P">P Agostinis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spisek, R" uniqKey="Spisek R">R Spisek</name></author><author><name sortKey="Charalambous, A" uniqKey="Charalambous A">A Charalambous</name></author><author><name sortKey="Mazumder, A" uniqKey="Mazumder A">A Mazumder</name></author><author><name sortKey="Vesole, Dh" uniqKey="Vesole D">DH Vesole</name></author><author><name sortKey="Jagannath, S" uniqKey="Jagannath S">S Jagannath</name></author><author><name sortKey="Dhodapkar, Mv" uniqKey="Dhodapkar M">MV Dhodapkar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Demaria, S" uniqKey="Demaria S">S Demaria</name></author><author><name sortKey="Santori, Fr" uniqKey="Santori F">FR Santori</name></author><author><name sortKey="Ng, B" uniqKey="Ng B">B Ng</name></author><author><name sortKey="Liebes, L" uniqKey="Liebes L">L Liebes</name></author><author><name sortKey="Formenti, Sc" uniqKey="Formenti S">SC Formenti</name></author><author><name sortKey="Vukmanovic, S" uniqKey="Vukmanovic S">S Vukmanovic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vacchelli, E" uniqKey="Vacchelli E">E Vacchelli</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Rousseau, V" uniqKey="Rousseau V">V Rousseau</name></author><author><name sortKey="Rigoni, A" uniqKey="Rigoni A">A Rigoni</name></author><author><name sortKey="Tesniere, A" uniqKey="Tesniere A">A Tesniere</name></author><author><name sortKey="Delahaye, N" uniqKey="Delahaye N">N Delahaye</name></author><author><name sortKey="Schlemmer, Fd" uniqKey="Schlemmer F">FD Schlemmer</name></author><author><name sortKey="Menger, L" uniqKey="Menger L">L Menger</name></author><author><name sortKey="Sukkurwala, Aq" uniqKey="Sukkurwala A">AQ Sukkurwala</name></author><author><name sortKey="Adjemian, S" uniqKey="Adjemian S">S Adjemian</name></author><author><name sortKey="Martins, I" uniqKey="Martins I">I Martins</name></author><author><name sortKey="Michaud, M" uniqKey="Michaud M">M Michaud</name></author><author><name sortKey="Dunant, A" uniqKey="Dunant A">A Dunant</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Gw" uniqKey="Muller G">GW Muller</name></author><author><name sortKey="Corral, Lg" uniqKey="Corral L">LG Corral</name></author><author><name sortKey="Shire, Mg" uniqKey="Shire M">MG Shire</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author><author><name sortKey="Moreira, A" uniqKey="Moreira A">A Moreira</name></author><author><name sortKey="Kaplan, G" uniqKey="Kaplan G">G Kaplan</name></author><author><name sortKey="Stirling, Di" uniqKey="Stirling D">DI Stirling</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Curran, Wj" uniqKey="Curran W">WJ Curran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sarno, En" uniqKey="Sarno E">EN Sarno</name></author><author><name sortKey="Grau, Ge" uniqKey="Grau G">GE Grau</name></author><author><name sortKey="Vieira, Lm" uniqKey="Vieira L">LM Vieira</name></author><author><name sortKey="Nery, Ja" uniqKey="Nery J">JA Nery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raje, N" uniqKey="Raje N">N Raje</name></author><author><name sortKey="Anderson, K" uniqKey="Anderson K">K Anderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singhal, S" uniqKey="Singhal S">S Singhal</name></author><author><name sortKey="Mehta, J" uniqKey="Mehta J">J Mehta</name></author><author><name sortKey="Desikan, R" uniqKey="Desikan R">R Desikan</name></author><author><name sortKey="Ayers, D" uniqKey="Ayers D">D Ayers</name></author><author><name sortKey="Roberson, P" uniqKey="Roberson P">P Roberson</name></author><author><name sortKey="Eddlemon, P" uniqKey="Eddlemon P">P Eddlemon</name></author><author><name sortKey="Munshi, N" uniqKey="Munshi N">N Munshi</name></author><author><name sortKey="Anaissie, E" uniqKey="Anaissie E">E Anaissie</name></author><author><name sortKey="Wilson, C" uniqKey="Wilson C">C Wilson</name></author><author><name sortKey="Dhodapkar, M" uniqKey="Dhodapkar M">M Dhodapkar</name></author><author><name sortKey="Zeddis, J" uniqKey="Zeddis J">J Zeddis</name></author><author><name sortKey="Barlogie, B" uniqKey="Barlogie B">B Barlogie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dimopoulos, M" uniqKey="Dimopoulos M">M Dimopoulos</name></author><author><name sortKey="Spencer, A" uniqKey="Spencer A">A Spencer</name></author><author><name sortKey="Attal, M" uniqKey="Attal M">M Attal</name></author><author><name sortKey="Prince, Hm" uniqKey="Prince H">HM Prince</name></author><author><name sortKey="Harousseau, Jl" uniqKey="Harousseau J">JL Harousseau</name></author><author><name sortKey="Dmoszynska, A" uniqKey="Dmoszynska A">A Dmoszynska</name></author><author><name sortKey="San Miguel, J" uniqKey="San Miguel J">J San Miguel</name></author><author><name sortKey="Hellmann, A" uniqKey="Hellmann A">A Hellmann</name></author><author><name sortKey="Facon, T" uniqKey="Facon T">T Facon</name></author><author><name sortKey="Foa, R" uniqKey="Foa R">R Foa</name></author><author><name sortKey="Corso, A" uniqKey="Corso A">A Corso</name></author><author><name sortKey="Masliak, Z" uniqKey="Masliak Z">Z Masliak</name></author><author><name sortKey="Olesnyckyj, M" uniqKey="Olesnyckyj M">M Olesnyckyj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weber, Dm" uniqKey="Weber D">DM Weber</name></author><author><name sortKey="Chen, C" uniqKey="Chen C">C Chen</name></author><author><name sortKey="Niesvizky, R" uniqKey="Niesvizky R">R Niesvizky</name></author><author><name sortKey="Wang, M" uniqKey="Wang M">M Wang</name></author><author><name sortKey="Belch, A" uniqKey="Belch A">A Belch</name></author><author><name sortKey="Stadtmauer, Ea" uniqKey="Stadtmauer E">EA Stadtmauer</name></author><author><name sortKey="Siegel, D" uniqKey="Siegel D">D Siegel</name></author><author><name sortKey="Borrello, I" uniqKey="Borrello I">I Borrello</name></author><author><name sortKey="Rajkumar, Sv" uniqKey="Rajkumar S">SV Rajkumar</name></author><author><name sortKey="Chanan Khan, Aa" uniqKey="Chanan Khan A">AA Chanan-Khan</name></author><author><name sortKey="Lonial, S" uniqKey="Lonial S">S Lonial</name></author><author><name sortKey="Yu, Z" uniqKey="Yu Z">Z Yu</name></author><author><name sortKey="Patin, J" uniqKey="Patin J">J Patin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="List, A" uniqKey="List A">A List</name></author><author><name sortKey="Dewald, G" uniqKey="Dewald G">G Dewald</name></author><author><name sortKey="Bennett, J" uniqKey="Bennett J">J Bennett</name></author><author><name sortKey="Giagounidis, A" uniqKey="Giagounidis A">A Giagounidis</name></author><author><name sortKey="Raza, A" uniqKey="Raza A">A Raza</name></author><author><name sortKey="Feldman, E" uniqKey="Feldman E">E Feldman</name></author><author><name sortKey="Powell, B" uniqKey="Powell B">B Powell</name></author><author><name sortKey="Greenberg, P" uniqKey="Greenberg P">P Greenberg</name></author><author><name sortKey="Thomas, D" uniqKey="Thomas D">D Thomas</name></author><author><name sortKey="Stone, R" uniqKey="Stone R">R Stone</name></author><author><name sortKey="Reeder, C" uniqKey="Reeder C">C Reeder</name></author><author><name sortKey="Wride, K" uniqKey="Wride K">K Wride</name></author><author><name sortKey="Patin, J" uniqKey="Patin J">J Patin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="List, A" uniqKey="List A">A List</name></author><author><name sortKey="Kurtin, S" uniqKey="Kurtin S">S Kurtin</name></author><author><name sortKey="Roe, Dj" uniqKey="Roe D">DJ Roe</name></author><author><name sortKey="Buresh, A" uniqKey="Buresh A">A Buresh</name></author><author><name sortKey="Mahadevan, D" uniqKey="Mahadevan D">D Mahadevan</name></author><author><name sortKey="Fuchs, D" uniqKey="Fuchs D">D Fuchs</name></author><author><name sortKey="Rimsza, L" uniqKey="Rimsza L">L Rimsza</name></author><author><name sortKey="Heaton, R" uniqKey="Heaton R">R Heaton</name></author><author><name sortKey="Knight, R" uniqKey="Knight R">R Knight</name></author><author><name sortKey="Zeldis, Jb" uniqKey="Zeldis J">JB Zeldis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="San Miguel, J" uniqKey="San Miguel J">J San Miguel</name></author><author><name sortKey="Weisel, K" uniqKey="Weisel K">K Weisel</name></author><author><name sortKey="Moreau, P" uniqKey="Moreau P">P Moreau</name></author><author><name sortKey="Lacy, M" uniqKey="Lacy M">M Lacy</name></author><author><name sortKey="Song, K" uniqKey="Song K">K Song</name></author><author><name sortKey="Delforge, M" uniqKey="Delforge M">M Delforge</name></author><author><name sortKey="Karlin, L" uniqKey="Karlin L">L Karlin</name></author><author><name sortKey="Goldschmidt, H" uniqKey="Goldschmidt H">H Goldschmidt</name></author><author><name sortKey="Banos, A" uniqKey="Banos A">A Banos</name></author><author><name sortKey="Oriol, A" uniqKey="Oriol A">A Oriol</name></author><author><name sortKey="Alegre, A" uniqKey="Alegre A">A Alegre</name></author><author><name sortKey="Chen, C" uniqKey="Chen C">C Chen</name></author><author><name sortKey="Cavo, M" uniqKey="Cavo M">M Cavo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goy, A" uniqKey="Goy A">A Goy</name></author><author><name sortKey="Sinha, R" uniqKey="Sinha R">R Sinha</name></author><author><name sortKey="Williams, Me" uniqKey="Williams M">ME Williams</name></author><author><name sortKey="Kalayoglu Besisik, S" uniqKey="Kalayoglu Besisik S">S Kalayoglu Besisik</name></author><author><name sortKey="Drach, J" uniqKey="Drach J">J Drach</name></author><author><name sortKey="Ramchandren, R" uniqKey="Ramchandren R">R Ramchandren</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Cicero, S" uniqKey="Cicero S">S Cicero</name></author><author><name sortKey="Fu, T" uniqKey="Fu T">T Fu</name></author><author><name sortKey="Witzig, Te" uniqKey="Witzig T">TE Witzig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, M" uniqKey="Wang M">M Wang</name></author><author><name sortKey="Fayad, L" uniqKey="Fayad L">L Fayad</name></author><author><name sortKey="Wagner Bartak, N" uniqKey="Wagner Bartak N">N Wagner-Bartak</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Hagemeister, F" uniqKey="Hagemeister F">F Hagemeister</name></author><author><name sortKey="Neelapu, Ss" uniqKey="Neelapu S">SS Neelapu</name></author><author><name sortKey="Samaniego, F" uniqKey="Samaniego F">F Samaniego</name></author><author><name sortKey="Mclaughlin, P" uniqKey="Mclaughlin P">P McLaughlin</name></author><author><name sortKey="Fanale, M" uniqKey="Fanale M">M Fanale</name></author><author><name sortKey="Younes, A" uniqKey="Younes A">A Younes</name></author><author><name sortKey="Cabanillas, F" uniqKey="Cabanillas F">F Cabanillas</name></author><author><name sortKey="Fowler, N" uniqKey="Fowler N">N Fowler</name></author><author><name sortKey="Newberry, Kj" uniqKey="Newberry K">KJ Newberry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bartlett, Jb" uniqKey="Bartlett J">JB Bartlett</name></author><author><name sortKey="Dredge, K" uniqKey="Dredge K">K Dredge</name></author><author><name sortKey="Dalgleish, Ag" uniqKey="Dalgleish A">AG Dalgleish</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Semeraro, M" uniqKey="Semeraro M">M Semeraro</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, G" uniqKey="Lu G">G Lu</name></author><author><name sortKey="Middleton, Re" uniqKey="Middleton R">RE Middleton</name></author><author><name sortKey="Sun, H" uniqKey="Sun H">H Sun</name></author><author><name sortKey="Naniong, M" uniqKey="Naniong M">M Naniong</name></author><author><name sortKey="Ott, Cj" uniqKey="Ott C">CJ Ott</name></author><author><name sortKey="Mitsiades, Cs" uniqKey="Mitsiades C">CS Mitsiades</name></author><author><name sortKey="Wong, Kk" uniqKey="Wong K">KK Wong</name></author><author><name sortKey="Bradner, Je" uniqKey="Bradner J">JE Bradner</name></author><author><name sortKey="Kaelin, Wg" uniqKey="Kaelin W">WG Kaelin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kronke, J" uniqKey="Kronke J">J Kronke</name></author><author><name sortKey="Udeshi, Nd" uniqKey="Udeshi N">ND Udeshi</name></author><author><name sortKey="Narla, A" uniqKey="Narla A">A Narla</name></author><author><name sortKey="Grauman, P" uniqKey="Grauman P">P Grauman</name></author><author><name sortKey="Hurst, Sn" uniqKey="Hurst S">SN Hurst</name></author><author><name sortKey="Mcconkey, M" uniqKey="Mcconkey M">M McConkey</name></author><author><name sortKey="Svinkina, T" uniqKey="Svinkina T">T Svinkina</name></author><author><name sortKey="Heckl, D" uniqKey="Heckl D">D Heckl</name></author><author><name sortKey="Comer, E" uniqKey="Comer E">E Comer</name></author><author><name sortKey="Li, X" uniqKey="Li X">X Li</name></author><author><name sortKey="Ciarlo, C" uniqKey="Ciarlo C">C Ciarlo</name></author><author><name sortKey="Hartman, E" uniqKey="Hartman E">E Hartman</name></author><author><name sortKey="Munshi, N" uniqKey="Munshi N">N Munshi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ito, T" uniqKey="Ito T">T Ito</name></author><author><name sortKey="Ando, H" uniqKey="Ando H">H Ando</name></author><author><name sortKey="Suzuki, T" uniqKey="Suzuki T">T Suzuki</name></author><author><name sortKey="Ogura, T" uniqKey="Ogura T">T Ogura</name></author><author><name sortKey="Hotta, K" uniqKey="Hotta K">K Hotta</name></author><author><name sortKey="Imamura, Y" uniqKey="Imamura Y">Y Imamura</name></author><author><name sortKey="Yamaguchi, Y" uniqKey="Yamaguchi Y">Y Yamaguchi</name></author><author><name sortKey="Handa, H" uniqKey="Handa H">H Handa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lopez Girona, A" uniqKey="Lopez Girona A">A Lopez-Girona</name></author><author><name sortKey="Mendy, D" uniqKey="Mendy D">D Mendy</name></author><author><name sortKey="Ito, T" uniqKey="Ito T">T Ito</name></author><author><name sortKey="Miller, K" uniqKey="Miller K">K Miller</name></author><author><name sortKey="Gandhi, Ak" uniqKey="Gandhi A">AK Gandhi</name></author><author><name sortKey="Kang, J" uniqKey="Kang J">J Kang</name></author><author><name sortKey="Karasawa, S" uniqKey="Karasawa S">S Karasawa</name></author><author><name sortKey="Carmel, G" uniqKey="Carmel G">G Carmel</name></author><author><name sortKey="Jackson, P" uniqKey="Jackson P">P Jackson</name></author><author><name sortKey="Abbasian, M" uniqKey="Abbasian M">M Abbasian</name></author><author><name sortKey="Mahmoudi, A" uniqKey="Mahmoudi A">A Mahmoudi</name></author><author><name sortKey="Cathers, B" uniqKey="Cathers B">B Cathers</name></author><author><name sortKey="Rychak, E" uniqKey="Rychak E">E Rychak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Loi, S" uniqKey="Loi S">S Loi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senovilla, L" uniqKey="Senovilla L">L Senovilla</name></author><author><name sortKey="Aranda, F" uniqKey="Aranda F">F Aranda</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Curiel, Tj" uniqKey="Curiel T">TJ Curiel</name></author><author><name sortKey="Coukos, G" uniqKey="Coukos G">G Coukos</name></author><author><name sortKey="Zou, L" uniqKey="Zou L">L Zou</name></author><author><name sortKey="Alvarez, X" uniqKey="Alvarez X">X Alvarez</name></author><author><name sortKey="Cheng, P" uniqKey="Cheng P">P Cheng</name></author><author><name sortKey="Mottram, P" uniqKey="Mottram P">P Mottram</name></author><author><name sortKey="Evdemon Hogan, M" uniqKey="Evdemon Hogan M">M Evdemon-Hogan</name></author><author><name sortKey="Conejo Garcia, Jr" uniqKey="Conejo Garcia J">JR Conejo-Garcia</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Burow, M" uniqKey="Burow M">M Burow</name></author><author><name sortKey="Zhu, Y" uniqKey="Zhu Y">Y Zhu</name></author><author><name sortKey="Wei, S" uniqKey="Wei S">S Wei</name></author><author><name sortKey="Kryczek, I" uniqKey="Kryczek I">I Kryczek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sica, A" uniqKey="Sica A">A Sica</name></author><author><name sortKey="Mantovani, A" uniqKey="Mantovani A">A Mantovani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kadin, Me" uniqKey="Kadin M">ME Kadin</name></author><author><name sortKey="Vonderheid, Ec" uniqKey="Vonderheid E">EC Vonderheid</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Attia, P" uniqKey="Attia P">P Attia</name></author><author><name sortKey="Maker, Av" uniqKey="Maker A">AV Maker</name></author><author><name sortKey="Haworth, Lr" uniqKey="Haworth L">LR Haworth</name></author><author><name sortKey="Rogers Freezer, L" uniqKey="Rogers Freezer L">L Rogers-Freezer</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dannull, J" uniqKey="Dannull J">J Dannull</name></author><author><name sortKey="Su, Z" uniqKey="Su Z">Z Su</name></author><author><name sortKey="Rizzieri, D" uniqKey="Rizzieri D">D Rizzieri</name></author><author><name sortKey="Yang, Bk" uniqKey="Yang B">BK Yang</name></author><author><name sortKey="Coleman, D" uniqKey="Coleman D">D Coleman</name></author><author><name sortKey="Yancey, D" uniqKey="Yancey D">D Yancey</name></author><author><name sortKey="Zhang, A" uniqKey="Zhang A">A Zhang</name></author><author><name sortKey="Dahm, P" uniqKey="Dahm P">P Dahm</name></author><author><name sortKey="Chao, N" uniqKey="Chao N">N Chao</name></author><author><name sortKey="Gilboa, E" uniqKey="Gilboa E">E Gilboa</name></author><author><name sortKey="Vieweg, J" uniqKey="Vieweg J">J Vieweg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morse, Ma" uniqKey="Morse M">MA Morse</name></author><author><name sortKey="Hobeika, Ac" uniqKey="Hobeika A">AC Hobeika</name></author><author><name sortKey="Osada, T" uniqKey="Osada T">T Osada</name></author><author><name sortKey="Serra, D" uniqKey="Serra D">D Serra</name></author><author><name sortKey="Niedzwiecki, D" uniqKey="Niedzwiecki D">D Niedzwiecki</name></author><author><name sortKey="Lyerly, Hk" uniqKey="Lyerly H">HK Lyerly</name></author><author><name sortKey="Clay, Tm" uniqKey="Clay T">TM Clay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamada, Y" uniqKey="Yamada Y">Y Yamada</name></author><author><name sortKey="Aoyama, A" uniqKey="Aoyama A">A Aoyama</name></author><author><name sortKey="Tocco, G" uniqKey="Tocco G">G Tocco</name></author><author><name sortKey="Boskovic, S" uniqKey="Boskovic S">S Boskovic</name></author><author><name sortKey="Nadazdin, O" uniqKey="Nadazdin O">O Nadazdin</name></author><author><name sortKey="Alessandrini, A" uniqKey="Alessandrini A">A Alessandrini</name></author><author><name sortKey="Madsen, Jc" uniqKey="Madsen J">JC Madsen</name></author><author><name sortKey="Cosimi, Ab" uniqKey="Cosimi A">AB Cosimi</name></author><author><name sortKey="Benichou, G" uniqKey="Benichou G">G Benichou</name></author><author><name sortKey="Kawai, T" uniqKey="Kawai T">T Kawai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baur, As" uniqKey="Baur A">AS Baur</name></author><author><name sortKey="Lutz, Mb" uniqKey="Lutz M">MB Lutz</name></author><author><name sortKey="Schierer, S" uniqKey="Schierer S">S Schierer</name></author><author><name sortKey="Beltrame, L" uniqKey="Beltrame L">L Beltrame</name></author><author><name sortKey="Theiner, G" uniqKey="Theiner G">G Theiner</name></author><author><name sortKey="Zinser, E" uniqKey="Zinser E">E Zinser</name></author><author><name sortKey="Ostalecki, C" uniqKey="Ostalecki C">C Ostalecki</name></author><author><name sortKey="Heidkamp, G" uniqKey="Heidkamp G">G Heidkamp</name></author><author><name sortKey="Haendle, I" uniqKey="Haendle I">I Haendle</name></author><author><name sortKey="Erdmann, M" uniqKey="Erdmann M">M Erdmann</name></author><author><name sortKey="Wiesinger, M" uniqKey="Wiesinger M">M Wiesinger</name></author><author><name sortKey="Leisgang, W" uniqKey="Leisgang W">W Leisgang</name></author><author><name sortKey="Gross, S" uniqKey="Gross S">S Gross</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burger, Ja" uniqKey="Burger J">JA Burger</name></author><author><name sortKey="Keating, Mj" uniqKey="Keating M">MJ Keating</name></author><author><name sortKey="Wierda, Wg" uniqKey="Wierda W">WG Wierda</name></author><author><name sortKey="Hartmann, E" uniqKey="Hartmann E">E Hartmann</name></author><author><name sortKey="Hoellenriegel, J" uniqKey="Hoellenriegel J">J Hoellenriegel</name></author><author><name sortKey="Rosin, Ny" uniqKey="Rosin N">NY Rosin</name></author><author><name sortKey="De Weerdt, I" uniqKey="De Weerdt I">I de Weerdt</name></author><author><name sortKey="Jeyakumar, G" uniqKey="Jeyakumar G">G Jeyakumar</name></author><author><name sortKey="Ferrajoli, A" uniqKey="Ferrajoli A">A Ferrajoli</name></author><author><name sortKey="Cardenas Turanzas, M" uniqKey="Cardenas Turanzas M">M Cardenas-Turanzas</name></author><author><name sortKey="Lerner, S" uniqKey="Lerner S">S Lerner</name></author><author><name sortKey="Jorgensen, Jl" uniqKey="Jorgensen J">JL Jorgensen</name></author><author><name sortKey="Nogueras Gonzalez, Gm" uniqKey="Nogueras Gonzalez G">GM Nogueras-Gonzalez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Brien, S" uniqKey="O Brien S">S O'Brien</name></author><author><name sortKey="Furman, Rr" uniqKey="Furman R">RR Furman</name></author><author><name sortKey="Coutre, Se" uniqKey="Coutre S">SE Coutre</name></author><author><name sortKey="Sharman, Jp" uniqKey="Sharman J">JP Sharman</name></author><author><name sortKey="Burger, Ja" uniqKey="Burger J">JA Burger</name></author><author><name sortKey="Blum, Ka" uniqKey="Blum K">KA Blum</name></author><author><name sortKey="Grant, B" uniqKey="Grant B">B Grant</name></author><author><name sortKey="Richards, Da" uniqKey="Richards D">DA Richards</name></author><author><name sortKey="Coleman, M" uniqKey="Coleman M">M Coleman</name></author><author><name sortKey="Wierda, Wg" uniqKey="Wierda W">WG Wierda</name></author><author><name sortKey="Jones, Ja" uniqKey="Jones J">JA Jones</name></author><author><name sortKey="Zhao, W" uniqKey="Zhao W">W Zhao</name></author><author><name sortKey="Heerema, Na" uniqKey="Heerema N">NA Heerema</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, Ml" uniqKey="Wang M">ML Wang</name></author><author><name sortKey="Rule, S" uniqKey="Rule S">S Rule</name></author><author><name sortKey="Martin, P" uniqKey="Martin P">P Martin</name></author><author><name sortKey="Goy, A" uniqKey="Goy A">A Goy</name></author><author><name sortKey="Auer, R" uniqKey="Auer R">R Auer</name></author><author><name sortKey="Kahl, Bs" uniqKey="Kahl B">BS Kahl</name></author><author><name sortKey="Jurczak, W" uniqKey="Jurczak W">W Jurczak</name></author><author><name sortKey="Advani, Rh" uniqKey="Advani R">RH Advani</name></author><author><name sortKey="Romaguera, Je" uniqKey="Romaguera J">JE Romaguera</name></author><author><name sortKey="Williams, Me" uniqKey="Williams M">ME Williams</name></author><author><name sortKey="Barrientos, Jc" uniqKey="Barrientos J">JC Barrientos</name></author><author><name sortKey="Chmielowska, E" uniqKey="Chmielowska E">E Chmielowska</name></author><author><name sortKey="Radford, J" uniqKey="Radford J">J Radford</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Affara, Ni" uniqKey="Affara N">NI Affara</name></author><author><name sortKey="Ruffell, B" uniqKey="Ruffell B">B Ruffell</name></author><author><name sortKey="Medler, Tr" uniqKey="Medler T">TR Medler</name></author><author><name sortKey="Gunderson, Aj" uniqKey="Gunderson A">AJ Gunderson</name></author><author><name sortKey="Johansson, M" uniqKey="Johansson M">M Johansson</name></author><author><name sortKey="Bornstein, S" uniqKey="Bornstein S">S Bornstein</name></author><author><name sortKey="Bergsland, E" uniqKey="Bergsland E">E Bergsland</name></author><author><name sortKey="Steinhoff, M" uniqKey="Steinhoff M">M Steinhoff</name></author><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author><author><name sortKey="Gong, Q" uniqKey="Gong Q">Q Gong</name></author><author><name sortKey="Ma, Y" uniqKey="Ma Y">Y Ma</name></author><author><name sortKey="Wiesen, Jf" uniqKey="Wiesen J">JF Wiesen</name></author><author><name sortKey="Wong, Mh" uniqKey="Wong M">MH Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dalrymple, Sl" uniqKey="Dalrymple S">SL Dalrymple</name></author><author><name sortKey="Becker, Re" uniqKey="Becker R">RE Becker</name></author><author><name sortKey="Isaacs, Jt" uniqKey="Isaacs J">JT Isaacs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Murdoch, C" uniqKey="Murdoch C">C Murdoch</name></author><author><name sortKey="Muthana, M" uniqKey="Muthana M">M Muthana</name></author><author><name sortKey="Coffelt, Sb" uniqKey="Coffelt S">SB Coffelt</name></author><author><name sortKey="Lewis, Ce" uniqKey="Lewis C">CE Lewis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Germano, G" uniqKey="Germano G">G Germano</name></author><author><name sortKey="Frapolli, R" uniqKey="Frapolli R">R Frapolli</name></author><author><name sortKey="Belgiovine, C" uniqKey="Belgiovine C">C Belgiovine</name></author><author><name sortKey="Anselmo, A" uniqKey="Anselmo A">A Anselmo</name></author><author><name sortKey="Pesce, S" uniqKey="Pesce S">S Pesce</name></author><author><name sortKey="Liguori, M" uniqKey="Liguori M">M Liguori</name></author><author><name sortKey="Erba, E" uniqKey="Erba E">E Erba</name></author><author><name sortKey="Uboldi, S" uniqKey="Uboldi S">S Uboldi</name></author><author><name sortKey="Zucchetti, M" uniqKey="Zucchetti M">M Zucchetti</name></author><author><name sortKey="Pasqualini, F" uniqKey="Pasqualini F">F Pasqualini</name></author><author><name sortKey="Nebuloni, M" uniqKey="Nebuloni M">M Nebuloni</name></author><author><name sortKey="Van Rooijen, N" uniqKey="Van Rooijen N">N van Rooijen</name></author><author><name sortKey="Mortarini, R" uniqKey="Mortarini R">R Mortarini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Allavena, P" uniqKey="Allavena P">P Allavena</name></author><author><name sortKey="Germano, G" uniqKey="Germano G">G Germano</name></author><author><name sortKey="Belgiovine, C" uniqKey="Belgiovine C">C Belgiovine</name></author><author><name sortKey="D Incalci, M" uniqKey="D Incalci M">M D'Incalci</name></author><author><name sortKey="Mantovani, A" uniqKey="Mantovani A">A Mantovani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sanford, De" uniqKey="Sanford D">DE Sanford</name></author><author><name sortKey="Belt, Ba" uniqKey="Belt B">BA Belt</name></author><author><name sortKey="Panni, Rz" uniqKey="Panni R">RZ Panni</name></author><author><name sortKey="Mayer, A" uniqKey="Mayer A">A Mayer</name></author><author><name sortKey="Deshpande, Ad" uniqKey="Deshpande A">AD Deshpande</name></author><author><name sortKey="Carpenter, D" uniqKey="Carpenter D">D Carpenter</name></author><author><name sortKey="Mitchem, Jb" uniqKey="Mitchem J">JB Mitchem</name></author><author><name sortKey="Plambeck Suess, Sm" uniqKey="Plambeck Suess S">SM Plambeck-Suess</name></author><author><name sortKey="Worley, La" uniqKey="Worley L">LA Worley</name></author><author><name sortKey="Goetz, Bd" uniqKey="Goetz B">BD Goetz</name></author><author><name sortKey="Wang Gillam, A" uniqKey="Wang Gillam A">A Wang-Gillam</name></author><author><name sortKey="Eberlein, Tj" uniqKey="Eberlein T">TJ Eberlein</name></author><author><name sortKey="Denardo, Dg" uniqKey="Denardo D">DG Denardo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuhne, Mr" uniqKey="Kuhne M">MR Kuhne</name></author><author><name sortKey="Mulvey, T" uniqKey="Mulvey T">T Mulvey</name></author><author><name sortKey="Belanger, B" uniqKey="Belanger B">B Belanger</name></author><author><name sortKey="Chen, S" uniqKey="Chen S">S Chen</name></author><author><name sortKey="Pan, C" uniqKey="Pan C">C Pan</name></author><author><name sortKey="Chong, C" uniqKey="Chong C">C Chong</name></author><author><name sortKey="Cao, F" uniqKey="Cao F">F Cao</name></author><author><name sortKey="Niekro, W" uniqKey="Niekro W">W Niekro</name></author><author><name sortKey="Kempe, T" uniqKey="Kempe T">T Kempe</name></author><author><name sortKey="Henning, Ka" uniqKey="Henning K">KA Henning</name></author><author><name sortKey="Cohen, Lj" uniqKey="Cohen L">LJ Cohen</name></author><author><name sortKey="Korman, Aj" uniqKey="Korman A">AJ Korman</name></author><author><name sortKey="Cardarelli, Pm" uniqKey="Cardarelli P">PM Cardarelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, J" uniqKey="Xu J">J Xu</name></author><author><name sortKey="Escamilla, J" uniqKey="Escamilla J">J Escamilla</name></author><author><name sortKey="Mok, S" uniqKey="Mok S">S Mok</name></author><author><name sortKey="David, J" uniqKey="David J">J David</name></author><author><name sortKey="Priceman, S" uniqKey="Priceman S">S Priceman</name></author><author><name sortKey="West, B" uniqKey="West B">B West</name></author><author><name sortKey="Bollag, G" uniqKey="Bollag G">G Bollag</name></author><author><name sortKey="Mcbride, W" uniqKey="Mcbride W">W McBride</name></author><author><name sortKey="Wu, L" uniqKey="Wu L">L Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, Y" uniqKey="Zhu Y">Y Zhu</name></author><author><name sortKey="Knolhoff, Bl" uniqKey="Knolhoff B">BL Knolhoff</name></author><author><name sortKey="Meyer, Ma" uniqKey="Meyer M">MA Meyer</name></author><author><name sortKey="Nywening, Tm" uniqKey="Nywening T">TM Nywening</name></author><author><name sortKey="West, Bl" uniqKey="West B">BL West</name></author><author><name sortKey="Luo, J" uniqKey="Luo J">J Luo</name></author><author><name sortKey="Wang Gillam, A" uniqKey="Wang Gillam A">A Wang-Gillam</name></author><author><name sortKey="Goedegebuure, Sp" uniqKey="Goedegebuure S">SP Goedegebuure</name></author><author><name sortKey="Linehan, Dc" uniqKey="Linehan D">DC Linehan</name></author><author><name sortKey="Denardo, Dg" uniqKey="Denardo D">DG DeNardo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Priceman, Sj" uniqKey="Priceman S">SJ Priceman</name></author><author><name sortKey="Sung, Jl" uniqKey="Sung J">JL Sung</name></author><author><name sortKey="Shaposhnik, Z" uniqKey="Shaposhnik Z">Z Shaposhnik</name></author><author><name sortKey="Burton, Jb" uniqKey="Burton J">JB Burton</name></author><author><name sortKey="Torres Collado, Ax" uniqKey="Torres Collado A">AX Torres-Collado</name></author><author><name sortKey="Moughon, Dl" uniqKey="Moughon D">DL Moughon</name></author><author><name sortKey="Johnson, M" uniqKey="Johnson M">M Johnson</name></author><author><name sortKey="Lusis, Aj" uniqKey="Lusis A">AJ Lusis</name></author><author><name sortKey="Cohen, Da" uniqKey="Cohen D">DA Cohen</name></author><author><name sortKey="Iruela Arispe, Ml" uniqKey="Iruela Arispe M">ML Iruela-Arispe</name></author><author><name sortKey="Wu, L" uniqKey="Wu L">L Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghansah, T" uniqKey="Ghansah T">T Ghansah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iclozan, C" uniqKey="Iclozan C">C Iclozan</name></author><author><name sortKey="Antonia, S" uniqKey="Antonia S">S Antonia</name></author><author><name sortKey="Chiappori, A" uniqKey="Chiappori A">A Chiappori</name></author><author><name sortKey="Chen, Dt" uniqKey="Chen D">DT Chen</name></author><author><name sortKey="Gabrilovich, D" uniqKey="Gabrilovich D">D Gabrilovich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abrams, Si" uniqKey="Abrams S">SI Abrams</name></author><author><name sortKey="Waight, Jd" uniqKey="Waight J">JD Waight</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Highfill, Sl" uniqKey="Highfill S">SL Highfill</name></author><author><name sortKey="Cui, Y" uniqKey="Cui Y">Y Cui</name></author><author><name sortKey="Giles, Aj" uniqKey="Giles A">AJ Giles</name></author><author><name sortKey="Smith, Jp" uniqKey="Smith J">JP Smith</name></author><author><name sortKey="Zhang, H" uniqKey="Zhang H">H Zhang</name></author><author><name sortKey="Morse, E" uniqKey="Morse E">E Morse</name></author><author><name sortKey="Kaplan, Rn" uniqKey="Kaplan R">RN Kaplan</name></author><author><name sortKey="Mackall, Cl" uniqKey="Mackall C">CL Mackall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weiskopf, K" uniqKey="Weiskopf K">K Weiskopf</name></author><author><name sortKey="Ring, Am" uniqKey="Ring A">AM Ring</name></author><author><name sortKey="Schnorr, Pj" uniqKey="Schnorr P">PJ Schnorr</name></author><author><name sortKey="Volkmer, Jp" uniqKey="Volkmer J">JP Volkmer</name></author><author><name sortKey="Volkmer, Ak" uniqKey="Volkmer A">AK Volkmer</name></author><author><name sortKey="Weissman, Il" uniqKey="Weissman I">IL Weissman</name></author><author><name sortKey="Garcia, Kc" uniqKey="Garcia K">KC Garcia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weiskopf, K" uniqKey="Weiskopf K">K Weiskopf</name></author><author><name sortKey="Ring, Am" uniqKey="Ring A">AM Ring</name></author><author><name sortKey="Ho, Cc" uniqKey="Ho C">CC Ho</name></author><author><name sortKey="Volkmer, Jp" uniqKey="Volkmer J">JP Volkmer</name></author><author><name sortKey="Levin, Am" uniqKey="Levin A">AM Levin</name></author><author><name sortKey="Volkmer, Ak" uniqKey="Volkmer A">AK Volkmer</name></author><author><name sortKey="Ozkan, E" uniqKey="Ozkan E">E Ozkan</name></author><author><name sortKey="Fernhoff, Nb" uniqKey="Fernhoff N">NB Fernhoff</name></author><author><name sortKey="Van De Rijn, M" uniqKey="Van De Rijn M">M van de Rijn</name></author><author><name sortKey="Weissman, Il" uniqKey="Weissman I">IL Weissman</name></author><author><name sortKey="Garcia, Kc" uniqKey="Garcia K">KC Garcia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tseng, D" uniqKey="Tseng D">D Tseng</name></author><author><name sortKey="Volkmer, Jp" uniqKey="Volkmer J">JP Volkmer</name></author><author><name sortKey="Willingham, Sb" uniqKey="Willingham S">SB Willingham</name></author><author><name sortKey="Contreras Trujillo, H" uniqKey="Contreras Trujillo H">H Contreras-Trujillo</name></author><author><name sortKey="Fathman, Jw" uniqKey="Fathman J">JW Fathman</name></author><author><name sortKey="Fernhoff, Nb" uniqKey="Fernhoff N">NB Fernhoff</name></author><author><name sortKey="Seita, J" uniqKey="Seita J">J Seita</name></author><author><name sortKey="Inlay, Ma" uniqKey="Inlay M">MA Inlay</name></author><author><name sortKey="Weiskopf, K" uniqKey="Weiskopf K">K Weiskopf</name></author><author><name sortKey="Miyanishi, M" uniqKey="Miyanishi M">M Miyanishi</name></author><author><name sortKey="Weissman, Il" uniqKey="Weissman I">IL Weissman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, Bd" uniqKey="Smith B">BD Smith</name></author><author><name sortKey="Kasamon, Yl" uniqKey="Kasamon Y">YL Kasamon</name></author><author><name sortKey="Kowalski, J" uniqKey="Kowalski J">J Kowalski</name></author><author><name sortKey="Gocke, C" uniqKey="Gocke C">C Gocke</name></author><author><name sortKey="Murphy, K" uniqKey="Murphy K">K Murphy</name></author><author><name sortKey="Miller, Cb" uniqKey="Miller C">CB Miller</name></author><author><name sortKey="Garrett Mayer, E" uniqKey="Garrett Mayer E">E Garrett-Mayer</name></author><author><name sortKey="Tsai, Hl" uniqKey="Tsai H">HL Tsai</name></author><author><name sortKey="Qin, L" uniqKey="Qin L">L Qin</name></author><author><name sortKey="Chia, C" uniqKey="Chia C">C Chia</name></author><author><name sortKey="Biedrzycki, B" uniqKey="Biedrzycki B">B Biedrzycki</name></author><author><name sortKey="Harding, Tc" uniqKey="Harding T">TC Harding</name></author><author><name sortKey="Tu, Gh" uniqKey="Tu G">GH Tu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Characiejus, D" uniqKey="Characiejus D">D Characiejus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Agur, Z" uniqKey="Agur Z">Z Agur</name></author><author><name sortKey="Vuk Pavlovic, S" uniqKey="Vuk Pavlovic S">S Vuk-Pavlovic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dranoff, G" uniqKey="Dranoff G">G Dranoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mittendorf, Ea" uniqKey="Mittendorf E">EA Mittendorf</name></author><author><name sortKey="Gurney, Jm" uniqKey="Gurney J">JM Gurney</name></author><author><name sortKey="Storrer, Ce" uniqKey="Storrer C">CE Storrer</name></author><author><name sortKey="Shriver, Cd" uniqKey="Shriver C">CD Shriver</name></author><author><name sortKey="Ponniah, S" uniqKey="Ponniah S">S Ponniah</name></author><author><name sortKey="Peoples, Ge" uniqKey="Peoples G">GE Peoples</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hardwick, N" uniqKey="Hardwick N">N Hardwick</name></author><author><name sortKey="Chain, B" uniqKey="Chain B">B Chain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olson, Bm" uniqKey="Olson B">BM Olson</name></author><author><name sortKey="Mcneel, Dg" uniqKey="Mcneel D">DG McNeel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Monjazeb, Am" uniqKey="Monjazeb A">AM Monjazeb</name></author><author><name sortKey="Zamora, Ae" uniqKey="Zamora A">AE Zamora</name></author><author><name sortKey="Grossenbacher, Sk" uniqKey="Grossenbacher S">SK Grossenbacher</name></author><author><name sortKey="Mirsoian, A" uniqKey="Mirsoian A">A Mirsoian</name></author><author><name sortKey="Sckisel, Gd" uniqKey="Sckisel G">GD Sckisel</name></author><author><name sortKey="Murphy, Wj" uniqKey="Murphy W">WJ Murphy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maletzki, C" uniqKey="Maletzki C">C Maletzki</name></author><author><name sortKey="Stier, S" uniqKey="Stier S">S Stier</name></author><author><name sortKey="Linnebacher, M" uniqKey="Linnebacher M">M Linnebacher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tran, E" uniqKey="Tran E">E Tran</name></author><author><name sortKey="Turcotte, S" uniqKey="Turcotte S">S Turcotte</name></author><author><name sortKey="Gros, A" uniqKey="Gros A">A Gros</name></author><author><name sortKey="Robbins, Pf" uniqKey="Robbins P">PF Robbins</name></author><author><name sortKey="Lu, Yc" uniqKey="Lu Y">YC Lu</name></author><author><name sortKey="Dudley, Me" uniqKey="Dudley M">ME Dudley</name></author><author><name sortKey="Wunderlich, Jr" uniqKey="Wunderlich J">JR Wunderlich</name></author><author><name sortKey="Somerville, Rp" uniqKey="Somerville R">RP Somerville</name></author><author><name sortKey="Hogan, K" uniqKey="Hogan K">K Hogan</name></author><author><name sortKey="Hinrichs, Cs" uniqKey="Hinrichs C">CS Hinrichs</name></author><author><name sortKey="Parkhurst, Mr" uniqKey="Parkhurst M">MR Parkhurst</name></author><author><name sortKey="Yang, Jc" uniqKey="Yang J">JC Yang</name></author><author><name sortKey="Rosenberg, Sa" uniqKey="Rosenberg S">SA Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gubin, Mm" uniqKey="Gubin M">MM Gubin</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Schuster, H" uniqKey="Schuster H">H Schuster</name></author><author><name sortKey="Caron, E" uniqKey="Caron E">E Caron</name></author><author><name sortKey="Ward, Jp" uniqKey="Ward J">JP Ward</name></author><author><name sortKey="Noguchi, T" uniqKey="Noguchi T">T Noguchi</name></author><author><name sortKey="Ivanova, Y" uniqKey="Ivanova Y">Y Ivanova</name></author><author><name sortKey="Hundal, J" uniqKey="Hundal J">J Hundal</name></author><author><name sortKey="Arthur, Cd" uniqKey="Arthur C">CD Arthur</name></author><author><name sortKey="Krebber, Wj" uniqKey="Krebber W">WJ Krebber</name></author><author><name sortKey="Mulder, Ge" uniqKey="Mulder G">GE Mulder</name></author><author><name sortKey="Toebes, M" uniqKey="Toebes M">M Toebes</name></author><author><name sortKey="Vesely, Md" uniqKey="Vesely M">MD Vesely</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Zitvogel, L" uniqKey="Zitvogel L">L Zitvogel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kepp, O" uniqKey="Kepp O">O Kepp</name></author><author><name sortKey="Galluzzi, L" uniqKey="Galluzzi L">L Galluzzi</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghiringhelli, F" uniqKey="Ghiringhelli F">F Ghiringhelli</name></author><author><name sortKey="Apetoh, L" uniqKey="Apetoh L">L Apetoh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Suzuki, E" uniqKey="Suzuki E">E Suzuki</name></author><author><name sortKey="Kapoor, V" uniqKey="Kapoor V">V Kapoor</name></author><author><name sortKey="Jassar, As" uniqKey="Jassar A">AS Jassar</name></author><author><name sortKey="Kaiser, Lr" uniqKey="Kaiser L">LR Kaiser</name></author><author><name sortKey="Albelda, Sm" uniqKey="Albelda S">SM Albelda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vincent, J" uniqKey="Vincent J">J Vincent</name></author><author><name sortKey="Mignot, G" uniqKey="Mignot G">G Mignot</name></author><author><name sortKey="Chalmin, F" uniqKey="Chalmin F">F Chalmin</name></author><author><name sortKey="Ladoire, S" uniqKey="Ladoire S">S Ladoire</name></author><author><name sortKey="Bruchard, M" uniqKey="Bruchard M">M Bruchard</name></author><author><name sortKey="Chevriaux, A" uniqKey="Chevriaux A">A Chevriaux</name></author><author><name sortKey="Martin, F" uniqKey="Martin F">F Martin</name></author><author><name sortKey="Apetoh, L" uniqKey="Apetoh L">L Apetoh</name></author><author><name sortKey="Rebe, C" uniqKey="Rebe C">C Rebe</name></author><author><name sortKey="Ghiringhelli, F" uniqKey="Ghiringhelli F">F Ghiringhelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghiringhelli, F" uniqKey="Ghiringhelli F">F Ghiringhelli</name></author><author><name sortKey="Bruchard, M" uniqKey="Bruchard M">M Bruchard</name></author><author><name sortKey="Apetoh, L" uniqKey="Apetoh L">L Apetoh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Malvicini, M" uniqKey="Malvicini M">M Malvicini</name></author><author><name sortKey="Piccioni, F" uniqKey="Piccioni F">F Piccioni</name></author><author><name sortKey="Bayo, J" uniqKey="Bayo J">J Bayo</name></author><author><name sortKey="Fiore, E" uniqKey="Fiore E">E Fiore</name></author><author><name sortKey="Atorrasagasti, C" uniqKey="Atorrasagasti C">C Atorrasagasti</name></author><author><name sortKey="Alaniz, L" uniqKey="Alaniz L">L Alaniz</name></author><author><name sortKey="Garcia, M" uniqKey="Garcia M">M Garcia</name></author><author><name sortKey="Aquino, Jb" uniqKey="Aquino J">JB Aquino</name></author><author><name sortKey="Gidekel, M" uniqKey="Gidekel M">M Gidekel</name></author><author><name sortKey="Matar, P" uniqKey="Matar P">P Matar</name></author><author><name sortKey="Mazzolini, G" uniqKey="Mazzolini G">G Mazzolini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Foy, Kc" uniqKey="Foy K">KC Foy</name></author><author><name sortKey="Miller, Mj" uniqKey="Miller M">MJ Miller</name></author><author><name sortKey="Moldovan, N" uniqKey="Moldovan N">N Moldovan</name></author><author><name sortKey="Bozanovic, T" uniqKey="Bozanovic T">T Bozanovic</name></author><author><name sortKey="Carson Iii, We" uniqKey="Carson Iii W">WE Carson Iii</name></author><author><name sortKey="Kaumaya, Pt" uniqKey="Kaumaya P">PT Kaumaya</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kadota, K" uniqKey="Kadota K">K Kadota</name></author><author><name sortKey="Nitadori, Ji" uniqKey="Nitadori J">JI Nitadori</name></author><author><name sortKey="Adusumilli, Ps" uniqKey="Adusumilli P">PS Adusumilli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Escors, D" uniqKey="Escors D">D Escors</name></author><author><name sortKey="Liechtenstein, T" uniqKey="Liechtenstein T">T Liechtenstein</name></author><author><name sortKey="Perez Janices, N" uniqKey="Perez Janices N">N Perez-Janices</name></author><author><name sortKey="Schwarze, J" uniqKey="Schwarze J">J Schwarze</name></author><author><name sortKey="Dufait, I" uniqKey="Dufait I">I Dufait</name></author><author><name sortKey="Goyvaerts, C" uniqKey="Goyvaerts C">C Goyvaerts</name></author><author><name sortKey="Lanna, A" uniqKey="Lanna A">A Lanna</name></author><author><name sortKey="Arce, F" uniqKey="Arce F">F Arce</name></author><author><name sortKey="Blanco Luquin, I" uniqKey="Blanco Luquin I">I Blanco-Luquin</name></author><author><name sortKey="Kochan, G" uniqKey="Kochan G">G Kochan</name></author><author><name sortKey="Guerrero Setas, D" uniqKey="Guerrero Setas D">D Guerrero-Setas</name></author><author><name sortKey="Breckpot, K" uniqKey="Breckpot K">K Breckpot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bindea, G" uniqKey="Bindea G">G Bindea</name></author><author><name sortKey="Mlecnik, B" uniqKey="Mlecnik B">B Mlecnik</name></author><author><name sortKey="Angell, Hk" uniqKey="Angell H">HK Angell</name></author><author><name sortKey="Galon, J" uniqKey="Galon J">J Galon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Malyguine, A" uniqKey="Malyguine A">A Malyguine</name></author><author><name sortKey="Umansky, V" uniqKey="Umansky V">V Umansky</name></author><author><name sortKey="Kotlan, B" uniqKey="Kotlan B">B Kotlan</name></author><author><name sortKey="Aptsiauri, N" uniqKey="Aptsiauri N">N Aptsiauri</name></author><author><name sortKey="Shurin, Mr" uniqKey="Shurin M">MR Shurin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Popadic, D" uniqKey="Popadic D">D Popadic</name></author><author><name sortKey="Anegon, I" uniqKey="Anegon I">I Anegon</name></author><author><name sortKey="Baeten, D" uniqKey="Baeten D">D Baeten</name></author><author><name sortKey="Eibel, H" uniqKey="Eibel H">H Eibel</name></author><author><name sortKey="Giese, T" uniqKey="Giese T">T Giese</name></author><author><name sortKey="Marits, P" uniqKey="Marits P">P Marits</name></author><author><name sortKey="Martinez Caceres, E" uniqKey="Martinez Caceres E">E Martinez-Caceres</name></author><author><name sortKey="Mascart, F" uniqKey="Mascart F">F Mascart</name></author><author><name sortKey="Nestle, F" uniqKey="Nestle F">F Nestle</name></author><author><name sortKey="Pujol Borrell, R" uniqKey="Pujol Borrell R">R Pujol-Borrell</name></author><author><name sortKey="Savic, E" uniqKey="Savic E">E Savic</name></author><author><name sortKey="Scheibenbogen, C" uniqKey="Scheibenbogen C">C Scheibenbogen</name></author><author><name sortKey="Seliger, B" uniqKey="Seliger B">B Seliger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Der Burg, Sh" uniqKey="Van Der Burg S">SH van der Burg</name></author><author><name sortKey="Kalos, M" uniqKey="Kalos M">M Kalos</name></author><author><name sortKey="Gouttefangeas, C" uniqKey="Gouttefangeas C">C Gouttefangeas</name></author><author><name sortKey="Janetzki, S" uniqKey="Janetzki S">S Janetzki</name></author><author><name sortKey="Ottensmeier, C" uniqKey="Ottensmeier C">C Ottensmeier</name></author><author><name sortKey="Welters, Mj" uniqKey="Welters M">MJ Welters</name></author><author><name sortKey="Romero, P" uniqKey="Romero P">P Romero</name></author><author><name sortKey="Britten, Cm" uniqKey="Britten C">CM Britten</name></author><author><name sortKey="Hoos, A" uniqKey="Hoos A">A Hoos</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25537519</article-id><article-id pub-id-type="pmc">4350348</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Classification of current anticancer immunotherapies</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Galluzzi</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vacchelli</surname><given-names>Erika</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pedro</surname><given-names>José-Manuel Bravo-San</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Buqué</surname><given-names>Aitziber</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Senovilla</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Baracco</surname><given-names>Elisa Elena</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bloy</surname><given-names>Norma</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Castoldi</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abastado</surname><given-names>Jean-Pierre</given-names></name><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Agostinis</surname><given-names>Patrizia</given-names></name><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Apte</surname><given-names>Ron N.</given-names></name><xref ref-type="aff" rid="A9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Aranda</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ayyoub</surname><given-names>Maha</given-names></name><xref ref-type="aff" rid="A11"><sup>11</sup></xref><xref ref-type="aff" rid="A12"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Beckhove</surname><given-names>Philipp</given-names></name><xref ref-type="aff" rid="A13"><sup>13</sup></xref></contrib><contrib contrib-type="author"><name><surname>Blay</surname><given-names>Jean-Yves</given-names></name><xref ref-type="aff" rid="A14"><sup>14</sup></xref><xref ref-type="aff" rid="A15"><sup>15</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bracci</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="A16"><sup>16</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caignard</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="A17"><sup>17</sup></xref><xref ref-type="aff" rid="A18"><sup>18</sup></xref></contrib><contrib contrib-type="author"><name><surname>Castelli</surname><given-names>Chiara</given-names></name><xref ref-type="aff" rid="A19"><sup>19</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cavallo</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="A20"><sup>20</sup></xref></contrib><contrib contrib-type="author"><name><surname>Celis</surname><given-names>Estaban</given-names></name><xref ref-type="aff" rid="A21"><sup>21</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cerundolo</surname><given-names>Vincenzo</given-names></name><xref ref-type="aff" rid="A22"><sup>22</sup></xref></contrib><contrib contrib-type="author"><name><surname>Clayton</surname><given-names>Aled</given-names></name><xref ref-type="aff" rid="A23"><sup>23</sup></xref><xref ref-type="aff" rid="A24"><sup>24</sup></xref></contrib><contrib contrib-type="author"><name><surname>Colombo</surname><given-names>Mario P.</given-names></name><xref ref-type="aff" rid="A19"><sup>19</sup></xref></contrib><contrib contrib-type="author"><name><surname>Coussens</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="A25"><sup>25</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dhodapkar</surname><given-names>Madhav V.</given-names></name><xref ref-type="aff" rid="A26"><sup>26</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eggermont</surname><given-names>Alexander M.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fearon</surname><given-names>Douglas T.</given-names></name><xref ref-type="aff" rid="A27"><sup>27</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fridman</surname><given-names>Wolf H.</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A28"><sup>28</sup></xref><xref ref-type="aff" rid="A29"><sup>29</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fučíková</surname><given-names>Jitka</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref><xref ref-type="aff" rid="A30"><sup>30</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gabrilovich</surname><given-names>Dmitry I.</given-names></name><xref ref-type="aff" rid="A31"><sup>31</sup></xref></contrib><contrib contrib-type="author"><name><surname>Galon</surname><given-names>Jérôme</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A28"><sup>28</sup></xref><xref ref-type="aff" rid="A32"><sup>32</sup></xref></contrib><contrib contrib-type="author"><name><surname>Garg</surname><given-names>Abhishek</given-names></name><xref ref-type="aff" rid="A8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ghiringhelli</surname><given-names>François</given-names></name><xref ref-type="aff" rid="A33"><sup>33</sup></xref><xref ref-type="aff" rid="A34"><sup>34</sup></xref><xref ref-type="aff" rid="A35"><sup>35</sup></xref></contrib><contrib contrib-type="author"><name><surname>Giaccone</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="A36"><sup>36</sup></xref><xref ref-type="aff" rid="A37"><sup>37</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gilboa</surname><given-names>Eli</given-names></name><xref ref-type="aff" rid="A38"><sup>38</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gnjatic</surname><given-names>Sacha</given-names></name><xref ref-type="aff" rid="A39"><sup>39</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hoos</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="A40"><sup>40</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hosmalin</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A41"><sup>41</sup></xref><xref ref-type="aff" rid="A42"><sup>42</sup></xref><xref ref-type="aff" rid="A43"><sup>43</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jäger</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="A44"><sup>44</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kalinski</surname><given-names>Pawel</given-names></name><xref ref-type="aff" rid="A45"><sup>45</sup></xref><xref ref-type="aff" rid="A46"><sup>46</sup></xref><xref ref-type="aff" rid="A47"><sup>47</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kärre</surname><given-names>Klas</given-names></name><xref ref-type="aff" rid="A48"><sup>48</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kepp</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A49"><sup>49</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kiessling</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="A50"><sup>50</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kirkwood</surname><given-names>John M.</given-names></name><xref ref-type="aff" rid="A51"><sup>51</sup></xref></contrib><contrib contrib-type="author"><name><surname>Klein</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="A48"><sup>48</sup></xref></contrib><contrib contrib-type="author"><name><surname>Knuth</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="A52"><sup>52</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Claire E.</given-names></name><xref ref-type="aff" rid="A53"><sup>53</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liblau</surname><given-names>Roland</given-names></name><xref ref-type="aff" rid="A54"><sup>54</sup></xref><xref ref-type="aff" rid="A55"><sup>55</sup></xref><xref ref-type="aff" rid="A56"><sup>56</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lotze</surname><given-names>Michael T.</given-names></name><xref ref-type="aff" rid="A45"><sup>45</sup></xref><xref ref-type="aff" rid="A46"><sup>46</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lugli</surname><given-names>Enrico</given-names></name><xref ref-type="aff" rid="A57"><sup>57</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mach</surname><given-names>Jean-Pierre</given-names></name><xref ref-type="aff" rid="A58"><sup>58</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mattei</surname><given-names>Fabrizio</given-names></name><xref ref-type="aff" rid="A16"><sup>16</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mavilio</surname><given-names>Domenico</given-names></name><xref ref-type="aff" rid="A57"><sup>57</sup></xref><xref ref-type="aff" rid="A59"><sup>59</sup></xref></contrib><contrib contrib-type="author"><name><surname>Melero</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="A60"><sup>60</sup></xref><xref ref-type="aff" rid="A61"><sup>61</sup></xref></contrib><contrib contrib-type="author"><name><surname>Melief</surname><given-names>Cornelis J.</given-names></name><xref ref-type="aff" rid="A62"><sup>62</sup></xref><xref ref-type="aff" rid="A63"><sup>63</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mittendorf</surname><given-names>Elizabeth A.</given-names></name><xref ref-type="aff" rid="A64"><sup>64</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moretta</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="A65"><sup>65</sup></xref></contrib><contrib contrib-type="author"><name><surname>Odunsi</surname><given-names>Adekunke</given-names></name><xref ref-type="aff" rid="A66"><sup>66</sup></xref></contrib><contrib contrib-type="author"><name><surname>Okada</surname><given-names>Hideho</given-names></name><xref ref-type="aff" rid="A67"><sup>67</sup></xref></contrib><contrib contrib-type="author"><name><surname>Palucka</surname><given-names>Anna Karolina</given-names></name><xref ref-type="aff" rid="A68"><sup>68</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peter</surname><given-names>Marcus E.</given-names></name><xref ref-type="aff" rid="A69"><sup>69</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pienta</surname><given-names>Kenneth J.</given-names></name><xref ref-type="aff" rid="A70"><sup>70</sup></xref></contrib><contrib contrib-type="author"><name><surname>Porgador</surname><given-names>Angel</given-names></name><xref ref-type="aff" rid="A9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Prendergast</surname><given-names>George C.</given-names></name><xref ref-type="aff" rid="A71"><sup>71</sup></xref><xref ref-type="aff" rid="A72"><sup>72</sup></xref><xref ref-type="aff" rid="A73"><sup>73</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rabinovich</surname><given-names>Gabriel A.</given-names></name><xref ref-type="aff" rid="A74"><sup>74</sup></xref></contrib><contrib contrib-type="author"><name><surname>Restifo</surname><given-names>Nicholas P.</given-names></name><xref ref-type="aff" rid="A75"><sup>75</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rizvi</surname><given-names>Naiyer</given-names></name><xref ref-type="aff" rid="A76"><sup>76</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sautès-Fridman</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A28"><sup>28</sup></xref><xref ref-type="aff" rid="A29"><sup>29</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schreiber</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="A77"><sup>77</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seliger</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="A78"><sup>78</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shiku</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="A79"><sup>79</sup></xref></contrib><contrib contrib-type="author"><name><surname>Silva-Santos</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="A80"><sup>80</sup></xref></contrib><contrib contrib-type="author"><name><surname>Smyth</surname><given-names>Mark J.</given-names></name><xref ref-type="aff" rid="A81"><sup>81</sup></xref><xref ref-type="aff" rid="A82"><sup>82</sup></xref></contrib><contrib contrib-type="author"><name><surname>Speiser</surname><given-names>Daniel E.</given-names></name><xref ref-type="aff" rid="A83"><sup>83</sup></xref><xref ref-type="aff" rid="A84"><sup>84</sup></xref></contrib><contrib contrib-type="author"><name><surname>Spisek</surname><given-names>Radek</given-names></name><xref ref-type="aff" rid="A6"><sup>6</sup></xref><xref ref-type="aff" rid="A30"><sup>30</sup></xref></contrib><contrib contrib-type="author"><name><surname>Srivastava</surname><given-names>Pramod K.</given-names></name><xref ref-type="aff" rid="A85"><sup>85</sup></xref><xref ref-type="aff" rid="A86"><sup>86</sup></xref></contrib><contrib contrib-type="author"><name><surname>Talmadge</surname><given-names>James E.</given-names></name><xref ref-type="aff" rid="A87"><sup>87</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tartour</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A88"><sup>88</sup></xref><xref ref-type="aff" rid="A89"><sup>89</sup></xref><xref ref-type="aff" rid="A90"><sup>90</sup></xref></contrib><contrib contrib-type="author"><name><surname>Van Der Burg</surname><given-names>Sjoerd H.</given-names></name><xref ref-type="aff" rid="A91"><sup>91</sup></xref></contrib><contrib contrib-type="author"><name><surname>Van Den Eynde</surname><given-names>Benoît J.</given-names></name><xref ref-type="aff" rid="A92"><sup>92</sup></xref><xref ref-type="aff" rid="A93"><sup>93</sup></xref><xref ref-type="aff" rid="A94"><sup>94</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vile</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="A95"><sup>95</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wagner</surname><given-names>Hermann</given-names></name><xref ref-type="aff" rid="A96"><sup>96</sup></xref></contrib><contrib contrib-type="author"><name><surname>Weber</surname><given-names>Jeffrey S.</given-names></name><xref ref-type="aff" rid="A97"><sup>97</sup></xref></contrib><contrib contrib-type="author"><name><surname>Whiteside</surname><given-names>Theresa L.</given-names></name><xref ref-type="aff" rid="A46"><sup>46</sup></xref><xref ref-type="aff" rid="A98"><sup>98</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wolchok</surname><given-names>Jedd D.</given-names></name><xref ref-type="aff" rid="A99"><sup>99</sup></xref><xref ref-type="aff" rid="A100"><sup>100</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zitvogel</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A101"><sup>101</sup></xref><xref ref-type="aff" rid="A102"><sup>102</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Weiping</given-names></name><xref ref-type="aff" rid="A103"><sup>103</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kroemer</surname><given-names>Guido</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A49"><sup>49</sup></xref><xref ref-type="aff" rid="A104"><sup>104</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</aff><aff id="A2"><sup>2</sup> INSERM, U1138, Paris, France</aff><aff id="A3"><sup>3</sup> Gustave Roussy Cancer Campus, Villejuif, France</aff><aff id="A4"><sup>4</sup> Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France</aff><aff id="A5"><sup>5</sup> Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France</aff><aff id="A6"><sup>6</sup> Sotio a.c., Prague, Czech Republic</aff><aff id="A7"><sup>7</sup> Pole d'innovation thérapeutique en oncologie, Institut de Recherches Internationales Servier, Suresnes, France</aff><aff id="A8"><sup>8</sup> Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium</aff><aff id="A9"><sup>9</sup> The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel</aff><aff id="A10"><sup>10</sup> Group of Immune receptors of the Innate and Adaptive System, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</aff><aff id="A11"><sup>11</sup> INSERM, U1102, Saint Herblain, France</aff><aff id="A12"><sup>12</sup> Institut de Cancérologie de l'Ouest, Saint Herblain, France</aff><aff id="A13"><sup>13</sup> Translational Immunology Division, German Cancer Research Center, Heidelberg, Germany</aff><aff id="A14"><sup>14</sup> Equipe 11, Centre Léon Bérard (CLR), Lyon, France</aff><aff id="A15"><sup>15</sup> Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France</aff><aff id="A16"><sup>16</sup> Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy</aff><aff id="A17"><sup>17</sup> INSERM, U1160, Paris, France</aff><aff id="A18"><sup>18</sup> Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France</aff><aff id="A19"><sup>19</sup> Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy</aff><aff id="A20"><sup>20</sup> Molecular Biotechnology Center, Dept. of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy</aff><aff id="A21"><sup>21</sup> Cancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA, USA</aff><aff id="A22"><sup>22</sup> MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK</aff><aff id="A23"><sup>23</sup> Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK</aff><aff id="A24"><sup>24</sup> Velindre Cancer Centre, Cardiff, UK</aff><aff id="A25"><sup>25</sup> Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA</aff><aff id="A26"><sup>26</sup> Sect. of Hematology and Immunobiology, Yale Cancer Center, Yale University, New Haven, CT, USA</aff><aff id="A27"><sup>27</sup> Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA</aff><aff id="A28"><sup>28</sup> Université Pierre et Marie Curie/Paris VI, Paris, France</aff><aff id="A29"><sup>29</sup> Equipe 13, Centre de Recherche des Cordeliers, Paris, France</aff><aff id="A30"><sup>30</sup> Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic</aff><aff id="A31"><sup>31</sup> Dept. of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA</aff><aff id="A32"><sup>32</sup> Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France</aff><aff id="A33"><sup>33</sup> INSERM, UMR866, Dijon, France</aff><aff id="A34"><sup>34</sup> Centre Georges François Leclerc, Dijon, France</aff><aff id="A35"><sup>35</sup> Université de Bourgogne, Dijon, France</aff><aff id="A36"><sup>36</sup> Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA</aff><aff id="A37"><sup>37</sup> Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA</aff><aff id="A38"><sup>38</sup> Dept. of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA</aff><aff id="A39"><sup>39</sup> Sect. of Hematology/Oncology, Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A40"><sup>40</sup> Glaxo Smith Kline, Cancer Immunotherapy Consortium, Collegeville, PA, USA</aff><aff id="A41"><sup>41</sup> INSERM, U1016, Paris, France</aff><aff id="A42"><sup>42</sup> CNRS, UMR8104, Paris, France</aff><aff id="A43"><sup>43</sup> Hôpital Cochin, AP-HP, Paris, France</aff><aff id="A44"><sup>44</sup> National Center for Tumor Diseases, University Medical Center Heidelberg, Heidelberg, Germany</aff><aff id="A45"><sup>45</sup> Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA</aff><aff id="A46"><sup>46</sup> University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA</aff><aff id="A47"><sup>47</sup> Dept. of Immunology and Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA</aff><aff id="A48"><sup>48</sup> Dept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden</aff><aff id="A49"><sup>49</sup> Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France</aff><aff id="A50"><sup>50</sup> Dept. of Oncology, Karolinska Institute Hospital, Stockholm, Sweden</aff><aff id="A51"><sup>51</sup> University of Pittsburgh Cancer Institute Laboratory, Pittsburgh, PA, USA</aff><aff id="A52"><sup>52</sup> National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar</aff><aff id="A53"><sup>53</sup> Academic Unit of Inflammation and Tumour Targeting, Dept. of Oncology, University of Sheffield Medical School, Sheffield, UK</aff><aff id="A54"><sup>54</sup> INSERM, UMR1043, Toulouse, France</aff><aff id="A55"><sup>55</sup> CNRS, UMR5282, Toulouse, France</aff><aff id="A56"><sup>56</sup> Laboratoire d'Immunologie, CHU Toulouse, Université Toulouse II, Toulouse, France</aff><aff id="A57"><sup>57</sup> Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy</aff><aff id="A58"><sup>58</sup> Dept. of Biochemistry, University of Lausanne, Epalinges, Switzerland</aff><aff id="A59"><sup>59</sup> Dept. of Medical Biotechnologies and Translational Medicine, University of Milan, Rozzano, Italy</aff><aff id="A60"><sup>60</sup> Dept. of Immunology, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain</aff><aff id="A61"><sup>61</sup> Dept. of Oncology, Clínica Universidad de Navarra, Pamplona, Spain</aff><aff id="A62"><sup>62</sup> ISA Therapeutics, Leiden, The Netherlands</aff><aff id="A63"><sup>63</sup> Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands</aff><aff id="A64"><sup>64</sup> Research Dept. of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA</aff><aff id="A65"><sup>65</sup> Istituto Giannina Gaslini, Genova, Italy</aff><aff id="A66"><sup>66</sup> Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA</aff><aff id="A67"><sup>67</sup> Dept. of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA</aff><aff id="A68"><sup>68</sup> The Jackson Laboratory for Genomics Medicine, Farmington, CT, USA</aff><aff id="A69"><sup>69</sup> Div. of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA</aff><aff id="A70"><sup>70</sup> The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA</aff><aff id="A71"><sup>71</sup> Lankenau Institute for Medical Research, Wynnewood, PA, USA</aff><aff id="A72"><sup>72</sup> Dept. of Pathology, Anatomy and Cell Biology, Sidney Kimmel Medical College, Philadelphia, PA, USA</aff><aff id="A73"><sup>73</sup> Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA</aff><aff id="A74"><sup>74</sup> Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina</aff><aff id="A75"><sup>75</sup> National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA</aff><aff id="A76"><sup>76</sup> Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA</aff><aff id="A77"><sup>77</sup> Dept. of Pathology, The Cancer Research Center, The University of Chicago, Chicago, IL, USA</aff><aff id="A78"><sup>78</sup> Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany</aff><aff id="A79"><sup>79</sup> Dept. of Immuno-GeneTherapy, Mie University Graduate School of Medicine, Tsu, Japan</aff><aff id="A80"><sup>80</sup> Instituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal</aff><aff id="A81"><sup>81</sup> Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia</aff><aff id="A82"><sup>82</sup> School of Medicine, University of Queensland, Herston, Queensland, Australia</aff><aff id="A83"><sup>83</sup> Dept. of Oncology, University of Lausanne, Lausanne, Switzerland</aff><aff id="A84"><sup>84</sup> Ludwig Cancer Research Center, Lausanne, Switzerland</aff><aff id="A85"><sup>85</sup> Dept. of Immunology, University of Connecticut School of Medicine, Farmington, CT, USA</aff><aff id="A86"><sup>86</sup> Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA</aff><aff id="A87"><sup>87</sup> Laboratory of Transplantation Immunology, Dept. of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA</aff><aff id="A88"><sup>88</sup> INSERM, U970, Paris, France</aff><aff id="A89"><sup>89</sup> Paris-Cardiovascular Research Center (PARCC), Paris, France</aff><aff id="A90"><sup>90</sup> Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France</aff><aff id="A91"><sup>91</sup> Dept. of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands</aff><aff id="A92"><sup>92</sup> Ludwig Institute for Cancer Research, Brussels, Belgium</aff><aff id="A93"><sup>93</sup> de Duve Institute, Brussels, Belgium</aff><aff id="A94"><sup>94</sup> Université Catholique de Louvain, Brussels, Belgium</aff><aff id="A95"><sup>95</sup> Dept. of Molecular Medicine and Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA</aff><aff id="A96"><sup>96</sup> Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Munich, Germany</aff><aff id="A97"><sup>97</sup> Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, FL, USA</aff><aff id="A98"><sup>98</sup> University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</aff><aff id="A99"><sup>99</sup> Dept. of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA</aff><aff id="A100"><sup>100</sup> Weill Cornell Medical College, New York, NY, USA</aff><aff id="A101"><sup>101</sup> INSERM, U1015, Villejuif, France</aff><aff id="A102"><sup>102</sup> Centre d'Investigation Clinique Biothérapie 507 (CICBT507), Gustave Roussy Cancer Campus, Villejuif, France</aff><aff id="A103"><sup>103</sup> University of Michigan, School of Medicine, Ann Arbor, MI, USA</aff><aff id="A104"><sup>104</sup> Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Lorenzo Galluzzi,</italic><email>deadoc@vodafone.it</email></corresp></author-notes><pub-date pub-type="collection"><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2014</year></pub-date><volume>5</volume><issue>24</issue><fpage>12472</fpage><lpage>12508</lpage><history><date date-type="received"><day>2</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: © 2014 Galluzzi et al.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into “passive” and “active” based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.</p></abstract><kwd-group><kwd>adoptive cell transfer</kwd><kwd>checkpoint blockers</kwd><kwd>dendritic cell-based interventions</kwd><kwd>DNA-based vaccines</kwd><kwd>immunostimulatory cytokines</kwd><kwd>peptide-based vaccines</kwd><kwd>oncolytic viruses</kwd><kwd>Toll-like receptor agonists</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Our perception of cancer has changed dramatically during the past 3 decades. For instance, it has been appreciated that tumors are not a purely clonal disorder, although in some cases they do evolve from a single (pre-)malignant cell [<xref rid="R1" ref-type="bibr">1</xref>-<xref rid="R3" ref-type="bibr">3</xref>]. It is now clear that established neoplasms do not consist only of transformed cells, but contain an abundant and heterogeneous non-transformed component, including stromal, endothelial and immune cells [<xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R6" ref-type="bibr">6</xref>]. We no longer consider the metabolism of cancer cells as completely distinct from that of their normal counterparts [<xref rid="R7" ref-type="bibr">7</xref>-<xref rid="R9" ref-type="bibr">9</xref>]. We have shown that the survival of transformed cells can critically depend on adaptive responses that <italic>per se</italic> are non-tumorigenic, establishing the concept of non-oncogene addiction [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>]. We discovered mechanisms other than intrinsic apoptosis that may be harnessed for therapeutic applications, such as several forms of regulated necrosis [<xref rid="R12" ref-type="bibr">12</xref>-<xref rid="R14" ref-type="bibr">14</xref>]. Finally, we obtained evidence indicating that the host immune system can recognize (and sometimes react against) (pre-)malignant cells as they transform, proliferate, evolve and respond to therapy, founding the theoretical grounds of anticancer immunosurveillance [<xref rid="R15" ref-type="bibr">15</xref>-<xref rid="R17" ref-type="bibr">17</xref>]. These conceptual shifts have profound therapeutic implications, some of which have already been translated into clinical realities. For instance, several anticancer agents that are now approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in cancer patients inhibit tumor-associated angiogenesis, perhaps the best characterized interaction between malignant and non-malignant components of the tumor microenvironment [<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>].</p><p>Over the last decade, great efforts have been dedicated to the development of interventions that mediate antineoplastic effects by initiating a novel or boosting an existing immune response against neoplastic cells (Table <xref ref-type="table" rid="T1">1</xref>) [<xref rid="R20" ref-type="bibr">20</xref>-<xref rid="R32" ref-type="bibr">32</xref>]. This intense wave of preclinical and clinical investigation culminated with the approval of various immunotherapeutic interventions for use in humans (Table <xref ref-type="table" rid="T2">2</xref>). In 2013, the extraordinary clinical success of immunotherapy was acknowledged by the Editors of Science Magazine with the designation of “Breakthrough of the Year” [<xref rid="R33" ref-type="bibr">33</xref>]. Nonetheless, we have just begun to unravel the therapeutic possibilities offered by anticancer immunotherapy. Clinical studies are being initiated at an ever accelerating pace to test the safety and efficacy of various immunotherapeutic regimens in cancer patients, either as standalone interventions or combined with other antineoplastic agents [<xref rid="R34" ref-type="bibr">34</xref>]. The hopes generated by this approach are immense, and several other forms of immunotherapy are expected to obtain regulatory approval within the next few years (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Currently available anticancer immunotherapies</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Paradigm</th><th align="left" valign="middle" rowspan="1" colspan="1">Licensed<xref ref-type="table-fn" rid="tfn-001">*</xref></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tumor-targeting mAbs</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Adoptive cell transfer</td><td align="left" valign="middle" rowspan="1" colspan="1">NO</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Oncolytic viruses</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DC-based interventions</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DNA-based vaccines</td><td align="left" valign="middle" rowspan="1" colspan="1">NO</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Peptide-based vaccines</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Immunostimulatory cytokines</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Immunomodulatory mAbs</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Inhibitors of immunosuppressive metabolism</td><td align="left" valign="middle" rowspan="1" colspan="1">NO</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PRR agonists</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICD inducers</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Others</td><td align="left" valign="middle" rowspan="1" colspan="1">YES</td></tr></tbody></table><table-wrap-foot><p>Abbreviations. ICD, immunogenic cell death; DC, dendritic cell; mAb, monoclonal antibody; PRR, pattern recognition receptor.</p><fn id="tfn-001"><label>*</label><p>in one of its forms for use in cancer patients, by the US Food and Drug Administration or equivalent regulatory agency worldwide.</p></fn></table-wrap-foot></table-wrap><p>Anticancer immunotherapies are generally classified as “passive” or “active” based on their ability to (re-)activate the host immune system against malignant cells [<xref rid="R35" ref-type="bibr">35</xref>]. From this standpoint, tumor-targeting monoclonal antibodies (mAbs) and adoptively transferred T cells (among other approaches) are considered passive forms of immunotherapy, as they are endowed with intrinsic antineoplastic activity [<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R37" ref-type="bibr">37</xref>]. Conversely, anticancer vaccines and checkpoint inhibitors exert anticancer effects only upon the engagement of the host immune system, constituting clear examples of active immunotherapy [<xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R38" ref-type="bibr">38</xref>]. An alternative classification of immunotherapeutic anticancer regimens is based on antigen-specificity. Thus, while tumor-targeting mAbs are widely considered antigen-specific interventions, immunostimulatory cytokines or checkpoint blockers activate anticancer immune responses of unknown (and generally broad) specificity [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R39" ref-type="bibr">39</xref>-<xref rid="R42" ref-type="bibr">42</xref>]. Herein, we critically revise these classifications while discussing the clinical relevance of various forms of anticancer immunotherapy.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Anticancer immunotherapeutics currently approved by regulatory agencies worldwide</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Paradigm</th><th align="left" valign="middle" rowspan="1" colspan="1">Agent</th><th align="left" valign="middle" rowspan="1" colspan="1">Indication(s)</th><th align="left" valign="middle" rowspan="1" colspan="1">Year<xref ref-type="table-fn" rid="tfn-002">*</xref></th><th align="left" valign="middle" rowspan="1" colspan="1">Proposed mechanism of action</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dendritic cell-based immunotherapies</td><td align="left" valign="middle" rowspan="1" colspan="1">Sipuleucel-T</td><td align="left" valign="middle" rowspan="1" colspan="1">Prostate carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2010</td><td align="left" valign="middle" rowspan="1" colspan="1">Priming of a PAP-specific immune response</td></tr><tr><td align="left" valign="middle" rowspan="9" colspan="1">Immunogenic cell death inducers</td><td align="left" valign="middle" rowspan="1" colspan="1">Bleomycin</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple hematological<break></break>and solid tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA-damaging agent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bortezomib</td><td align="left" valign="middle" rowspan="1" colspan="1">Mantle cell lymphoma<break></break>Multiple myeloma</td><td align="left" valign="middle" rowspan="1" colspan="1">2003</td><td align="left" valign="middle" rowspan="1" colspan="1">Proteasomal inhibitor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cyclophosphamide</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple hematological<break></break>and solid tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">Alkylating agent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Doxorubicin</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple hematological<break></break>and solid tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA-intercalating agent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Epirubicin</td><td align="left" valign="middle" rowspan="1" colspan="1">Breast carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">1999</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA-intercalating agent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mitoxantrone</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute myeloid leukemia<break></break>Prostate carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA-intercalating agent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Oxaliplatin</td><td align="left" valign="middle" rowspan="1" colspan="1">Colorectal carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2002</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA-damaging agent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Photodynamic therapy</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple hematological<break></break>and solid tumors</td><td align="left" valign="middle" rowspan="1" colspan="1">1996</td><td align="left" valign="middle" rowspan="1" colspan="1">Induction of oxidative stress with damage to (intra)cellular membranes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Radiation therapy</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple hematological<break></break>and solid tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA-damaging agent and oxidative stress inducer</td></tr><tr><td align="left" valign="middle" rowspan="3" colspan="1">Immunostimulatory cytokines</td><td align="left" valign="middle" rowspan="1" colspan="1">IL-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma<break></break>Renal cell carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-specific immunostimulation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IFN-α2a</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic myeloid leukemia<break></break>Hairy cell leukemia<break></break>Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">1999</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-specific immunostimulation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IFN-α2b</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple hematological<break></break>and solid tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-specific immunostimulation</td></tr><tr><td align="left" valign="middle" rowspan="3" colspan="1">Immunomodulatory mAbs</td><td align="left" valign="middle" rowspan="1" colspan="1">Ipilimumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2011</td><td align="left" valign="middle" rowspan="1" colspan="1">Blockage of CTLA4-dependent immunological checkpoints</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nivolumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" rowspan="1" colspan="1">Blockage of PDCD1-dependent immunological checkpoints</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pembrolizumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" rowspan="1" colspan="1">Blockage of PDCD1-dependent immunological checkpoints</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Oncolytic viruses</td><td align="left" valign="middle" rowspan="1" colspan="1">Oncorine H101</td><td align="left" valign="middle" rowspan="1" colspan="1">Head and neck cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">2005</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective lysis of malignant cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Peptide-based vaccines</td><td align="left" valign="middle" rowspan="1" colspan="1">Vitespen</td><td align="left" valign="middle" rowspan="1" colspan="1">Renal cell carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2008</td><td align="left" valign="middle" rowspan="1" colspan="1">Activation of a tumor-specific immune response</td></tr><tr><td align="left" valign="middle" rowspan="5" colspan="1">PRR agonists</td><td align="left" valign="middle" rowspan="1" colspan="1">Bacillus Calmette-Guérin</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-invasive bladder<break></break>transitional cell carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">TLR2/TLR4 agonist</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Imiquimod</td><td align="left" valign="middle" rowspan="1" colspan="1">Actinic keratosis<break></break>Condylomata acuminata<break></break>Superficial basal cell carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">1997</td><td align="left" valign="middle" rowspan="1" colspan="1">TLR7 agonist</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mifamurtide</td><td align="left" valign="middle" rowspan="1" colspan="1">Osteosarcoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2009</td><td align="left" valign="middle" rowspan="1" colspan="1">NOD2 agonist</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Monophosphoryl lipid A</td><td align="left" valign="middle" rowspan="1" colspan="1">Prevention of HPV-associated cervical carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2009</td><td align="left" valign="middle" rowspan="1" colspan="1">TLR2/TLR4 agonist</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Picibanil</td><td align="left" valign="middle" rowspan="1" colspan="1">Gastric carcinoma<break></break>Head and neck cancer<break></break>Lung carcinoma<break></break>Thyroid carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1"><1995</td><td align="left" valign="middle" rowspan="1" colspan="1">TLR2/TLR4 agonist</td></tr><tr><td align="left" valign="middle" rowspan="18" colspan="1">Tumor-targeting mAbs</td><td align="left" valign="middle" rowspan="1" colspan="1">Alemtuzumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic lymphocytic leukemia</td><td align="left" valign="middle" rowspan="1" colspan="1">2001</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective recognition/opsonization of CD52<sup>+</sup> neoplastic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bevacizumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Colorectal carcinoma<break></break>Glioblastoma multiforme<break></break>Cervical carcinoma<break></break>Lung carcinoma<break></break>Renal cell carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2004</td><td align="left" valign="middle" rowspan="1" colspan="1">VEGFA neutralization</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Brentuximab vedotin</td><td align="left" valign="middle" rowspan="1" colspan="1">Anaplastic large cell lymphoma<break></break>Hodgkin's lymphoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2011</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective delivery of MMAE to CD30<sup>+</sup> neoplastic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Blinatumumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute lymphoblastic leukemia</td><td align="left" valign="middle" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" rowspan="1" colspan="1">CD3- and CD19-specific BiTE</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Catumaxomab</td><td align="left" valign="middle" rowspan="1" colspan="1">Malignant ascites in patients<break></break>with EPCAM<sup>+</sup> cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">2009</td><td align="left" valign="middle" rowspan="1" colspan="1">CD3- and EPCAM-specific BiTE</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cetuximab</td><td align="left" valign="middle" rowspan="1" colspan="1">Head and neck cancer<break></break>Colorectal carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2004</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibition of EGFR signaling</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Denosumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Breast carcinoma<break></break>Prostate carcinoma<break></break>Bone giant cell tumors</td><td align="left" valign="middle" rowspan="1" colspan="1">2011</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibition of RANKL signaling</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gemtuzumab ozogamicin</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute myeloid leukemia</td><td align="left" valign="middle" rowspan="1" colspan="1">2000</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective delivery of calicheamicin to CD33<sup>+</sup> neoplastic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ibritumomab tiuxetan</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-Hodgkin lymphoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2002</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective delivery of <sup>90</sup>Y or <sup>111</sup>In to CD20<sup>+</sup> neoplastic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Panitumumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Colorectal carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2006</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibition of EGFR signaling</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pertuzumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Breast carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2012</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibition of HER2 signaling</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Obinutuzumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic lymphocytic leukemia</td><td align="left" valign="middle" rowspan="1" colspan="1">2013</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective recognition/opsonization of CD20<sup>+</sup> neoplastic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ofatumumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic lymphocytic leukemia</td><td align="left" valign="middle" rowspan="1" colspan="1">2009</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective recognition/opsonization of CD20<sup>+</sup> neoplastic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ramucirumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Gastric or gastroesophageal<break></break>junction adenocarcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibition of KDR signaling</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Rituximab</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic lymphocytic leukemia<break></break>Non-Hodgkin lymphoma</td><td align="left" valign="middle" rowspan="1" colspan="1">1997</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective recognition/opsonization of CD20<sup>+</sup> neoplastic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Siltuximab</td><td align="left" valign="middle" rowspan="1" colspan="1">Multicentric Castleman's disease</td><td align="left" valign="middle" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" rowspan="1" colspan="1">IL-6 neutralization</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tositumomab</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-Hodgkin lymphoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2003</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective recognition/opsonization of, or selective delivery of <sup>90</sup>Y or <sup>111</sup>In to, CD20<sup>+</sup> neoplastic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Trastuzumab</td><td align="left" valign="middle" rowspan="1" colspan="1">Breast carcinoma<break></break>Gastric or gastroesophageal<break></break>junction adenocarcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">1998</td><td align="left" valign="middle" rowspan="1" colspan="1">Selective recognition/opsonization of, or selective delivery of mertansine to, HER2<sup>+</sup> cancer cells</td></tr><tr><td align="left" valign="middle" rowspan="4" colspan="1">Others</td><td align="left" valign="middle" rowspan="1" colspan="1">Lenalidomide</td><td align="left" valign="middle" rowspan="1" colspan="1">Mantle cell lymphoma<break></break>Myelodysplastic syndrome<break></break>Multiple myeloma</td><td align="left" valign="middle" rowspan="1" colspan="1">2005</td><td align="left" valign="middle" rowspan="1" colspan="1">IKZF degradation and immunomodulation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pomalidomide</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple myeloma</td><td align="left" valign="middle" rowspan="1" colspan="1">2013</td><td align="left" valign="middle" rowspan="1" colspan="1">IKZF degradation and immunomodulation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Thalidomide</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple myeloma</td><td align="left" valign="middle" rowspan="1" colspan="1">2006</td><td align="left" valign="middle" rowspan="1" colspan="1">IKZF degradation and immunomodulation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Trabectedin</td><td align="left" valign="middle" rowspan="1" colspan="1">Soft tissue sarcoma<break></break>Ovarian carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1">2007</td><td align="left" valign="middle" rowspan="1" colspan="1">Reprogramming of tumor-associated macrophages</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ACPP, acid phosphatase, prostate; BiTE, Bispecific T-cell engager; CTLA4, cytotoxic T lymphocyte-associated protein 4; EGFR, epidermal growth factor receptor; EPCAM, epithelial cell adhesion molecule; HPV, human papillomavirus; IL, interleukin; IKZF, IKAROS family zinc finger; KDR, kinase insert domain receptor; mAb, monoclonal antibody; MMAE, monomethyl auristatin E; NOD2, nucleotide-binding oligomerization domain containing 2; PDCD1, programmed cell death 1; PRR, pattern recognition receptor; RANKL, Receptor activator of NF-κB ligand; TLR, Toll-like receptor; VEGFA, vascular endothelial growth factor A.</p><fn id="tfn-002"><label>*</label><p>year of first approval.</p></fn></table-wrap-foot></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Anticancer immunotherapy</title><p>Several anticancer immunotherapeutics have been developed during the last three decades, including tumor-targeting and immunomodulatory monoclonal antibodies (mAbs); dendritic cell (DC)-, peptide- and DNA-based anticancer vaccines; oncolytic viruses; pattern recognition receptor (PRR) agonists; immunostimulatory cytokines; immunogenic cell death inducers; inhibitors of immunosuppressive metabolism; and adoptive cell transfer. 1MT, 1-methyltryptophan; APC, antigen-presenting cell; IDO, indoleamine 2,3-dioxigenase; IFN, interferon; IL, interleukin; IMiD, immunomodulatory drug; NLR, NOD-like receptor; TLR, Toll-like receptor.</p></caption><graphic xlink:href="oncotarget-05-12472-g001"></graphic></fig><sec id="s1_1"><title>Passive immunotherapy</title><sec id="s1_1_1"><title>Tumor-targeting mAbs</title><p>Tumor-targeting mAbs are the best-characterized form of anticancer immunotherapy, and perhaps the most widely employed in the clinic [<xref rid="R43" ref-type="bibr">43</xref>-<xref rid="R46" ref-type="bibr">46</xref>]. The expression “tumor-targeting” refers to mAbs that (1) specifically alter the signaling functions of receptors expressed on the surface of malignant cells [<xref rid="R47" ref-type="bibr">47</xref>-<xref rid="R49" ref-type="bibr">49</xref>]; (2) bind to, and hence neutralize, trophic signals produced by malignant cells or by stromal components of neoplastic lesions [<xref rid="R50" ref-type="bibr">50</xref>, <xref rid="R51" ref-type="bibr">51</xref>]; (3) selectively recognize cancer cells based on the expression of a “tumor-associated antigen” (TAA), i.e., an antigen specifically (or at least predominantly) expressed by transformed cells but not (or at least less so) by their non-malignant counterparts [<xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R52" ref-type="bibr">52</xref>]. Tumor-targeting mAbs exist in at least 5 functionally distinct variants. First, naked mAbs that inhibit signaling pathways required for the survival or progression of neoplastic cells, but not of their non-malignant counterparts, such as the epidermal growth factor receptor (EGFR)-specific mAb cetuximab, which is approved by the US FDA for the treatment of head and neck cancer (HNC) and colorectal carcinoma (CRC) [<xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R53" ref-type="bibr">53</xref>]. Second, naked mAbs that activate potentially lethal receptors expressed on the surface of malignant cells, but not of their non-transformed counterparts, such as tigatuzumab (CS-1008), a mAb specific for tumor necrosis factor receptor superfamily, member 10B, (TNFRSF10B, best known as TRAILR2 or DR5) that is currently under clinical development [<xref rid="R49" ref-type="bibr">49</xref>, <xref rid="R54" ref-type="bibr">54</xref>]. Third, immune conjugates, i.e., TAA-specific mAbs coupled to toxins or radionuclides, such as gemtuzumab ozogamicin, an anti-CD33 calicheamicin conjugate currently approved for use in acute myeloid leukemia patients [<xref rid="R55" ref-type="bibr">55</xref>, <xref rid="R56" ref-type="bibr">56</xref>]. Fourth, naked TAA-specific mAbs that opsonize cancer cells and hence activate antibody-dependent cell-mediated cytotoxicity (ADCC) [<xref rid="R44" ref-type="bibr">44</xref>, <xref rid="R57" ref-type="bibr">57</xref>-<xref rid="R59" ref-type="bibr">59</xref>], antibody-dependent cellular phagocytosis [<xref rid="R60" ref-type="bibr">60</xref>], and complement-dependent cytotoxicity [<xref rid="R61" ref-type="bibr">61</xref>], such as the CD20-specific mAb rituximab, which is currently approved for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma [<xref rid="R62" ref-type="bibr">62</xref>, <xref rid="R63" ref-type="bibr">63</xref>]. Fifth, so-called “bispecific T-cell engagers” (BiTEs), <italic>i.e.</italic>, chimeric proteins consisting of two single-chain variable fragments from distinct mAbs, one targeting a TAA and one specific for a T-cell surface antigen (<italic>e.g.</italic>, blinatumomab, a CD19- and CD3 BiTE recently approved for the therapy of Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia) [<xref rid="R64" ref-type="bibr">64</xref>-<xref rid="R69" ref-type="bibr">69</xref>].</p><p>The therapeutic activity of opsonizing mAbs and BiTEs clearly relies on the host immune system, implying that these molecules should be considered active immunotherapeutics. Conversely, tumor-targeting mAbs of the first two classes are endowed with intrinsic antineoplastic activity, and have been considered for a long time as passive forms of immunotherapy. However, growing evidence indicates that the actual antineoplastic potential of these molecules does not simply reflect their direct tumor-inhibitory activity, but also involves (at least to some degree) the activation of an anticancer immune response. For instance, cetuximab does not only inhibit EGFR signaling [<xref rid="R53" ref-type="bibr">53</xref>], but also promotes ADCC [<xref rid="R70" ref-type="bibr">70</xref>], and mediates immunostimulatory effects [<xref rid="R71" ref-type="bibr">71</xref>, <xref rid="R72" ref-type="bibr">72</xref>]. Similarly, bevacizumab, a vascular endothelial growth factor A (VEGFA)-neutralizing mAb approved for the treatment of glioblastoma multiforme, CRC, as well as cervical carcinoma, renal cell carcinoma (RCC) and lung carcinoma, not only exerts anti-angiogenic effects [<xref rid="R50" ref-type="bibr">50</xref>, <xref rid="R73" ref-type="bibr">73</xref>], but also boosts tumor infiltration by B and T lymphocytes, [<xref rid="R74" ref-type="bibr">74</xref>, <xref rid="R75" ref-type="bibr">75</xref>], while inhibiting CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells (Tregs) [<xref rid="R76" ref-type="bibr">76</xref>]. Moreover, polymorphisms in the genes coding for the receptors mainly responsible for ADCC, <italic>i.e.</italic>, Fc fragment of IgG, low affinity IIa, receptor (FCGR2A, also known as CD32) and FCGR3A (also known as CD16a), have been shown to influence the response of cancer patients to most tumor-targeting mAbs [<xref rid="R77" ref-type="bibr">77</xref>]. Thus, it is possible (although not formally demonstrated) that tumor-targeting mAbs operate as active immunotherapeutics. Irrespective of this possibility, 18 distinct tumor-targeting mAbs are currently approved by the US FDA for use in cancer patients (source <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link>) [<xref rid="R45" ref-type="bibr">45</xref>, <xref rid="R46" ref-type="bibr">46</xref>], demonstrating the extraordinary success of this immunotherapeutic paradigm.</p></sec><sec id="s1_1_2"><title>Adoptive cell transfer</title><p>The term “adoptive cell transfer” (ACT) refers to a particular variant of cell-based anticancer immunotherapy that generally involves: (1) the collection of circulating or tumor-infiltrating lymphocytes; (2) their selection/modification/expansion/activation <italic>ex vivo</italic>; and (3) their (re-)administration to patients, most often after lymphodepleting pre-conditioning and in combination with immunostimulatory agents [<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R78" ref-type="bibr">78</xref>-<xref rid="R80" ref-type="bibr">80</xref>]. Other anticancer (immune)therapies involving the (re)infusion of living cells, such as hematopoietic stem cell transplantation (HSCT), conceptually differ from ACT. ACT involves the (re-)introduction of a cell population enriched in potentially tumor-reactive immune effectors [<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R81" ref-type="bibr">81</xref>]. HSCT is employed as a means to reconstitute a healthy, allogeneic (and hence potentially tumor-reactive) immune system in patients with hematological malignancies previously subjected to myelo- and lymphoablating treatments (which aim at eradicating the majority of neoplastic cells) [<xref rid="R82" ref-type="bibr">82</xref>]. Dendritic cell (DC)-based interventions should also be conceptually differentiated from ACT for two reasons. First, (re-)infused DCs are not endowed with intrinsic anticancer activity, but act as anticancer vaccines to elicit a tumor-targeting immune response [<xref rid="R83" ref-type="bibr">83</xref>, <xref rid="R84" ref-type="bibr">84</xref>]. Second, DCs are not administered in the context of lympho/myeloablating chemo(radio)therapy [<xref rid="R85" ref-type="bibr">85</xref>-<xref rid="R87" ref-type="bibr">87</xref>].</p><p>Several strategies have been devised to improve the therapeutic potential of ACT [<xref rid="R79" ref-type="bibr">79</xref>, <xref rid="R80" ref-type="bibr">80</xref>, <xref rid="R88" ref-type="bibr">88</xref>]. For instance, genetic engineering has been employed to endow peripheral blood lymphocytes (PBLs) with features such as a unique antigen specificity [<xref rid="R89" ref-type="bibr">89</xref>], an increased proliferative potential and persistence <italic>in vivo</italic> [<xref rid="R90" ref-type="bibr">90</xref>-<xref rid="R93" ref-type="bibr">93</xref>], an improved secretory profile [<xref rid="R91" ref-type="bibr">91</xref>], an elevated tumor-infiltrating capacity [<xref rid="R94" ref-type="bibr">94</xref>, <xref rid="R95" ref-type="bibr">95</xref>], and superior cytotoxicity [<xref rid="R96" ref-type="bibr">96</xref>]. The specificity of PBLs can be altered prior to (re-)infusion by genetically modifying them to express: (1) a TAA-specific T-cell receptor (TCR) [<xref rid="R89" ref-type="bibr">89</xref>, <xref rid="R97" ref-type="bibr">97</xref>-<xref rid="R99" ref-type="bibr">99</xref>], or (2) a so-called “chimeric antigen receptor” (CAR), i.e., a transmembrane protein comprising the TAA-binding domain of an immunoglobulin linked to one or more immunostimulatory domains [<xref rid="R100" ref-type="bibr">100</xref>-<xref rid="R106" ref-type="bibr">106</xref>]. The latter approach is advantageous in that it renders T cells capable of recognizing (and hence potentially killing) TAA-expressing cells in an MHC-independent fashion. Several clinical trials have already demonstrated the therapeutic potential of CAR-expressing T cells, in particular (but not only) for patients affected by hematological malignancies [<xref rid="R102" ref-type="bibr">102</xref>, <xref rid="R107" ref-type="bibr">107</xref>-<xref rid="R111" ref-type="bibr">111</xref>]. T cells expressing TAA-specific TCRs have also been shown to provide objective benefit to cancer patients [<xref rid="R89" ref-type="bibr">89</xref>, <xref rid="R97" ref-type="bibr">97</xref>-<xref rid="R99" ref-type="bibr">99</xref>]. Conversely, in spite of promising preclinical findings [<xref rid="R112" ref-type="bibr">112</xref>-<xref rid="R117" ref-type="bibr">117</xref>], the adoptive transfer of purified natural killer (NK) cells to cancer patients has been associated with limited therapeutic activity [<xref rid="R118" ref-type="bibr">118</xref>-<xref rid="R120" ref-type="bibr">120</xref>]. To the best of our knowledge, the adoptive transfer of purified B lymphocytes has not yet been investigated in the clinic [<xref rid="R121" ref-type="bibr">121</xref>], possibly because B cells (or at least some subsets thereof) can exert potent immunosuppressive effects [<xref rid="R122" ref-type="bibr">122</xref>-<xref rid="R125" ref-type="bibr">125</xref>]. Of note, no ACT protocol is currently approved by the US FDA for use in cancer patients (source <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link>).</p><p>Since (re-)infused T cells are endowed with intrinsic antineoplastic activity, ACT is generally considered as a passive form of immunotherapy. However, the survival, expansion, migration and cytotoxic activity of adoptively transferred T cells rely on several cytokines, some of which are supplied by the host immune system. Current ACT protocols involve indeed the administration of exogenous interleukins (ILs), including IL-2, IL-15 or IL-21 [<xref rid="R126" ref-type="bibr">126</xref>-<xref rid="R130" ref-type="bibr">130</xref>], but these stimulate a cytokine cascade in the host that sustains the survival and activity of adoptively transferred cells. Thus, ACT may not represent a <italic>bona fide</italic> paradigm of passive immunotherapy.</p></sec><sec id="s1_1_3"><title>Oncolytic viruses</title><p>The term “oncolytic viruses” refers to non-pathogenic viral strains that specifically infect cancer cells, triggering their demise [<xref rid="R131" ref-type="bibr">131</xref>-<xref rid="R133" ref-type="bibr">133</xref>]. Oncolytic viruses must be conceptually differentiated from so-called “oncotropic viruses”, i.e., viruses that exhibit a preferential tropism for malignant cells but no (or very limited) cytotoxic activity [<xref rid="R134" ref-type="bibr">134</xref>, <xref rid="R135" ref-type="bibr">135</xref>]. The antineoplastic potential of oncolytic viruses can be innate and simply originate from the so-called cytopathic effect, i.e., the lethal overload of cellular metabolism resulting from a productive viral infection [<xref rid="R136" ref-type="bibr">136</xref>, <xref rid="R137" ref-type="bibr">137</xref>]. As an alternative, these viruses can mediate an oncolytic activity because of (endogenous or exogenous) gene products that are potentially lethal for the host cell, irrespective of their capacity to massively replicate and cause a cytopathic effect [<xref rid="R131" ref-type="bibr">131</xref>, <xref rid="R132" ref-type="bibr">132</xref>]. Of note, genetic engineering has been successfully employed to endow oncolytic virus with various advantageous traits, including sequences coding for (1) enzymes that convert an innocuous pro-drug into a cytotoxic agent [<xref rid="R138" ref-type="bibr">138</xref>-<xref rid="R143" ref-type="bibr">143</xref>]; (2) proteins that (at least theoretically) trigger lethal signaling cascades in cancer cells only [<xref rid="R144" ref-type="bibr">144</xref>-<xref rid="R146" ref-type="bibr">146</xref>]; or (3) short-hairpin RNAs that target factors that are strictly required for the survival of transformed, but not normal cells [<xref rid="R147" ref-type="bibr">147</xref>, <xref rid="R148" ref-type="bibr">148</xref>]. Of note, no oncolytic virus has been approved by the US FDA for use in cancer patients (source <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link>). Conversely, a recombinant adenovirus (H101, commercialized under the name of Oncorine<sup>®</sup>) has been approved by the regulatory authorities of the People's Republic of China for the treatment of HNC (in combination with chemotherapy) as early as in November 2005 [<xref rid="R149" ref-type="bibr">149</xref>, <xref rid="R150" ref-type="bibr">150</xref>].</p><p>As oncolytic viruses are endowed with intrinsic anticancer activity, they are generally viewed as passive immunotherapeutics. Moreover, several effectors of innate and adaptive immunity limit the efficacy of oncolytic therapy because they can neutralize viral particles before they reach neoplastic lesions [<xref rid="R131" ref-type="bibr">131</xref>, <xref rid="R132" ref-type="bibr">132</xref>, <xref rid="R151" ref-type="bibr">151</xref>]. This is particularly true for the mononuclear phagocytic system of the liver and spleen, which is able to sequester large amounts of oncolytic viruses upon injection [<xref rid="R152" ref-type="bibr">152</xref>, <xref rid="R153" ref-type="bibr">153</xref>]; the complement system, to which oncolytic viruses are particularly sensitive [<xref rid="R154" ref-type="bibr">154</xref>, <xref rid="R155" ref-type="bibr">155</xref>]; and neutralizing antibodies, which can exist in patients prior to oncolytic virotherapy owing to their exposure to naturally occurring variants of the viral strains commonly employed for this purpose [<xref rid="R156" ref-type="bibr">156</xref>, <xref rid="R157" ref-type="bibr">157</xref>]. This being said, accumulating preclinical and clinical evidence indicates that the therapeutic activity of oncolytic viruses stems, for the most part, from their ability to elicit tumor-targeting immune responses as they promote the release of TAAs in an immunostimulatory context. In support of this notion, oncolytic viruses engineered to drive the expression of co-stimulatory receptors [<xref rid="R158" ref-type="bibr">158</xref>-<xref rid="R160" ref-type="bibr">160</xref>] or immunostimulatory cytokines/chemokines [<xref rid="R161" ref-type="bibr">161</xref>-<xref rid="R165" ref-type="bibr">165</xref>] reportedly mediate superior antineoplastic effects as compared to their unmodified counterparts [<xref rid="R131" ref-type="bibr">131</xref>, <xref rid="R132" ref-type="bibr">132</xref>]. Thus, conventional oncolytic viruses also appear to be active, rather than passive, immunotherapeutics.</p></sec></sec><sec id="s1_2"><title>Active immunotherapy</title><sec id="s1_2_1"><title>DC-based immunotherapies</title><p>Throughout the past 2 decades, remarkable efforts have been invested in the development of anticancer immunotherapeutics based on (most often autologous) DCs [<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R166" ref-type="bibr">166</xref>, <xref rid="R167" ref-type="bibr">167</xref>]. This intense wave of preclinical and clinical investigation reflects the critical position occupied by DCs at the interface between innate and adaptive immunity, and the ability of some DC subsets to prime robust, therapeutically relevant anticancer immune responses [<xref rid="R168" ref-type="bibr">168</xref>]. Several forms of DC-based immunotherapy have been developed, most of which involve the isolation of patient- or donor-derived circulating monocytes and their amplification/differentiation <italic>ex vivo</italic>, invariably in the presence of agents that promote DC maturation, such as granulocyte macrophage colony-stimulating factor (GM-CSF) [<xref rid="R28" ref-type="bibr">28</xref>]. This is particularly important because immature DCs exert immunosuppressive, rather than immunostimulatory, functions [<xref rid="R169" ref-type="bibr">169</xref>-<xref rid="R171" ref-type="bibr">171</xref>]. Most often, autologous DCs are re-infused into cancer patients upon exposure to a source of TAAs, including (1) TAA-derived peptides [<xref rid="R172" ref-type="bibr">172</xref>-<xref rid="R175" ref-type="bibr">175</xref>]; (2) mRNAs coding for one or more specific TAAs [<xref rid="R176" ref-type="bibr">176</xref>]; (3) expression vectors coding for one or more specific TAAs [<xref rid="R177" ref-type="bibr">177</xref>-<xref rid="R180" ref-type="bibr">180</xref>]; (4) bulk cancer cell lysates (of either autologous or heterologous derivation) [<xref rid="R181" ref-type="bibr">181</xref>-<xref rid="R186" ref-type="bibr">186</xref>]; (5) or bulk cancer cell-derived mRNA [<xref rid="R187" ref-type="bibr">187</xref>-<xref rid="R191" ref-type="bibr">191</xref>]. As an alternative, DCs are allowed to fuse <italic>ex vivo</italic> with inactivated cancer cells, generating so-called dendritomes [<xref rid="R192" ref-type="bibr">192</xref>-<xref rid="R197" ref-type="bibr">197</xref>]. The rationale behind all these approaches is that DCs become loaded <italic>ex vivo</italic> with TAAs or TAA-coding molecules, hence becoming able to prime TAA-targeting immune responses upon reinfusion. Additional DC-based anticancer immunotherapies include the targeting of specific TAAs to DCs <italic>in vivo</italic> [<xref rid="R169" ref-type="bibr">169</xref>, <xref rid="R198" ref-type="bibr">198</xref>-<xref rid="R205" ref-type="bibr">205</xref>], the use of DC-derived exosomes [<xref rid="R206" ref-type="bibr">206</xref>-<xref rid="R208" ref-type="bibr">208</xref>], and the (re-)administration of autologous or allogeneic DCs amplified, matured and optionally genetically modified <italic>ex vivo</italic>, but not loaded with TAAs [<xref rid="R209" ref-type="bibr">209</xref>-<xref rid="R214" ref-type="bibr">214</xref>]. In the former setting, TAAs are fused to mAbs, polypeptides or carbohydrates that selectively bind to DCs [<xref rid="R169" ref-type="bibr">169</xref>, <xref rid="R198" ref-type="bibr">198</xref>-<xref rid="R202" ref-type="bibr">202</xref>, <xref rid="R215" ref-type="bibr">215</xref>, <xref rid="R216" ref-type="bibr">216</xref>], encapsulated in DC-targeting immunoliposomes [<xref rid="R217" ref-type="bibr">217</xref>, <xref rid="R218" ref-type="bibr">218</xref>], or (3) encoded by DC-specific vectors [<xref rid="R219" ref-type="bibr">219</xref>-<xref rid="R221" ref-type="bibr">221</xref>]. In the latter scenarios, DCs or their exosomes are administered as a relatively non-specific immunostimulatory intervention [<xref rid="R209" ref-type="bibr">209</xref>-<xref rid="R213" ref-type="bibr">213</xref>]. Interestingly, one cellular product containing a significant proportion of (partially immature) DCs is currently licensed for use in cancer patients, namely sipuleucel-T (also known as Provenge<sup>®</sup>) (source <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link>). Sipuleucel-T has been approved by the US FDA and the EMA for the therapy of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer as early as in 2010 [<xref rid="R222" ref-type="bibr">222</xref>-<xref rid="R224" ref-type="bibr">224</xref>]. However, the manufacturer of sipuleucel-T, Dendreon Co. (Seattle, WA, US), filed for bankruptcy in November 2014 (source <ext-link ext-link-type="uri" xlink:href="http://dealbook.nytimes.com/2014/11/10/dendreon-maker-of-prostate-cancer-drug-provenge-files-for-bankruptcy/?_r=0">http://dealbook.nytimes.com/2014/11/10/dendreon-maker-of-prostate-cancer-drug-provenge-files-for-bankruptcy/?_r=0</ext-link>). This reflects the disadvantageous cost-benefit ratio of such a cellular therapy, whose preparation requires a relatively elevated quantity of each patient's peripheral blood mononuclear cells [<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R222" ref-type="bibr">222</xref>, <xref rid="R223" ref-type="bibr">223</xref>]. The safety and efficacy of many DC-based cellular preparations other than are sipuleucel-T are currently being investigated in clinical settings, with promising results [<xref rid="R225" ref-type="bibr">225</xref>].</p><p>Although DCs isolated from cancer patients have been shown to exert cytotoxic activity against malignant cells [<xref rid="R226" ref-type="bibr">226</xref>], DC-based immunotherapies mediate antineoplastic effects mainly because they engage the host immune system against malignant lesions [<xref rid="R227" ref-type="bibr">227</xref>, <xref rid="R228" ref-type="bibr">228</xref>]. Thus, all forms of DC-based anticancer interventions constitute paradigms of active immunotherapy.</p></sec><sec id="s1_2_2"><title>Peptide- and DNA-based anticancer vaccines</title><p>DCs and other antigen-presenting cells (APCs) are also targeted by peptide- and DNA-based anticancer vaccines [<xref rid="R83" ref-type="bibr">83</xref>, <xref rid="R84" ref-type="bibr">84</xref>, <xref rid="R229" ref-type="bibr">229</xref>-<xref rid="R231" ref-type="bibr">231</xref>]. In the former scenario, full-length recombinant TAAs or peptides thereof are administered to cancer patients, most often via the intramuscular, subcutaneous or intradermal route, together with one or more immunostimulatory agents commonly known as adjuvants (which potently promote DC maturation) [<xref rid="R232" ref-type="bibr">232</xref>-<xref rid="R237" ref-type="bibr">237</xref>]. The rationale behind this approach is that resident DCs (or other APCs) acquire the ability to present the TAA-derived epitopes while maturing, hence priming a robust TAA-specific immune response [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R238" ref-type="bibr">238</xref>, <xref rid="R239" ref-type="bibr">239</xref>]. The mechanisms underlying the priming of anticancer immune responses by peptide-based vaccines, and hence their efficacy, depend (at least in part) on their size [<xref rid="R38" ref-type="bibr">38</xref>]. Thus, while short peptides (8-12 amino acids) are conceived to directly bind to MHC molecules expressed on the surface of APCs, synthetic long peptides (25-30 residues) must be taken up, processed and presented by APCs for eliciting an immune response [<xref rid="R38" ref-type="bibr">38</xref>]. Normally, the therapeutic activity of synthetic long peptides is superior to that of their short counterparts, especially when they include epitopes recognized by both cytotoxic and helper T cells or when conjugated to efficient adjuvants [<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R240" ref-type="bibr">240</xref>, <xref rid="R241" ref-type="bibr">241</xref>]. This said, some commonly used immunostimulants such as the so-called incomplete Freund's adjuvant (IFA) have recently been shown to limit the efficacy of peptide-based anticancer vaccination [<xref rid="R242" ref-type="bibr">242</xref>], calling for the use of alternative immunostimulants. A peculiar type of peptide-based vaccines is constituted by autologous tumor lysates complexed with immunostimulatory chaperones, most often members of the heat-shock protein (HSP) family [<xref rid="R243" ref-type="bibr">243</xref>]. This approach is advantageous in that it does not rely on a single TAA but (at least hypothetically) on all TAAs that bind to HSPs (including patient-specific neo-TAAs) [<xref rid="R243" ref-type="bibr">243</xref>]. However, generating anticancer vaccines on a personalized basis is associated with considerable costs [<xref rid="R243" ref-type="bibr">243</xref>].</p><p>DNA-based anticancer vaccines rely on TAA-coding constructs, be them naked or vectored (by viral particles, non-pathogenic bacteria or yeast cells) [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R244" ref-type="bibr">244</xref>-<xref rid="R246" ref-type="bibr">246</xref>]. DNA-based vaccines either become a source of such TAA (as it is the case for bacterial and yeast vectors) or transform APCs or muscular cells to do so (as it is the case for naked constructs and viral vectors) [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R244" ref-type="bibr">244</xref>-<xref rid="R247" ref-type="bibr">247</xref>]. Theoretically, and especially in the presence of adequate adjuvants, this prompts resident DCs or other APCs to prime a TAA-targeting immune response [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R183" ref-type="bibr">183</xref>, <xref rid="R248" ref-type="bibr">248</xref>, <xref rid="R249" ref-type="bibr">249</xref>]. A particularly interesting approach in this context is represented by so-called “oncolytic vaccines”, i.e., oncolytic viruses genetically altered to code for a TAA [<xref rid="R250" ref-type="bibr">250</xref>-<xref rid="R252" ref-type="bibr">252</xref>]. Promising results have also been obtained with DNA-based vaccines administered <italic>per os</italic> [<xref rid="R253" ref-type="bibr">253</xref>-<xref rid="R256" ref-type="bibr">256</xref>]. In this setting, live-attenuated bacteria expressing a full-length TAA are taken up by APCs in the intestinal mucosa, resulting in the priming of a robust, TAA-specific immune response in the so-called “mucosa-associated lymphoid tissue” [<xref rid="R253" ref-type="bibr">253</xref>-<xref rid="R256" ref-type="bibr">256</xref>].</p><p>Both peptide- and DNA-based vaccines have been associated with clinical activity in patients affected by various neoplasms [<xref rid="R83" ref-type="bibr">83</xref>, <xref rid="R84" ref-type="bibr">84</xref>, <xref rid="R229" ref-type="bibr">229</xref>-<xref rid="R231" ref-type="bibr">231</xref>, <xref rid="R257" ref-type="bibr">257</xref>]. For instance, a peptide-based vaccine targeting the human papillomavirus type 16 (HPV-16) proteins E6 and E7 have been shown to promote complete, long-lasting responses in a significant fraction of patients with vulvar intraepithelial neoplasia [<xref rid="R258" ref-type="bibr">258</xref>]. Along similar lines, the administration of a multipeptide vaccine after single-dose cyclophosphamide (an immunogenic alkylating agent, see below) has been shown to prolong overall survival in a cohort of RCC patients [<xref rid="R259" ref-type="bibr">259</xref>]. No peptide- or DNA-based anticancer vaccine is currently approved by the US FDA and EMA for use in humans (sources <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/">http://www.ema.europa.eu/ema/</ext-link>). However, vitespen (Oncophage<sup>®</sup>), a heat shock protein 90kDa beta (Grp94), member 1 (HSP90B1)-based anticancer vaccine, has been approved in Russia for the treatment of RCC patients with intermediate risk of recurrence as early as in 2008 [<xref rid="R257" ref-type="bibr">257</xref>]. Moreover, three DNA-based anticancer vaccines have been licensed for veterinary use [<xref rid="R260" ref-type="bibr">260</xref>-<xref rid="R263" ref-type="bibr">263</xref>], one of which relies on a human TAA (<italic>i.e.</italic>, tyrosinase) [<xref rid="R263" ref-type="bibr">263</xref>].</p><p>Similar to DC-based interventions, both peptide- and DNA-based anticancer vaccines mediate antineoplastic effects as they (re-)activate the host immune system against malignant cells, hence constituting active forms of anticancer immunotherapy.</p></sec><sec id="s1_2_3"><title>Immunostimulatory cytokines</title><p>Taken as a family, cytokines regulate (via autocrine, paracrine or endocrine circuits) virtually all biological functions [<xref rid="R264" ref-type="bibr">264</xref>-<xref rid="R267" ref-type="bibr">267</xref>]. It is therefore not surprising that various attempts have been made to harness the biological potency of specific cytokines to elicit novel or reinvigorate pre-existent tumor-targeting immune responses [<xref rid="R268" ref-type="bibr">268</xref>-<xref rid="R271" ref-type="bibr">271</xref>]. The administration of most immunostimulatory cytokines to cancer patients as standalone therapeutic interventions, however, is generally associated with little, if any, clinical activity [<xref rid="R272" ref-type="bibr">272</xref>-<xref rid="R275" ref-type="bibr">275</xref>]. Thus, immunostimulatory cytokines are generally employed as adjuvants for other anticancer (immuno)therapeutics, either as recombinant molecules or encoded within expression vectors [<xref rid="R276" ref-type="bibr">276</xref>-<xref rid="R284" ref-type="bibr">284</xref>]. Notable exceptions include interferon (IFN)-α2b (also known as Intron A<sup>®</sup>), and IL-2 (also known as aldesleukin and Proleukin<sup>®</sup>), which mediate single agent therapeutic activity in patients affected by melanoma, a tumor type particularly sensitive to immunotherapy [<xref rid="R274" ref-type="bibr">274</xref>, <xref rid="R284" ref-type="bibr">284</xref>]. IFN-α2b is currently approved by the US FDA and EMA for the therapy of hairy cell leukemia (HCL), AIDS-related Kaposi's sarcoma, follicular lymphoma, multiple myeloma, melanoma, external genital/perianal warts (<italic>condylomata acuminata</italic>) and cervical intraepithelial neoplasms (both as a recombinant, unmodified protein, and as a pegylated variant), while IL-2 is licensed for the treatment of metastatic forms of melanoma and RCC. Moreover, IFN-α2a (also known as Roferon-A<sup>®</sup>) is approved for use in subjects with HCL and chronic phase, Philadelphia chromosome-positive chronic myeloid leukemia, upon minimal pretreatment (within 1 year of diagnosis). In Europe, IFN-α2a is also licensed for the treatment of melanoma. Of note, GM-CSF (also known as molgramostim, sargramostim, Leukomax<sup>®</sup>, Mielogen<sup>®</sup> or Leukine<sup>®</sup>) and granulocyte colony-stimulating factor (G-CSF, also known as filgrastim, lenograstim or Neupogen<sup>®</sup>) are approved by the US FDA and EMA for use in humans, but not as part of anticancer regimens [<xref rid="R285" ref-type="bibr">285</xref>-<xref rid="R288" ref-type="bibr">288</xref>]. Nonetheless, GM-CSF has been shown to potentiate the clinical activity of several immunotherapeutics, including (but not limited to) peptide-based vaccines and immunomodulatory mAbs [<xref rid="R259" ref-type="bibr">259</xref>, <xref rid="R289" ref-type="bibr">289</xref>]. Recombinant tumor necrosis factor α (TNFα) is also licensed by several regulatory agencies worldwide (but not by the US FDA), for the treatment of limb-threatening soft tissue sarcoma and melanoma [<xref rid="R290" ref-type="bibr">290</xref>-<xref rid="R292" ref-type="bibr">292</xref>]. However, in this setting TNFα is not employed as an immunostimulatory agent but administered in combination with melphalan (an alkylating agent) to increment the local concentration of the drug (and hence boost its cytotoxicity), and to promote the selective destruction of the tumor vasculature [<xref rid="R293" ref-type="bibr">293</xref>].</p><p>The antineoplastic activity of immunostimulatory cytokines is expected to depend on the host immune system, implying that they underlie a <italic>bona fide</italic> paradigm of active immunotherapy. However, the actual mode of action of immunostimulatory cytokines has not yet been fully explored. Moreover, some of these agents may promote a cytokine cascade with unwarranted, potentially lethal effects, and hence should be employed with caution.</p></sec><sec id="s1_2_4"><title>Immunomodulatory mAbs</title><p>At odds with their tumor-targeting counterparts, immunomodulatory mAbs operate by interacting with (hence altering the function of) soluble or cellular components of the immune system [<xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R294" ref-type="bibr">294</xref>]. Thus, immunomodulatory mAbs are designed to elicit a novel or reinstate an existing anticancer immune response [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R295" ref-type="bibr">295</xref>, <xref rid="R296" ref-type="bibr">296</xref>]. So far, this has been achieved through four general strategies: (1) the inhibition of immunosuppressive receptors expressed by activated T lymphocytes, such as cytotoxic T lymphocyte-associated protein 4 (CTLA4) [<xref rid="R297" ref-type="bibr">297</xref>-<xref rid="R299" ref-type="bibr">299</xref>] and programmed cell death 1 (PDCD1, best known as PD-1) [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R42" ref-type="bibr">42</xref>, <xref rid="R300" ref-type="bibr">300</xref>, <xref rid="R301" ref-type="bibr">301</xref>], or NK cells, like various members of the killer cell immunoglobulin-like receptor (KIR) family [<xref rid="R302" ref-type="bibr">302</xref>-<xref rid="R304" ref-type="bibr">304</xref>]; (2) the inhibition of the principal ligands of these receptors, such as the PD-1 ligand CD274 (best known as PD-L1 or B7-H1) [<xref rid="R300" ref-type="bibr">300</xref>, <xref rid="R305" ref-type="bibr">305</xref>-<xref rid="R307" ref-type="bibr">307</xref>]; (3) the activation of co-stimulatory receptors expressed on the surface of immune effector cells [<xref rid="R308" ref-type="bibr">308</xref>] such as tumor necrosis factor receptor superfamily, member 4 (TNFRSF4, best known as OX40) [<xref rid="R309" ref-type="bibr">309</xref>-<xref rid="R313" ref-type="bibr">313</xref>], TNFRSF9 (best known as CD137 or 4-1BB) [<xref rid="R58" ref-type="bibr">58</xref>, <xref rid="R314" ref-type="bibr">314</xref>, <xref rid="R315" ref-type="bibr">315</xref>], and TNFRSF18 (best known as GITR) [<xref rid="R316" ref-type="bibr">316</xref>-<xref rid="R318" ref-type="bibr">318</xref>]; and (4) the neutralization of immunosuppressive factors released in the tumor microenvironment, such as transforming growth factor β1 (TGFβ1) [<xref rid="R319" ref-type="bibr">319</xref>, <xref rid="R320" ref-type="bibr">320</xref>].</p><p>The first of these approaches, which is commonly referred to as “checkpoint blockade”, has been shown to induce robust and durable responses in cohorts of patients with a variety of solid tumors [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R300" ref-type="bibr">300</xref>, <xref rid="R321" ref-type="bibr">321</xref>-<xref rid="R327" ref-type="bibr">327</xref>]. As it stands, no less than three checkpoint-blocking mAbs are currently approved by international regulatory agencies for use in humans (source <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link>): (1) the anti-CTLA4 mAb ipilimumab (Yervoy™), which was licensed by the US FDA for use in individuals with unresectable or metastatic melanoma on 2011, March 25<sup>th</sup> [<xref rid="R328" ref-type="bibr">328</xref>-<xref rid="R332" ref-type="bibr">332</xref>]; the anti-PD-1 mAb pembrolizumab (Keytruda™), which received accelerated approval by the US FDA for the treatment of advanced or unresectable melanoma patients who fail to respond to other therapies on 2014, September 4<sup>th</sup> [<xref rid="R333" ref-type="bibr">333</xref>-<xref rid="R338" ref-type="bibr">338</xref>]; and nivolumab (Opvido™), another PD-1-targeting mAb licensed by the Japanese Ministry of Health and Welfare for use in humans on 2014, July 07<sup>th</sup> [<xref rid="R339" ref-type="bibr">339</xref>]. Based on the results of a recently completed Phase III clinical trial demonstrating that nivolumab significantly improves the progression-free and overall survival of patients with BRAF<sup>WT</sup> melanoma [<xref rid="R340" ref-type="bibr">340</xref>], the approval of this mAb by the US FDA is expected within the next few months. The safety and efficacy of ipilimumab, pembrolizumab, nivolumab and other checkpoint-blocking mAbs are being demonstrated in a steadily expanding panel of oncological indications [<xref rid="R45" ref-type="bibr">45</xref>, <xref rid="R46" ref-type="bibr">46</xref>, <xref rid="R341" ref-type="bibr">341</xref>, <xref rid="R342" ref-type="bibr">342</xref>]. Of note, some co-stimulatory mAbs including urelumab and PF-0582566 (both of which target CD137) are also under clinical development, with promising results [<xref rid="R46" ref-type="bibr">46</xref>, <xref rid="R341" ref-type="bibr">341</xref>]. Preclinical data suggest that combining checkpoint blockers with co-stimulatory mAb mediates superior antineoplastic effects [<xref rid="R294" ref-type="bibr">294</xref>, <xref rid="R343" ref-type="bibr">343</xref>, <xref rid="R344" ref-type="bibr">344</xref>]. At least in part, this reflects the ability of co-stimulatory mAbs to promote NK cell functions [<xref rid="R58" ref-type="bibr">58</xref>, <xref rid="R345" ref-type="bibr">345</xref>, <xref rid="R346" ref-type="bibr">346</xref>]. In line with this notion, a few clinical trials testing checkpoint blockers in combination with urelumab or lirilumab (a KIR-inhibiting mAb) have just been initiated (source <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>).</p><p>Designed to (re-)activate the host immune system against malignant cells, immunomodulatory mAbs constitute an established and clinically promising paradigm of active immunotherapy. Interestingly, despite their non-specific mechanism of action, the clinical efficacy of immunomodulatory mAbs (and in particular checkpoint blockers) may be profoundly influenced by the panel of (neo-)TAAs specific to each neoplasm [<xref rid="R347" ref-type="bibr">347</xref>].</p></sec><sec id="s1_2_5"><title>Inhibitors of immunosuppressive metabolism</title><p>Indoleamine 2,3-dioxigenase 1 (IDO1) catalyzes the first, rate-limiting step in the so-called “kynurenine pathway”, the catabolic cascade that converts <italic>L</italic>-tryptophan (Trp) into <italic>L</italic>-kynurenine (Kyn) [<xref rid="R348" ref-type="bibr">348</xref>]. Although this enzyme was initially believed to mediate immunostimulatory effects (partly because inflammatory cues including IFNγ promote its expression in cells of the innate immune system) [<xref rid="R349" ref-type="bibr">349</xref>, <xref rid="R350" ref-type="bibr">350</xref>], IDO1 mediates robust immunosuppressive effects, in both physiological (<italic>e.g.</italic>, tolerance during pregnancy) and pathological (mostly oncological) settings [<xref rid="R351" ref-type="bibr">351</xref>-<xref rid="R356" ref-type="bibr">356</xref>]. IDO1 has been proposed to inhibit both innate and adaptive immune responses (1) by depleting immune effector cells of Trp, resulting in irresponsiveness to immunological challenges [<xref rid="R352" ref-type="bibr">352</xref>, <xref rid="R353" ref-type="bibr">353</xref>, <xref rid="R357" ref-type="bibr">357</xref>-<xref rid="R359" ref-type="bibr">359</xref>]; (2) by favoring the accumulation of Kyn and some of its derivatives, which exert cytotoxic effects on immune effector cells while promoting the differentiation of Tregs [<xref rid="R360" ref-type="bibr">360</xref>-<xref rid="R364" ref-type="bibr">364</xref>]; or (3) through various indirect mechanisms mediated by IDO1-expressing DCs [<xref rid="R124" ref-type="bibr">124</xref>, <xref rid="R365" ref-type="bibr">365</xref>-<xref rid="R371" ref-type="bibr">371</xref>]. Evidence accumulated during the last decade indicates that both 1-methyltryptophan (an inhibitor of IDO1 and IDO2) and genetic interventions targeting IDO1 mediate antineoplastic effects while eliciting novel or reinvigorating existent anticancer immune responses [<xref rid="R372" ref-type="bibr">372</xref>-<xref rid="R375" ref-type="bibr">375</xref>]. No IDO1 inhibitor is currently approved by the US FDA for use in humans (source <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link>). However, the results of recent Phase I-II studies suggest that 1-methyl-<italic>D</italic>-tryptophan (an inhibitor of the IDO pathway also known as indoximod), other pharmacological blockers of IDO1 (such as INCB024360), and IDO1-targeting vaccines are well tolerated by cancer patients and mediate antineoplastic effects, at least in a subset of individuals [<xref rid="R376" ref-type="bibr">376</xref>-<xref rid="R382" ref-type="bibr">382</xref>].</p><p>Extracellular ATP mediates robust immunostimulatory functions as it recruits and activates APCs via purinergic receptor P2Y, G-protein coupled, 2 (P2RY2) and purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7), respectively [<xref rid="R383" ref-type="bibr">383</xref>-<xref rid="R386" ref-type="bibr">386</xref>]. On the contrary, the degradation products of ATP (notably AMP and adenosine), have a pronounced immunosuppressive activity upon binding to adenosine A2a receptor (ADORA2A) and ADORA2B [<xref rid="R387" ref-type="bibr">387</xref>-<xref rid="R389" ref-type="bibr">389</xref>]. Two enzymes operates sequentially to degrade extracellular ATP, ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, best known as CD39), which converts ATP into ADP and AMP [<xref rid="R390" ref-type="bibr">390</xref>-<xref rid="R392" ref-type="bibr">392</xref>], and 5′-nucleotidase, ecto (NT5E, best known as CD73), which transforms AMP into adenosine [<xref rid="R393" ref-type="bibr">393</xref>, <xref rid="R394" ref-type="bibr">394</xref>]. Some human neoplasms express increased amounts of CD39 and/or CD73, reflecting the evolutionary advantage conferred to cancer cells by the stimulation of adenosine receptors [<xref rid="R395" ref-type="bibr">395</xref>, <xref rid="R396" ref-type="bibr">396</xref>]. Efforts have therefore been dedicated to the development of agents that would limit the extracellular availability of adenosine or inhibit adenosine receptors [<xref rid="R392" ref-type="bibr">392</xref>, <xref rid="R397" ref-type="bibr">397</xref>]. Preclinical evidence indicates that CD39- or CD79-targeting agents (mostly mAbs) mediate antineoplastic effects as standalone interventions and improve the efficacy of other anticancer agents [<xref rid="R397" ref-type="bibr">397</xref>]. The clinical development of these agents, however, has not yet been initiated. Conversely, ADORA2A antagonists are currently being tested in late-stage clinical trials, but as a therapeutic option against Parkinsonism [<xref rid="R397" ref-type="bibr">397</xref>]. It will be interesting to determine the safety and efficacy of inhibitors of adenosine generation or signaling in cancer patients.</p><p>Although it remains unclear whether these agents truly operate by altering the microenvironmental availability of Trp and Kyn [<xref rid="R398" ref-type="bibr">398</xref>], the antineoplastic effects of IDO inhibitors critically rely on the host immune system, implying that this constitutes an instance of active anticancer immunotherapy [<xref rid="R399" ref-type="bibr">399</xref>]. This also applies to strategies aimed at limiting the extracellular availability of adenosine.</p></sec><sec id="s1_2_6"><title>PRR agonists</title><p>Pattern recognition receptors (PRRs) are evolutionarily conserved proteins involved in the recognition of danger signals [<xref rid="R400" ref-type="bibr">400</xref>, <xref rid="R401" ref-type="bibr">401</xref>]. PRRs include (but are not limited to) Toll-like receptors (TLRs) [<xref rid="R402" ref-type="bibr">402</xref>, <xref rid="R403" ref-type="bibr">403</xref>] and nucleotide-binding oligomerization domain containing (NOD)-like receptors (NLRs) [<xref rid="R404" ref-type="bibr">404</xref>, <xref rid="R405" ref-type="bibr">405</xref>]. TLRs are transmembrane enzymatically-inactive proteins expressed by most APCs, including monocytes, macrophages and DCs, as well as by some types of epithelial cells [<xref rid="R402" ref-type="bibr">402</xref>, <xref rid="R403" ref-type="bibr">403</xref>]. NLRs are expressed by a variety of cell types, including various components of the innate and adaptive immune system [<xref rid="R404" ref-type="bibr">404</xref>, <xref rid="R405" ref-type="bibr">405</xref>]. Taken together, PRRs sense a wide panel of danger signals, including exogenous “microbe-associated molecular patterns” (MAMPs) like bacterial lipopolysaccharide (LPS) or muramyl dipeptide (MDP), and endogenous “damage-associated molecular patterns” (DAMPs), like the non-histone nuclear protein high-mobility group box 1 (HMGB1) and mitochondrial DNA [<xref rid="R406" ref-type="bibr">406</xref>-<xref rid="R410" ref-type="bibr">410</xref>]. The activation of various PRRs ignites a signal transduction cascade with potent pro-inflammatory outcomes, including the activation of NF-κB [<xref rid="R411" ref-type="bibr">411</xref>-<xref rid="R413" ref-type="bibr">413</xref>], and the secretion of immunostimulatory cytokines, like type I IFNs and TNFα [<xref rid="R413" ref-type="bibr">413</xref>-<xref rid="R415" ref-type="bibr">415</xref>]. Moreover, PRR signaling favors the maturation of DCs as well as the activation of macrophages and NK cells [<xref rid="R416" ref-type="bibr">416</xref>]. Besides being critical for the response of the host to viral and bacterial challenges [<xref rid="R402" ref-type="bibr">402</xref>, <xref rid="R403" ref-type="bibr">403</xref>], some PRRs play a key role in the (re)activation of anticancer immune responses by chemo-, radio- and immunotherapeutic interventions [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R413" ref-type="bibr">413</xref>, <xref rid="R417" ref-type="bibr">417</xref>-<xref rid="R422" ref-type="bibr">422</xref>].</p><p>Thus, PRR agonists have spurred interest not only as adjuvants for conventional vaccines [<xref rid="R423" ref-type="bibr">423</xref>, <xref rid="R424" ref-type="bibr">424</xref>], but also as immunotherapeutic interventions that may mediate antineoplastic effects <italic>per se</italic> or boost the therapeutic activity of other anticancer agents [<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R425" ref-type="bibr">425</xref>]. Three TLR agonists are approved by the US FDA for use in cancer patients: (1) the bacillus Calmette-Guérin (BCG), an attenuated variant of <italic>Mycobacterium bovis</italic> that presumably operates as a mixed TLR2/TLR4 agonist, which is currently used as a standalone immunotherapeutic agent in subjects with non-invasive transitional cell carcinoma of the bladder [<xref rid="R426" ref-type="bibr">426</xref>]; (2) monophosphoryl lipid A (MPL), a TLR2/TLR4-activating derivative of <italic>Salmonella minnesota</italic> LPS currently utilized as adjuvant in Cervarix<sup>®</sup>, a vaccine for the prevention of HPV-16 and -18 infection [<xref rid="R427" ref-type="bibr">427</xref>]; and (3) imiquimod, an imidazoquinoline derivative that triggers TLR7 signaling, currently employed for the treatment of actinic keratosis, superficial basal cell carcinoma and <italic>condylomata acuminata</italic> [<xref rid="R422" ref-type="bibr">422</xref>, <xref rid="R426" ref-type="bibr">426</xref>]. Of note, picibanil (a lyophilized preparation of <italic>Streptococcus pyogenes</italic> that operates as a TLR2/TLR4 agonist has been licensed for use in cancer patients by the Japanese Ministry of Health and Welfare (but not by the US FDA) as early as in 1975 [<xref rid="R428" ref-type="bibr">428</xref>, <xref rid="R429" ref-type="bibr">429</xref>]; while mifamurtide (a synthetic lipophilic glycopeptide that activates NOD2) has been approved by the EMA for the treatment of osteosarcoma in 2009 [<xref rid="R430" ref-type="bibr">430</xref>-<xref rid="R432" ref-type="bibr">432</xref>]. Moreover, the safety and efficacy of several other PRR agonists are currently being evaluated in clinical trials [<xref rid="R433" ref-type="bibr">433</xref>-<xref rid="R435" ref-type="bibr">435</xref>]. These molecules include agatolimod (CpG-7909, PF-3512676, Promune<sup>®</sup>), an unmethylated CpG oligodeoxynucleotide that activates TLR9 [<xref rid="R436" ref-type="bibr">436</xref>]; polyriboinosinic polyribocytidylic acid (polyI:C, Ampligen™, Rintatolimod), a synthetic double-strand RNA that signals via TLR3 [<xref rid="R437" ref-type="bibr">437</xref>]; and Hiltonol™, a particular formulation of polyI:C that involves carboxymethylcellulose and poly-<italic>L</italic>-lysine [<xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R438" ref-type="bibr">438</xref>].</p><p>Some malignant cells express PRRs [<xref rid="R439" ref-type="bibr">439</xref>-<xref rid="R445" ref-type="bibr">445</xref>], implying that PRR agonists may not be completely devoid of intrinsic tumor-modulating functions. Nonetheless, a large body of preclinical and clinical literature indicates that the antineoplastic effects of PRR agonists stem from their ability to engage the host immune system. Thus, PRR agonists constitute active immunotherapeutics.</p></sec><sec id="s1_2_7"><title>Immunogenic cell death inducers</title><p>Some conventional chemotherapeutics, often employed at metronomic doses [<xref rid="R446" ref-type="bibr">446</xref>, <xref rid="R447" ref-type="bibr">447</xref>], as well as some forms of radiation therapy, can kill malignant cells while stimulating them to release specific DAMPs in a spatiotemporally coordinated manner [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R420" ref-type="bibr">420</xref>, <xref rid="R448" ref-type="bibr">448</xref>]. Such DAMPs bind to receptors expressed on the surface of APCs (including TLR4), and not only boost their ability to engulf particulate material (including TAAs and cancer cell debris) but also trigger their maturation/activation [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R418" ref-type="bibr">418</xref>, <xref rid="R448" ref-type="bibr">448</xref>, <xref rid="R449" ref-type="bibr">449</xref>]. As a result, APCs acquire the ability to elicit a cancer-specific immune response that (at least in mice) is associated with the development of immunological memory [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R450" ref-type="bibr">450</xref>]. We have dubbed such a functionally atypical form of apoptosis “immunogenic cell death” (ICD) [<xref rid="R15" ref-type="bibr">15</xref>]. Importantly, ICD inducers exert optimal antineoplastic effects in immunocompetent, but not in immunodeficient, mice [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R451" ref-type="bibr">451</xref>-<xref rid="R454" ref-type="bibr">454</xref>]. However, the ability of a specific stimulus to trigger ICD can be properly assessed only by means of vaccination experiments involving immunocompetent mice and syngeneic tumor models [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R455" ref-type="bibr">455</xref>]. As it stands, a few FDA-approved therapies have been shown to constitute <italic>bona fide</italic> ICD inducers, including: doxorubicin, mitoxantrone and epirubicin (three anthracyclines currently employed against various carcinomas) [<xref rid="R186" ref-type="bibr">186</xref>, <xref rid="R449" ref-type="bibr">449</xref>], bleomycin (a glycopeptide antibiotic endowed with antineoplastic properties) [<xref rid="R456" ref-type="bibr">456</xref>], oxaliplatin (a platinum derivative generally used for the therapy of colorectal carcinoma) [<xref rid="R453" ref-type="bibr">453</xref>, <xref rid="R457" ref-type="bibr">457</xref>], cyclophosphamide (an alkylating agent employed against neoplastic and autoimmune conditions) [<xref rid="R458" ref-type="bibr">458</xref>-<xref rid="R460" ref-type="bibr">460</xref>], specific forms of radiation therapy [<xref rid="R419" ref-type="bibr">419</xref>, <xref rid="R461" ref-type="bibr">461</xref>-<xref rid="R466" ref-type="bibr">466</xref>], photodynamic therapy (an intervention that relies on the administration of a photosensitizing agent coupled to light irradiation) [<xref rid="R448" ref-type="bibr">448</xref>, <xref rid="R467" ref-type="bibr">467</xref>, <xref rid="R468" ref-type="bibr">468</xref>], and bortezomib (a proteasomal inhibitor used for the treatment of multiple myeloma) [<xref rid="R469" ref-type="bibr">469</xref>, <xref rid="R470" ref-type="bibr">470</xref>].</p><p>These and other (hitherto experimental) ICD inducers have been viewed as conventional forms of anticancer therapy, exerting antineoplastic effects via cytostatic or cytotoxic mechanisms. However, accumulating evidence indicates that the full-blown therapeutic potential of these molecules relies on the host immune system [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R471" ref-type="bibr">471</xref>]. Thus, we propose to classify ICD inducers as a form of active anticancer immunotherapy.</p></sec><sec id="s1_2_8"><title>Others</title><p>Other anticancer immunotherapies are approved by regulatory agencies worldwide for use in cancer patients or are currently being investigated for safety and efficacy in preclinical or clinical settings.</p><p>Lenalidomide (Revlimid<sup>®</sup>, also known as CC-5013) and pomalidomide (Pomalyst<sup>®</sup>, also known as CC-4047) are two derivatives of thalidomide (Thalomid<sup>®</sup>) originally developed in the 1990s to achieve improved potency in the absence of significant side effects [<xref rid="R472" ref-type="bibr">472</xref>]. Thalidomide was indeed marketed as an over-the-counter sedative, tranquilizer, and antiemetic for morning sickness in various countries in the late 1950s, but was rapidly withdrawn following a peak of infants born with malformation of the limbs [<xref rid="R473" ref-type="bibr">473</xref>]. In spite of its pronounced teratogenic activity, thalidomide raised renewed interest as an inhibitor of TNFα secretion in the 1990s [<xref rid="R474" ref-type="bibr">474</xref>], and was approved by the US FDA (under a strictly controlled distribution program) for the therapy of erythema nodosum leprosum (a complication of leprosy etiologically linked to TNFα) in 1998 [<xref rid="R475" ref-type="bibr">475</xref>]. The combination of thalidomide with dexamethasone (a glucocorticoid) rapidly turned out to mediate therapeutic effects in patients with hematological malignancies, eventually resulting in the approval by the US FDA of this regimen for the treatment of newly diagnosed multiple myeloma [<xref rid="R476" ref-type="bibr">476</xref>]. Alongside, lenalidomide (which retains some degree of teratogenicity) was licensed for use in patients with multiple myeloma (also in combination with dexamethasone) and low or intermediate-1 risk myelodysplastic syndromes that harbor 5q cytogenetic abnormalities (as a standalone intervention) [<xref rid="R477" ref-type="bibr">477</xref>-<xref rid="R480" ref-type="bibr">480</xref>]. Conversely, pomalidomide (which is devoid of teratogenic activity) has been approved for use in multiple myeloma patients only in 2013, when the approval of lenalidomide has been extended to mantle cell lymphoma (MCL) [<xref rid="R481" ref-type="bibr">481</xref>-<xref rid="R483" ref-type="bibr">483</xref>]. Although the effects of thalidomide, lenalidomide and pomalidomide, which are collectively referred to as “immunomodulatory drugs” (IMiDs), on the immune system have been characterized with increasing precision throughout the past two decades [<xref rid="R484" ref-type="bibr">484</xref>], the underlying molecular mechanisms remained obscure [<xref rid="R485" ref-type="bibr">485</xref>]. Recent findings indicate that the therapeutic activity of IMiDs depend, at least in part, on their ability to bind the E3 ubiquitin ligase cereblon (CRBN) and hence boost the proteasomal degradation of the B cell-specific transcription factors IKAROS family zinc finger 1 (IKZF1) and IKZF3 [<xref rid="R486" ref-type="bibr">486</xref>, <xref rid="R487" ref-type="bibr">487</xref>]. Of note, CRBN, which is also involved in the teratogenic effects of thalidomide and lenalidomide [<xref rid="R488" ref-type="bibr">488</xref>], regulates the abundance of interferon regulatory factor 4, perhaps accounting for the immunomodulatory functions of IMiDs [<xref rid="R489" ref-type="bibr">489</xref>]. Although endowed with intrinsic antineoplastic activity, IMiDs should be considered active immunotherapeutics.</p><p>As they progress and respond to treatment, neoplastic lesions are infiltrated by a significant amount of lymphoid and myeloid cells, including CD8<sup>+</sup> T lymphocytes, Tregs, tumor-associated macrophages (TAMs) and immunosuppressive B-cell populations [<xref rid="R122" ref-type="bibr">122</xref>-<xref rid="R124" ref-type="bibr">124</xref>, <xref rid="R490" ref-type="bibr">490</xref>, <xref rid="R491" ref-type="bibr">491</xref>]. Robust tumor infiltration by CD8<sup>+</sup> T lymphocytes is generally associated with a good prognosis, especially when the intratumoral levels of Tregs are limited [<xref rid="R124" ref-type="bibr">124</xref>, <xref rid="R492" ref-type="bibr">492</xref>]. Along similar lines, high intratumoral levels of TAMs with a “classically-activated” M1 phenotype (which exert tumoricidal functions, stimulate NK cells and secrete T<sub>H</sub>1-polarizing cytokines) generally correlate with improved disease outcome [<xref rid="R491" ref-type="bibr">491</xref>, <xref rid="R493" ref-type="bibr">493</xref>]. The contrary holds true when the myeloid tumor infiltrate contains high levels of “alternatively-activated” M2 TAMs or specific B-cell subsets, which can secrete not only immunosuppressive cytokines like IL-10 and TGFβ1, but also angiogenic mediators such as VEGFA and enzymes that remodel the extracellular matrix [<xref rid="R491" ref-type="bibr">491</xref>, <xref rid="R493" ref-type="bibr">493</xref>]. These observations prompted the development of immunotherapeutic regimens based on the depletion/inhibition of Tregs or B lymphocytes, as well as on the conversion of M2 TAMs to their M1 counterparts.</p><p>Denileukin diftitox (also known as Ontak<sup>®</sup>) is a recombinant variant of IL-2 fused to the diphtheria toxin [<xref rid="R494" ref-type="bibr">494</xref>]. Owing to its selective cytotoxicity for cells expressing IL-2 receptor α (IL2RA, best known as CD25), denileukin diftitox has been approved by the US FDA and EMA for the treatment of CD25<sup>+</sup> cutaneous T-cell lymphoma in the early 2000s [<xref rid="R494" ref-type="bibr">494</xref>]. More recently, denileukin diftitox has been tested for its ability to improve the efficacy of various immunotherapies by efficiently depleting Tregs (which also express CD25) in patients affected by various neoplasms [<xref rid="R495" ref-type="bibr">495</xref>-<xref rid="R497" ref-type="bibr">497</xref>]. In some (but not all) these clinical settings, denileukin diftitox enhanced the efficacy of immunotherapy as it provoked a sizeable Treg depletion [<xref rid="R496" ref-type="bibr">496</xref>, <xref rid="R497" ref-type="bibr">497</xref>]. However, denileukin diftitox has recently been ascribed with a number of immunosuppressive effects [<xref rid="R498" ref-type="bibr">498</xref>, <xref rid="R499" ref-type="bibr">499</xref>]. This may explain why in some cases denileukin diftitox had no clinical activity [<xref rid="R495" ref-type="bibr">495</xref>], and casts doubts on the possibility to use such Treg-depleting agent as a routine anticancer immunotherapeutic. This said, several conventional antineoplastic agents commonly used in the clinic appear to deplete or inhibit Treg, which presumably contributes to their therapeutic activity (see below) [<xref rid="R420" ref-type="bibr">420</xref>, <xref rid="R421" ref-type="bibr">421</xref>]. Along similar lines, at least part of the clinical activity of ibrutinib (PCI-32765), a small molecule inhibitor of bruton tyrosine kinase (BTK) recently approved by the US FDA for use in patients with MCL and CLL [<xref rid="R500" ref-type="bibr">500</xref>-<xref rid="R502" ref-type="bibr">502</xref>], may stem from its ability to target tumor-infiltrating B lymphocytes or myeloid cells [<xref rid="R503" ref-type="bibr">503</xref>]. A clinical trial testing this possibility in pancreatic cancer patients will soon be initiated (LC, personal communication).</p><p>Several immunotherapeutic agents exert antineoplastic effects by altering the relative proportion between M2 and M1 TAMs in favor of the latter [<xref rid="R491" ref-type="bibr">491</xref>]. These include: (1) tasquinimod, a second-generation orally active quinoline-3-carboxamide analog initially developed as an antiangiogenic agent [<xref rid="R504" ref-type="bibr">504</xref>, <xref rid="R505" ref-type="bibr">505</xref>]; trabectedin (Yondelis<sup>®</sup>), a marine antineoplastic agent currently approved in Europe, Russia and South Korea for the treatment of soft tissue sarcoma and ovarian carcinoma [<xref rid="R506" ref-type="bibr">506</xref>, <xref rid="R507" ref-type="bibr">507</xref>]; (3) inhibitors of chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 (CCL2/CCR2) signaling [<xref rid="R508" ref-type="bibr">508</xref>]; (3) mAbs specific for chemokine (C-X-C motif) receptor 4 (CXCR4) [<xref rid="R509" ref-type="bibr">509</xref>]; and (4) small molecule inhibitors and mAbs that suppress colony stimulating factor 1/colony stimulating factor 1 receptor (CSF1/CSFR1) signaling [<xref rid="R510" ref-type="bibr">510</xref>-<xref rid="R512" ref-type="bibr">512</xref>]. With the single exception of trabectedin (which was not developed as an immunotherapeutic agent), none of these strategies is currently approved by the US FDA or EMA for use in humans (sources <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">http://www.fda.gov</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/">http://www.ema.europa.eu/ema/</ext-link>). However, several Phase II-III clinical trials are currently ongoing to establish the safety and efficacy of these active immunotherapeutic agents in patients with various solid tumors (source <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>).</p><p>Additional, hitherto experimental immunotherapeutic regimens act by stimulating the host immune system to mount a novel (or unleash an existing) immune response against malignant cells. These include: (1) strategies for the depletion of circulating myeloid-derived suppressor cells (MDSCs), a blood-borne population of immature, immunosuppressive myeloid cells that generally accumulate in the course of tumor progression [<xref rid="R513" ref-type="bibr">513</xref>-<xref rid="R516" ref-type="bibr">516</xref>]; (2) mAbs that block CD47, one of the major antiphagocytic receptor expressed by malignant cells [<xref rid="R517" ref-type="bibr">517</xref>-<xref rid="R519" ref-type="bibr">519</xref>]; and (3) vaccines relying on the administration of cancer cell lines expressing immunostimulatory molecules (e.g., GM-CSF) upon inactivation or lysis [<xref rid="R520" ref-type="bibr">520</xref>].</p></sec></sec></sec><sec id="s3"><title>CONCLUDING REMARKS</title><p>During the past three decades, immunotherapy has become a clinical reality [<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R78" ref-type="bibr">78</xref>, <xref rid="R521" ref-type="bibr">521</xref>], and an ever-increasing number of cancer patients are expected to receive, at some stage of their disease, an immunotherapeutic intervention [<xref rid="R522" ref-type="bibr">522</xref>, <xref rid="R523" ref-type="bibr">523</xref>]. The observations presented above suggest that various immunotherapies previously classified as passive, including several (if not all) tumor-targeting mAbs, ACT and oncolytic viruses, may <italic>de facto</italic> constitute active forms of immunotherapy. Moreover, accumulating preclinical and clinical evidence indicates that therapeutically relevant anticancer immune responses invariably exhibit some degree of epitope spreading, i.e., they eventually target several TAAs even when they were initially directed against a single one [<xref rid="R524" ref-type="bibr">524</xref>, <xref rid="R525" ref-type="bibr">525</xref>]. This is not surprising considering that malignant cells exhibit a high degree of genetic/genomic instability and hence are relatively prone to generate so-called “antigen loss variants” that would render TAA-specific immunotherapies completely ineffective with time [<xref rid="R526" ref-type="bibr">526</xref>-<xref rid="R528" ref-type="bibr">528</xref>]. Thus, even if immunotherapies that truly generate an anticancer response with a unique antigen specificity existed [<xref rid="R529" ref-type="bibr">529</xref>, <xref rid="R530" ref-type="bibr">530</xref>], they presumably would not mediate clinically relevant, long-term immune responses. In turn, this casts some doubts on the practical utility of classifying immunotherapies into “antigen-specific” or “non-specific”.</p><p>Recently, great attention has been given to the immunostimulatory effects of conventional chemotherapeutics [<xref rid="R420" ref-type="bibr">420</xref>, <xref rid="R421" ref-type="bibr">421</xref>, <xref rid="R531" ref-type="bibr">531</xref>, <xref rid="R532" ref-type="bibr">532</xref>]. Indeed, several compounds that have been successfully used in the clinic, including the nucleoside analogs gemcitabine (which is approved by the US FDA for the treatment of pancreatic, ovarian, breast and non-small cell carcinoma) [<xref rid="R533" ref-type="bibr">533</xref>, <xref rid="R534" ref-type="bibr">534</xref>] and 5-fluorouracil (which is licensed for use in patients affected by various neoplasms) [<xref rid="R535" ref-type="bibr">535</xref>, <xref rid="R536" ref-type="bibr">536</xref>] have off-target immunostimulatory effects, in particular when administered as low doses and according to metronomic schedules (while, similar to radiation therapy, they are generally immunosuppressive when given at high doses) [<xref rid="R537" ref-type="bibr">537</xref>, <xref rid="R538" ref-type="bibr">538</xref>]. It is therefore tempting to speculate that most (if not all) anticancer agents that are truly beneficial to patients operate as active immunotherapeutics, stimulating the host immune system to mount an antigenically broad (and hence insensitive to antigen loss) response against malignant cells. In support of this notion, an ever increasing number of combinatorial immuno(chemo)therapeutic regimens is being designed and tested in clinical trials, with promising results [<xref rid="R34" ref-type="bibr">34</xref>]. This being said, only the adequate implementation of protocols to monitor immune system-related parameters among patients participating in clinical trials (immunomonitoring) will provide insights into this possibility [<xref rid="R539" ref-type="bibr">539</xref>-<xref rid="R543" ref-type="bibr">543</xref>]. Such protocols are inherently complex, calling for international efforts toward standardization [<xref rid="R544" ref-type="bibr">544</xref>]. Harmonized immunomonitoring procedures will undoubtedly guide the development of new (immuno)therapies, and facilitate the identification of novel prognostic or predictive biomarkers [<xref rid="R544" ref-type="bibr">544</xref>]. We are positive that the next clinical success of anticancer immunotherapy is just behind the door.</p></sec></body><back><ack><p>GK is supported by the Ligue contre le Cancer (équipe labelisée); Agence Nationale de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). MPC is supported by Association for Cancer Research (AIRC). SG is supported by Cancer Vaccine Collaborative and Cancer Research Institute. MJS is supported by the National Health and Medical Research Council of Australia; the QIMR Berghofer Medical Research Institute; and the Susan G Komen Breast Cancer Foundation. FM is supported by a grant from the Italian Ministry of Health.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>ACT</term><def><p>adoptive cell transfer</p></def></def-item><def-item><term>ADCC</term><def><p>antibody-dependent cell-mediated cytotoxicity</p></def></def-item><def-item><term>ADORA</term><def><p>adenosine receptor</p></def></def-item><def-item><term>APC</term><def><p>antigen-presenting cell</p></def></def-item><def-item><term>BiTE</term><def><p>bispecific T-cell engager</p></def></def-item><def-item><term>CAR</term><def><p>chimeric antigen receptor</p></def></def-item><def-item><term>CLL</term><def><p>chronic lymphocytic leukemia</p></def></def-item><def-item><term>CRBN</term><def><p>cereblon</p></def></def-item><def-item><term>CRC</term><def><p>colorectal carcinoma</p></def></def-item><def-item><term>CTLA4</term><def><p>cytotoxic T lymphocyte-associated protein 4</p></def></def-item><def-item><term>DAMP</term><def><p>damage-associated molecular pattern</p></def></def-item><def-item><term>DC</term><def><p>dendritic cell</p></def></def-item><def-item><term>EGFR</term><def><p>epidermal growth factor receptor</p></def></def-item><def-item><term>EMA</term><def><p>European Medicines Agency</p></def></def-item><def-item><term>FCGR2A</term><def><p>Fc fragment of IgG, low affinity IIa, receptor</p></def></def-item><def-item><term>FCGR3A</term><def><p>Fc fragment of IgG, low affinity IIIa, receptor</p></def></def-item><def-item><term>FDA</term><def><p>Food and Drug Administration</p></def></def-item><def-item><term>GM-CSF</term><def><p>granulocyte macrophage colony-stimulating factor</p></def></def-item><def-item><term>HCL</term><def><p>hairy cell leukemia</p></def></def-item><def-item><term>HNC</term><def><p>head and neck cancer</p></def></def-item><def-item><term>HPV</term><def><p>human papillomavirus</p></def></def-item><def-item><term>HSCT</term><def><p>hematopoietic stem cell transplantation</p></def></def-item><def-item><term>HSP</term><def><p>heat shock protein</p></def></def-item><def-item><term>ICD</term><def><p>immunogenic cell death</p></def></def-item><def-item><term>IDO1</term><def><p>indoleamine 2,3-dioxigenase 1</p></def></def-item><def-item><term>IFN</term><def><p>interferon</p></def></def-item><def-item><term>IKZF</term><def><p>IKAROS family zinc finger</p></def></def-item><def-item><term>IL</term><def><p>interleukin</p></def></def-item><def-item><term>IMiD</term><def><p>immunomodulatory drug</p></def></def-item><def-item><term>KIR</term><def><p>killer cell immunoglobulin-like receptor</p></def></def-item><def-item><term>Kyn</term><def><p><italic>L</italic>-kynurenine</p></def></def-item><def-item><term>LPS</term><def><p>lipopolysaccharide</p></def></def-item><def-item><term>mAb</term><def><p>monoclonal antibody</p></def></def-item><def-item><term>MCL</term><def><p>mantle cell lymphoma</p></def></def-item><def-item><term>NLR</term><def><p>NOD-like receptors</p></def></def-item><def-item><term>NK</term><def><p>natural killer</p></def></def-item><def-item><term>PBL</term><def><p>peripheral blood lymphocyte</p></def></def-item><def-item><term>PRR</term><def><p>pattern recognition receptor</p></def></def-item><def-item><term>RCC</term><def><p>renal cell carcinoma</p></def></def-item><def-item><term>TAA</term><def><p>tumor-associated antigen</p></def></def-item><def-item><term>TAM</term><def><p>tumor-associated macrophage</p></def></def-item><def-item><term>TCR</term><def><p>T-cell receptor</p></def></def-item><def-item><term>TGFß1</term><def><p>transforming growth factor ß1</p></def></def-item><def-item><term>TLR</term><def><p>Toll-like receptor</p></def></def-item><def-item><term>TNFa</term><def><p>tumor necrosis factor a</p></def></def-item><def-item><term>TNFRSF</term><def><p>tumor necrosis factor receptor superfamily</p></def></def-item><def-item><term>Treg</term><def><p>regulatory T cell</p></def></def-item><def-item><term>Trp</term><def><p>tryptophan</p></def></def-item><def-item><term>VEGFA</term><def><p>vascular endothelial growth factor A</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Fojo</surname><given-names>T</given-names></name><name><surname>Bates</surname><given-names>S</given-names></name></person-group><article-title>Tumour stem cells and drug resistance</article-title><source>Nat Rev Cancer</source><year>2005</year><volume>5</volume><fpage>275</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">15803154</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group><name><surname>Visvader</surname><given-names>JE</given-names></name><name><surname>Lindeman</surname><given-names>GJ</given-names></name></person-group><article-title>Cancer stem cells in solid tumours: accumulating evidence and unresolved questions</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>755</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">18784658</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group><name><surname>Beck</surname><given-names>B</given-names></name><name><surname>Blanpain</surname><given-names>C</given-names></name></person-group><article-title>Unravelling cancer stem cell potential</article-title><source>Nat Rev Cancer</source><year>2013</year><volume>13</volume><fpage>727</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">24060864</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group><name><surname>Mueller</surname><given-names>MM</given-names></name><name><surname>Fusenig</surname><given-names>NE</given-names></name></person-group><article-title>Friends or foes - bipolar effects of the tumour stroma in cancer</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>839</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">15516957</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group><name><surname>Albini</surname><given-names>A</given-names></name><name><surname>Sporn</surname><given-names>MB</given-names></name></person-group><article-title>The tumour microenvironment as a target for chemoprevention</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">17218951</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group><name><surname>Holzel</surname><given-names>M</given-names></name><name><surname>Bovier</surname><given-names>A</given-names></name><name><surname>Tuting</surname><given-names>T</given-names></name></person-group><article-title>Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?</article-title><source>Nat Rev Cancer</source><year>2013</year><volume>13</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">23535846</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group><name><surname>Wellen</surname><given-names>KE</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><article-title>A two-way street: reciprocal regulation of metabolism and signalling</article-title><source>Nat Rev Mol Cell Biol</source><year>2012</year><volume>13</volume><fpage>270</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">22395772</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Metabolic targets for cancer therapy</article-title><source>Nat Rev Drug Discov</source><year>2013</year><volume>12</volume><fpage>829</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">24113830</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Cell biology. Metabolic control of cell death</article-title><source>Science</source><year>2014</year><volume>345</volume><fpage>1250256</fpage><pub-id pub-id-type="pmid">25237106</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group><name><surname>Solimini</surname><given-names>NL</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><article-title>Non-oncogene addiction and the stress phenotype of cancer cells</article-title><source>Cell</source><year>2007</year><volume>130</volume><fpage>986</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">17889643</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Solimini</surname><given-names>NL</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><article-title>Principles of cancer therapy: oncogene and non-oncogene addiction</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>823</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">19269363</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Bravo-San Pedro</surname><given-names>JM</given-names></name><name><surname>Vitale</surname><given-names>I</given-names></name><name><surname>Aaronson</surname><given-names>SA</given-names></name><name><surname>Abrams</surname><given-names>JM</given-names></name><name><surname>Adam</surname><given-names>D</given-names></name><name><surname>Alnemri</surname><given-names>ES</given-names></name><name><surname>Altucci</surname><given-names>L</given-names></name><name><surname>Andrews</surname><given-names>D</given-names></name><name><surname>Annicchiarico-Petruzzelli</surname><given-names>M</given-names></name><name><surname>Baehrecke</surname><given-names>EH</given-names></name><name><surname>Bazan</surname><given-names>NG</given-names></name><name><surname>Bertrand</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Essential versus accessory aspects of cell death: recommendations of the NCCD 2015</article-title><source>Cell Death Differ</source><year>2014</year></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Krautwald</surname><given-names>S</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Linkermann</surname><given-names>A</given-names></name></person-group><article-title>Molecular mechanisms of regulated necrosis</article-title><source>Semin Cell Dev Biol</source><year>2014</year></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group><name><surname>Vanden Berghe</surname><given-names>T</given-names></name><name><surname>Linkermann</surname><given-names>A</given-names></name><name><surname>Jouan-Lanhouet</surname><given-names>S</given-names></name><name><surname>Walczak</surname><given-names>H</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name></person-group><article-title>Regulated necrosis: the expanding network of non-apoptotic cell death pathways</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><fpage>135</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">24452471</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><article-title>Immunogenic cell death in cancer therapy</article-title><source>Annu Rev Immunol</source><year>2013</year></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion</article-title><source>Science</source><year>2011</year><volume>331</volume><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">21436444</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Cancer despite immunosurveillance: immunoselection and immunosubversion</article-title><source>Nat Rev Immunol</source><year>2006</year><volume>6</volume><fpage>715</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">16977338</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases</article-title><source>Nat Rev Drug Discov</source><year>2011</year><volume>10</volume><fpage>417</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">21629292</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group><name><surname>Albini</surname><given-names>A</given-names></name><name><surname>Tosetti</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>VW</given-names></name><name><surname>Noonan</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>WW</given-names></name></person-group><article-title>Cancer prevention by targeting angiogenesis</article-title><source>Nat Rev Clin Oncol</source><year>2012</year><volume>9</volume><fpage>498</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">22850752</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group><name><surname>Lake</surname><given-names>RA</given-names></name><name><surname>Robinson</surname><given-names>BW</given-names></name></person-group><article-title>Immunotherapy and chemotherapy--a practical partnership</article-title><source>Nat Rev Cancer</source><year>2005</year><volume>5</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">15864281</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group><name><surname>Muller</surname><given-names>AJ</given-names></name><name><surname>Scherle</surname><given-names>PA</given-names></name></person-group><article-title>Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors</article-title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><fpage>613</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">16862192</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group><name><surname>Melero</surname><given-names>I</given-names></name><name><surname>Hervas-Stubbs</surname><given-names>S</given-names></name><name><surname>Glennie</surname><given-names>M</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Immunostimulatory monoclonal antibodies for cancer therapy</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>95</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">17251916</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group><name><surname>Humphries</surname><given-names>C</given-names></name></person-group><article-title>Adoptive cell therapy: Honing that killer instinct</article-title><source>Nature</source><year>2013</year><volume>504</volume><fpage>S13</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">24352359</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group><name><surname>Maus</surname><given-names>MV</given-names></name><name><surname>Fraietta</surname><given-names>JA</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Adoptive Immunotherapy for Cancer or Viruses</article-title><source>Annu Rev Immunol</source><year>2014</year></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Wagner</surname><given-names>K</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>Novel cancer immunotherapy agents with survival benefit: recent successes and next steps</article-title><source>Nat Rev Cancer</source><year>2011</year><volume>11</volume><fpage>805</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">22020206</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group><name><surname>Vanneman</surname><given-names>M</given-names></name><name><surname>Dranoff</surname><given-names>G</given-names></name></person-group><article-title>Combining immunotherapy and targeted therapies in cancer treatment</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><fpage>237</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">22437869</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group><name><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">22437870</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group><name><surname>Palucka</surname><given-names>K</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>Cancer immunotherapy via dendritic cells</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">22437871</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group><name><surname>Kershaw</surname><given-names>MH</given-names></name><name><surname>Westwood</surname><given-names>JA</given-names></name><name><surname>Darcy</surname><given-names>PK</given-names></name></person-group><article-title>Gene-engineered T cells for cancer therapy</article-title><source>Nat Rev Cancer</source><year>2013</year><volume>13</volume><fpage>525</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">23880905</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group><name><surname>Coulie</surname><given-names>PG</given-names></name><name><surname>Van den Eynde</surname><given-names>BJ</given-names></name><name><surname>van der Bruggen</surname><given-names>P</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name></person-group><article-title>Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">24457417</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group><name><surname>Lichty</surname><given-names>BD</given-names></name><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Stojdl</surname><given-names>DF</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name></person-group><article-title>Going viral with cancer immunotherapy</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><fpage>559</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">24990523</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group><name><surname>Rice</surname><given-names>J</given-names></name><name><surname>Ottensmeier</surname><given-names>CH</given-names></name><name><surname>Stevenson</surname><given-names>FK</given-names></name></person-group><article-title>DNA vaccines: precision tools for activating effective immunity against cancer</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>108</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">18219306</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group><name><surname>Couzin-Frankel</surname><given-names>J</given-names></name></person-group><article-title>Breakthrough of the year 2013. Cancer immunotherapy</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>1432</fpage><lpage>1433</lpage><pub-id pub-id-type="pmid">24357284</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Prada</surname><given-names>N</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Current trends of anticancer immunochemotherapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25396</fpage><pub-id pub-id-type="pmid">23894726</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>Haanen</surname><given-names>JB</given-names></name><name><surname>Punt</surname><given-names>CJ</given-names></name></person-group><article-title>Cancer immunotherapy--revisited</article-title><source>Nat Rev Drug Discov</source><year>2011</year><volume>10</volume><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">21804596</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group><name><surname>Weiner</surname><given-names>LM</given-names></name></person-group><article-title>Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>701</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">17721434</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group><name><surname>Strebhardt</surname><given-names>K</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name></person-group><article-title>Paul Ehrlich's magic bullet concept: 100 years of progress</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">18469827</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name></person-group><article-title>Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">18418403</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Targeting PD-1/PD-L1 interactions for cancer immunotherapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1223</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">23243584</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group><name><surname>Dronca</surname><given-names>RS</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name></person-group><article-title>Immunomodulatory Antibody Therapy of Cancer: The Closer the Better</article-title><source>Clin Cancer Res</source><year>2014</year></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group><name><surname>Westin</surname><given-names>JR</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Fayad</surname><given-names>LE</given-names></name><name><surname>Kwak</surname><given-names>LW</given-names></name><name><surname>Fowler</surname><given-names>N</given-names></name><name><surname>Romaguera</surname><given-names>J</given-names></name><name><surname>Hagemeister</surname><given-names>F</given-names></name><name><surname>Fanale</surname><given-names>M</given-names></name><name><surname>Samaniego</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Baladandayuthapani</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal></etal></person-group><article-title>Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">24332512</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group><name><surname>Lipson</surname><given-names>EJ</given-names></name></person-group><article-title>Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23661</fpage><pub-id pub-id-type="pmid">23734322</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group><name><surname>Alkan</surname><given-names>SS</given-names></name></person-group><article-title>Monoclonal antibodies: the story of a discovery that revolutionized science and medicine</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><fpage>153</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">15040588</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group><name><surname>Weiner</surname><given-names>LM</given-names></name><name><surname>Surana</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Monoclonal antibodies: versatile platforms for cancer immunotherapy</article-title><source>Nat Rev Immunol</source><year>2010</year><volume>10</volume><fpage>317</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">20414205</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Trial Watch: Monoclonal antibodies in cancer therapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">22720209</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial watch: Monoclonal antibodies in cancer therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22789</fpage><pub-id pub-id-type="pmid">23482847</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group><name><surname>Weiner</surname><given-names>LM</given-names></name><name><surname>Belldegrun</surname><given-names>AS</given-names></name><name><surname>Crawford</surname><given-names>J</given-names></name><name><surname>Tolcher</surname><given-names>AW</given-names></name><name><surname>Lockbaum</surname><given-names>P</given-names></name><name><surname>Arends</surname><given-names>RH</given-names></name><name><surname>Navale</surname><given-names>L</given-names></name><name><surname>Amado</surname><given-names>RG</given-names></name><name><surname>Schwab</surname><given-names>G</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name></person-group><article-title>Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>502</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">18223225</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group><name><surname>Ming Lim</surname><given-names>C</given-names></name><name><surname>Stephenson</surname><given-names>R</given-names></name><name><surname>Salazar</surname><given-names>AM</given-names></name><name><surname>Ferris</surname><given-names>RL</given-names></name></person-group><article-title>TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24677</fpage><pub-id pub-id-type="pmid">23894722</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group><name><surname>Kaplan-Lefko</surname><given-names>PJ</given-names></name><name><surname>Graves</surname><given-names>JD</given-names></name><name><surname>Zoog</surname><given-names>SJ</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Wall</surname><given-names>J</given-names></name><name><surname>Branstetter</surname><given-names>DG</given-names></name><name><surname>Moriguchi</surname><given-names>J</given-names></name><name><surname>Coxon</surname><given-names>A</given-names></name><name><surname>Huard</surname><given-names>JN</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Peach</surname><given-names>ML</given-names></name><name><surname>Juan</surname><given-names>G</given-names></name><name><surname>Kaufman</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types</article-title><source>Cancer Biol Ther</source><year>2010</year><volume>9</volume><fpage>618</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">20150762</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Hillan</surname><given-names>KJ</given-names></name><name><surname>Gerber</surname><given-names>HP</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name></person-group><article-title>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</article-title><source>Nat Rev Drug Discov</source><year>2004</year><volume>3</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">15136787</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group><name><surname>Michielsen</surname><given-names>AJ</given-names></name><name><surname>Ryan</surname><given-names>EJ</given-names></name><name><surname>O'Sullivan</surname><given-names>JN</given-names></name></person-group><article-title>Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1445</fpage><lpage>1447</lpage><pub-id pub-id-type="pmid">23243624</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group><name><surname>Cavallo</surname><given-names>F</given-names></name><name><surname>Calogero</surname><given-names>RA</given-names></name><name><surname>Forni</surname><given-names>G</given-names></name></person-group><article-title>Are oncoantigens suitable targets for anti-tumour therapy?</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">17700704</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group><name><surname>de La Motte Rouge</surname><given-names>T</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Olaussen</surname><given-names>KA</given-names></name><name><surname>Zermati</surname><given-names>Y</given-names></name><name><surname>Tasdemir</surname><given-names>E</given-names></name><name><surname>Robert</surname><given-names>T</given-names></name><name><surname>Ripoche</surname><given-names>H</given-names></name><name><surname>Lazar</surname><given-names>V</given-names></name><name><surname>Dessen</surname><given-names>P</given-names></name><name><surname>Harper</surname><given-names>F</given-names></name><name><surname>Pierron</surname><given-names>G</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Araujo</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>6253</fpage><lpage>6262</lpage><pub-id pub-id-type="pmid">17616683</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group><name><surname>Forero-Torres</surname><given-names>A</given-names></name><name><surname>Infante</surname><given-names>JR</given-names></name><name><surname>Waterhouse</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name><name><surname>Vickers</surname><given-names>S</given-names></name><name><surname>Arrowsmith</surname><given-names>E</given-names></name><name><surname>He</surname><given-names>AR</given-names></name><name><surname>Hart</surname><given-names>L</given-names></name><name><surname>Trent</surname><given-names>D</given-names></name><name><surname>Wade</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Austin</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer</article-title><source>Cancer Med</source><year>2013</year><volume>2</volume><fpage>925</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">24403266</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group><name><surname>Hughes</surname><given-names>B</given-names></name></person-group><article-title>Antibody-drug conjugates for cancer: poised to deliver?</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><fpage>665</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">20811367</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group><name><surname>Leal</surname><given-names>M</given-names></name><name><surname>Sapra</surname><given-names>P</given-names></name><name><surname>Hurvitz</surname><given-names>SA</given-names></name><name><surname>Senter</surname><given-names>P</given-names></name><name><surname>Wahl</surname><given-names>A</given-names></name><name><surname>Schutten</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>DK</given-names></name><name><surname>Haddish-Berhane</surname><given-names>N</given-names></name><name><surname>Kabbarah</surname><given-names>O</given-names></name></person-group><article-title>Antibody-drug conjugates: an emerging modality for the treatment of cancer</article-title><source>Ann N Y Acad Sci</source><year>2014</year><volume>1321</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">25123209</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group><name><surname>Hubert</surname><given-names>P</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name></person-group><article-title>Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>103</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">22720225</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group><name><surname>Houot</surname><given-names>R</given-names></name><name><surname>Kohrt</surname><given-names>H</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name></person-group><article-title>Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>957</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">23162770</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group><name><surname>Kute</surname><given-names>T</given-names></name><name><surname>Stehle Jr</surname><given-names>JR</given-names></name><name><surname>Ornelles</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>N</given-names></name><name><surname>Delbono</surname><given-names>O</given-names></name><name><surname>Vaughn</surname><given-names>JP</given-names></name></person-group><article-title>Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>810</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">23162748</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group><name><surname>Winiarska</surname><given-names>M</given-names></name><name><surname>Glodkowska-Mrowka</surname><given-names>E</given-names></name><name><surname>Bil</surname><given-names>J</given-names></name><name><surname>Golab</surname><given-names>J</given-names></name></person-group><article-title>Molecular mechanisms of the antitumor effects of anti-CD20 antibodies</article-title><source>Front Biosci (Landmark Ed)</source><year>2011</year><volume>16</volume><fpage>277</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">21196171</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group><name><surname>Zipfel</surname><given-names>PF</given-names></name><name><surname>Skerka</surname><given-names>C</given-names></name></person-group><article-title>Complement regulators and inhibitory proteins</article-title><source>Nat Rev Immunol</source><year>2009</year><volume>9</volume><fpage>729</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">19730437</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group><name><surname>Scott</surname><given-names>SD</given-names></name></person-group><article-title>Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma</article-title><source>Cancer Pract</source><year>1998</year><volume>6</volume><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">9652253</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group><name><surname>Jones</surname><given-names>B</given-names></name></person-group><article-title>Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL</article-title><source>Nat Rev Clin Oncol</source><year>2013</year><volume>10</volume><fpage>607</fpage><pub-id pub-id-type="pmid">23999211</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group><name><surname>Armeanu-Ebinger</surname><given-names>S</given-names></name><name><surname>Hoh</surname><given-names>A</given-names></name><name><surname>Wenz</surname><given-names>J</given-names></name><name><surname>Fuchs</surname><given-names>J</given-names></name></person-group><article-title>Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22620</fpage><pub-id pub-id-type="pmid">23482411</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group><name><surname>Topp</surname><given-names>MS</given-names></name><name><surname>Gokbuget</surname><given-names>N</given-names></name><name><surname>Zugmaier</surname><given-names>G</given-names></name><name><surname>Degenhard</surname><given-names>E</given-names></name><name><surname>Goebeler</surname><given-names>ME</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>SA</given-names></name><name><surname>Horst</surname><given-names>HA</given-names></name><name><surname>Raff</surname><given-names>T</given-names></name><name><surname>Viardot</surname><given-names>A</given-names></name><name><surname>Stelljes</surname><given-names>M</given-names></name><name><surname>Schaich</surname><given-names>M</given-names></name><name><surname>Kohne-Volland</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>5185</fpage><lpage>5187</lpage><pub-id pub-id-type="pmid">23024237</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group><name><surname>Walter</surname><given-names>RB</given-names></name></person-group><article-title>Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia</article-title><source>Expert Rev Hematol</source><year>2014</year><volume>7</volume><fpage>317</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">24617311</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group><name><surname>Choi</surname><given-names>BD</given-names></name><name><surname>Gedeon</surname><given-names>PC</given-names></name><name><surname>Sanchez-Perez</surname><given-names>L</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Sampson</surname><given-names>JH</given-names></name></person-group><article-title>Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26757</fpage><pub-id pub-id-type="pmid">24475376</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group><name><surname>Choi</surname><given-names>BD</given-names></name><name><surname>Pastan</surname><given-names>I</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Sampson</surname><given-names>JH</given-names></name></person-group><article-title>A novel bispecific antibody recruits T cells to eradicate tumors in the «immunologically privileged» central nervous system</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23639</fpage><pub-id pub-id-type="pmid">23734318</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group><name><surname>Hoffman</surname><given-names>LM</given-names></name><name><surname>Gore</surname><given-names>L</given-names></name></person-group><article-title>Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE((R)) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications</article-title><source>Front Oncol</source><year>2014</year><volume>4</volume><fpage>63</fpage><pub-id pub-id-type="pmid">24744989</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Kono</surname><given-names>K</given-names></name><name><surname>Mimura</surname><given-names>K</given-names></name><name><surname>Sugai</surname><given-names>H</given-names></name><name><surname>Akaike</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name></person-group><article-title>Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma</article-title><source>Int J Cancer</source><year>2007</year><volume>120</volume><fpage>781</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">17096332</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group><name><surname>Srivastava</surname><given-names>RM</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Andrade Filho</surname><given-names>PA</given-names></name><name><surname>Lord</surname><given-names>CA</given-names></name><name><surname>Jie</surname><given-names>HB</given-names></name><name><surname>Davidson</surname><given-names>HC</given-names></name><name><surname>Lopez-Albaitero</surname><given-names>A</given-names></name><name><surname>Gibson</surname><given-names>SP</given-names></name><name><surname>Gooding</surname><given-names>WE</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name><name><surname>Ferris</surname><given-names>RL</given-names></name></person-group><article-title>Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>1858</fpage><lpage>1872</lpage><pub-id pub-id-type="pmid">23444227</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group><name><surname>Derer</surname><given-names>S</given-names></name><name><surname>Lohse</surname><given-names>S</given-names></name><name><surname>Valerius</surname><given-names>T</given-names></name></person-group><article-title>EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24052</fpage><pub-id pub-id-type="pmid">23762793</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group><name><surname>Mansfield</surname><given-names>AS</given-names></name><name><surname>Nevala</surname><given-names>WK</given-names></name><name><surname>Lieser</surname><given-names>EA</given-names></name><name><surname>Leontovich</surname><given-names>AA</given-names></name><name><surname>Markovic</surname><given-names>SN</given-names></name></person-group><article-title>The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24436</fpage><pub-id pub-id-type="pmid">23762809</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group><name><surname>Manzoni</surname><given-names>M</given-names></name><name><surname>Rovati</surname><given-names>B</given-names></name><name><surname>Ronzoni</surname><given-names>M</given-names></name><name><surname>Loupakis</surname><given-names>F</given-names></name><name><surname>Mariucci</surname><given-names>S</given-names></name><name><surname>Ricci</surname><given-names>V</given-names></name><name><surname>Gattoni</surname><given-names>E</given-names></name><name><surname>Salvatore</surname><given-names>L</given-names></name><name><surname>Tinelli</surname><given-names>C</given-names></name><name><surname>Villa</surname><given-names>E</given-names></name><name><surname>Danova</surname><given-names>M</given-names></name></person-group><article-title>Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer</article-title><source>Oncology</source><year>2010</year><volume>79</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">21358206</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Lezcano</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sasada</surname><given-names>T</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Giobbie-Hurder</surname><given-names>A</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Friedlander</surname><given-names>P</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Murphy</surname><given-names>GF</given-names></name><etal></etal></person-group><article-title>Bevacizumab plus ipilimumab in patients with metastatic melanoma</article-title><source>Cancer Immunol Res</source><year>2014</year><volume>2</volume><fpage>632</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">24838938</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group><name><surname>Terme</surname><given-names>M</given-names></name><name><surname>Pernot</surname><given-names>S</given-names></name><name><surname>Marcheteau</surname><given-names>E</given-names></name><name><surname>Sandoval</surname><given-names>F</given-names></name><name><surname>Benhamouda</surname><given-names>N</given-names></name><name><surname>Colussi</surname><given-names>O</given-names></name><name><surname>Dubreuil</surname><given-names>O</given-names></name><name><surname>Carpentier</surname><given-names>AF</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Taieb</surname><given-names>J</given-names></name></person-group><article-title>VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer</article-title><source>Cancer Res</source><year>2013</year><volume>73</volume><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">23108136</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group><name><surname>Mellor</surname><given-names>JD</given-names></name><name><surname>Brown</surname><given-names>MP</given-names></name><name><surname>Irving</surname><given-names>HR</given-names></name><name><surname>Zalcberg</surname><given-names>JR</given-names></name><name><surname>Dobrovic</surname><given-names>A</given-names></name></person-group><article-title>A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer</article-title><source>J Hematol Oncol</source><year>2013</year><volume>6</volume><fpage>1</fpage><pub-id pub-id-type="pmid">23286345</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Adoptive immunotherapy for cancer: harnessing the T cell response</article-title><source>Nat Rev Immunol</source><year>2012</year><volume>12</volume><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">22437939</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial Watch: Adoptive cell transfer for anticancer immunotherapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24238</fpage><pub-id pub-id-type="pmid">23762803</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Trial Watch: Adoptive cell transfer immunotherapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>306</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">22737606</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group><name><surname>Lerret</surname><given-names>NM</given-names></name><name><surname>Marzo</surname><given-names>AL</given-names></name></person-group><article-title>Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22731</fpage><pub-id pub-id-type="pmid">23525138</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group><name><surname>Jenq</surname><given-names>RR</given-names></name><name><surname>van den Brink</surname><given-names>MR</given-names></name></person-group><article-title>Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer</article-title><source>Nat Rev Cancer</source><year>2010</year><volume>10</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">20168320</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Trial watch: Dendritic cell-based interventions for cancer therapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1111</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">23170259</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Vitale</surname><given-names>I</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Fucikova</surname><given-names>J</given-names></name><name><surname>Cremer</surname><given-names>I</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial watch: Dendritic cell-based interventions for cancer therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25771</fpage><pub-id pub-id-type="pmid">24286020</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group><name><surname>Ueno</surname><given-names>H</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>The expanding family of dendritic cell subsets</article-title><source>Nat Biotechnol</source><year>2010</year><volume>28</volume><fpage>813</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">20697407</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group><name><surname>Palucka</surname><given-names>K</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group><article-title>Designing vaccines based on biology of human dendritic cell subsets</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>464</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">21029958</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Royal</surname><given-names>RE</given-names></name><name><surname>Kammula</surname><given-names>U</given-names></name><name><surname>White</surname><given-names>DE</given-names></name><name><surname>Mavroukakis</surname><given-names>SA</given-names></name><name><surname>Rogers</surname><given-names>LJ</given-names></name><name><surname>Gracia</surname><given-names>GJ</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><etal></etal></person-group><article-title>Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2346</fpage><lpage>2357</lpage><pub-id pub-id-type="pmid">15800326</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Lugli</surname><given-names>E</given-names></name></person-group><article-title>Rejuvenated T cells attack old tumors</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24103</fpage><pub-id pub-id-type="pmid">23526137</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know</article-title><source>Nat Rev Clin Oncol</source><year>2011</year><volume>8</volume><fpage>577</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">21808266</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group><name><surname>Merhavi-Shoham</surname><given-names>E</given-names></name><name><surname>Haga-Friedman</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>CJ</given-names></name></person-group><article-title>Genetically modulating T-cell function to target cancer</article-title><source>Semin Cancer Biol</source><year>2012</year><volume>22</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">22210183</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><fpage>6356</fpage><lpage>6365</lpage><pub-id pub-id-type="pmid">11714800</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Hodes</surname><given-names>RJ</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name></person-group><article-title>Telomere length of transferred lymphocytes correlates with <italic>in vivo</italic> persistence and tumor regression in melanoma patients receiving cell transfer therapy</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>7046</fpage><lpage>7052</lpage><pub-id pub-id-type="pmid">16272366</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group><name><surname>Kalbasi</surname><given-names>A</given-names></name><name><surname>Shrimali</surname><given-names>RK</given-names></name><name><surname>Chinnasamy</surname><given-names>D</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein</article-title><source>J Immunother</source><year>2010</year><volume>33</volume><fpage>672</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">20664359</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group><name><surname>Hinrichs</surname><given-names>CS</given-names></name><name><surname>Borman</surname><given-names>ZA</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Burns</surname><given-names>WR</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Klebanoff</surname><given-names>CA</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Kerkar</surname><given-names>SP</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Muranski</surname><given-names>P</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Scott</surname><given-names>CD</given-names></name><etal></etal></person-group><article-title>Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>808</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">20971955</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group><name><surname>Bellone</surname><given-names>M</given-names></name><name><surname>Calcinotto</surname><given-names>A</given-names></name><name><surname>Corti</surname><given-names>A</given-names></name></person-group><article-title>Won't you come on in? How to favor lymphocyte infiltration in tumors</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>986</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">23162781</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group><name><surname>Kershaw</surname><given-names>MH</given-names></name><name><surname>Teng</surname><given-names>MW</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Darcy</surname><given-names>PK</given-names></name></person-group><article-title>Supernatural T cells: genetic modification of T cells for cancer therapy</article-title><source>Nat Rev Immunol</source><year>2005</year><volume>5</volume><fpage>928</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">16322746</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group><name><surname>Ray</surname><given-names>S</given-names></name><name><surname>Chhabra</surname><given-names>A</given-names></name><name><surname>Chakraborty</surname><given-names>NG</given-names></name><name><surname>Hegde</surname><given-names>U</given-names></name><name><surname>Dorsky</surname><given-names>DI</given-names></name><name><surname>Chodon</surname><given-names>T</given-names></name><name><surname>von Euw</surname><given-names>E</given-names></name><name><surname>Comin-Anduix</surname><given-names>B</given-names></name><name><surname>Koya</surname><given-names>RC</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Economou</surname><given-names>JS</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Mukherji</surname><given-names>B</given-names></name></person-group><article-title>MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, <italic>in vitro</italic></article-title><source>Clin Immunol</source><year>2010</year><volume>136</volume><fpage>338</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">20547105</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group><name><surname>Sadelain</surname><given-names>M</given-names></name><name><surname>Riviere</surname><given-names>I</given-names></name><name><surname>Brentjens</surname><given-names>R</given-names></name></person-group><article-title>Targeting tumours with genetically enhanced T lymphocytes</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">12509765</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Nahvi</surname><given-names>AV</given-names></name><name><surname>Helman</surname><given-names>LJ</given-names></name><name><surname>Mackall</surname><given-names>CL</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><etal></etal></person-group><article-title>Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">21282551</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group><name><surname>Dotti</surname><given-names>G</given-names></name><name><surname>Gottschalk</surname><given-names>S</given-names></name><name><surname>Savoldo</surname><given-names>B</given-names></name><name><surname>Brenner</surname><given-names>MK</given-names></name></person-group><article-title>Design and development of therapies using chimeric antigen receptor-expressing T cells</article-title><source>Immunol Rev</source><year>2014</year><volume>257</volume><fpage>107</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">24329793</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">21830940</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors</article-title><source>Nat Rev Clin Oncol</source><year>2013</year><volume>10</volume><fpage>267</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">23546520</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group><name><surname>Long</surname><given-names>AH</given-names></name><name><surname>Haso</surname><given-names>WM</given-names></name><name><surname>Orentas</surname><given-names>RJ</given-names></name></person-group><article-title>Lessons learned from a highly-active CD22-specific chimeric antigen receptor</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23621</fpage><pub-id pub-id-type="pmid">23734316</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group><name><surname>Spear</surname><given-names>P</given-names></name><name><surname>Barber</surname><given-names>A</given-names></name><name><surname>Sentman</surname><given-names>CL</given-names></name></person-group><article-title>Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23564</fpage><pub-id pub-id-type="pmid">23734311</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group><name><surname>Badoual</surname><given-names>C</given-names></name><name><surname>Bastier</surname><given-names>PL</given-names></name><name><surname>Roussel</surname><given-names>H</given-names></name><name><surname>Mandavit</surname><given-names>M</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name></person-group><article-title>An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e27156</fpage><pub-id pub-id-type="pmid">24753987</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal"><person-group><name><surname>Boissel</surname><given-names>L</given-names></name><name><surname>Betancur-Boissel</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Krause</surname><given-names>DS</given-names></name><name><surname>Van Etten</surname><given-names>RA</given-names></name><name><surname>Wels</surname><given-names>WS</given-names></name><name><surname>Klingemann</surname><given-names>H</given-names></name></person-group><article-title>Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26527</fpage><pub-id pub-id-type="pmid">24404423</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal"><person-group><name><surname>Brentjens</surname><given-names>RJ</given-names></name><name><surname>Riviere</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Davila</surname><given-names>ML</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Stefanski</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Yeh</surname><given-names>R</given-names></name><name><surname>Bartido</surname><given-names>S</given-names></name><name><surname>Borquez-Ojeda</surname><given-names>O</given-names></name><name><surname>Olszewska</surname><given-names>M</given-names></name><name><surname>Bernal</surname><given-names>Y</given-names></name><name><surname>Pegram</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>4817</fpage><lpage>4828</lpage><pub-id pub-id-type="pmid">21849486</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal"><person-group><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><fpage>95ra73</fpage></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal"><person-group><name><surname>Brentjens</surname><given-names>RJ</given-names></name><name><surname>Davila</surname><given-names>ML</given-names></name><name><surname>Riviere</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cowell</surname><given-names>LG</given-names></name><name><surname>Bartido</surname><given-names>S</given-names></name><name><surname>Stefanski</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Olszewska</surname><given-names>M</given-names></name><name><surname>Borquez-Ojeda</surname><given-names>O</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Wasielewska</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia</article-title><source>Sci Transl Med</source><year>2013</year><volume>5</volume><fpage>177ra138</fpage></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal"><person-group><name><surname>Louis</surname><given-names>CU</given-names></name><name><surname>Savoldo</surname><given-names>B</given-names></name><name><surname>Dotti</surname><given-names>G</given-names></name><name><surname>Pule</surname><given-names>M</given-names></name><name><surname>Yvon</surname><given-names>E</given-names></name><name><surname>Myers</surname><given-names>GD</given-names></name><name><surname>Rossig</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>HV</given-names></name><name><surname>Diouf</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>MF</given-names></name><name><surname>Gee</surname><given-names>AP</given-names></name><etal></etal></person-group><article-title>Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>6050</fpage><lpage>6056</lpage><pub-id pub-id-type="pmid">21984804</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal"><person-group><name><surname>Beatty</surname><given-names>GL</given-names></name><name><surname>Haas</surname><given-names>AR</given-names></name><name><surname>Maus</surname><given-names>MV</given-names></name><name><surname>Torigian</surname><given-names>DA</given-names></name><name><surname>Soulen</surname><given-names>MC</given-names></name><name><surname>Plesa</surname><given-names>G</given-names></name><name><surname>Chew</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Albelda</surname><given-names>SM</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies</article-title><source>Cancer Immunol Res</source><year>2014</year><volume>2</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">24579088</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal"><person-group><name><surname>Pegram</surname><given-names>HJ</given-names></name><name><surname>Jackson</surname><given-names>JT</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Kershaw</surname><given-names>MH</given-names></name><name><surname>Darcy</surname><given-names>PK</given-names></name></person-group><article-title>Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression <italic>in vivo</italic></article-title><source>J Immunol</source><year>2008</year><volume>181</volume><fpage>3449</fpage><lpage>3455</lpage><pub-id pub-id-type="pmid">18714017</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal"><person-group><name><surname>Ruggeri</surname><given-names>L</given-names></name><name><surname>Capanni</surname><given-names>M</given-names></name><name><surname>Urbani</surname><given-names>E</given-names></name><name><surname>Perruccio</surname><given-names>K</given-names></name><name><surname>Shlomchik</surname><given-names>WD</given-names></name><name><surname>Tosti</surname><given-names>A</given-names></name><name><surname>Posati</surname><given-names>S</given-names></name><name><surname>Rogaia</surname><given-names>D</given-names></name><name><surname>Frassoni</surname><given-names>F</given-names></name><name><surname>Aversa</surname><given-names>F</given-names></name><name><surname>Martelli</surname><given-names>MF</given-names></name><name><surname>Velardi</surname><given-names>A</given-names></name></person-group><article-title>Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants</article-title><source>Science</source><year>2002</year><volume>295</volume><fpage>2097</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">11896281</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal"><person-group><name><surname>Okada</surname><given-names>K</given-names></name><name><surname>Nannmark</surname><given-names>U</given-names></name><name><surname>Vujanovic</surname><given-names>NL</given-names></name><name><surname>Watkins</surname><given-names>S</given-names></name><name><surname>Basse</surname><given-names>P</given-names></name><name><surname>Herberman</surname><given-names>RB</given-names></name><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group><article-title>Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>1599</fpage><lpage>1608</lpage><pub-id pub-id-type="pmid">8603408</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal"><person-group><name><surname>Besser</surname><given-names>MJ</given-names></name><name><surname>Shoham</surname><given-names>T</given-names></name><name><surname>Harari-Steinberg</surname><given-names>O</given-names></name><name><surname>Zabari</surname><given-names>N</given-names></name><name><surname>Ortenberg</surname><given-names>R</given-names></name><name><surname>Yakirevitch</surname><given-names>A</given-names></name><name><surname>Nagler</surname><given-names>A</given-names></name><name><surname>Loewenthal</surname><given-names>R</given-names></name><name><surname>Schachter</surname><given-names>J</given-names></name><name><surname>Markel</surname><given-names>G</given-names></name></person-group><article-title>Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: <italic>in vitro</italic> preclinical optimization studies</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e57922</fpage><pub-id pub-id-type="pmid">23483943</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="journal"><person-group><name><surname>Terme</surname><given-names>M</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name></person-group><article-title>NK cells from pleural effusions are potent antitumor effector cells</article-title><source>Eur J Immunol</source><year>2013</year><volume>43</volume><fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">23322344</pub-id></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal"><person-group><name><surname>Mattarollo</surname><given-names>SR</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>NKT cell adjuvants in therapeutic vaccines against hematological cancers</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22615</fpage><pub-id pub-id-type="pmid">23482240</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal"><person-group><name><surname>Lister</surname><given-names>J</given-names></name><name><surname>Rybka</surname><given-names>WB</given-names></name><name><surname>Donnenberg</surname><given-names>AD</given-names></name><name><surname>deMagalhaes-Silverman</surname><given-names>M</given-names></name><name><surname>Pincus</surname><given-names>SM</given-names></name><name><surname>Bloom</surname><given-names>EJ</given-names></name><name><surname>Elder</surname><given-names>EM</given-names></name><name><surname>Ball</surname><given-names>ED</given-names></name><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group><article-title>Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period</article-title><source>Clin Cancer Res</source><year>1995</year><volume>1</volume><fpage>607</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">9816022</pub-id></element-citation></ref><ref id="R119"><label>119</label><element-citation publication-type="journal"><person-group><name><surname>Parkhurst</surname><given-names>MR</given-names></name><name><surname>Riley</surname><given-names>JP</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>6287</fpage><lpage>6297</lpage><pub-id pub-id-type="pmid">21844012</pub-id></element-citation></ref><ref id="R120"><label>120</label><element-citation publication-type="journal"><person-group><name><surname>Iliopoulou</surname><given-names>EG</given-names></name><name><surname>Kountourakis</surname><given-names>P</given-names></name><name><surname>Karamouzis</surname><given-names>MV</given-names></name><name><surname>Doufexis</surname><given-names>D</given-names></name><name><surname>Ardavanis</surname><given-names>A</given-names></name><name><surname>Baxevanis</surname><given-names>CN</given-names></name><name><surname>Rigatos</surname><given-names>G</given-names></name><name><surname>Papamichail</surname><given-names>M</given-names></name><name><surname>Perez</surname><given-names>SA</given-names></name></person-group><article-title>A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer</article-title><source>Cancer Immunol Immunother</source><year>2010</year><volume>59</volume><fpage>1781</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">20703455</pub-id></element-citation></ref><ref id="R121"><label>121</label><element-citation publication-type="journal"><person-group><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Lao</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Ning</surname><given-names>N</given-names></name><name><surname>Yet</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>AE</given-names></name></person-group><article-title>Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>4987</fpage><lpage>4995</lpage><pub-id pub-id-type="pmid">21690573</pub-id></element-citation></ref><ref id="R122"><label>122</label><element-citation publication-type="journal"><person-group><name><surname>de Visser</surname><given-names>KE</given-names></name><name><surname>Korets</surname><given-names>LV</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name></person-group><article-title>De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent</article-title><source>Cancer Cell</source><year>2005</year><volume>7</volume><fpage>411</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">15894262</pub-id></element-citation></ref><ref id="R123"><label>123</label><element-citation publication-type="journal"><person-group><name><surname>Schioppa</surname><given-names>T</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>RG</given-names></name><name><surname>Rosser</surname><given-names>EC</given-names></name><name><surname>Kulbe</surname><given-names>H</given-names></name><name><surname>Nedospasov</surname><given-names>S</given-names></name><name><surname>Mauri</surname><given-names>C</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Balkwill</surname><given-names>FR</given-names></name></person-group><article-title>B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>10662</fpage><lpage>10667</lpage><pub-id pub-id-type="pmid">21670304</pub-id></element-citation></ref><ref id="R124"><label>124</label><element-citation publication-type="journal"><person-group><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial watch: Prognostic and predictive value of the immune infiltrate in cancer</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1323</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">23243596</pub-id></element-citation></ref><ref id="R125"><label>125</label><element-citation publication-type="journal"><person-group><name><surname>Fremd</surname><given-names>C</given-names></name><name><surname>Schuetz</surname><given-names>F</given-names></name><name><surname>Sohn</surname><given-names>C</given-names></name><name><surname>Beckhove</surname><given-names>P</given-names></name><name><surname>Domschke</surname><given-names>C</given-names></name></person-group><article-title>B cell-regulated immune responses in tumor models and cancer patients</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25443</fpage><pub-id pub-id-type="pmid">24073382</pub-id></element-citation></ref><ref id="R126"><label>126</label><element-citation publication-type="journal"><person-group><name><surname>Mignot</surname><given-names>G</given-names></name><name><surname>Ullrich</surname><given-names>E</given-names></name><name><surname>Bonmort</surname><given-names>M</given-names></name><name><surname>Menard</surname><given-names>C</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Taieb</surname><given-names>J</given-names></name><name><surname>Bosisio</surname><given-names>D</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Ferrantini</surname><given-names>M</given-names></name><name><surname>Schmitz</surname><given-names>J</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Ryffel</surname><given-names>B</given-names></name><name><surname>Bulfone-Paus</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2</article-title><source>J Immunol</source><year>2008</year><volume>180</volume><fpage>6477</fpage><lpage>6483</lpage><pub-id pub-id-type="pmid">18453565</pub-id></element-citation></ref><ref id="R127"><label>127</label><element-citation publication-type="journal"><person-group><name><surname>Ullrich</surname><given-names>E</given-names></name><name><surname>Bonmort</surname><given-names>M</given-names></name><name><surname>Mignot</surname><given-names>G</given-names></name><name><surname>Jacobs</surname><given-names>B</given-names></name><name><surname>Bosisio</surname><given-names>D</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Jalil</surname><given-names>A</given-names></name><name><surname>Louache</surname><given-names>F</given-names></name><name><surname>Bulanova</surname><given-names>E</given-names></name><name><surname>Geissman</surname><given-names>F</given-names></name><name><surname>Ryffel</surname><given-names>B</given-names></name><name><surname>Chaput</surname><given-names>N</given-names></name><name><surname>Bulfone-Paus</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions</article-title><source>J Immunol</source><year>2008</year><volume>180</volume><fpage>7887</fpage><lpage>7897</lpage><pub-id pub-id-type="pmid">18523252</pub-id></element-citation></ref><ref id="R128"><label>128</label><element-citation publication-type="journal"><person-group><name><surname>Besser</surname><given-names>MJ</given-names></name><name><surname>Shapira-Frommer</surname><given-names>R</given-names></name><name><surname>Itzhaki</surname><given-names>O</given-names></name><name><surname>Treves</surname><given-names>AJ</given-names></name><name><surname>Zippel</surname><given-names>DB</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Kubi</surname><given-names>A</given-names></name><name><surname>Shoshani</surname><given-names>N</given-names></name><name><surname>Zikich</surname><given-names>D</given-names></name><name><surname>Ohayon</surname><given-names>Y</given-names></name><name><surname>Ohayon</surname><given-names>D</given-names></name><name><surname>Shalmon</surname><given-names>B</given-names></name><name><surname>Markel</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>4792</fpage><lpage>4800</lpage><pub-id pub-id-type="pmid">23690483</pub-id></element-citation></ref><ref id="R129"><label>129</label><element-citation publication-type="journal"><person-group><name><surname>Santegoets</surname><given-names>SJ</given-names></name><name><surname>Turksma</surname><given-names>AW</given-names></name><name><surname>Powell Jr</surname><given-names>DJ</given-names></name><name><surname>Hooijberg</surname><given-names>E</given-names></name><name><surname>de Gruijl</surname><given-names>TD</given-names></name></person-group><article-title>IL-21 in cancer immunotherapy: At the right place at the right time</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24522</fpage><pub-id pub-id-type="pmid">23894713</pub-id></element-citation></ref><ref id="R130"><label>130</label><element-citation publication-type="journal"><person-group><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Figliola</surname><given-names>MJ</given-names></name><name><surname>Dawson</surname><given-names>MJ</given-names></name><name><surname>Huls</surname><given-names>H</given-names></name><name><surname>Olivares</surname><given-names>S</given-names></name><name><surname>Switzer</surname><given-names>K</given-names></name><name><surname>Mi</surname><given-names>T</given-names></name><name><surname>Maiti</surname><given-names>S</given-names></name><name><surname>Kebriaei</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>DA</given-names></name><name><surname>Champlin</surname><given-names>RE</given-names></name><name><surname>Cooper</surname><given-names>LJ</given-names></name></person-group><article-title>Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>3516</fpage><lpage>3527</lpage><pub-id pub-id-type="pmid">21558388</pub-id></element-citation></ref><ref id="R131"><label>131</label><element-citation publication-type="journal"><person-group><name><surname>Russell</surname><given-names>SJ</given-names></name><name><surname>Peng</surname><given-names>KW</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name></person-group><article-title>Oncolytic virotherapy</article-title><source>Nat Biotechnol</source><year>2012</year><volume>30</volume><fpage>658</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">22781695</pub-id></element-citation></ref><ref id="R132"><label>132</label><element-citation publication-type="journal"><person-group><name><surname>Vaha-Koskela</surname><given-names>MJ</given-names></name><name><surname>Heikkila</surname><given-names>JE</given-names></name><name><surname>Hinkkanen</surname><given-names>AE</given-names></name></person-group><article-title>Oncolytic viruses in cancer therapy</article-title><source>Cancer Lett</source><year>2007</year><volume>254</volume><fpage>178</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">17383089</pub-id></element-citation></ref><ref id="R133"><label>133</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial watch: Oncolytic viruses for cancer therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24612</fpage><pub-id pub-id-type="pmid">23894720</pub-id></element-citation></ref><ref id="R134"><label>134</label><element-citation publication-type="journal"><person-group><name><surname>Makela</surname><given-names>AR</given-names></name><name><surname>Matilainen</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Ruoslahti</surname><given-names>E</given-names></name><name><surname>Oker-Blom</surname><given-names>C</given-names></name></person-group><article-title>Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides</article-title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>6603</fpage><lpage>6611</lpage><pub-id pub-id-type="pmid">16775347</pub-id></element-citation></ref><ref id="R135"><label>135</label><element-citation publication-type="journal"><person-group><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Destito</surname><given-names>G</given-names></name><name><surname>Schneemann</surname><given-names>A</given-names></name><name><surname>Manchester</surname><given-names>M</given-names></name></person-group><article-title>Canine parvovirus-like particles, a novel nanomaterial for tumor targeting</article-title><source>J Nanobiotechnology</source><year>2006</year><volume>4</volume><fpage>2</fpage><pub-id pub-id-type="pmid">16476163</pub-id></element-citation></ref><ref id="R136"><label>136</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Brenner</surname><given-names>C</given-names></name><name><surname>Morselli</surname><given-names>E</given-names></name><name><surname>Touat</surname><given-names>Z</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Viral control of mitochondrial apoptosis</article-title><source>PLoS Pathog</source><year>2008</year><volume>4</volume><fpage>e1000018</fpage><pub-id pub-id-type="pmid">18516228</pub-id></element-citation></ref><ref id="R137"><label>137</label><element-citation publication-type="journal"><person-group><name><surname>Boisgerault</surname><given-names>N</given-names></name><name><surname>Guillerme</surname><given-names>JB</given-names></name><name><surname>Pouliquen</surname><given-names>D</given-names></name><name><surname>Mesel-Lemoine</surname><given-names>M</given-names></name><name><surname>Achard</surname><given-names>C</given-names></name><name><surname>Combredet</surname><given-names>C</given-names></name><name><surname>Fonteneau</surname><given-names>JF</given-names></name><name><surname>Tangy</surname><given-names>F</given-names></name><name><surname>Gregoire</surname><given-names>M</given-names></name></person-group><article-title>Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas</article-title><source>Biomed Res Int</source><year>2013</year><volume>2013</volume><fpage>387362</fpage><pub-id pub-id-type="pmid">23586034</pub-id></element-citation></ref><ref id="R138"><label>138</label><element-citation publication-type="journal"><person-group><name><surname>Wildner</surname><given-names>O</given-names></name><name><surname>Blaese</surname><given-names>RM</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name></person-group><article-title>Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>410</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">9927055</pub-id></element-citation></ref><ref id="R139"><label>139</label><element-citation publication-type="journal"><person-group><name><surname>Tseng</surname><given-names>JC</given-names></name><name><surname>Zanzonico</surname><given-names>PB</given-names></name><name><surname>Levin</surname><given-names>B</given-names></name><name><surname>Finn</surname><given-names>R</given-names></name><name><surname>Larson</surname><given-names>SM</given-names></name><name><surname>Meruelo</surname><given-names>D</given-names></name></person-group><article-title>Tumor-specific <italic>in vivo</italic> transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET</article-title><source>J Nucl Med</source><year>2006</year><volume>47</volume><fpage>1136</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">16818948</pub-id></element-citation></ref><ref id="R140"><label>140</label><element-citation publication-type="journal"><person-group><name><surname>Foloppe</surname><given-names>J</given-names></name><name><surname>Kintz</surname><given-names>J</given-names></name><name><surname>Futin</surname><given-names>N</given-names></name><name><surname>Findeli</surname><given-names>A</given-names></name><name><surname>Cordier</surname><given-names>P</given-names></name><name><surname>Schlesinger</surname><given-names>Y</given-names></name><name><surname>Hoffmann</surname><given-names>C</given-names></name><name><surname>Tosch</surname><given-names>C</given-names></name><name><surname>Balloul</surname><given-names>JM</given-names></name><name><surname>Erbs</surname><given-names>P</given-names></name></person-group><article-title>Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus</article-title><source>Gene Ther</source><year>2008</year><volume>15</volume><fpage>1361</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">18480846</pub-id></element-citation></ref><ref id="R141"><label>141</label><element-citation publication-type="journal"><person-group><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Deisseroth</surname><given-names>A</given-names></name></person-group><article-title>Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy</article-title><source>Cancer Gene Ther</source><year>2006</year><volume>13</volume><fpage>845</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">16710344</pub-id></element-citation></ref><ref id="R142"><label>142</label><element-citation publication-type="journal"><person-group><name><surname>Leveille</surname><given-names>S</given-names></name><name><surname>Samuel</surname><given-names>S</given-names></name><name><surname>Goulet</surname><given-names>ML</given-names></name><name><surname>Hiscott</surname><given-names>J</given-names></name></person-group><article-title>Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy</article-title><source>Cancer Gene Ther</source><year>2011</year><volume>18</volume><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">21394109</pub-id></element-citation></ref><ref id="R143"><label>143</label><element-citation publication-type="journal"><person-group><name><surname>Lampe</surname><given-names>J</given-names></name><name><surname>Bossow</surname><given-names>S</given-names></name><name><surname>Weiland</surname><given-names>T</given-names></name><name><surname>Smirnow</surname><given-names>I</given-names></name><name><surname>Lehmann</surname><given-names>R</given-names></name><name><surname>Neubert</surname><given-names>W</given-names></name><name><surname>Bitzer</surname><given-names>M</given-names></name><name><surname>Lauer</surname><given-names>UM</given-names></name></person-group><article-title>An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis</article-title><source>Gene Ther</source><year>2013</year><volume>20</volume><fpage>1033</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">23719065</pub-id></element-citation></ref><ref id="R144"><label>144</label><element-citation publication-type="journal"><person-group><name><surname>Shinoura</surname><given-names>N</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Asai</surname><given-names>A</given-names></name><name><surname>Kirino</surname><given-names>T</given-names></name><name><surname>Hamada</surname><given-names>H</given-names></name></person-group><article-title>Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas</article-title><source>Cancer Gene Ther</source><year>2000</year><volume>7</volume><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">10830720</pub-id></element-citation></ref><ref id="R145"><label>145</label><element-citation publication-type="journal"><person-group><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>A</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Qian</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer</article-title><source>Cancer Gene Ther</source><year>2006</year><volume>13</volume><fpage>1011</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">16799468</pub-id></element-citation></ref><ref id="R146"><label>146</label><element-citation publication-type="journal"><person-group><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name></person-group><article-title>Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer</article-title><source>Cancer Biol Ther</source><year>2013</year><volume>14</volume><fpage>1016</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">24025362</pub-id></element-citation></ref><ref id="R147"><label>147</label><element-citation publication-type="journal"><person-group><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Xian</surname><given-names>L</given-names></name></person-group><article-title>Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma</article-title><source>Cancer Biol Ther</source><year>2006</year><volume>5</volume><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">16575205</pub-id></element-citation></ref><ref id="R148"><label>148</label><element-citation publication-type="journal"><person-group><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Tu</surname><given-names>JK</given-names></name><name><surname>Wang</surname><given-names>XH</given-names></name><name><surname>Fu</surname><given-names>ZX</given-names></name></person-group><article-title>Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer</article-title><source>Oncol Rep</source><year>2010</year><volume>24</volume><fpage>1285</fpage><lpage>1290</lpage><pub-id pub-id-type="pmid">20878122</pub-id></element-citation></ref><ref id="R149"><label>149</label><element-citation publication-type="journal"><person-group><name><surname>Liang</surname><given-names>M</given-names></name></person-group><article-title>Clinical development of oncolytic viruses in China</article-title><source>Curr Pharm Biotechnol</source><year>2012</year><volume>13</volume><fpage>1852</fpage><lpage>1857</lpage><pub-id pub-id-type="pmid">21740357</pub-id></element-citation></ref><ref id="R150"><label>150</label><element-citation publication-type="journal"><person-group><name><surname>Raty</surname><given-names>JK</given-names></name><name><surname>Pikkarainen</surname><given-names>JT</given-names></name><name><surname>Wirth</surname><given-names>T</given-names></name><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name></person-group><article-title>Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications</article-title><source>Curr Mol Pharmacol</source><year>2008</year><volume>1</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">20021420</pub-id></element-citation></ref><ref id="R151"><label>151</label><element-citation publication-type="journal"><person-group><name><surname>Alvarez-Breckenridge</surname><given-names>CA</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Chiocca</surname><given-names>EA</given-names></name></person-group><article-title>Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23658</fpage><pub-id pub-id-type="pmid">23734319</pub-id></element-citation></ref><ref id="R152"><label>152</label><element-citation publication-type="journal"><person-group><name><surname>Bernt</surname><given-names>KM</given-names></name><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Gaggar</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>ZY</given-names></name><name><surname>Shayakhmetov</surname><given-names>DM</given-names></name><name><surname>Lieber</surname><given-names>A</given-names></name></person-group><article-title>The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors</article-title><source>Mol Ther</source><year>2003</year><volume>8</volume><fpage>746</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">14599807</pub-id></element-citation></ref><ref id="R153"><label>153</label><element-citation publication-type="journal"><person-group><name><surname>Underhill</surname><given-names>DM</given-names></name><name><surname>Ozinsky</surname><given-names>A</given-names></name></person-group><article-title>Phagocytosis of microbes: complexity in action</article-title><source>Annu Rev Immunol</source><year>2002</year><volume>20</volume><fpage>825</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">11861619</pub-id></element-citation></ref><ref id="R154"><label>154</label><element-citation publication-type="journal"><person-group><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Wakimoto</surname><given-names>H</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Jhung</surname><given-names>S</given-names></name><name><surname>Hochberg</surname><given-names>FH</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Chiocca</surname><given-names>EA</given-names></name></person-group><article-title>Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant</article-title><source>J Virol</source><year>2000</year><volume>74</volume><fpage>4765</fpage><lpage>4775</lpage><pub-id pub-id-type="pmid">10775615</pub-id></element-citation></ref><ref id="R155"><label>155</label><element-citation publication-type="journal"><person-group><name><surname>Pensiero</surname><given-names>MN</given-names></name><name><surname>Wysocki</surname><given-names>CA</given-names></name><name><surname>Nader</surname><given-names>K</given-names></name><name><surname>Kikuchi</surname><given-names>GE</given-names></name></person-group><article-title>Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum</article-title><source>Hum Gene Ther</source><year>1996</year><volume>7</volume><fpage>1095</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">8773511</pub-id></element-citation></ref><ref id="R156"><label>156</label><element-citation publication-type="journal"><person-group><name><surname>Fisher</surname><given-names>KD</given-names></name><name><surname>Stallwood</surname><given-names>Y</given-names></name><name><surname>Green</surname><given-names>NK</given-names></name><name><surname>Ulbrich</surname><given-names>K</given-names></name><name><surname>Mautner</surname><given-names>V</given-names></name><name><surname>Seymour</surname><given-names>LW</given-names></name></person-group><article-title>Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies</article-title><source>Gene Ther</source><year>2001</year><volume>8</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">11313809</pub-id></element-citation></ref><ref id="R157"><label>157</label><element-citation publication-type="journal"><person-group><name><surname>Massari</surname><given-names>I</given-names></name><name><surname>Donnini</surname><given-names>A</given-names></name><name><surname>Argentati</surname><given-names>K</given-names></name><name><surname>Straino</surname><given-names>S</given-names></name><name><surname>Mangoni</surname><given-names>A</given-names></name><name><surname>Gaetano</surname><given-names>C</given-names></name><name><surname>Viticchi</surname><given-names>C</given-names></name><name><surname>Capogrossi</surname><given-names>M</given-names></name><name><surname>Provinciali</surname><given-names>M</given-names></name></person-group><article-title>Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats</article-title><source>Exp Gerontol</source><year>2002</year><volume>37</volume><fpage>823</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">12175482</pub-id></element-citation></ref><ref id="R158"><label>158</label><element-citation publication-type="journal"><person-group><name><surname>Diaconu</surname><given-names>I</given-names></name><name><surname>Cerullo</surname><given-names>V</given-names></name><name><surname>Hirvinen</surname><given-names>ML</given-names></name><name><surname>Escutenaire</surname><given-names>S</given-names></name><name><surname>Ugolini</surname><given-names>M</given-names></name><name><surname>Pesonen</surname><given-names>SK</given-names></name><name><surname>Bramante</surname><given-names>S</given-names></name><name><surname>Parviainen</surname><given-names>S</given-names></name><name><surname>Kanerva</surname><given-names>A</given-names></name><name><surname>Loskog</surname><given-names>AS</given-names></name><name><surname>Eliopoulos</surname><given-names>AG</given-names></name><name><surname>Pesonen</surname><given-names>S</given-names></name><name><surname>Hemminki</surname><given-names>A</given-names></name></person-group><article-title>Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>2327</fpage><lpage>2338</lpage><pub-id pub-id-type="pmid">22396493</pub-id></element-citation></ref><ref id="R159"><label>159</label><element-citation publication-type="journal"><person-group><name><surname>Pesonen</surname><given-names>S</given-names></name><name><surname>Diaconu</surname><given-names>I</given-names></name><name><surname>Kangasniemi</surname><given-names>L</given-names></name><name><surname>Ranki</surname><given-names>T</given-names></name><name><surname>Kanerva</surname><given-names>A</given-names></name><name><surname>Pesonen</surname><given-names>SK</given-names></name><name><surname>Gerdemann</surname><given-names>U</given-names></name><name><surname>Leen</surname><given-names>AM</given-names></name><name><surname>Kairemo</surname><given-names>K</given-names></name><name><surname>Oksanen</surname><given-names>M</given-names></name><name><surname>Haavisto</surname><given-names>E</given-names></name><name><surname>Holm</surname><given-names>SL</given-names></name><name><surname>Karioja-Kallio</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>1621</fpage><lpage>1631</lpage><pub-id pub-id-type="pmid">22323527</pub-id></element-citation></ref><ref id="R160"><label>160</label><element-citation publication-type="journal"><person-group><name><surname>Gomes</surname><given-names>EM</given-names></name><name><surname>Rodrigues</surname><given-names>MS</given-names></name><name><surname>Phadke</surname><given-names>AP</given-names></name><name><surname>Butcher</surname><given-names>LD</given-names></name><name><surname>Starling</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>D</given-names></name><name><surname>Hernandez-Alcoceba</surname><given-names>R</given-names></name><name><surname>Newman</surname><given-names>JT</given-names></name><name><surname>Stone</surname><given-names>MJ</given-names></name><name><surname>Tong</surname><given-names>AW</given-names></name></person-group><article-title>Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>1317</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">19228733</pub-id></element-citation></ref><ref id="R161"><label>161</label><element-citation publication-type="journal"><person-group><name><surname>Choi</surname><given-names>IK</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Oh</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Yun</surname><given-names>CO</given-names></name></person-group><article-title>Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-gamma- and TNF-alpha-co-producing T cell-mediated antitumor immunity</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e67512</fpage><pub-id pub-id-type="pmid">23844018</pub-id></element-citation></ref><ref id="R162"><label>162</label><element-citation publication-type="journal"><person-group><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>T</given-names></name><name><surname>Ruo</surname><given-names>L</given-names></name><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Rose</surname><given-names>S</given-names></name><name><surname>Bloomston</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>CW</given-names></name><name><surname>Burke</surname><given-names>J</given-names></name><name><surname>Lencioni</surname><given-names>R</given-names></name><name><surname>Hickman</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">23396206</pub-id></element-citation></ref><ref id="R163"><label>163</label><element-citation publication-type="journal"><person-group><name><surname>Kanerva</surname><given-names>A</given-names></name><name><surname>Nokisalmi</surname><given-names>P</given-names></name><name><surname>Diaconu</surname><given-names>I</given-names></name><name><surname>Koski</surname><given-names>A</given-names></name><name><surname>Cerullo</surname><given-names>V</given-names></name><name><surname>Liikanen</surname><given-names>I</given-names></name><name><surname>Tahtinen</surname><given-names>S</given-names></name><name><surname>Oksanen</surname><given-names>M</given-names></name><name><surname>Heiskanen</surname><given-names>R</given-names></name><name><surname>Pesonen</surname><given-names>S</given-names></name><name><surname>Joensuu</surname><given-names>T</given-names></name><name><surname>Alanko</surname><given-names>T</given-names></name><name><surname>Partanen</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>2734</fpage><lpage>2744</lpage><pub-id pub-id-type="pmid">23493351</pub-id></element-citation></ref><ref id="R164"><label>164</label><element-citation publication-type="journal"><person-group><name><surname>Egilmez</surname><given-names>NK</given-names></name><name><surname>Harden</surname><given-names>JL</given-names></name><name><surname>Rowswell-Turner</surname><given-names>RB</given-names></name></person-group><article-title>Chemoimmunotherapy as long-term maintenance therapy for cancer</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>563</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">22754788</pub-id></element-citation></ref><ref id="R165"><label>165</label><element-citation publication-type="journal"><person-group><name><surname>Li</surname><given-names>J</given-names></name><name><surname>O'Malley</surname><given-names>M</given-names></name><name><surname>Sampath</surname><given-names>P</given-names></name><name><surname>Kalinski</surname><given-names>P</given-names></name><name><surname>Bartlett</surname><given-names>DL</given-names></name><name><surname>Thorne</surname><given-names>SH</given-names></name></person-group><article-title>Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity</article-title><source>Neoplasia</source><year>2012</year><volume>14</volume><fpage>1115</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">23308044</pub-id></element-citation></ref><ref id="R166"><label>166</label><element-citation publication-type="journal"><person-group><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name></person-group><article-title>Dendritic cells as therapeutic vaccines against cancer</article-title><source>Nat Rev Immunol</source><year>2005</year><volume>5</volume><fpage>296</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">15803149</pub-id></element-citation></ref><ref id="R167"><label>167</label><element-citation publication-type="journal"><person-group><name><surname>Coosemans</surname><given-names>A</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Van Gool</surname><given-names>SW</given-names></name></person-group><article-title>Dendritic cell-based immunotherapy in ovarian cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e27059</fpage><pub-id pub-id-type="pmid">24501688</pub-id></element-citation></ref><ref id="R168"><label>168</label><element-citation publication-type="journal"><person-group><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Sathe</surname><given-names>P</given-names></name><name><surname>Helft</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Mortha</surname><given-names>A</given-names></name></person-group><article-title>The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting</article-title><source>Annu Rev Immunol</source><year>2013</year><volume>31</volume><fpage>563</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">23516985</pub-id></element-citation></ref><ref id="R169"><label>169</label><element-citation publication-type="journal"><person-group><name><surname>Bonifaz</surname><given-names>L</given-names></name><name><surname>Bonnyay</surname><given-names>D</given-names></name><name><surname>Mahnke</surname><given-names>K</given-names></name><name><surname>Rivera</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><article-title>Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance</article-title><source>J Exp Med</source><year>2002</year><volume>196</volume><fpage>1627</fpage><lpage>1638</lpage><pub-id pub-id-type="pmid">12486105</pub-id></element-citation></ref><ref id="R170"><label>170</label><element-citation publication-type="journal"><person-group><name><surname>Hawiger</surname><given-names>D</given-names></name><name><surname>Inaba</surname><given-names>K</given-names></name><name><surname>Dorsett</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Mahnke</surname><given-names>K</given-names></name><name><surname>Rivera</surname><given-names>M</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><article-title>Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions <italic>in vivo</italic></article-title><source>J Exp Med</source><year>2001</year><volume>194</volume><fpage>769</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">11560993</pub-id></element-citation></ref><ref id="R171"><label>171</label><element-citation publication-type="journal"><person-group><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>Carreno</surname><given-names>BM</given-names></name></person-group><article-title>Dendritic cell-based vaccines: Shining the spotlight on signal 3</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26512</fpage><pub-id pub-id-type="pmid">24404428</pub-id></element-citation></ref><ref id="R172"><label>172</label><element-citation publication-type="journal"><person-group><name><surname>Mayordomo</surname><given-names>JI</given-names></name><name><surname>Zorina</surname><given-names>T</given-names></name><name><surname>Storkus</surname><given-names>WJ</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Celluzzi</surname><given-names>C</given-names></name><name><surname>Falo</surname><given-names>LD</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>Ildstad</surname><given-names>ST</given-names></name><name><surname>Kast</surname><given-names>WM</given-names></name><name><surname>Deleo</surname><given-names>AB</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name></person-group><article-title>Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>1297</fpage><lpage>1302</lpage><pub-id pub-id-type="pmid">7489412</pub-id></element-citation></ref><ref id="R173"><label>173</label><element-citation publication-type="journal"><person-group><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Mayordomo</surname><given-names>JI</given-names></name><name><surname>Tjandrawan</surname><given-names>T</given-names></name><name><surname>DeLeo</surname><given-names>AB</given-names></name><name><surname>Clarke</surname><given-names>MR</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Storkus</surname><given-names>WJ</given-names></name></person-group><article-title>Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines</article-title><source>J Exp Med</source><year>1996</year><volume>183</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">8551248</pub-id></element-citation></ref><ref id="R174"><label>174</label><element-citation publication-type="journal"><person-group><name><surname>Fernandez</surname><given-names>NC</given-names></name><name><surname>Lozier</surname><given-names>A</given-names></name><name><surname>Flament</surname><given-names>C</given-names></name><name><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></name><name><surname>Bellet</surname><given-names>D</given-names></name><name><surname>Suter</surname><given-names>M</given-names></name><name><surname>Perricaudet</surname><given-names>M</given-names></name><name><surname>Tursz</surname><given-names>T</given-names></name><name><surname>Maraskovsky</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><article-title>Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses <italic>in vivo</italic></article-title><source>Nat Med</source><year>1999</year><volume>5</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">10202929</pub-id></element-citation></ref><ref id="R175"><label>175</label><element-citation publication-type="journal"><person-group><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Kalinski</surname><given-names>P</given-names></name><name><surname>Ueda</surname><given-names>R</given-names></name><name><surname>Hoji</surname><given-names>A</given-names></name><name><surname>Kohanbash</surname><given-names>G</given-names></name><name><surname>Donegan</surname><given-names>TE</given-names></name><name><surname>Mintz</surname><given-names>AH</given-names></name><name><surname>Engh</surname><given-names>JA</given-names></name><name><surname>Bartlett</surname><given-names>DL</given-names></name><name><surname>Brown</surname><given-names>CK</given-names></name><name><surname>Zeh</surname><given-names>H</given-names></name><name><surname>Holtzman</surname><given-names>MP</given-names></name><name><surname>Reinhart</surname><given-names>TA</given-names></name><etal></etal></person-group><article-title>Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>330</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">21149657</pub-id></element-citation></ref><ref id="R176"><label>176</label><element-citation publication-type="journal"><person-group><name><surname>Zeis</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>M</given-names></name><name><surname>Marget</surname><given-names>M</given-names></name><name><surname>Kuhl-Burmeister</surname><given-names>R</given-names></name><name><surname>Adamzik</surname><given-names>I</given-names></name><name><surname>Kabelitz</surname><given-names>D</given-names></name><name><surname>Dreger</surname><given-names>P</given-names></name><name><surname>Schmitz</surname><given-names>N</given-names></name><name><surname>Heiser</surname><given-names>A</given-names></name></person-group><article-title>Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><fpage>5391</fpage><lpage>5397</lpage><pub-id pub-id-type="pmid">12759413</pub-id></element-citation></ref><ref id="R177"><label>177</label><element-citation publication-type="journal"><person-group><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Mirza</surname><given-names>N</given-names></name><name><surname>Fricke</surname><given-names>I</given-names></name><name><surname>Chiappori</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>N</given-names></name><name><surname>Bepler</surname><given-names>G</given-names></name><name><surname>Simon</surname><given-names>G</given-names></name><name><surname>Janssen</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Menander</surname><given-names>K</given-names></name><name><surname>Chada</surname><given-names>S</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name></person-group><article-title>Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>878</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">16467102</pub-id></element-citation></ref><ref id="R178"><label>178</label><element-citation publication-type="journal"><person-group><name><surname>Irvine</surname><given-names>AS</given-names></name><name><surname>Trinder</surname><given-names>PK</given-names></name><name><surname>Laughton</surname><given-names>DL</given-names></name><name><surname>Ketteringham</surname><given-names>H</given-names></name><name><surname>McDermott</surname><given-names>RH</given-names></name><name><surname>Reid</surname><given-names>SC</given-names></name><name><surname>Haines</surname><given-names>AM</given-names></name><name><surname>Amir</surname><given-names>A</given-names></name><name><surname>Husain</surname><given-names>R</given-names></name><name><surname>Doshi</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>LS</given-names></name><name><surname>Mountain</surname><given-names>A</given-names></name></person-group><article-title>Efficient nonviral transfection of dendritic cells and their use for <italic>in vivo</italic> immunization</article-title><source>Nat Biotechnol</source><year>2000</year><volume>18</volume><fpage>1273</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">11101806</pub-id></element-citation></ref><ref id="R179"><label>179</label><element-citation publication-type="journal"><person-group><name><surname>Manickan</surname><given-names>E</given-names></name><name><surname>Kanangat</surname><given-names>S</given-names></name><name><surname>Rouse</surname><given-names>RJ</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Rouse</surname><given-names>BT</given-names></name></person-group><article-title>Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells</article-title><source>J Leukoc Biol</source><year>1997</year><volume>61</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">9021916</pub-id></element-citation></ref><ref id="R180"><label>180</label><element-citation publication-type="journal"><person-group><name><surname>Blalock</surname><given-names>LT</given-names></name><name><surname>Landsberg</surname><given-names>J</given-names></name><name><surname>Messmer</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Pardee</surname><given-names>AD</given-names></name><name><surname>Haskell</surname><given-names>R</given-names></name><name><surname>Vujanovic</surname><given-names>L</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Butterfield</surname><given-names>LH</given-names></name></person-group><article-title>Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>287</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">22737604</pub-id></element-citation></ref><ref id="R181"><label>181</label><element-citation publication-type="journal"><person-group><name><surname>Fields</surname><given-names>RC</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Mule</surname><given-names>JJ</given-names></name></person-group><article-title>Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>9482</fpage><lpage>9487</lpage><pub-id pub-id-type="pmid">9689106</pub-id></element-citation></ref><ref id="R182"><label>182</label><element-citation publication-type="journal"><person-group><name><surname>Kokhaei</surname><given-names>P</given-names></name><name><surname>Rezvany</surname><given-names>MR</given-names></name><name><surname>Virving</surname><given-names>L</given-names></name><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>Rabbani</surname><given-names>H</given-names></name><name><surname>Osterborg</surname><given-names>A</given-names></name><name><surname>Mellstedt</surname><given-names>H</given-names></name></person-group><article-title>Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>894</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">12750703</pub-id></element-citation></ref><ref id="R183"><label>183</label><element-citation publication-type="journal"><person-group><name><surname>Albert</surname><given-names>ML</given-names></name><name><surname>Sauter</surname><given-names>B</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group><article-title>Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>86</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">9510252</pub-id></element-citation></ref><ref id="R184"><label>184</label><element-citation publication-type="journal"><person-group><name><surname>Kandalaft</surname><given-names>LE</given-names></name><name><surname>Powell</surname><given-names>DJ</given-names><suffix>Jr</suffix></name><name><surname>Chiang</surname><given-names>CL</given-names></name><name><surname>Tanyi</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Bosch</surname><given-names>M</given-names></name><name><surname>Montone</surname><given-names>K</given-names></name><name><surname>Mick</surname><given-names>R</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Torigian</surname><given-names>DA</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name></person-group><article-title>Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22664</fpage><pub-id pub-id-type="pmid">23482679</pub-id></element-citation></ref><ref id="R185"><label>185</label><element-citation publication-type="journal"><person-group><name><surname>Fucikova</surname><given-names>J</given-names></name><name><surname>Rozkova</surname><given-names>D</given-names></name><name><surname>Ulcova</surname><given-names>H</given-names></name><name><surname>Budinsky</surname><given-names>V</given-names></name><name><surname>Sochorova</surname><given-names>K</given-names></name><name><surname>Pokorna</surname><given-names>K</given-names></name><name><surname>Bartunkova</surname><given-names>J</given-names></name><name><surname>Spisek</surname><given-names>R</given-names></name></person-group><article-title>Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials</article-title><source>J Transl Med</source><year>2011</year><volume>9</volume><fpage>223</fpage><pub-id pub-id-type="pmid">22208910</pub-id></element-citation></ref><ref id="R186"><label>186</label><element-citation publication-type="journal"><person-group><name><surname>Fucikova</surname><given-names>J</given-names></name><name><surname>Kralikova</surname><given-names>P</given-names></name><name><surname>Fialova</surname><given-names>A</given-names></name><name><surname>Brtnicky</surname><given-names>T</given-names></name><name><surname>Rob</surname><given-names>L</given-names></name><name><surname>Bartunkova</surname><given-names>J</given-names></name><name><surname>Spisek</surname><given-names>R</given-names></name></person-group><article-title>Human tumor cells killed by anthracyclines induce a tumor-specific immune response</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>4821</fpage><lpage>4833</lpage><pub-id pub-id-type="pmid">21602432</pub-id></element-citation></ref><ref id="R187"><label>187</label><element-citation publication-type="journal"><person-group><name><surname>Boczkowski</surname><given-names>D</given-names></name><name><surname>Nair</surname><given-names>SK</given-names></name><name><surname>Nam</surname><given-names>JH</given-names></name><name><surname>Lyerly</surname><given-names>HK</given-names></name><name><surname>Gilboa</surname><given-names>E</given-names></name></person-group><article-title>Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>1028</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">10706120</pub-id></element-citation></ref><ref id="R188"><label>188</label><element-citation publication-type="journal"><person-group><name><surname>Boczkowski</surname><given-names>D</given-names></name><name><surname>Nair</surname><given-names>SK</given-names></name><name><surname>Snyder</surname><given-names>D</given-names></name><name><surname>Gilboa</surname><given-names>E</given-names></name></person-group><article-title>Dendritic cells pulsed with RNA are potent antigen-presenting cells <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">8760800</pub-id></element-citation></ref><ref id="R189"><label>189</label><element-citation publication-type="journal"><person-group><name><surname>Ashley</surname><given-names>DM</given-names></name><name><surname>Faiola</surname><given-names>B</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Hale</surname><given-names>LP</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Gilboa</surname><given-names>E</given-names></name></person-group><article-title>Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors</article-title><source>J Exp Med</source><year>1997</year><volume>186</volume><fpage>1177</fpage><lpage>1182</lpage><pub-id pub-id-type="pmid">9314567</pub-id></element-citation></ref><ref id="R190"><label>190</label><element-citation publication-type="journal"><person-group><name><surname>Garg</surname><given-names>NK</given-names></name><name><surname>Dwivedi</surname><given-names>P</given-names></name><name><surname>Prabha</surname><given-names>P</given-names></name><name><surname>Tyagi</surname><given-names>RK</given-names></name></person-group><article-title>RNA pulsed dendritic cells: an approach for cancer immunotherapy</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>1141</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">23306369</pub-id></element-citation></ref><ref id="R191"><label>191</label><element-citation publication-type="journal"><person-group><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Ziske</surname><given-names>C</given-names></name><name><surname>Marten</surname><given-names>A</given-names></name><name><surname>Endres</surname><given-names>S</given-names></name><name><surname>Tiemann</surname><given-names>K</given-names></name><name><surname>Schmitz</surname><given-names>V</given-names></name><name><surname>Gorschluter</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Sauerbruch</surname><given-names>T</given-names></name><name><surname>Schmidt-Wolf</surname><given-names>IG</given-names></name></person-group><article-title>Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>8962</fpage><lpage>8967</lpage><pub-id pub-id-type="pmid">14695214</pub-id></element-citation></ref><ref id="R192"><label>192</label><element-citation publication-type="journal"><person-group><name><surname>Celluzzi</surname><given-names>CM</given-names></name><name><surname>Falo</surname><given-names>LD</given-names><suffix>Jr</suffix></name></person-group><article-title>Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection</article-title><source>J Immunol</source><year>1998</year><volume>160</volume><fpage>3081</fpage><lpage>3085</lpage><pub-id pub-id-type="pmid">9531260</pub-id></element-citation></ref><ref id="R193"><label>193</label><element-citation publication-type="journal"><person-group><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Saffold</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Krauss</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>5516</fpage><lpage>5524</lpage><pub-id pub-id-type="pmid">9820528</pub-id></element-citation></ref><ref id="R194"><label>194</label><element-citation publication-type="journal"><person-group><name><surname>Orentas</surname><given-names>RJ</given-names></name><name><surname>Schauer</surname><given-names>D</given-names></name><name><surname>Bin</surname><given-names>Q</given-names></name><name><surname>Johnson</surname><given-names>BD</given-names></name></person-group><article-title>Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine</article-title><source>Cell Immunol</source><year>2001</year><volume>213</volume><fpage>4</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11747351</pub-id></element-citation></ref><ref id="R195"><label>195</label><element-citation publication-type="journal"><person-group><name><surname>Koido</surname><given-names>S</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Namiki</surname><given-names>Y</given-names></name><name><surname>Kan</surname><given-names>S</given-names></name><name><surname>Takakura</surname><given-names>K</given-names></name><name><surname>Kajihara</surname><given-names>M</given-names></name><name><surname>Uchiyama</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>E</given-names></name><name><surname>Ohkusa</surname><given-names>T</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Tajiri</surname><given-names>H</given-names></name></person-group><article-title>Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25375</fpage><pub-id pub-id-type="pmid">24167764</pub-id></element-citation></ref><ref id="R196"><label>196</label><element-citation publication-type="journal"><person-group><name><surname>Koido</surname><given-names>S</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Namiki</surname><given-names>Y</given-names></name><name><surname>Takakura</surname><given-names>K</given-names></name><name><surname>Uchiyama</surname><given-names>K</given-names></name><name><surname>Kajihara</surname><given-names>M</given-names></name><name><surname>Arihiro</surname><given-names>S</given-names></name><name><surname>Imazu</surname><given-names>H</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Kan</surname><given-names>S</given-names></name><name><surname>Komita</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Fusions between dendritic cells and whole tumor cells as anticancer vaccines</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24437</fpage><pub-id pub-id-type="pmid">23762810</pub-id></element-citation></ref><ref id="R197"><label>197</label><element-citation publication-type="journal"><person-group><name><surname>Koido</surname><given-names>S</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Namiki</surname><given-names>Y</given-names></name><name><surname>Takakura</surname><given-names>K</given-names></name><name><surname>Uchiyama</surname><given-names>K</given-names></name><name><surname>Kajihara</surname><given-names>M</given-names></name><name><surname>Arihiro</surname><given-names>S</given-names></name><name><surname>Imazu</surname><given-names>H</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Kan</surname><given-names>S</given-names></name><name><surname>Komita</surname><given-names>H</given-names></name><name><surname>Kamata</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25994</fpage><pub-id pub-id-type="pmid">24228229</pub-id></element-citation></ref><ref id="R198"><label>198</label><element-citation publication-type="journal"><person-group><name><surname>Bonifaz</surname><given-names>LC</given-names></name><name><surname>Bonnyay</surname><given-names>DP</given-names></name><name><surname>Charalambous</surname><given-names>A</given-names></name><name><surname>Darguste</surname><given-names>DI</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Soares</surname><given-names>H</given-names></name><name><surname>Brimnes</surname><given-names>MK</given-names></name><name><surname>Moltedo</surname><given-names>B</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><article-title><italic>In vivo</italic> targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><fpage>815</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">15024047</pub-id></element-citation></ref><ref id="R199"><label>199</label><element-citation publication-type="journal"><person-group><name><surname>Berraondo</surname><given-names>P</given-names></name><name><surname>Nouze</surname><given-names>C</given-names></name><name><surname>Preville</surname><given-names>X</given-names></name><name><surname>Ladant</surname><given-names>D</given-names></name><name><surname>Leclerc</surname><given-names>C</given-names></name></person-group><article-title>Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>8847</fpage><lpage>8855</lpage><pub-id pub-id-type="pmid">17875726</pub-id></element-citation></ref><ref id="R200"><label>200</label><element-citation publication-type="journal"><person-group><name><surname>Klechevsky</surname><given-names>E</given-names></name><name><surname>Flamar</surname><given-names>AL</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Blanck</surname><given-names>JP</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>O'Bar</surname><given-names>A</given-names></name><name><surname>Agouna-Deciat</surname><given-names>O</given-names></name><name><surname>Klucar</surname><given-names>P</given-names></name><name><surname>Thompson-Snipes</surname><given-names>L</given-names></name><name><surname>Zurawski</surname><given-names>S</given-names></name><name><surname>Reiter</surname><given-names>Y</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name><name><surname>Zurawski</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>1685</fpage><lpage>1697</lpage><pub-id pub-id-type="pmid">20530286</pub-id></element-citation></ref><ref id="R201"><label>201</label><element-citation publication-type="journal"><person-group><name><surname>Schreibelt</surname><given-names>G</given-names></name><name><surname>Klinkenberg</surname><given-names>LJ</given-names></name><name><surname>Cruz</surname><given-names>LJ</given-names></name><name><surname>Tacken</surname><given-names>PJ</given-names></name><name><surname>Tel</surname><given-names>J</given-names></name><name><surname>Kreutz</surname><given-names>M</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>de Vries</surname><given-names>IJ</given-names></name></person-group><article-title>The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>2284</fpage><lpage>2292</lpage><pub-id pub-id-type="pmid">22234694</pub-id></element-citation></ref><ref id="R202"><label>202</label><element-citation publication-type="journal"><person-group><name><surname>Tacken</surname><given-names>PJ</given-names></name><name><surname>Ginter</surname><given-names>W</given-names></name><name><surname>Berod</surname><given-names>L</given-names></name><name><surname>Cruz</surname><given-names>LJ</given-names></name><name><surname>Joosten</surname><given-names>B</given-names></name><name><surname>Sparwasser</surname><given-names>T</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>Cambi</surname><given-names>A</given-names></name></person-group><article-title>Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>4111</fpage><lpage>4119</lpage><pub-id pub-id-type="pmid">21860028</pub-id></element-citation></ref><ref id="R203"><label>203</label><element-citation publication-type="journal"><person-group><name><surname>Tacken</surname><given-names>PJ</given-names></name><name><surname>Zeelenberg</surname><given-names>IS</given-names></name><name><surname>Cruz</surname><given-names>LJ</given-names></name><name><surname>van Hout-Kuijer</surname><given-names>MA</given-names></name><name><surname>van de Glind</surname><given-names>G</given-names></name><name><surname>Fokkink</surname><given-names>RG</given-names></name><name><surname>Lambeck</surname><given-names>AJ</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name></person-group><article-title>Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>6836</fpage><lpage>6844</lpage><pub-id pub-id-type="pmid">21967977</pub-id></element-citation></ref><ref id="R204"><label>204</label><element-citation publication-type="journal"><person-group><name><surname>Wang</surname><given-names>B</given-names></name></person-group><article-title>Targeting dendritic cells in situ for breast cancer immunotherapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1398</fpage><lpage>1400</lpage><pub-id pub-id-type="pmid">23243606</pub-id></element-citation></ref><ref id="R205"><label>205</label><element-citation publication-type="journal"><person-group><name><surname>Garcia-Vallejo</surname><given-names>JJ</given-names></name><name><surname>Unger</surname><given-names>WW</given-names></name><name><surname>Kalay</surname><given-names>H</given-names></name><name><surname>van Kooyk</surname><given-names>Y</given-names></name></person-group><article-title>Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23040</fpage><pub-id pub-id-type="pmid">23525136</pub-id></element-citation></ref><ref id="R206"><label>206</label><element-citation publication-type="journal"><person-group><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Regnault</surname><given-names>A</given-names></name><name><surname>Lozier</surname><given-names>A</given-names></name><name><surname>Wolfers</surname><given-names>J</given-names></name><name><surname>Flament</surname><given-names>C</given-names></name><name><surname>Tenza</surname><given-names>D</given-names></name><name><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name></person-group><article-title>Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><fpage>594</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">9585234</pub-id></element-citation></ref><ref id="R207"><label>207</label><element-citation publication-type="journal"><person-group><name><surname>Viaud</surname><given-names>S</given-names></name><name><surname>Thery</surname><given-names>C</given-names></name><name><surname>Ploix</surname><given-names>S</given-names></name><name><surname>Tursz</surname><given-names>T</given-names></name><name><surname>Lapierre</surname><given-names>V</given-names></name><name><surname>Lantz</surname><given-names>O</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Chaput</surname><given-names>N</given-names></name></person-group><article-title>Dendritic cell-derived exosomes for cancer immunotherapy: what's next?</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>1281</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">20145139</pub-id></element-citation></ref><ref id="R208"><label>208</label><element-citation publication-type="journal"><person-group><name><surname>Munich</surname><given-names>S</given-names></name><name><surname>Sobo-Vujanovic</surname><given-names>A</given-names></name><name><surname>Buchser</surname><given-names>WJ</given-names></name><name><surname>Beer-Stolz</surname><given-names>D</given-names></name><name><surname>Vujanovic</surname><given-names>NL</given-names></name></person-group><article-title>Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1074</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">23170255</pub-id></element-citation></ref><ref id="R209"><label>209</label><element-citation publication-type="journal"><person-group><name><surname>Satoh</surname><given-names>Y</given-names></name><name><surname>Esche</surname><given-names>C</given-names></name><name><surname>Gambotto</surname><given-names>A</given-names></name><name><surname>Shurin</surname><given-names>GV</given-names></name><name><surname>Yurkovetsky</surname><given-names>ZR</given-names></name><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Watkins</surname><given-names>SC</given-names></name><name><surname>Todo</surname><given-names>S</given-names></name><name><surname>Herberman</surname><given-names>RB</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Shurin</surname><given-names>MR</given-names></name></person-group><article-title>Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice</article-title><source>J Exp Ther Oncol</source><year>2002</year><volume>2</volume><fpage>337</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">12440225</pub-id></element-citation></ref><ref id="R210"><label>210</label><element-citation publication-type="journal"><person-group><name><surname>Nishioka</surname><given-names>Y</given-names></name><name><surname>Hirao</surname><given-names>M</given-names></name><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Tahara</surname><given-names>H</given-names></name></person-group><article-title>Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>4035</fpage><lpage>4041</lpage><pub-id pub-id-type="pmid">10463604</pub-id></element-citation></ref><ref id="R211"><label>211</label><element-citation publication-type="journal"><person-group><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Kenjo</surname><given-names>A</given-names></name><name><surname>Hoshino</surname><given-names>M</given-names></name><name><surname>Terashima</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Anazawa</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>T</given-names></name><name><surname>Irisawa</surname><given-names>A</given-names></name><name><surname>Ohira</surname><given-names>H</given-names></name><name><surname>Hikichi</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients</article-title><source>J Hepatobiliary Pancreat Sci</source><year>2012</year><volume>19</volume><fpage>465</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">21983893</pub-id></element-citation></ref><ref id="R212"><label>212</label><element-citation publication-type="journal"><person-group><name><surname>You</surname><given-names>CX</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Hermonat</surname><given-names>PL</given-names></name></person-group><article-title>AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>847</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">23162752</pub-id></element-citation></ref><ref id="R213"><label>213</label><element-citation publication-type="journal"><person-group><name><surname>Bol</surname><given-names>KF</given-names></name><name><surname>Tel</surname><given-names>J</given-names></name><name><surname>de Vries</surname><given-names>IJ</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name></person-group><article-title>Naturally circulating dendritic cells to vaccinate cancer patients</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23431</fpage><pub-id pub-id-type="pmid">23802086</pub-id></element-citation></ref><ref id="R214"><label>214</label><element-citation publication-type="journal"><person-group><name><surname>Harfuddin</surname><given-names>Z</given-names></name><name><surname>Kwajah</surname><given-names>S</given-names></name><name><surname>Chong Nyi Sim</surname><given-names>A</given-names></name><name><surname>Macary</surname><given-names>PA</given-names></name><name><surname>Schwarz</surname><given-names>H</given-names></name></person-group><article-title>CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26859</fpage><pub-id pub-id-type="pmid">24482752</pub-id></element-citation></ref><ref id="R215"><label>215</label><element-citation publication-type="journal"><person-group><name><surname>Tacken</surname><given-names>PJ</given-names></name><name><surname>de Vries</surname><given-names>IJ</given-names></name><name><surname>Gijzen</surname><given-names>K</given-names></name><name><surname>Joosten</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Rother</surname><given-names>RP</given-names></name><name><surname>Faas</surname><given-names>SJ</given-names></name><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Torensma</surname><given-names>R</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name></person-group><article-title>Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>1278</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">15878980</pub-id></element-citation></ref><ref id="R216"><label>216</label><element-citation publication-type="journal"><person-group><name><surname>Haicheur</surname><given-names>N</given-names></name><name><surname>Bismuth</surname><given-names>E</given-names></name><name><surname>Bosset</surname><given-names>S</given-names></name><name><surname>Adotevi</surname><given-names>O</given-names></name><name><surname>Warnier</surname><given-names>G</given-names></name><name><surname>Lacabanne</surname><given-names>V</given-names></name><name><surname>Regnault</surname><given-names>A</given-names></name><name><surname>Desaymard</surname><given-names>C</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name><name><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></name><name><surname>Goud</surname><given-names>B</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Johannes</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>3301</fpage><lpage>3308</lpage><pub-id pub-id-type="pmid">10975847</pub-id></element-citation></ref><ref id="R217"><label>217</label><element-citation publication-type="journal"><person-group><name><surname>van Broekhoven</surname><given-names>CL</given-names></name><name><surname>Parish</surname><given-names>CR</given-names></name><name><surname>Demangel</surname><given-names>C</given-names></name><name><surname>Britton</surname><given-names>WJ</given-names></name><name><surname>Altin</surname><given-names>JG</given-names></name></person-group><article-title>Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>4357</fpage><lpage>4365</lpage><pub-id pub-id-type="pmid">15205352</pub-id></element-citation></ref><ref id="R218"><label>218</label><element-citation publication-type="journal"><person-group><name><surname>Badiee</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>N</given-names></name><name><surname>McDonald</surname><given-names>K</given-names></name><name><surname>Radford</surname><given-names>K</given-names></name><name><surname>Michiue</surname><given-names>H</given-names></name><name><surname>Hart</surname><given-names>D</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name></person-group><article-title>Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4757</fpage><lpage>4766</lpage><pub-id pub-id-type="pmid">17512099</pub-id></element-citation></ref><ref id="R219"><label>219</label><element-citation publication-type="journal"><person-group><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Rideout</surname><given-names>K</given-names></name><name><surname>Cho</surname><given-names>T</given-names></name><name><surname>Joo</surname><given-names>KI</given-names></name><name><surname>Ziegler</surname><given-names>L</given-names></name><name><surname>Elliot</surname><given-names>A</given-names></name><name><surname>Walls</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title>Engineered lentivector targeting of dendritic cells for <italic>in vivo</italic> immunization</article-title><source>Nat Biotechnol</source><year>2008</year><volume>26</volume><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">18297056</pub-id></element-citation></ref><ref id="R220"><label>220</label><element-citation publication-type="journal"><person-group><name><surname>Hangalapura</surname><given-names>BN</given-names></name><name><surname>Oosterhoff</surname><given-names>D</given-names></name><name><surname>de Groot</surname><given-names>J</given-names></name><name><surname>Boon</surname><given-names>L</given-names></name><name><surname>Tuting</surname><given-names>T</given-names></name><name><surname>van den Eertwegh</surname><given-names>AJ</given-names></name><name><surname>Gerritsen</surname><given-names>WR</given-names></name><name><surname>van Beusechem</surname><given-names>VW</given-names></name><name><surname>Pereboev</surname><given-names>A</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>de Gruijl</surname><given-names>TD</given-names></name></person-group><article-title>Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>5827</fpage><lpage>5837</lpage><pub-id pub-id-type="pmid">21747119</pub-id></element-citation></ref><ref id="R221"><label>221</label><element-citation publication-type="journal"><person-group><name><surname>Korokhov</surname><given-names>N</given-names></name><name><surname>de Gruijl</surname><given-names>TD</given-names></name><name><surname>Aldrich</surname><given-names>WA</given-names></name><name><surname>Triozzi</surname><given-names>PL</given-names></name><name><surname>Banerjee</surname><given-names>PT</given-names></name><name><surname>Gillies</surname><given-names>SD</given-names></name><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Douglas</surname><given-names>JT</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name></person-group><article-title>High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN</article-title><source>Cancer Biol Ther</source><year>2005</year><volume>4</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">15753654</pub-id></element-citation></ref><ref id="R222"><label>222</label><element-citation publication-type="journal"><person-group><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Shore</surname><given-names>ND</given-names></name><name><surname>Berger</surname><given-names>ER</given-names></name><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Penson</surname><given-names>DF</given-names></name><name><surname>Redfern</surname><given-names>CH</given-names></name><name><surname>Ferrari</surname><given-names>AC</given-names></name><name><surname>Dreicer</surname><given-names>R</given-names></name><name><surname>Sims</surname><given-names>RB</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Frohlich</surname><given-names>MW</given-names></name><name><surname>Schellhammer</surname><given-names>PF</given-names></name><etal></etal></person-group><article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">20818862</pub-id></element-citation></ref><ref id="R223"><label>223</label><element-citation publication-type="journal"><person-group><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Schellhammer</surname><given-names>P</given-names></name><name><surname>Yasothan</surname><given-names>U</given-names></name><name><surname>Gubernick</surname><given-names>S</given-names></name><name><surname>Kirkpatrick</surname><given-names>P</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name></person-group><article-title>Sipuleucel-T</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><fpage>513</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">20592741</pub-id></element-citation></ref><ref id="R224"><label>224</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>New immunotherapeutic paradigms for castration-resistant prostate cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26084</fpage></element-citation></ref><ref id="R225"><label>225</label><element-citation publication-type="journal"><person-group><name><surname>Palucka</surname><given-names>K</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>Dendritic-cell-based therapeutic cancer vaccines</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">23890062</pub-id></element-citation></ref><ref id="R226"><label>226</label><element-citation publication-type="journal"><person-group><name><surname>Lakomy</surname><given-names>D</given-names></name><name><surname>Janikashvili</surname><given-names>N</given-names></name><name><surname>Fraszczak</surname><given-names>J</given-names></name><name><surname>Trad</surname><given-names>M</given-names></name><name><surname>Audia</surname><given-names>S</given-names></name><name><surname>Samson</surname><given-names>M</given-names></name><name><surname>Ciudad</surname><given-names>M</given-names></name><name><surname>Vinit</surname><given-names>J</given-names></name><name><surname>Vergely</surname><given-names>C</given-names></name><name><surname>Caillot</surname><given-names>D</given-names></name><name><surname>Foucher</surname><given-names>P</given-names></name><name><surname>Lagrost</surname><given-names>L</given-names></name><name><surname>Chouaib</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Cytotoxic dendritic cells generated from cancer patients</article-title><source>J Immunol</source><year>2011</year><volume>187</volume><fpage>2775</fpage><lpage>2782</lpage><pub-id pub-id-type="pmid">21804019</pub-id></element-citation></ref><ref id="R227"><label>227</label><element-citation publication-type="journal"><person-group><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>de Vries</surname><given-names>IJ</given-names></name><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name></person-group><article-title>Dendritic cell immunotherapy: mapping the way</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">15122249</pub-id></element-citation></ref><ref id="R228"><label>228</label><element-citation publication-type="journal"><person-group><name><surname>Gilboa</surname><given-names>E</given-names></name></person-group><article-title>DC-based cancer vaccines</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>1195</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">17476349</pub-id></element-citation></ref><ref id="R229"><label>229</label><element-citation publication-type="journal"><person-group><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Garcia</surname><given-names>P</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial watch: DNA vaccines for cancer therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23803</fpage><pub-id pub-id-type="pmid">23734328</pub-id></element-citation></ref><ref id="R230"><label>230</label><element-citation publication-type="journal"><person-group><name><surname>Aranda</surname><given-names>F</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial Watch: Peptide vaccines in cancer therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26621</fpage><pub-id pub-id-type="pmid">24498550</pub-id></element-citation></ref><ref id="R231"><label>231</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial watch: Peptide vaccines in cancer therapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1557</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">23264902</pub-id></element-citation></ref><ref id="R232"><label>232</label><element-citation publication-type="journal"><person-group><name><surname>Aruga</surname><given-names>A</given-names></name></person-group><article-title>Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24882</fpage><pub-id pub-id-type="pmid">24073370</pub-id></element-citation></ref><ref id="R233"><label>233</label><element-citation publication-type="journal"><person-group><name><surname>Ricupito</surname><given-names>A</given-names></name><name><surname>Grioni</surname><given-names>M</given-names></name><name><surname>Calcinotto</surname><given-names>A</given-names></name><name><surname>Bellone</surname><given-names>M</given-names></name></person-group><article-title>Boosting anticancer vaccines: Too much of a good thing?</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25032</fpage><pub-id pub-id-type="pmid">24073378</pub-id></element-citation></ref><ref id="R234"><label>234</label><element-citation publication-type="journal"><person-group><name><surname>Hailemichael</surname><given-names>Y</given-names></name><name><surname>Overwijk</surname><given-names>WW</given-names></name></person-group><article-title>Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24743</fpage><pub-id pub-id-type="pmid">24073366</pub-id></element-citation></ref><ref id="R235"><label>235</label><element-citation publication-type="journal"><person-group><name><surname>Bijker</surname><given-names>MS</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name></person-group><article-title>Design and development of synthetic peptide vaccines: past, present and future</article-title><source>Expert Rev Vaccines</source><year>2007</year><volume>6</volume><fpage>591</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">17669012</pub-id></element-citation></ref><ref id="R236"><label>236</label><element-citation publication-type="journal"><person-group><name><surname>Yaddanapudi</surname><given-names>K</given-names></name><name><surname>Mitchell</surname><given-names>RA</given-names></name><name><surname>Eaton</surname><given-names>JW</given-names></name></person-group><article-title>Cancer vaccines: Looking to the future</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23403</fpage><pub-id pub-id-type="pmid">23802081</pub-id></element-citation></ref><ref id="R237"><label>237</label><element-citation publication-type="journal"><person-group><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Souleimanian</surname><given-names>NE</given-names></name><name><surname>Tosello</surname><given-names>V</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>O'Neill</surname><given-names>D</given-names></name><name><surname>Pavlick</surname><given-names>A</given-names></name><name><surname>Escalon</surname><given-names>JB</given-names></name><name><surname>Cruz</surname><given-names>CM</given-names></name><name><surname>Angiulli</surname><given-names>A</given-names></name><name><surname>Angiulli</surname><given-names>F</given-names></name><name><surname>Mears</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>SM</given-names></name><etal></etal></person-group><article-title>Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>8947</fpage><lpage>8952</lpage><pub-id pub-id-type="pmid">17517626</pub-id></element-citation></ref><ref id="R238"><label>238</label><element-citation publication-type="journal"><person-group><name><surname>Melero</surname><given-names>I</given-names></name><name><surname>Gaudernack</surname><given-names>G</given-names></name><name><surname>Gerritsen</surname><given-names>W</given-names></name><name><surname>Huber</surname><given-names>C</given-names></name><name><surname>Parmiani</surname><given-names>G</given-names></name><name><surname>Scholl</surname><given-names>S</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Wagstaff</surname><given-names>J</given-names></name><name><surname>Zielinski</surname><given-names>C</given-names></name><name><surname>Faulkner</surname><given-names>I</given-names></name><name><surname>Mellstedt</surname><given-names>H</given-names></name></person-group><article-title>Therapeutic vaccines for cancer: an overview of clinical trials</article-title><source>Nat Rev Clin Oncol</source><year>2014</year><volume>11</volume><fpage>509</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">25001465</pub-id></element-citation></ref><ref id="R239"><label>239</label><element-citation publication-type="journal"><person-group><name><surname>Binder</surname><given-names>DC</given-names></name><name><surname>Schreiber</surname><given-names>H</given-names></name></person-group><article-title>High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26704</fpage><pub-id pub-id-type="pmid">24563823</pub-id></element-citation></ref><ref id="R240"><label>240</label><element-citation publication-type="journal"><person-group><name><surname>Bijker</surname><given-names>MS</given-names></name><name><surname>van den Eeden</surname><given-names>SJ</given-names></name><name><surname>Franken</surname><given-names>KL</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name></person-group><article-title>CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>5033</fpage><lpage>5040</lpage><pub-id pub-id-type="pmid">17911588</pub-id></element-citation></ref><ref id="R241"><label>241</label><element-citation publication-type="journal"><person-group><name><surname>Zom</surname><given-names>GG</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Britten</surname><given-names>CM</given-names></name><name><surname>Sommandas</surname><given-names>V</given-names></name><name><surname>Camps</surname><given-names>MG</given-names></name><name><surname>Loof</surname><given-names>NM</given-names></name><name><surname>Budden</surname><given-names>CF</given-names></name><name><surname>Meeuwenoord</surname><given-names>NJ</given-names></name><name><surname>Filippov</surname><given-names>DV</given-names></name><name><surname>van der Marel</surname><given-names>GA</given-names></name><name><surname>Overkleeft</surname><given-names>HS</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>Ossendorp</surname><given-names>F</given-names></name></person-group><article-title>Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates</article-title><source>Cancer Immunol Res</source><year>2014</year><volume>2</volume><fpage>756</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">24950688</pub-id></element-citation></ref><ref id="R242"><label>242</label><element-citation publication-type="journal"><person-group><name><surname>Hailemichael</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Jaffarzad</surname><given-names>N</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Medina</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>XF</given-names></name><name><surname>Dorta-Estremera</surname><given-names>SM</given-names></name><name><surname>Greeley</surname><given-names>NR</given-names></name><name><surname>Nitti</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Lou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal></etal></person-group><article-title>Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">23455713</pub-id></element-citation></ref><ref id="R243"><label>243</label><element-citation publication-type="journal"><person-group><name><surname>Ciocca</surname><given-names>DR</given-names></name><name><surname>Cayado-Gutierrez</surname><given-names>N</given-names></name><name><surname>Maccioni</surname><given-names>M</given-names></name><name><surname>Cuello-Carrion</surname><given-names>FD</given-names></name></person-group><article-title>Heat shock proteins (HSPs) based anti-cancer vaccines</article-title><source>Curr Mol Med</source><year>2012</year><volume>12</volume><fpage>1183</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">22804241</pub-id></element-citation></ref><ref id="R244"><label>244</label><element-citation publication-type="journal"><person-group><name><surname>Fioretti</surname><given-names>D</given-names></name><name><surname>Iurescia</surname><given-names>S</given-names></name><name><surname>Fazio</surname><given-names>VM</given-names></name><name><surname>Rinaldi</surname><given-names>M</given-names></name></person-group><article-title>DNA vaccines: developing new strategies against cancer</article-title><source>J Biomed Biotechnol</source><year>2010</year><volume>2010</volume><fpage>174378</fpage><pub-id pub-id-type="pmid">20368780</pub-id></element-citation></ref><ref id="R245"><label>245</label><element-citation publication-type="journal"><person-group><name><surname>Liu</surname><given-names>MA</given-names></name></person-group><article-title>DNA vaccines: an historical perspective and view to the future</article-title><source>Immunol Rev</source><year>2011</year><volume>239</volume><fpage>62</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">21198665</pub-id></element-citation></ref><ref id="R246"><label>246</label><element-citation publication-type="journal"><person-group><name><surname>Stevenson</surname><given-names>FK</given-names></name><name><surname>Ottensmeier</surname><given-names>CH</given-names></name><name><surname>Rice</surname><given-names>J</given-names></name></person-group><article-title>DNA vaccines against cancer come of age</article-title><source>Curr Opin Immunol</source><year>2010</year><volume>22</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">20172703</pub-id></element-citation></ref><ref id="R247"><label>247</label><element-citation publication-type="journal"><person-group><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Buchholz</surname><given-names>CJ</given-names></name></person-group><article-title>Cell type specific gene delivery by lentiviral vectors: New options in immunotherapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22566</fpage><pub-id pub-id-type="pmid">23483777</pub-id></element-citation></ref><ref id="R248"><label>248</label><element-citation publication-type="journal"><person-group><name><surname>Shirota</surname><given-names>H</given-names></name><name><surname>Petrenko</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>C</given-names></name><name><surname>Klinman</surname><given-names>DM</given-names></name></person-group><article-title>Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">17579053</pub-id></element-citation></ref><ref id="R249"><label>249</label><element-citation publication-type="journal"><person-group><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Belz</surname><given-names>GT</given-names></name><name><surname>Behrens</surname><given-names>GM</given-names></name><name><surname>Smith</surname><given-names>CM</given-names></name><name><surname>Forehan</surname><given-names>SP</given-names></name><name><surname>Parish</surname><given-names>IA</given-names></name><name><surname>Davey</surname><given-names>GM</given-names></name><name><surname>Wilson</surname><given-names>NS</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Villadangos</surname><given-names>JA</given-names></name></person-group><article-title>Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens</article-title><source>Immunol Rev</source><year>2004</year><volume>199</volume><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">15233723</pub-id></element-citation></ref><ref id="R250"><label>250</label><element-citation publication-type="journal"><person-group><name><surname>Pol</surname><given-names>JG</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bridle</surname><given-names>BW</given-names></name><name><surname>Stephenson</surname><given-names>KB</given-names></name><name><surname>Resseguier</surname><given-names>J</given-names></name><name><surname>Hanson</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Kazdhan</surname><given-names>N</given-names></name><name><surname>Bramson</surname><given-names>JL</given-names></name><name><surname>Stojdl</surname><given-names>DF</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Lichty</surname><given-names>BD</given-names></name></person-group><article-title>Maraba virus as a potent oncolytic vaccine vector</article-title><source>Mol Ther</source><year>2014</year><volume>22</volume><fpage>420</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">24322333</pub-id></element-citation></ref><ref id="R251"><label>251</label><element-citation publication-type="journal"><person-group><name><surname>Bridle</surname><given-names>BW</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Lemay</surname><given-names>CG</given-names></name><name><surname>Diallo</surname><given-names>JS</given-names></name><name><surname>Pol</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Capretta</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Bramson</surname><given-names>JL</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name><name><surname>Lichty</surname><given-names>BD</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name></person-group><article-title>HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy</article-title><source>Mol Ther</source><year>2013</year><volume>21</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">23295947</pub-id></element-citation></ref><ref id="R252"><label>252</label><element-citation publication-type="journal"><person-group><name><surname>Bridle</surname><given-names>BW</given-names></name><name><surname>Clouthier</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Pol</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Lichty</surname><given-names>BD</given-names></name><name><surname>Bramson</surname><given-names>JL</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name></person-group><article-title>Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 T-cell responses to anticancer vaccines</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26013</fpage><pub-id pub-id-type="pmid">24083086</pub-id></element-citation></ref><ref id="R253"><label>253</label><element-citation publication-type="journal"><person-group><name><surname>Bolhassani</surname><given-names>A</given-names></name><name><surname>Zahedifard</surname><given-names>F</given-names></name></person-group><article-title>Therapeutic live vaccines as a potential anticancer strategy</article-title><source>Int J Cancer</source><year>2012</year><volume>131</volume><fpage>1733</fpage><lpage>1743</lpage><pub-id pub-id-type="pmid">22610886</pub-id></element-citation></ref><ref id="R254"><label>254</label><element-citation publication-type="journal"><person-group><name><surname>Gardlik</surname><given-names>R</given-names></name><name><surname>Fruehauf</surname><given-names>JH</given-names></name></person-group><article-title>Bacterial vectors and delivery systems in cancer therapy</article-title><source>IDrugs</source><year>2010</year><volume>13</volume><fpage>701</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">20878592</pub-id></element-citation></ref><ref id="R255"><label>255</label><element-citation publication-type="journal"><person-group><name><surname>Moreno</surname><given-names>M</given-names></name><name><surname>Kramer</surname><given-names>MG</given-names></name><name><surname>Yim</surname><given-names>L</given-names></name><name><surname>Chabalgoity</surname><given-names>JA</given-names></name></person-group><article-title>Salmonella as live trojan horse for vaccine development and cancer gene therapy</article-title><source>Curr Gene Ther</source><year>2010</year><volume>10</volume><fpage>56</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">20156188</pub-id></element-citation></ref><ref id="R256"><label>256</label><element-citation publication-type="journal"><person-group><name><surname>Toussaint</surname><given-names>B</given-names></name><name><surname>Chauchet</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Polack</surname><given-names>B</given-names></name><name><surname>Le Gouellec</surname><given-names>A</given-names></name></person-group><article-title>Live-attenuated bacteria as a cancer vaccine vector</article-title><source>Expert Rev Vaccines</source><year>2013</year><volume>12</volume><fpage>1139</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">24124876</pub-id></element-citation></ref><ref id="R257"><label>257</label><element-citation publication-type="journal"><person-group><name><surname>Wood</surname><given-names>C</given-names></name><name><surname>Srivastava</surname><given-names>P</given-names></name><name><surname>Bukowski</surname><given-names>R</given-names></name><name><surname>Lacombe</surname><given-names>L</given-names></name><name><surname>Gorelov</surname><given-names>AI</given-names></name><name><surname>Gorelov</surname><given-names>S</given-names></name><name><surname>Mulders</surname><given-names>P</given-names></name><name><surname>Zielinski</surname><given-names>H</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name><name><surname>Teofilovici</surname><given-names>F</given-names></name><name><surname>Isakov</surname><given-names>L</given-names></name><name><surname>Flanigan</surname><given-names>R</given-names></name><name><surname>Figlin</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">18602688</pub-id></element-citation></ref><ref id="R258"><label>258</label><element-citation publication-type="journal"><person-group><name><surname>Kenter</surname><given-names>GG</given-names></name><name><surname>Welters</surname><given-names>MJ</given-names></name><name><surname>Valentijn</surname><given-names>AR</given-names></name><name><surname>Lowik</surname><given-names>MJ</given-names></name><name><surname>Berends-van der Meer</surname><given-names>DM</given-names></name><name><surname>Vloon</surname><given-names>AP</given-names></name><name><surname>Essahsah</surname><given-names>F</given-names></name><name><surname>Fathers</surname><given-names>LM</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>Drijfhout</surname><given-names>JW</given-names></name><name><surname>Wafelman</surname><given-names>AR</given-names></name><name><surname>Oostendorp</surname><given-names>J</given-names></name><name><surname>Fleuren</surname><given-names>GJ</given-names></name><etal></etal></person-group><article-title>Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1838</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">19890126</pub-id></element-citation></ref><ref id="R259"><label>259</label><element-citation publication-type="journal"><person-group><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Weinschenk</surname><given-names>T</given-names></name><name><surname>Stenzl</surname><given-names>A</given-names></name><name><surname>Zdrojowy</surname><given-names>R</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Staehler</surname><given-names>M</given-names></name><name><surname>Brugger</surname><given-names>W</given-names></name><name><surname>Dietrich</surname><given-names>PY</given-names></name><name><surname>Mendrzyk</surname><given-names>R</given-names></name><name><surname>Hilf</surname><given-names>N</given-names></name><name><surname>Schoor</surname><given-names>O</given-names></name><name><surname>Fritsche</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><fpage>1254</fpage><lpage>1261</lpage><pub-id pub-id-type="pmid">22842478</pub-id></element-citation></ref><ref id="R260"><label>260</label><element-citation publication-type="journal"><person-group><name><surname>Davis</surname><given-names>BS</given-names></name><name><surname>Chang</surname><given-names>GJ</given-names></name><name><surname>Cropp</surname><given-names>B</given-names></name><name><surname>Roehrig</surname><given-names>JT</given-names></name><name><surname>Martin</surname><given-names>DA</given-names></name><name><surname>Mitchell</surname><given-names>CJ</given-names></name><name><surname>Bowen</surname><given-names>R</given-names></name><name><surname>Bunning</surname><given-names>ML</given-names></name></person-group><article-title>West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses <italic>in vitro</italic> a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>4040</fpage><lpage>4047</lpage><pub-id pub-id-type="pmid">11287553</pub-id></element-citation></ref><ref id="R261"><label>261</label><element-citation publication-type="journal"><person-group><name><surname>Anderson</surname><given-names>ED</given-names></name><name><surname>Mourich</surname><given-names>DV</given-names></name><name><surname>Leong</surname><given-names>JA</given-names></name></person-group><article-title>Gene expression in rainbow trout (Oncorhynchus mykiss) following intramuscular injection of DNA</article-title><source>Mol Mar Biol Biotechnol</source><year>1996</year><volume>5</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">8680523</pub-id></element-citation></ref><ref id="R262"><label>262</label><element-citation publication-type="journal"><person-group><name><surname>Anderson</surname><given-names>ED</given-names></name><name><surname>Mourich</surname><given-names>DV</given-names></name><name><surname>Fahrenkrug</surname><given-names>SC</given-names></name><name><surname>LaPatra</surname><given-names>S</given-names></name><name><surname>Shepherd</surname><given-names>J</given-names></name><name><surname>Leong</surname><given-names>JA</given-names></name></person-group><article-title>Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus</article-title><source>Mol Mar Biol Biotechnol</source><year>1996</year><volume>5</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">8680524</pub-id></element-citation></ref><ref id="R263"><label>263</label><element-citation publication-type="journal"><person-group><name><surname>Bergman</surname><given-names>PJ</given-names></name><name><surname>McKnight</surname><given-names>J</given-names></name><name><surname>Novosad</surname><given-names>A</given-names></name><name><surname>Charney</surname><given-names>S</given-names></name><name><surname>Farrelly</surname><given-names>J</given-names></name><name><surname>Craft</surname><given-names>D</given-names></name><name><surname>Wulderk</surname><given-names>M</given-names></name><name><surname>Jeffers</surname><given-names>Y</given-names></name><name><surname>Sadelain</surname><given-names>M</given-names></name><name><surname>Hohenhaus</surname><given-names>AE</given-names></name><name><surname>Segal</surname><given-names>N</given-names></name><name><surname>Gregor</surname><given-names>P</given-names></name><name><surname>Engelhorn</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>1284</fpage><lpage>1290</lpage><pub-id pub-id-type="pmid">12684396</pub-id></element-citation></ref><ref id="R264"><label>264</label><element-citation publication-type="journal"><person-group><name><surname>Tato</surname><given-names>CM</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name></person-group><article-title>SnapShot: Cytokines I</article-title><source>Cell</source><year>2008</year><volume>132:324</volume><fpage>324</fpage><lpage>e321</lpage><pub-id pub-id-type="pmid">18243106</pub-id></element-citation></ref><ref id="R265"><label>265</label><element-citation publication-type="journal"><person-group><name><surname>Tato</surname><given-names>CM</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name></person-group><article-title>SnapShot: Cytokines II</article-title><source>Cell</source><year>2008</year><volume>132</volume><fpage>500</fpage><pub-id pub-id-type="pmid">18267079</pub-id></element-citation></ref><ref id="R266"><label>266</label><element-citation publication-type="journal"><person-group><name><surname>Tato</surname><given-names>CM</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name></person-group><article-title>SnapShot: Cytokines III</article-title><source>Cell</source><year>2008</year><volume>132</volume><fpage>900</fpage><pub-id pub-id-type="pmid">18329374</pub-id></element-citation></ref><ref id="R267"><label>267</label><element-citation publication-type="journal"><person-group><name><surname>Tato</surname><given-names>CM</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name></person-group><article-title>SnapShot: Cytokines IV</article-title><source>Cell</source><year>2008</year><volume>132:1062</volume><fpage>e1061</fpage><lpage>1062</lpage></element-citation></ref><ref id="R268"><label>268</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial Watch: Immunostimulatory cytokines</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24850</fpage><pub-id pub-id-type="pmid">24073369</pub-id></element-citation></ref><ref id="R269"><label>269</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Trial Watch: Immunostimulatory cytokines</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>493</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">22754768</pub-id></element-citation></ref><ref id="R270"><label>270</label><element-citation publication-type="journal"><person-group><name><surname>Papatriantafyllou</surname><given-names>M</given-names></name></person-group><article-title>Cytokines: true to their family name</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><fpage>544</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">23827957</pub-id></element-citation></ref><ref id="R271"><label>271</label><element-citation publication-type="journal"><person-group><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Balachandran</surname><given-names>S</given-names></name></person-group><article-title>Development of interferon gamma-based immunocytokines targeting renal cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24964</fpage><pub-id pub-id-type="pmid">24073376</pub-id></element-citation></ref><ref id="R272"><label>272</label><element-citation publication-type="journal"><person-group><name><surname>Ahmadzadeh</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>2409</fpage><lpage>2414</lpage><pub-id pub-id-type="pmid">16304057</pub-id></element-citation></ref><ref id="R273"><label>273</label><element-citation publication-type="journal"><person-group><name><surname>Cesana</surname><given-names>GC</given-names></name><name><surname>DeRaffele</surname><given-names>G</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Moroziewicz</surname><given-names>D</given-names></name><name><surname>Mitcham</surname><given-names>J</given-names></name><name><surname>Stoutenburg</surname><given-names>J</given-names></name><name><surname>Cheung</surname><given-names>K</given-names></name><name><surname>Hesdorffer</surname><given-names>C</given-names></name><name><surname>Kim-Schulze</surname><given-names>S</given-names></name><name><surname>Kaufman</surname><given-names>HL</given-names></name></person-group><article-title>Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>1169</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">16505437</pub-id></element-citation></ref><ref id="R274"><label>274</label><element-citation publication-type="journal"><person-group><name><surname>Sim</surname><given-names>GC</given-names></name><name><surname>Martin-Orozco</surname><given-names>N</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Washington</surname><given-names>E</given-names></name><name><surname>Sanders</surname><given-names>D</given-names></name><name><surname>Lacey</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Vence</surname><given-names>L</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Radvanyi</surname><given-names>L</given-names></name></person-group><article-title>IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">24292706</pub-id></element-citation></ref><ref id="R275"><label>275</label><element-citation publication-type="journal"><person-group><name><surname>Camisaschi</surname><given-names>C</given-names></name><name><surname>Filipazzi</surname><given-names>P</given-names></name><name><surname>Tazzari</surname><given-names>M</given-names></name><name><surname>Casati</surname><given-names>C</given-names></name><name><surname>Beretta</surname><given-names>V</given-names></name><name><surname>Pilla</surname><given-names>L</given-names></name><name><surname>Patuzzo</surname><given-names>R</given-names></name><name><surname>Maurichi</surname><given-names>A</given-names></name><name><surname>Cova</surname><given-names>A</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Chiarion-Sileni</surname><given-names>V</given-names></name><name><surname>Tragni</surname><given-names>G</given-names></name><name><surname>Santinami</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response</article-title><source>Cancer Immunol Immunother</source><year>2013</year><volume>62</volume><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">23589107</pub-id></element-citation></ref><ref id="R276"><label>276</label><element-citation publication-type="journal"><person-group><name><surname>Tomov</surname><given-names>B</given-names></name><name><surname>Popov</surname><given-names>D</given-names></name><name><surname>Tomova</surname><given-names>R</given-names></name><name><surname>Vladov</surname><given-names>N</given-names></name><name><surname>Den Otter</surname><given-names>W</given-names></name><name><surname>Krastev</surname><given-names>Z</given-names></name></person-group><article-title>Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2, BCG and melatonin</article-title><source>Anticancer Res</source><year>2013</year><volume>33</volume><fpage>4531</fpage><lpage>4535</lpage><pub-id pub-id-type="pmid">24123026</pub-id></element-citation></ref><ref id="R277"><label>277</label><element-citation publication-type="journal"><person-group><name><surname>Robertson</surname><given-names>MJ</given-names></name><name><surname>Kline</surname><given-names>J</given-names></name><name><surname>Struemper</surname><given-names>H</given-names></name><name><surname>Koch</surname><given-names>KM</given-names></name><name><surname>Bauman</surname><given-names>JW</given-names></name><name><surname>Gardner</surname><given-names>OS</given-names></name><name><surname>Murray</surname><given-names>SC</given-names></name><name><surname>Germaschewski</surname><given-names>F</given-names></name><name><surname>Weisenbach</surname><given-names>J</given-names></name><name><surname>Jonak</surname><given-names>Z</given-names></name><name><surname>Toso</surname><given-names>JF</given-names></name></person-group><article-title>A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma</article-title><source>J Immunother</source><year>2013</year><volume>36</volume><fpage>331</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">23799412</pub-id></element-citation></ref><ref id="R278"><label>278</label><element-citation publication-type="journal"><person-group><name><surname>Gorin</surname><given-names>NC</given-names></name><name><surname>Isnard</surname><given-names>F</given-names></name><name><surname>Garderet</surname><given-names>L</given-names></name><name><surname>Ikhlef</surname><given-names>S</given-names></name><name><surname>Corm</surname><given-names>S</given-names></name><name><surname>Quesnel</surname><given-names>B</given-names></name><name><surname>Legrand</surname><given-names>O</given-names></name><name><surname>Cachanado</surname><given-names>M</given-names></name><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>Laporte</surname><given-names>JP</given-names></name></person-group><article-title>Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study</article-title><source>Eur J Haematol</source><year>2013</year><volume>91</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">23738686</pub-id></element-citation></ref><ref id="R279"><label>279</label><element-citation publication-type="journal"><person-group><name><surname>Cheung</surname><given-names>IY</given-names></name><name><surname>Hsu</surname><given-names>K</given-names></name><name><surname>Cheung</surname><given-names>NK</given-names></name></person-group><article-title>Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>426</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">22203761</pub-id></element-citation></ref><ref id="R280"><label>280</label><element-citation publication-type="journal"><person-group><name><surname>Cheung</surname><given-names>NK</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Tassev</surname><given-names>DV</given-names></name><name><surname>Cheung</surname><given-names>IY</given-names></name></person-group><article-title>Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting <italic>in vivo</italic></article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">22754766</pub-id></element-citation></ref><ref id="R281"><label>281</label><element-citation publication-type="journal"><person-group><name><surname>Coker</surname><given-names>SA</given-names></name><name><surname>Dandamudi</surname><given-names>UB</given-names></name><name><surname>Beelen</surname><given-names>AP</given-names></name><name><surname>Crosby</surname><given-names>NA</given-names></name><name><surname>Fisher</surname><given-names>JL</given-names></name><name><surname>Obrocea</surname><given-names>M</given-names></name><name><surname>Ernstoff</surname><given-names>MS</given-names></name><name><surname>Lewis</surname><given-names>LD</given-names></name></person-group><article-title>A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours</article-title><source>J Chemother</source><year>2013</year><volume>25</volume><fpage>362</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">24093213</pub-id></element-citation></ref><ref id="R282"><label>282</label><element-citation publication-type="journal"><person-group><name><surname>West</surname><given-names>EE</given-names></name><name><surname>Jin</surname><given-names>HT</given-names></name><name><surname>Rasheed</surname><given-names>AU</given-names></name><name><surname>Penaloza-Macmaster</surname><given-names>P</given-names></name><name><surname>Ha</surname><given-names>SJ</given-names></name><name><surname>Tan</surname><given-names>WG</given-names></name><name><surname>Youngblood</surname><given-names>B</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group><article-title>PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>2604</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">23676462</pub-id></element-citation></ref><ref id="R283"><label>283</label><element-citation publication-type="journal"><person-group><name><surname>Omori</surname><given-names>R</given-names></name><name><surname>Eguchi</surname><given-names>J</given-names></name><name><surname>Hiroishi</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>S</given-names></name><name><surname>Hiraide</surname><given-names>A</given-names></name><name><surname>Sakaki</surname><given-names>M</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name><name><surname>Kajiwara</surname><given-names>A</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Kogo</surname><given-names>M</given-names></name><name><surname>Imawari</surname><given-names>M</given-names></name></person-group><article-title>Effects of interferon-alpha-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors</article-title><source>Cancer Gene Ther</source><year>2012</year><volume>19</volume><fpage>637</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">22790963</pub-id></element-citation></ref><ref id="R284"><label>284</label><element-citation publication-type="journal"><person-group><name><surname>Prieto</surname><given-names>PA</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>White</surname><given-names>DE</given-names></name><name><surname>Levy</surname><given-names>CL</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Phan</surname><given-names>GQ</given-names></name></person-group><article-title>CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>2039</fpage><lpage>2047</lpage><pub-id pub-id-type="pmid">22271879</pub-id></element-citation></ref><ref id="R285"><label>285</label><element-citation publication-type="journal"><person-group><name><surname>Arellano</surname><given-names>M</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name></person-group><article-title>Clinical uses of GM-CSF, a critical appraisal and update</article-title><source>Biologics</source><year>2008</year><volume>2</volume><fpage>13</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">19707424</pub-id></element-citation></ref><ref id="R286"><label>286</label><element-citation publication-type="journal"><person-group><name><surname>Demirer</surname><given-names>T</given-names></name><name><surname>Ayli</surname><given-names>M</given-names></name><name><surname>Ozcan</surname><given-names>M</given-names></name><name><surname>Gunel</surname><given-names>N</given-names></name><name><surname>Haznedar</surname><given-names>R</given-names></name><name><surname>Dagli</surname><given-names>M</given-names></name><name><surname>Fen</surname><given-names>T</given-names></name><name><surname>Genc</surname><given-names>Y</given-names></name><name><surname>Dincer</surname><given-names>S</given-names></name><name><surname>Arslan</surname><given-names>O</given-names></name><name><surname>Gurman</surname><given-names>G</given-names></name><name><surname>Demirer</surname><given-names>S</given-names></name><name><surname>Ozet</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF</article-title><source>Br J Haematol</source><year>2002</year><volume>116</volume><fpage>468</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">11841454</pub-id></element-citation></ref><ref id="R287"><label>287</label><element-citation publication-type="journal"><person-group><name><surname>Chan</surname><given-names>KK</given-names></name><name><surname>Siu</surname><given-names>E</given-names></name><name><surname>Krahn</surname><given-names>MD</given-names></name><name><surname>Imrie</surname><given-names>K</given-names></name><name><surname>Alibhai</surname><given-names>SM</given-names></name></person-group><article-title>Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>1064</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">22393098</pub-id></element-citation></ref><ref id="R288"><label>288</label><element-citation publication-type="journal"><person-group><name><surname>Pabst</surname><given-names>T</given-names></name><name><surname>Vellenga</surname><given-names>E</given-names></name><name><surname>van Putten</surname><given-names>W</given-names></name><name><surname>Schouten</surname><given-names>HC</given-names></name><name><surname>Graux</surname><given-names>C</given-names></name><name><surname>Vekemans</surname><given-names>MC</given-names></name><name><surname>Biemond</surname><given-names>B</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Passweg</surname><given-names>J</given-names></name><name><surname>Verdonck</surname><given-names>L</given-names></name><name><surname>Legdeur</surname><given-names>MC</given-names></name><name><surname>Theobald</surname><given-names>M</given-names></name><name><surname>Jacky</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>5367</fpage><lpage>5373</lpage><pub-id pub-id-type="pmid">22422824</pub-id></element-citation></ref><ref id="R289"><label>289</label><element-citation publication-type="journal"><person-group><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Rao</surname><given-names>UN</given-names></name><name><surname>Butterfield</surname><given-names>LH</given-names></name><name><surname>Tarhini</surname><given-names>AA</given-names></name><name><surname>Leming</surname><given-names>P</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name></person-group><article-title>Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial</article-title><source>JAMA</source><year>2014</year><volume>312</volume><fpage>1744</fpage><lpage>1753</lpage><pub-id pub-id-type="pmid">25369488</pub-id></element-citation></ref><ref id="R290"><label>290</label><element-citation publication-type="journal"><person-group><name><surname>Deroose</surname><given-names>JP</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>van Geel</surname><given-names>AN</given-names></name><name><surname>de Wilt</surname><given-names>JH</given-names></name><name><surname>Burger</surname><given-names>JW</given-names></name><name><surname>Verhoef</surname><given-names>C</given-names></name></person-group><article-title>20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters</article-title><source>Ann Surg Oncol</source><year>2012</year><volume>19</volume><fpage>627</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">21879272</pub-id></element-citation></ref><ref id="R291"><label>291</label><element-citation publication-type="journal"><person-group><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Schraffordt Koops</surname><given-names>H</given-names></name><name><surname>Lienard</surname><given-names>D</given-names></name><name><surname>Kroon</surname><given-names>BB</given-names></name><name><surname>van Geel</surname><given-names>AN</given-names></name><name><surname>Hoekstra</surname><given-names>HJ</given-names></name><name><surname>Lejeune</surname><given-names>FJ</given-names></name></person-group><article-title>Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>2653</fpage><lpage>2665</lpage><pub-id pub-id-type="pmid">8874324</pub-id></element-citation></ref><ref id="R292"><label>292</label><element-citation publication-type="journal"><person-group><name><surname>Deroose</surname><given-names>JP</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>van Geel</surname><given-names>AN</given-names></name><name><surname>Burger</surname><given-names>JW</given-names></name><name><surname>den Bakker</surname><given-names>MA</given-names></name><name><surname>de Wilt</surname><given-names>JH</given-names></name><name><surname>Verhoef</surname><given-names>C</given-names></name></person-group><article-title>Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>4036</fpage><lpage>4044</lpage><pub-id pub-id-type="pmid">21931039</pub-id></element-citation></ref><ref id="R293"><label>293</label><element-citation publication-type="journal"><person-group><name><surname>van Horssen</surname><given-names>R</given-names></name><name><surname>Ten Hagen</surname><given-names>TL</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name></person-group><article-title>TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility</article-title><source>Oncologist</source><year>2006</year><volume>11</volume><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">16614236</pub-id></element-citation></ref><ref id="R294"><label>294</label><element-citation publication-type="journal"><person-group><name><surname>Melero</surname><given-names>I</given-names></name><name><surname>Grimaldi</surname><given-names>AM</given-names></name><name><surname>Perez-Gracia</surname><given-names>JL</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name></person-group><article-title>Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>997</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">23460531</pub-id></element-citation></ref><ref id="R295"><label>295</label><element-citation publication-type="journal"><person-group><name><surname>Chawla</surname><given-names>A</given-names></name><name><surname>Philips</surname><given-names>AV</given-names></name><name><surname>Alatrash</surname><given-names>G</given-names></name><name><surname>Mittendorf</surname><given-names>E</given-names></name></person-group><article-title>Immune checkpoints: A therapeutic target in triple negative breast cancer</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e28325</fpage><pub-id pub-id-type="pmid">24843833</pub-id></element-citation></ref><ref id="R296"><label>296</label><element-citation publication-type="journal"><person-group><name><surname>Nowak</surname><given-names>AK</given-names></name></person-group><article-title>Immunological checkpoint inhibitors enter adolescence</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>1035</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">24035406</pub-id></element-citation></ref><ref id="R297"><label>297</label><element-citation publication-type="journal"><person-group><name><surname>Walker</surname><given-names>LS</given-names></name><name><surname>Sansom</surname><given-names>DM</given-names></name></person-group><article-title>The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses</article-title><source>Nat Rev Immunol</source><year>2011</year><volume>11</volume><fpage>852</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">22116087</pub-id></element-citation></ref><ref id="R298"><label>298</label><element-citation publication-type="journal"><person-group><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><fpage>336</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">15122199</pub-id></element-citation></ref><ref id="R299"><label>299</label><element-citation publication-type="journal"><person-group><name><surname>Waitz</surname><given-names>R</given-names></name><name><surname>Fasso</surname><given-names>M</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>544</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">22754781</pub-id></element-citation></ref><ref id="R300"><label>300</label><element-citation publication-type="journal"><person-group><name><surname>Munir</surname><given-names>S</given-names></name><name><surname>Andersen</surname><given-names>GH</given-names></name><name><surname>Svane</surname><given-names>IM</given-names></name><name><surname>Andersen</surname><given-names>MH</given-names></name></person-group><article-title>The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23991</fpage><pub-id pub-id-type="pmid">23734334</pub-id></element-citation></ref><ref id="R301"><label>301</label><element-citation publication-type="journal"><person-group><name><surname>Fife</surname><given-names>BT</given-names></name><name><surname>Pauken</surname><given-names>KE</given-names></name><name><surname>Eagar</surname><given-names>TN</given-names></name><name><surname>Obu</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><article-title>Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal</article-title><source>Nat Immunol</source><year>2009</year><volume>10</volume><fpage>1185</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">19783989</pub-id></element-citation></ref><ref id="R302"><label>302</label><element-citation publication-type="journal"><person-group><name><surname>Raulet</surname><given-names>DH</given-names></name><name><surname>Guerra</surname><given-names>N</given-names></name></person-group><article-title>Oncogenic stress sensed by the immune system: role of natural killer cell receptors</article-title><source>Nat Rev Immunol</source><year>2009</year><volume>9</volume><fpage>568</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">19629084</pub-id></element-citation></ref><ref id="R303"><label>303</label><element-citation publication-type="journal"><person-group><name><surname>Joncker</surname><given-names>NT</given-names></name><name><surname>Raulet</surname><given-names>DH</given-names></name></person-group><article-title>Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells</article-title><source>Immunol Rev</source><year>2008</year><volume>224</volume><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">18759922</pub-id></element-citation></ref><ref id="R304"><label>304</label><element-citation publication-type="journal"><person-group><name><surname>Long</surname><given-names>EO</given-names></name></person-group><article-title>Negative signaling by inhibitory receptors: the NK cell paradigm</article-title><source>Immunol Rev</source><year>2008</year><volume>224</volume><fpage>70</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">18759921</pub-id></element-citation></ref><ref id="R305"><label>305</label><element-citation publication-type="journal"><person-group><name><surname>Schalper</surname><given-names>KA</given-names></name></person-group><article-title>PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e29288</fpage><pub-id pub-id-type="pmid">25083339</pub-id></element-citation></ref><ref id="R306"><label>306</label><element-citation publication-type="journal"><person-group><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><name><surname>Krzysiek</surname><given-names>R</given-names></name><name><surname>Knutson</surname><given-names>KL</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Zimmermann</surname><given-names>MC</given-names></name><name><surname>David</surname><given-names>O</given-names></name><name><surname>Burow</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>562</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">12704383</pub-id></element-citation></ref><ref id="R307"><label>307</label><element-citation publication-type="journal"><person-group><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Inhibitory B7-family molecules in the tumour microenvironment</article-title><source>Nat Rev Immunol</source><year>2008</year><volume>8</volume><fpage>467</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">18500231</pub-id></element-citation></ref><ref id="R308"><label>308</label><element-citation publication-type="journal"><person-group><name><surname>Melero</surname><given-names>I</given-names></name><name><surname>Hirschhorn-Cymerman</surname><given-names>D</given-names></name><name><surname>Morales-Kastresana</surname><given-names>A</given-names></name><name><surname>Sanmamed</surname><given-names>MF</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name></person-group><article-title>Agonist antibodies to TNFR molecules that costimulate T and NK cells</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>1044</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">23460535</pub-id></element-citation></ref><ref id="R309"><label>309</label><element-citation publication-type="journal"><person-group><name><surname>Adler</surname><given-names>AJ</given-names></name><name><surname>Vella</surname><given-names>AT</given-names></name></person-group><article-title>Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22837</fpage><pub-id pub-id-type="pmid">23482891</pub-id></element-citation></ref><ref id="R310"><label>310</label><element-citation publication-type="journal"><person-group><name><surname>Withers</surname><given-names>DR</given-names></name><name><surname>Gaspal</surname><given-names>FM</given-names></name><name><surname>Bekiaris</surname><given-names>V</given-names></name><name><surname>McConnell</surname><given-names>FM</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Lane</surname><given-names>PJ</given-names></name></person-group><article-title>OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function</article-title><source>Immunol Rev</source><year>2011</year><volume>244</volume><fpage>134</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">22017436</pub-id></element-citation></ref><ref id="R311"><label>311</label><element-citation publication-type="journal"><person-group><name><surname>Croft</surname><given-names>M</given-names></name></person-group><article-title>The role of TNF superfamily members in T-cell function and diseases</article-title><source>Nat Rev Immunol</source><year>2009</year><volume>9</volume><fpage>271</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">19319144</pub-id></element-citation></ref><ref id="R312"><label>312</label><element-citation publication-type="journal"><person-group><name><surname>Sugamura</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Weinberg</surname><given-names>AD</given-names></name></person-group><article-title>Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><fpage>420</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">15173831</pub-id></element-citation></ref><ref id="R313"><label>313</label><element-citation publication-type="journal"><person-group><name><surname>Hombach</surname><given-names>AA</given-names></name><name><surname>Heiders</surname><given-names>J</given-names></name><name><surname>Foppe</surname><given-names>M</given-names></name><name><surname>Chmielewski</surname><given-names>M</given-names></name><name><surname>Abken</surname><given-names>H</given-names></name></person-group><article-title>OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>458</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">22754764</pub-id></element-citation></ref><ref id="R314"><label>314</label><element-citation publication-type="journal"><person-group><name><surname>Melero</surname><given-names>I</given-names></name><name><surname>Shuford</surname><given-names>WW</given-names></name><name><surname>Newby</surname><given-names>SA</given-names></name><name><surname>Aruffo</surname><given-names>A</given-names></name><name><surname>Ledbetter</surname><given-names>JA</given-names></name><name><surname>Hellstrom</surname><given-names>KE</given-names></name><name><surname>Mittler</surname><given-names>RS</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors</article-title><source>Nat Med</source><year>1997</year><volume>3</volume><fpage>682</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">9176498</pub-id></element-citation></ref><ref id="R315"><label>315</label><element-citation publication-type="journal"><person-group><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>DG</given-names></name><name><surname>Powell Jr</surname><given-names>DJ</given-names></name></person-group><article-title>Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e27184</fpage><pub-id pub-id-type="pmid">24501691</pub-id></element-citation></ref><ref id="R316"><label>316</label><element-citation publication-type="journal"><person-group><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Stephens</surname><given-names>GL</given-names></name></person-group><article-title>The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?</article-title><source>Nat Rev Immunol</source><year>2006</year><volume>6</volume><fpage>613</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">16868552</pub-id></element-citation></ref><ref id="R317"><label>317</label><element-citation publication-type="journal"><person-group><name><surname>Shimizu</surname><given-names>J</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Ishida</surname><given-names>Y</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">11812990</pub-id></element-citation></ref><ref id="R318"><label>318</label><element-citation publication-type="journal"><person-group><name><surname>Chacon</surname><given-names>JA</given-names></name><name><surname>Pilon-Thomas</surname><given-names>S</given-names></name><name><surname>Sarnaik</surname><given-names>AA</given-names></name><name><surname>Radvanyi</surname><given-names>LG</given-names></name></person-group><article-title>Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25581</fpage><pub-id pub-id-type="pmid">24319633</pub-id></element-citation></ref><ref id="R319"><label>319</label><element-citation publication-type="journal"><person-group><name><surname>Schnurr</surname><given-names>M</given-names></name><name><surname>Duewell</surname><given-names>P</given-names></name></person-group><article-title>Breaking tumor-induced immunosuppression with 5′-triphosphate siRNA silencing TGFbeta and activating RIG-I</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24170</fpage><pub-id pub-id-type="pmid">23762798</pub-id></element-citation></ref><ref id="R320"><label>320</label><element-citation publication-type="journal"><person-group><name><surname>Pickup</surname><given-names>M</given-names></name><name><surname>Novitskiy</surname><given-names>S</given-names></name><name><surname>Moses</surname><given-names>HL</given-names></name></person-group><article-title>The roles of TGFbeta in the tumour microenvironment</article-title><source>Nat Rev Cancer</source><year>2013</year><volume>13</volume><fpage>788</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">24132110</pub-id></element-citation></ref><ref id="R321"><label>321</label><element-citation publication-type="journal"><person-group><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Lizee</surname><given-names>G</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name></person-group><article-title>Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22691</fpage><pub-id pub-id-type="pmid">23524510</pub-id></element-citation></ref><ref id="R322"><label>322</label><element-citation publication-type="journal"><person-group><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Luft</surname><given-names>A</given-names></name><name><surname>Serwatowski</surname><given-names>P</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Chacko</surname><given-names>R</given-names></name><name><surname>Sebastian</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Cuillerot</surname><given-names>JM</given-names></name><name><surname>Lynch</surname><given-names>TJ</given-names></name></person-group><article-title>Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">22858559</pub-id></element-citation></ref><ref id="R323"><label>323</label><element-citation publication-type="journal"><person-group><name><surname>Mavilio</surname><given-names>D</given-names></name><name><surname>Lugli</surname><given-names>E</given-names></name></person-group><article-title>Inhibiting the inhibitors: Checkpoints blockade in solid tumors</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26535</fpage><pub-id pub-id-type="pmid">24244910</pub-id></element-citation></ref><ref id="R324"><label>324</label><element-citation publication-type="journal"><person-group><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Kluger</surname><given-names>H</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Postow</surname><given-names>MA</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Lesokhin</surname><given-names>AM</given-names></name><name><surname>Segal</surname><given-names>NH</given-names></name><name><surname>Ariyan</surname><given-names>CE</given-names></name><name><surname>Gordon</surname><given-names>RA</given-names></name><name><surname>Reed</surname><given-names>K</given-names></name><name><surname>Burke</surname><given-names>MM</given-names></name><name><surname>Caldwell</surname><given-names>A</given-names></name><name><surname>Kronenberg</surname><given-names>SA</given-names></name><etal></etal></person-group><article-title>Nivolumab plus ipilimumab in advanced melanoma</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>122</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">23724867</pub-id></element-citation></ref><ref id="R325"><label>325</label><element-citation publication-type="journal"><person-group><name><surname>Lipson</surname><given-names>EJ</given-names></name><name><surname>Sharfman</surname><given-names>WH</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Wollner</surname><given-names>I</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Pons</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name></person-group><article-title>Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>462</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">23169436</pub-id></element-citation></ref><ref id="R326"><label>326</label><element-citation publication-type="journal"><person-group><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Kefford</surname><given-names>R</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name><name><surname>Joseph</surname><given-names>RW</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Dronca</surname><given-names>R</given-names></name><name><surname>Gangadhar</surname><given-names>TC</given-names></name><name><surname>Patnaik</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>134</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">23724846</pub-id></element-citation></ref><ref id="R327"><label>327</label><element-citation publication-type="journal"><person-group><name><surname>Cooper</surname><given-names>ZA</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Ahmed</surname><given-names>Z</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name></person-group><article-title>Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24320</fpage><pub-id pub-id-type="pmid">23762807</pub-id></element-citation></ref><ref id="R328"><label>328</label><element-citation publication-type="journal"><person-group><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>O'Day</surname><given-names>SJ</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Weber</surname><given-names>RW</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Haanen</surname><given-names>JB</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Hassel</surname><given-names>JC</given-names></name><name><surname>Akerley</surname><given-names>W</given-names></name><name><surname>van den Eertwegh</surname><given-names>AJ</given-names></name><name><surname>Lutzky</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">20525992</pub-id></element-citation></ref><ref id="R329"><label>329</label><element-citation publication-type="journal"><article-title>Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><fpage>584</fpage></element-citation></ref><ref id="R330"><label>330</label><element-citation publication-type="journal"><person-group><name><surname>Erdmann</surname><given-names>MK</given-names></name></person-group><article-title>Immunity unleashed in melanoma</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>108</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">20152761</pub-id></element-citation></ref><ref id="R331"><label>331</label><element-citation publication-type="journal"><person-group><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Neyns</surname><given-names>B</given-names></name><name><surname>Linette</surname><given-names>G</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Lutzky</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Waterfield</surname><given-names>W</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Smylie</surname><given-names>M</given-names></name><name><surname>Guthrie</surname><given-names>T</given-names><suffix>Jr</suffix></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Chesney</surname><given-names>J</given-names></name><name><surname>Chin</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>155</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">20004617</pub-id></element-citation></ref><ref id="R332"><label>332</label><element-citation publication-type="journal"><person-group><name><surname>Sondak</surname><given-names>VK</given-names></name><name><surname>Smalley</surname><given-names>KS</given-names></name><name><surname>Kudchadkar</surname><given-names>R</given-names></name><name><surname>Grippon</surname><given-names>S</given-names></name><name><surname>Kirkpatrick</surname><given-names>P</given-names></name></person-group><article-title>Ipilimumab</article-title><source>Nat Rev Drug Discov</source><year>2011</year><volume>10</volume><fpage>411</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">21629286</pub-id></element-citation></ref><ref id="R333"><label>333</label><element-citation publication-type="journal"><person-group><name><surname>Tumeh</surname><given-names>PC</given-names></name><name><surname>Harview</surname><given-names>CL</given-names></name><name><surname>Yearley</surname><given-names>JH</given-names></name><name><surname>Shintaku</surname><given-names>IP</given-names></name><name><surname>Taylor</surname><given-names>EJ</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Spasic</surname><given-names>M</given-names></name><name><surname>Henry</surname><given-names>G</given-names></name><name><surname>Ciobanu</surname><given-names>V</given-names></name><name><surname>West</surname><given-names>AN</given-names></name><name><surname>Carmona</surname><given-names>M</given-names></name><name><surname>Kivork</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">25428505</pub-id></element-citation></ref><ref id="R334"><label>334</label><element-citation publication-type="journal"><article-title>PD-1 Inhibitor Approved for Melanoma</article-title><source>Cancer Discov</source><year>2014</year><volume>4</volume><fpage>1249</fpage><pub-id pub-id-type="pmid">25367933</pub-id></element-citation></ref><ref id="R335"><label>335</label><element-citation publication-type="journal"><person-group><name><surname>Poole</surname><given-names>RM</given-names></name></person-group><article-title>Pembrolizumab: first global approval</article-title><source>Drugs</source><year>2014</year><volume>74</volume><fpage>1973</fpage><lpage>1981</lpage><pub-id pub-id-type="pmid">25331768</pub-id></element-citation></ref><ref id="R336"><label>336</label><element-citation publication-type="journal"><person-group><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Kefford</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Joshua</surname><given-names>AM</given-names></name><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Gangadhar</surname><given-names>TC</given-names></name><name><surname>Patnaik</surname><given-names>A</given-names></name><name><surname>Dronca</surname><given-names>R</given-names></name><name><surname>Zarour</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial</article-title><source>Lancet</source><year>2014</year><volume>384</volume><fpage>1109</fpage><lpage>1117</lpage><pub-id pub-id-type="pmid">25034862</pub-id></element-citation></ref><ref id="R337"><label>337</label><element-citation publication-type="journal"><person-group><name><surname>Bagcchi</surname><given-names>S</given-names></name></person-group><article-title>Pembrolizumab for treatment of refractory melanoma</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>e419</fpage><pub-id pub-id-type="pmid">25328942</pub-id></element-citation></ref><ref id="R338"><label>338</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name></person-group><article-title>Novel immune checkpoint blocker approved for the treatment of advanced melanoma</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><comment>in press</comment></element-citation></ref><ref id="R339"><label>339</label><element-citation publication-type="journal"><person-group><name><surname>Deeks</surname><given-names>ED</given-names></name></person-group><article-title>Nivolumab: a review of its use in patients with malignant melanoma</article-title><source>Drugs</source><year>2014</year><volume>74</volume><fpage>1233</fpage><lpage>1239</lpage><pub-id pub-id-type="pmid">25022950</pub-id></element-citation></ref><ref id="R340"><label>340</label><element-citation publication-type="journal"><person-group><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Brady</surname><given-names>B</given-names></name><name><surname>Dutriaux</surname><given-names>C</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Mortier</surname><given-names>L</given-names></name><name><surname>Hassel</surname><given-names>JC</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>McNeil</surname><given-names>C</given-names></name><name><surname>Kalinka-Warzocha</surname><given-names>E</given-names></name><name><surname>Savage</surname><given-names>KJ</given-names></name><name><surname>Hernberg</surname><given-names>MM</given-names></name><name><surname>Lebbe</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Nivolumab in previously untreated melanoma without BRAF mutation</article-title><source>N Engl J Med</source><year>2014</year></element-citation></ref><ref id="R341"><label>341</label><element-citation publication-type="journal"><person-group><name><surname>Aranda</surname><given-names>F</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e27297</fpage><pub-id pub-id-type="pmid">24701370</pub-id></element-citation></ref><ref id="R342"><label>342</label><element-citation publication-type="journal"><person-group><name><surname>Ansell</surname><given-names>SM</given-names></name><name><surname>Lesokhin</surname><given-names>AM</given-names></name><name><surname>Borrello</surname><given-names>I</given-names></name><name><surname>Halwani</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>EC</given-names></name><name><surname>Gutierrez</surname><given-names>M</given-names></name><name><surname>Schuster</surname><given-names>SJ</given-names></name><name><surname>Millenson</surname><given-names>MM</given-names></name><name><surname>Cattry</surname><given-names>D</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Chapuy</surname><given-names>B</given-names></name><name><surname>Ligon</surname><given-names>AH</given-names></name><etal></etal></person-group><article-title>PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma</article-title><source>N Engl J Med</source><year>2014</year></element-citation></ref><ref id="R343"><label>343</label><element-citation publication-type="journal"><person-group><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Yip</surname><given-names>YY</given-names></name><name><surname>Hellstrom</surname><given-names>I</given-names></name><name><surname>Hellstrom</surname><given-names>KE</given-names></name></person-group><article-title>Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies</article-title><source>Clin Cancer Res</source><year>2014</year></element-citation></ref><ref id="R344"><label>344</label><element-citation publication-type="journal"><person-group><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Hellstrom</surname><given-names>I</given-names></name><name><surname>Hellstrom</surname><given-names>KE</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name></person-group><article-title>Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e28248</fpage><pub-id pub-id-type="pmid">25050196</pub-id></element-citation></ref><ref id="R345"><label>345</label><element-citation publication-type="journal"><person-group><name><surname>Kohrt</surname><given-names>HE</given-names></name><name><surname>Colevas</surname><given-names>AD</given-names></name><name><surname>Houot</surname><given-names>R</given-names></name><name><surname>Weiskopf</surname><given-names>K</given-names></name><name><surname>Goldstein</surname><given-names>MJ</given-names></name><name><surname>Lund</surname><given-names>P</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Sagiv-Barfi</surname><given-names>I</given-names></name><name><surname>Marabelle</surname><given-names>A</given-names></name><name><surname>Lira</surname><given-names>R</given-names></name><name><surname>Troutner</surname><given-names>E</given-names></name><name><surname>Richards</surname><given-names>L</given-names></name><name><surname>Rajapaska</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Targeting CD137 enhances the efficacy of cetuximab</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><fpage>2668</fpage><lpage>2682</lpage><pub-id pub-id-type="pmid">24837434</pub-id></element-citation></ref><ref id="R346"><label>346</label><element-citation publication-type="journal"><person-group><name><surname>Kohrt</surname><given-names>HE</given-names></name><name><surname>Houot</surname><given-names>R</given-names></name><name><surname>Weiskopf</surname><given-names>K</given-names></name><name><surname>Goldstein</surname><given-names>MJ</given-names></name><name><surname>Scheeren</surname><given-names>F</given-names></name><name><surname>Czerwinski</surname><given-names>D</given-names></name><name><surname>Colevas</surname><given-names>AD</given-names></name><name><surname>Weng</surname><given-names>WK</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><name><surname>Carlson</surname><given-names>RW</given-names></name><name><surname>Stockdale</surname><given-names>FE</given-names></name><name><surname>Mollick</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><fpage>1066</fpage><lpage>1075</lpage><pub-id pub-id-type="pmid">22326955</pub-id></element-citation></ref><ref id="R347"><label>347</label><element-citation publication-type="journal"><person-group><name><surname>Snyder</surname><given-names>A</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Zaretsky</surname><given-names>JM</given-names></name><name><surname>Desrichard</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>LA</given-names></name><name><surname>Postow</surname><given-names>MA</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Ho</surname><given-names>TS</given-names></name><name><surname>Hollmann</surname><given-names>TJ</given-names></name><name><surname>Bruggeman</surname><given-names>C</given-names></name><name><surname>Kannan</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>2189</fpage><lpage>2199</lpage><pub-id pub-id-type="pmid">25409260</pub-id></element-citation></ref><ref id="R348"><label>348</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Aranda</surname><given-names>F</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Kennedy</surname><given-names>EP</given-names></name><name><surname>Platten</surname><given-names>M</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial Watch: IDO inhibitors in cancer therapy</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><comment>in press</comment></element-citation></ref><ref id="R349"><label>349</label><element-citation publication-type="journal"><person-group><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Hayaishi</surname><given-names>O</given-names></name></person-group><article-title>Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide</article-title><source>Proc Natl Acad Sci U S A</source><year>1978</year><volume>75</volume><fpage>3998</fpage><lpage>4000</lpage><pub-id pub-id-type="pmid">279015</pub-id></element-citation></ref><ref id="R350"><label>350</label><element-citation publication-type="journal"><person-group><name><surname>Pfefferkorn</surname><given-names>ER</given-names></name></person-group><article-title>Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan</article-title><source>Proc Natl Acad Sci U S A</source><year>1984</year><volume>81</volume><fpage>908</fpage><lpage>912</lpage><pub-id pub-id-type="pmid">6422465</pub-id></element-citation></ref><ref id="R351"><label>351</label><element-citation publication-type="journal"><person-group><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Attwood</surname><given-names>JT</given-names></name><name><surname>Bondarev</surname><given-names>I</given-names></name><name><surname>Conway</surname><given-names>SJ</given-names></name><name><surname>Marshall</surname><given-names>B</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Mellor</surname><given-names>AL</given-names></name></person-group><article-title>Prevention of allogeneic fetal rejection by tryptophan catabolism</article-title><source>Science</source><year>1998</year><volume>281</volume><fpage>1191</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">9712583</pub-id></element-citation></ref><ref id="R352"><label>352</label><element-citation publication-type="journal"><person-group><name><surname>Uyttenhove</surname><given-names>C</given-names></name><name><surname>Pilotte</surname><given-names>L</given-names></name><name><surname>Theate</surname><given-names>I</given-names></name><name><surname>Stroobant</surname><given-names>V</given-names></name><name><surname>Colau</surname><given-names>D</given-names></name><name><surname>Parmentier</surname><given-names>N</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name><name><surname>Van den Eynde</surname><given-names>BJ</given-names></name></person-group><article-title>Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>1269</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">14502282</pub-id></element-citation></ref><ref id="R353"><label>353</label><element-citation publication-type="journal"><person-group><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Sharma</surname><given-names>MD</given-names></name><name><surname>Baban</surname><given-names>B</given-names></name><name><surname>Harding</surname><given-names>HP</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ron</surname><given-names>D</given-names></name><name><surname>Mellor</surname><given-names>AL</given-names></name></person-group><article-title>GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase</article-title><source>Immunity</source><year>2005</year><volume>22</volume><fpage>633</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">15894280</pub-id></element-citation></ref><ref id="R354"><label>354</label><element-citation publication-type="journal"><person-group><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Sharma</surname><given-names>MD</given-names></name><name><surname>Hou</surname><given-names>D</given-names></name><name><surname>Baban</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>JR</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Messina</surname><given-names>JL</given-names></name><name><surname>Chandler</surname><given-names>P</given-names></name><name><surname>Koni</surname><given-names>PA</given-names></name><name><surname>Mellor</surname><given-names>AL</given-names></name></person-group><article-title>Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>280</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">15254595</pub-id></element-citation></ref><ref id="R355"><label>355</label><element-citation publication-type="journal"><person-group><name><surname>Muller</surname><given-names>AJ</given-names></name><name><surname>Sharma</surname><given-names>MD</given-names></name><name><surname>Chandler</surname><given-names>PR</given-names></name><name><surname>Duhadaway</surname><given-names>JB</given-names></name><name><surname>Everhart</surname><given-names>ME</given-names></name><name><surname>Johnson</surname><given-names>BA</given-names><suffix>3rd</suffix></name><name><surname>Kahler</surname><given-names>DJ</given-names></name><name><surname>Pihkala</surname><given-names>J</given-names></name><name><surname>Soler</surname><given-names>AP</given-names></name><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Prendergast</surname><given-names>GC</given-names></name><name><surname>Mellor</surname><given-names>AL</given-names></name></person-group><article-title>Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>17073</fpage><lpage>17078</lpage><pub-id pub-id-type="pmid">18952840</pub-id></element-citation></ref><ref id="R356"><label>356</label><element-citation publication-type="journal"><person-group><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>MY</given-names></name><name><surname>Parker</surname><given-names>KH</given-names></name><name><surname>Beury</surname><given-names>DW</given-names></name><name><surname>DuHadaway</surname><given-names>JB</given-names></name><name><surname>Flick</surname><given-names>HE</given-names></name><name><surname>Boulden</surname><given-names>J</given-names></name><name><surname>Sutanto-Ward</surname><given-names>E</given-names></name><name><surname>Soler</surname><given-names>AP</given-names></name><name><surname>Laury-Kleintop</surname><given-names>LD</given-names></name><name><surname>Mandik-Nayak</surname><given-names>L</given-names></name><name><surname>Metz</surname><given-names>R</given-names></name><name><surname>Ostrand-Rosenberg</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>IDO is a nodal pathogenic driver of lung cancer and metastasis development</article-title><source>Cancer Discov</source><year>2012</year><volume>2</volume><fpage>722</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">22822050</pub-id></element-citation></ref><ref id="R357"><label>357</label><element-citation publication-type="journal"><person-group><name><surname>Abe</surname><given-names>BT</given-names></name><name><surname>Macian</surname><given-names>F</given-names></name></person-group><article-title>Uncovering the mechanisms that regulate tumor-induced T-cell anergy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22679</fpage><pub-id pub-id-type="pmid">23524444</pub-id></element-citation></ref><ref id="R358"><label>358</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Bravo-San Pedro</surname><given-names>JM</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Organelle-specific initiation of cell death</article-title><source>Nat Cell Biol</source><year>2014</year><volume>16</volume><fpage>728</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">25082195</pub-id></element-citation></ref><ref id="R359"><label>359</label><element-citation publication-type="journal"><person-group><name><surname>Creelan</surname><given-names>BC</given-names></name><name><surname>Antonia</surname><given-names>S</given-names></name><name><surname>Bepler</surname><given-names>G</given-names></name><name><surname>Garrett</surname><given-names>TJ</given-names></name><name><surname>Simon</surname><given-names>GR</given-names></name><name><surname>Soliman</surname><given-names>HH</given-names></name></person-group><article-title>Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23428</fpage><pub-id pub-id-type="pmid">23802083</pub-id></element-citation></ref><ref id="R360"><label>360</label><element-citation publication-type="journal"><person-group><name><surname>Mezrich</surname><given-names>JD</given-names></name><name><surname>Fechner</surname><given-names>JH</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Johnson</surname><given-names>BP</given-names></name><name><surname>Burlingham</surname><given-names>WJ</given-names></name><name><surname>Bradfield</surname><given-names>CA</given-names></name></person-group><article-title>An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells</article-title><source>J Immunol</source><year>2010</year><volume>185</volume><fpage>3190</fpage><lpage>3198</lpage><pub-id pub-id-type="pmid">20720200</pub-id></element-citation></ref><ref id="R361"><label>361</label><element-citation publication-type="journal"><person-group><name><surname>Favre</surname><given-names>D</given-names></name><name><surname>Mold</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Kanwar</surname><given-names>B</given-names></name><name><surname>Loke</surname><given-names>P</given-names></name><name><surname>Seu</surname><given-names>L</given-names></name><name><surname>Barbour</surname><given-names>JD</given-names></name><name><surname>Lowe</surname><given-names>MM</given-names></name><name><surname>Jayawardene</surname><given-names>A</given-names></name><name><surname>Aweeka</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease</article-title><source>Sci Transl Med</source><year>2010</year><volume>2</volume><fpage>32ra36</fpage></element-citation></ref><ref id="R362"><label>362</label><element-citation publication-type="journal"><person-group><name><surname>Gandhi</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Burns</surname><given-names>EJ</given-names></name><name><surname>Nadeau</surname><given-names>M</given-names></name><name><surname>Dake</surname><given-names>B</given-names></name><name><surname>Laroni</surname><given-names>A</given-names></name><name><surname>Kozoriz</surname><given-names>D</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name><name><surname>Quintana</surname><given-names>FJ</given-names></name></person-group><article-title>Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells</article-title><source>Nat Immunol</source><year>2010</year><volume>11</volume><fpage>846</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">20676092</pub-id></element-citation></ref><ref id="R363"><label>363</label><element-citation publication-type="journal"><person-group><name><surname>Platten</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>PP</given-names></name><name><surname>Youssef</surname><given-names>S</given-names></name><name><surname>Fontoura</surname><given-names>P</given-names></name><name><surname>Garren</surname><given-names>H</given-names></name><name><surname>Hur</surname><given-names>EM</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>LY</given-names></name><name><surname>Kidd</surname><given-names>BA</given-names></name><name><surname>Robinson</surname><given-names>WH</given-names></name><name><surname>Sobel</surname><given-names>RA</given-names></name><name><surname>Selley</surname><given-names>ML</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name></person-group><article-title>Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite</article-title><source>Science</source><year>2005</year><volume>310</volume><fpage>850</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">16272121</pub-id></element-citation></ref><ref id="R364"><label>364</label><element-citation publication-type="journal"><person-group><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Mo</surname><given-names>JH</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Rossetto</surname><given-names>C</given-names></name><name><surname>Jang</surname><given-names>A</given-names></name><name><surname>Beck</surname><given-names>L</given-names></name><name><surname>Elliott</surname><given-names>GI</given-names></name><name><surname>Kufareva</surname><given-names>I</given-names></name><name><surname>Abagyan</surname><given-names>R</given-names></name><name><surname>Broide</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Raz</surname><given-names>E</given-names></name></person-group><article-title>3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>18619</fpage><lpage>18624</lpage><pub-id pub-id-type="pmid">18003900</pub-id></element-citation></ref><ref id="R365"><label>365</label><element-citation publication-type="journal"><person-group><name><surname>Mellor</surname><given-names>AL</given-names></name><name><surname>Baban</surname><given-names>B</given-names></name><name><surname>Chandler</surname><given-names>P</given-names></name><name><surname>Marshall</surname><given-names>B</given-names></name><name><surname>Jhaver</surname><given-names>K</given-names></name><name><surname>Hansen</surname><given-names>A</given-names></name><name><surname>Koni</surname><given-names>PA</given-names></name><name><surname>Iwashima</surname><given-names>M</given-names></name><name><surname>Munn</surname><given-names>DH</given-names></name></person-group><article-title>Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>1652</fpage><lpage>1655</lpage><pub-id pub-id-type="pmid">12902462</pub-id></element-citation></ref><ref id="R366"><label>366</label><element-citation publication-type="journal"><person-group><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>MX</given-names></name><name><surname>Lapointe</surname><given-names>R</given-names></name><name><surname>Do</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>MW</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name></person-group><article-title>Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation</article-title><source>J Immunol</source><year>2000</year><volume>164</volume><fpage>3596</fpage><lpage>3599</lpage><pub-id pub-id-type="pmid">10725715</pub-id></element-citation></ref><ref id="R367"><label>367</label><element-citation publication-type="journal"><person-group><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Sharma</surname><given-names>MD</given-names></name><name><surname>Lee</surname><given-names>JR</given-names></name><name><surname>Jhaver</surname><given-names>KG</given-names></name><name><surname>Johnson</surname><given-names>TS</given-names></name><name><surname>Keskin</surname><given-names>DB</given-names></name><name><surname>Marshall</surname><given-names>B</given-names></name><name><surname>Chandler</surname><given-names>P</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Burgess</surname><given-names>R</given-names></name><name><surname>Slingluff</surname><given-names>CL</given-names><suffix>Jr</suffix></name><name><surname>Mellor</surname><given-names>AL</given-names></name></person-group><article-title>Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>1867</fpage><lpage>1870</lpage><pub-id pub-id-type="pmid">12228717</pub-id></element-citation></ref><ref id="R368"><label>368</label><element-citation publication-type="journal"><person-group><name><surname>Fallarino</surname><given-names>F</given-names></name><name><surname>Orabona</surname><given-names>C</given-names></name><name><surname>Vacca</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>R</given-names></name><name><surname>Gizzi</surname><given-names>S</given-names></name><name><surname>Asselin-Paturel</surname><given-names>C</given-names></name><name><surname>Fioretti</surname><given-names>MC</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Grohmann</surname><given-names>U</given-names></name><name><surname>Puccetti</surname><given-names>P</given-names></name></person-group><article-title>Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells</article-title><source>Int Immunol</source><year>2005</year><volume>17</volume><fpage>1429</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">16172135</pub-id></element-citation></ref><ref id="R369"><label>369</label><element-citation publication-type="journal"><person-group><name><surname>Fallarino</surname><given-names>F</given-names></name><name><surname>Asselin-Paturel</surname><given-names>C</given-names></name><name><surname>Vacca</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>R</given-names></name><name><surname>Gizzi</surname><given-names>S</given-names></name><name><surname>Fioretti</surname><given-names>MC</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Grohmann</surname><given-names>U</given-names></name><name><surname>Puccetti</surname><given-names>P</given-names></name></person-group><article-title>Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>3748</fpage><lpage>3754</lpage><pub-id pub-id-type="pmid">15356121</pub-id></element-citation></ref><ref id="R370"><label>370</label><element-citation publication-type="journal"><person-group><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Gilliet</surname><given-names>M</given-names></name></person-group><article-title>Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23887</fpage><pub-id pub-id-type="pmid">23762788</pub-id></element-citation></ref><ref id="R371"><label>371</label><element-citation publication-type="journal"><person-group><name><surname>Sisirak</surname><given-names>V</given-names></name><name><surname>Faget</surname><given-names>J</given-names></name><name><surname>Vey</surname><given-names>N</given-names></name><name><surname>Blay</surname><given-names>JY</given-names></name><name><surname>Menetrier-Caux</surname><given-names>C</given-names></name><name><surname>Caux</surname><given-names>C</given-names></name><name><surname>Bendriss-Vermare</surname><given-names>N</given-names></name></person-group><article-title>Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22338</fpage><pub-id pub-id-type="pmid">23482834</pub-id></element-citation></ref><ref id="R372"><label>372</label><element-citation publication-type="journal"><person-group><name><surname>Muller</surname><given-names>AJ</given-names></name><name><surname>DuHadaway</surname><given-names>JB</given-names></name><name><surname>Donover</surname><given-names>PS</given-names></name><name><surname>Sutanto-Ward</surname><given-names>E</given-names></name><name><surname>Prendergast</surname><given-names>GC</given-names></name></person-group><article-title>Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15711557</pub-id></element-citation></ref><ref id="R373"><label>373</label><element-citation publication-type="journal"><person-group><name><surname>Manuel</surname><given-names>ER</given-names></name><name><surname>Diamond</surname><given-names>DJ</given-names></name></person-group><article-title>A road less traveled paved by IDO silencing: Harnessing the antitumor activity of neutrophils</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23322</fpage><pub-id pub-id-type="pmid">23802075</pub-id></element-citation></ref><ref id="R374"><label>374</label><element-citation publication-type="journal"><person-group><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Koropatnick</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Velenosi</surname><given-names>T</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>N</given-names></name><name><surname>Navarro</surname><given-names>B</given-names></name><name><surname>Ichim</surname><given-names>TE</given-names></name><name><surname>Urquhart</surname><given-names>B</given-names></name><name><surname>Min</surname><given-names>W</given-names></name></person-group><article-title>Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model</article-title><source>Int J Cancer</source><year>2013</year><volume>132</volume><fpage>967</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">22870862</pub-id></element-citation></ref><ref id="R375"><label>375</label><element-citation publication-type="journal"><person-group><name><surname>Blache</surname><given-names>CA</given-names></name><name><surname>Manuel</surname><given-names>ER</given-names></name><name><surname>Kaltcheva</surname><given-names>TI</given-names></name><name><surname>Wong</surname><given-names>AN</given-names></name><name><surname>Ellenhorn</surname><given-names>JD</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name><name><surname>Diamond</surname><given-names>DJ</given-names></name></person-group><article-title>Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>6447</fpage><lpage>6456</lpage><pub-id pub-id-type="pmid">23090116</pub-id></element-citation></ref><ref id="R376"><label>376</label><element-citation publication-type="journal"><person-group><name><surname>Iversen</surname><given-names>TZ</given-names></name><name><surname>Engell-Noerregaard</surname><given-names>L</given-names></name><name><surname>Ellebaek</surname><given-names>E</given-names></name><name><surname>Andersen</surname><given-names>R</given-names></name><name><surname>Larsen</surname><given-names>SK</given-names></name><name><surname>Bjoern</surname><given-names>J</given-names></name><name><surname>Zeyher</surname><given-names>C</given-names></name><name><surname>Gouttefangeas</surname><given-names>C</given-names></name><name><surname>Thomsen</surname><given-names>BM</given-names></name><name><surname>Holm</surname><given-names>B</given-names></name><name><surname>Thor Straten</surname><given-names>P</given-names></name><name><surname>Mellemgaard</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>MH</given-names></name><etal></etal></person-group><article-title>Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">24218513</pub-id></element-citation></ref><ref id="R377"><label>377</label><element-citation publication-type="journal"><person-group><name><surname>Soliman</surname><given-names>HH</given-names></name><name><surname>Minton</surname><given-names>SE</given-names></name><name><surname>Ismail-Khan</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>HS</given-names></name><name><surname>Vahanian</surname><given-names>NN</given-names></name><name><surname>Ramsey</surname><given-names>WJ</given-names></name><name><surname>Kennedy</surname><given-names>E</given-names></name><name><surname>Link</surname><given-names>CJ</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name></person-group><article-title>A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><comment>abstr TPS3124</comment></element-citation></ref><ref id="R378"><label>378</label><element-citation publication-type="journal"><person-group><name><surname>Jackson</surname><given-names>E</given-names></name><name><surname>Dees</surname><given-names>EC</given-names></name><name><surname>Kauh</surname><given-names>JS</given-names></name><name><surname>Harvey</surname><given-names>RD</given-names></name><name><surname>Neuger</surname><given-names>A</given-names></name><name><surname>Lush</surname><given-names>R</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Minton</surname><given-names>SE</given-names></name><name><surname>Ismail-Khan</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>HS</given-names></name><name><surname>Vahanian</surname><given-names>NN</given-names></name><name><surname>Ramsey</surname><given-names>WJ</given-names></name><name><surname>Link</surname><given-names>CJ</given-names></name><etal></etal></person-group><article-title>A phase I study of indoximod in combination with docetaxel in metastatic solid tumors</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><comment>abstr 3026</comment></element-citation></ref><ref id="R379"><label>379</label><element-citation publication-type="journal"><person-group><name><surname>Soliman</surname><given-names>HH</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Vanahanian</surname><given-names>N</given-names></name><name><surname>Link</surname><given-names>CJ</given-names></name></person-group><article-title>Overcoming tumor antigen anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT)</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><comment>abstr 3004</comment></element-citation></ref><ref id="R380"><label>380</label><element-citation publication-type="journal"><person-group><name><surname>Beatty</surname><given-names>GL</given-names></name><name><surname>O'Dwyer</surname><given-names>PJ</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>JG</given-names></name><name><surname>Newton</surname><given-names>RC</given-names></name><name><surname>Schaub</surname><given-names>R</given-names></name><name><surname>Maleski</surname><given-names>J</given-names></name><name><surname>Leopold</surname><given-names>L</given-names></name><name><surname>Gajewski</surname><given-names>T</given-names></name></person-group><article-title>Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><comment>abstr 3025</comment></element-citation></ref><ref id="R381"><label>381</label><element-citation publication-type="journal"><person-group><name><surname>Gibney</surname><given-names>GT</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Gangadhar</surname><given-names>TC</given-names></name><name><surname>Lutzky</surname><given-names>J</given-names></name><name><surname>Olszanski</surname><given-names>AJ</given-names></name><name><surname>Gajewski</surname><given-names>T</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Boasberg</surname><given-names>PD</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Newton</surname><given-names>RC</given-names></name><name><surname>Scherle</surname><given-names>PA</given-names></name><name><surname>Bowman</surname><given-names>J</given-names></name><name><surname>Maleski</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><comment>abstr 3010</comment></element-citation></ref><ref id="R382"><label>382</label><element-citation publication-type="journal"><person-group><name><surname>Newton</surname><given-names>RC</given-names></name><name><surname>Scherle</surname><given-names>PA</given-names></name><name><surname>Bowman</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Beatty</surname><given-names>GL</given-names></name><name><surname>O'Dwyer</surname><given-names>PJ</given-names></name><name><surname>Gajewski</surname><given-names>T</given-names></name><name><surname>Bowman</surname><given-names>J</given-names></name><name><surname>Schaub</surname><given-names>R</given-names></name><name><surname>Leopold</surname><given-names>L</given-names></name></person-group><article-title>Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><comment>abstr 2500</comment></element-citation></ref><ref id="R383"><label>383</label><element-citation publication-type="journal"><person-group><name><surname>Aymeric</surname><given-names>L</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><article-title>Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>855</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">20086177</pub-id></element-citation></ref><ref id="R384"><label>384</label><element-citation publication-type="journal"><person-group><name><surname>Cauwels</surname><given-names>A</given-names></name><name><surname>Rogge</surname><given-names>E</given-names></name><name><surname>Vandendriessche</surname><given-names>B</given-names></name><name><surname>Shiva</surname><given-names>S</given-names></name><name><surname>Brouckaert</surname><given-names>P</given-names></name></person-group><article-title>Extracellular ATP drives systemic inflammation, tissue damage and mortality</article-title><source>Cell Death Dis</source><year>2014</year><volume>5</volume><fpage>e1102</fpage><pub-id pub-id-type="pmid">24603330</pub-id></element-citation></ref><ref id="R385"><label>385</label><element-citation publication-type="journal"><person-group><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Catani</surname><given-names>JP</given-names></name><name><surname>Hannani</surname><given-names>D</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Sukkurwala</surname><given-names>AQ</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24568</fpage><pub-id pub-id-type="pmid">23894718</pub-id></element-citation></ref><ref id="R386"><label>386</label><element-citation publication-type="journal"><person-group><name><surname>Elliott</surname><given-names>MR</given-names></name><name><surname>Chekeni</surname><given-names>FB</given-names></name><name><surname>Trampont</surname><given-names>PC</given-names></name><name><surname>Lazarowski</surname><given-names>ER</given-names></name><name><surname>Kadl</surname><given-names>A</given-names></name><name><surname>Walk</surname><given-names>SF</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Woodson</surname><given-names>RI</given-names></name><name><surname>Ostankovich</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Lysiak</surname><given-names>JJ</given-names></name><name><surname>Harden</surname><given-names>TK</given-names></name><name><surname>Leitinger</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance</article-title><source>Nature</source><year>2009</year><volume>461</volume><fpage>282</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">19741708</pub-id></element-citation></ref><ref id="R387"><label>387</label><element-citation publication-type="journal"><person-group><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Urade</surname><given-names>Y</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name></person-group><article-title>Immunosuppression via adenosine receptor activation by adenosine monophosphate released from apoptotic cells</article-title><source>Elife</source><year>2014</year><volume>3</volume><fpage>e02172</fpage><pub-id pub-id-type="pmid">24668173</pub-id></element-citation></ref><ref id="R388"><label>388</label><element-citation publication-type="journal"><person-group><name><surname>Sorrentino</surname><given-names>R</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Morello</surname><given-names>S</given-names></name></person-group><article-title>The adenosinergic system in cancer: Key therapeutic target</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22448</fpage><pub-id pub-id-type="pmid">23483072</pub-id></element-citation></ref><ref id="R389"><label>389</label><element-citation publication-type="journal"><person-group><name><surname>Deaglio</surname><given-names>S</given-names></name><name><surname>Dwyer</surname><given-names>KM</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Usheva</surname><given-names>A</given-names></name><name><surname>Erat</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>JF</given-names></name><name><surname>Enjyoji</surname><given-names>K</given-names></name><name><surname>Linden</surname><given-names>J</given-names></name><name><surname>Oukka</surname><given-names>M</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name><name><surname>Strom</surname><given-names>TB</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name></person-group><article-title>Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression</article-title><source>J Exp Med</source><year>2007</year><volume>204</volume><fpage>1257</fpage><lpage>1265</lpage><pub-id pub-id-type="pmid">17502665</pub-id></element-citation></ref><ref id="R390"><label>390</label><element-citation publication-type="journal"><person-group><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Sukkurwala</surname><given-names>AQ</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>393</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">22737627</pub-id></element-citation></ref><ref id="R391"><label>391</label><element-citation publication-type="journal"><person-group><name><surname>Antonioli</surname><given-names>L</given-names></name><name><surname>Pacher</surname><given-names>P</given-names></name><name><surname>Vizi</surname><given-names>ES</given-names></name><name><surname>Hasko</surname><given-names>G</given-names></name></person-group><article-title>CD39 and CD73 in immunity and inflammation</article-title><source>Trends Mol Med</source><year>2013</year><volume>19</volume><fpage>355</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">23601906</pub-id></element-citation></ref><ref id="R392"><label>392</label><element-citation publication-type="journal"><person-group><name><surname>Bastid</surname><given-names>J</given-names></name><name><surname>Cottalorda-Regairaz</surname><given-names>A</given-names></name><name><surname>Alberici</surname><given-names>G</given-names></name><name><surname>Bonnefoy</surname><given-names>N</given-names></name><name><surname>Eliaou</surname><given-names>JF</given-names></name><name><surname>Bensussan</surname><given-names>A</given-names></name></person-group><article-title>ENTPD1/CD39 is a promising therapeutic target in oncology</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>1743</fpage><lpage>1751</lpage><pub-id pub-id-type="pmid">22751118</pub-id></element-citation></ref><ref id="R393"><label>393</label><element-citation publication-type="journal"><person-group><name><surname>Salmi</surname><given-names>M</given-names></name><name><surname>Jalkanen</surname><given-names>S</given-names></name></person-group><article-title>Host CD73 impairs anti-tumor immunity</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>247</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">22720259</pub-id></element-citation></ref><ref id="R394"><label>394</label><element-citation publication-type="journal"><person-group><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>CD73 promotes tumor growth and metastasis</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>67</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">22720214</pub-id></element-citation></ref><ref id="R395"><label>395</label><element-citation publication-type="journal"><person-group><name><surname>Aliagas</surname><given-names>E</given-names></name><name><surname>Vidal</surname><given-names>A</given-names></name><name><surname>Texido</surname><given-names>L</given-names></name><name><surname>Ponce</surname><given-names>J</given-names></name><name><surname>Condom</surname><given-names>E</given-names></name><name><surname>Martin-Satue</surname><given-names>M</given-names></name></person-group><article-title>High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors</article-title><source>Mediators Inflamm</source><year>2014</year><volume>2014</volume><fpage>509027</fpage><pub-id pub-id-type="pmid">24707115</pub-id></element-citation></ref><ref id="R396"><label>396</label><element-citation publication-type="journal"><person-group><name><surname>Clayton</surname><given-names>A</given-names></name><name><surname>Al-Taei</surname><given-names>S</given-names></name><name><surname>Webber</surname><given-names>J</given-names></name><name><surname>Mason</surname><given-names>MD</given-names></name><name><surname>Tabi</surname><given-names>Z</given-names></name></person-group><article-title>Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production</article-title><source>J Immunol</source><year>2011</year><volume>187</volume><fpage>676</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">21677139</pub-id></element-citation></ref><ref id="R397"><label>397</label><element-citation publication-type="journal"><person-group><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Mittal</surname><given-names>D</given-names></name><name><surname>Stagg</surname><given-names>J</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Targeting cancer-derived adenosine: new therapeutic approaches</article-title><source>Cancer Discov</source><year>2014</year><volume>4</volume><fpage>879</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">25035124</pub-id></element-citation></ref><ref id="R398"><label>398</label><element-citation publication-type="journal"><person-group><name><surname>Metz</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>DuHadaway</surname><given-names>JB</given-names></name><name><surname>Chandler</surname><given-names>P</given-names></name><name><surname>Baban</surname><given-names>B</given-names></name><name><surname>Merlo</surname><given-names>LM</given-names></name><name><surname>Pigott</surname><given-names>E</given-names></name><name><surname>Keough</surname><given-names>MP</given-names></name><name><surname>Rust</surname><given-names>S</given-names></name><name><surname>Mellor</surname><given-names>AL</given-names></name><name><surname>Mandik-Nayak</surname><given-names>L</given-names></name><name><surname>Muller</surname><given-names>AJ</given-names></name><name><surname>Prendergast</surname><given-names>GC</given-names></name></person-group><article-title>IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation</article-title><source>Int Immunol</source><year>2014</year><volume>26</volume><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">24402311</pub-id></element-citation></ref><ref id="R399"><label>399</label><element-citation publication-type="journal"><person-group><name><surname>Prendergast</surname><given-names>GC</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Mandik-Nayak</surname><given-names>L</given-names></name><name><surname>Laury-Kleintop</surname><given-names>L</given-names></name><name><surname>Metz</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>AJ</given-names></name></person-group><article-title>Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer</article-title><source>Cancer Immunol Immunother</source><year>2014</year><volume>63</volume><fpage>721</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">24711084</pub-id></element-citation></ref><ref id="R400"><label>400</label><element-citation publication-type="journal"><person-group><name><surname>Palm</surname><given-names>NW</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><article-title>Pattern recognition receptors and control of adaptive immunity</article-title><source>Immunol Rev</source><year>2009</year><volume>227</volume><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">19120487</pub-id></element-citation></ref><ref id="R401"><label>401</label><element-citation publication-type="journal"><person-group><name><surname>Delgado</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>De Haro</surname><given-names>S</given-names></name><name><surname>Master</surname><given-names>S</given-names></name><name><surname>Ponpuak</surname><given-names>M</given-names></name><name><surname>Dinkins</surname><given-names>C</given-names></name><name><surname>Ornatowski</surname><given-names>W</given-names></name><name><surname>Vergne</surname><given-names>I</given-names></name><name><surname>Deretic</surname><given-names>V</given-names></name></person-group><article-title>Autophagy and pattern recognition receptors in innate immunity</article-title><source>Immunol Rev</source><year>2009</year><volume>227</volume><fpage>189</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">19120485</pub-id></element-citation></ref><ref id="R402"><label>402</label><element-citation publication-type="journal"><person-group><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Toll-like receptors and their crosstalk with other innate receptors in infection and immunity</article-title><source>Immunity</source><year>2011</year><volume>34</volume><fpage>637</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">21616434</pub-id></element-citation></ref><ref id="R403"><label>403</label><element-citation publication-type="journal"><person-group><name><surname>Hennessy</surname><given-names>EJ</given-names></name><name><surname>Parker</surname><given-names>AE</given-names></name><name><surname>O'Neill</surname><given-names>LA</given-names></name></person-group><article-title>Targeting Toll-like receptors: emerging therapeutics?</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><fpage>293</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">20380038</pub-id></element-citation></ref><ref id="R404"><label>404</label><element-citation publication-type="journal"><person-group><name><surname>Saleh</surname><given-names>M</given-names></name></person-group><article-title>The machinery of Nod-like receptors: refining the paths to immunity and cell death</article-title><source>Immunol Rev</source><year>2011</year><volume>243</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">21884180</pub-id></element-citation></ref><ref id="R405"><label>405</label><element-citation publication-type="journal"><person-group><name><surname>Franchi</surname><given-names>L</given-names></name><name><surname>Warner</surname><given-names>N</given-names></name><name><surname>Viani</surname><given-names>K</given-names></name><name><surname>Nunez</surname><given-names>G</given-names></name></person-group><article-title>Function of Nod-like receptors in microbial recognition and host defense</article-title><source>Immunol Rev</source><year>2009</year><volume>227</volume><fpage>106</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">19120480</pub-id></element-citation></ref><ref id="R406"><label>406</label><element-citation publication-type="journal"><person-group><name><surname>Garg</surname><given-names>AD</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Golab</surname><given-names>J</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name></person-group><article-title>Danger signalling during cancer cell death: origins, plasticity and regulation</article-title><source>Cell Death Differ</source><year>2014</year><volume>21</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">23686135</pub-id></element-citation></ref><ref id="R407"><label>407</label><element-citation publication-type="journal"><person-group><name><surname>Brenner</surname><given-names>C</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Decoding cell death signals in liver inflammation</article-title><source>J Hepatol</source><year>2013</year><volume>59</volume><fpage>583</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">23567086</pub-id></element-citation></ref><ref id="R408"><label>408</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Mitochondria: master regulators of danger signalling</article-title><source>Nat Rev Mol Cell Biol</source><year>2012</year><volume>13</volume><fpage>780</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">23175281</pub-id></element-citation></ref><ref id="R409"><label>409</label><element-citation publication-type="journal"><person-group><name><surname>Spel</surname><given-names>L</given-names></name><name><surname>Boelens</surname><given-names>JJ</given-names></name><name><surname>Nierkens</surname><given-names>S</given-names></name><name><surname>Boes</surname><given-names>M</given-names></name></person-group><article-title>Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26403</fpage><pub-id pub-id-type="pmid">24482744</pub-id></element-citation></ref><ref id="R410"><label>410</label><element-citation publication-type="journal"><person-group><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Shu</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Twitty</surname><given-names>C</given-names></name><name><surname>Hilton</surname><given-names>TL</given-names></name><name><surname>Aung</surname><given-names>S</given-names></name><name><surname>Urba</surname><given-names>WJ</given-names></name><name><surname>Fox</surname><given-names>BA</given-names></name><name><surname>Hu</surname><given-names>HM</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>976</fpage><lpage>978</lpage><pub-id pub-id-type="pmid">23162777</pub-id></element-citation></ref><ref id="R411"><label>411</label><element-citation publication-type="journal"><person-group><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Palsson-McDermott</surname><given-names>EM</given-names></name><name><surname>Bowie</surname><given-names>AG</given-names></name><name><surname>Jefferies</surname><given-names>CA</given-names></name><name><surname>Mansell</surname><given-names>AS</given-names></name><name><surname>Brady</surname><given-names>G</given-names></name><name><surname>Brint</surname><given-names>E</given-names></name><name><surname>Dunne</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>P</given-names></name><name><surname>Harte</surname><given-names>MT</given-names></name><name><surname>McMurray</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>DE</given-names></name><name><surname>Sims</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction</article-title><source>Nature</source><year>2001</year><volume>413</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11544529</pub-id></element-citation></ref><ref id="R412"><label>412</label><element-citation publication-type="journal"><person-group><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Preston-Hurlburt</surname><given-names>P</given-names></name><name><surname>Kopp</surname><given-names>E</given-names></name><name><surname>Stadlen</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Janeway</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group><article-title>MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways</article-title><source>Mol Cell</source><year>1998</year><volume>2</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">9734363</pub-id></element-citation></ref><ref id="R413"><label>413</label><element-citation publication-type="journal"><person-group><name><surname>Strober</surname><given-names>W</given-names></name><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Kitani</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name></person-group><article-title>Signalling pathways and molecular interactions of NOD1 and NOD2</article-title><source>Nat Rev Immunol</source><year>2006</year><volume>6</volume><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16493424</pub-id></element-citation></ref><ref id="R414"><label>414</label><element-citation publication-type="journal"><person-group><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Hoshino</surname><given-names>K</given-names></name><name><surname>Kaisho</surname><given-names>T</given-names></name><name><surname>Sanjo</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Sugiyama</surname><given-names>M</given-names></name><name><surname>Okabe</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway</article-title><source>Science</source><year>2003</year><volume>301</volume><fpage>640</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">12855817</pub-id></element-citation></ref><ref id="R415"><label>415</label><element-citation publication-type="journal"><person-group><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Negishi</surname><given-names>H</given-names></name><name><surname>Asagiri</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Ohba</surname><given-names>Y</given-names></name><name><surname>Takaoka</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><article-title>IRF-7 is the master regulator of type-I interferon-dependent immune responses</article-title><source>Nature</source><year>2005</year><volume>434</volume><fpage>772</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">15800576</pub-id></element-citation></ref><ref id="R416"><label>416</label><element-citation publication-type="journal"><person-group><name><surname>Brennan</surname><given-names>TV</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Cardona</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Dredge</surname><given-names>K</given-names></name><name><surname>Chao</surname><given-names>NJ</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>2899</fpage><lpage>2908</lpage><pub-id pub-id-type="pmid">22760779</pub-id></element-citation></ref><ref id="R417"><label>417</label><element-citation publication-type="journal"><person-group><name><surname>Krysko</surname><given-names>DV</given-names></name><name><surname>Garg</surname><given-names>AD</given-names></name><name><surname>Kaczmarek</surname><given-names>A</given-names></name><name><surname>Krysko</surname><given-names>O</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name></person-group><article-title>Immunogenic cell death and DAMPs in cancer therapy</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><fpage>860</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">23151605</pub-id></element-citation></ref><ref id="R418"><label>418</label><element-citation publication-type="journal"><person-group><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Schlemmer</surname><given-names>F</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Sukkurwala</surname><given-names>AQ</given-names></name><name><surname>Menger</surname><given-names>L</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy</article-title><source>Cancer Metastasis Rev</source><year>2011</year><volume>30</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">21249425</pub-id></element-citation></ref><ref id="R419"><label>419</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Vitale</surname><given-names>I</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial Watch: Anticancer radioimmunotherapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25595</fpage><pub-id pub-id-type="pmid">24319634</pub-id></element-citation></ref><ref id="R420"><label>420</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>The secret ally: immunostimulation by anticancer drugs</article-title><source>Nat Rev Drug Discov</source><year>2012</year><volume>11</volume><fpage>215</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">22301798</pub-id></element-citation></ref><ref id="R421"><label>421</label><element-citation publication-type="journal"><person-group><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>74</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">23890065</pub-id></element-citation></ref><ref id="R422"><label>422</label><element-citation publication-type="journal"><person-group><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Vanpouille-Box</surname><given-names>C</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name></person-group><article-title>The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25997</fpage><pub-id pub-id-type="pmid">24404422</pub-id></element-citation></ref><ref id="R423"><label>423</label><element-citation publication-type="journal"><person-group><name><surname>Brito</surname><given-names>LA</given-names></name><name><surname>O'Hagan</surname><given-names>DT</given-names></name></person-group><article-title>Designing and building the next generation of improved vaccine adjuvants</article-title><source>J Control Release</source><year>2014</year><volume>190</volume><fpage>563</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">24998942</pub-id></element-citation></ref><ref id="R424"><label>424</label><element-citation publication-type="journal"><person-group><name><surname>Maisonneuve</surname><given-names>C</given-names></name><name><surname>Bertholet</surname><given-names>S</given-names></name><name><surname>Philpott</surname><given-names>DJ</given-names></name><name><surname>De Gregorio</surname><given-names>E</given-names></name></person-group><article-title>Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>12294</fpage><lpage>12299</lpage><pub-id pub-id-type="pmid">25136133</pub-id></element-citation></ref><ref id="R425"><label>425</label><element-citation publication-type="journal"><person-group><name><surname>Narayan</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Bentow</surname><given-names>JJ</given-names></name><name><surname>Moy</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>DK</given-names></name><name><surname>Greger</surname><given-names>S</given-names></name><name><surname>Haskell</surname><given-names>J</given-names></name><name><surname>Vanchinathan</surname><given-names>V</given-names></name><name><surname>Chang</surname><given-names>PL</given-names></name><name><surname>Tsui</surname><given-names>S</given-names></name><name><surname>Konishi</surname><given-names>T</given-names></name><name><surname>Comin-Anduix</surname><given-names>B</given-names></name><name><surname>Dauphine</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Immunomodulation by imiquimod in patients with high-risk primary melanoma</article-title><source>J Invest Dermatol</source><year>2012</year><volume>132</volume><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">21850019</pub-id></element-citation></ref><ref id="R426"><label>426</label><element-citation publication-type="journal"><person-group><name><surname>Hoffman</surname><given-names>ES</given-names></name><name><surname>Smith</surname><given-names>RE</given-names></name><name><surname>Renaud</surname><given-names>RC</given-names><suffix>Jr</suffix></name></person-group><article-title>From the analyst's couch: TLR-targeted therapeutics</article-title><source>Nat Rev Drug Discov</source><year>2005</year><volume>4</volume><fpage>879</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">16299917</pub-id></element-citation></ref><ref id="R427"><label>427</label><element-citation publication-type="journal"><person-group><name><surname>Paavonen</surname><given-names>J</given-names></name><name><surname>Naud</surname><given-names>P</given-names></name><name><surname>Salmeron</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Chow</surname><given-names>SN</given-names></name><name><surname>Apter</surname><given-names>D</given-names></name><name><surname>Kitchener</surname><given-names>H</given-names></name><name><surname>Castellsague</surname><given-names>X</given-names></name><name><surname>Teixeira</surname><given-names>JC</given-names></name><name><surname>Skinner</surname><given-names>SR</given-names></name><name><surname>Hedrick</surname><given-names>J</given-names></name><name><surname>Jaisamrarn</surname><given-names>U</given-names></name><name><surname>Limson</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women</article-title><source>Lancet</source><year>2009</year><volume>374</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">19586656</pub-id></element-citation></ref><ref id="R428"><label>428</label><element-citation publication-type="journal"><person-group><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Shoin</surname><given-names>S</given-names></name><name><surname>Koshimura</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>R</given-names></name></person-group><article-title>Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci</article-title><source>Jpn J Microbiol</source><year>1967</year><volume>11</volume><fpage>323</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">4875331</pub-id></element-citation></ref><ref id="R429"><label>429</label><element-citation publication-type="journal"><person-group><name><surname>Rakoff-Nahoum</surname><given-names>S</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><article-title>Toll-like receptors and cancer</article-title><source>Nat Rev Cancer</source><year>2009</year><volume>9</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">19052556</pub-id></element-citation></ref><ref id="R430"><label>430</label><element-citation publication-type="journal"><person-group><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Corradini</surname><given-names>N</given-names></name><name><surname>Redini</surname><given-names>F</given-names></name><name><surname>Heymann</surname><given-names>D</given-names></name></person-group><article-title>Mifamurtide for the treatment of nonmetastatic osteosarcoma</article-title><source>Expert Opin Pharmacother</source><year>2011</year><volume>12</volume><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">21226638</pub-id></element-citation></ref><ref id="R431"><label>431</label><element-citation publication-type="journal"><person-group><name><surname>Murray</surname><given-names>JL</given-names></name><name><surname>Kleinerman</surname><given-names>ES</given-names></name><name><surname>Cunningham</surname><given-names>JE</given-names></name><name><surname>Tatom</surname><given-names>JR</given-names></name><name><surname>Andrejcio</surname><given-names>K</given-names></name><name><surname>Lepe-Zuniga</surname><given-names>J</given-names></name><name><surname>Lamki</surname><given-names>LM</given-names></name><name><surname>Rosenblum</surname><given-names>MG</given-names></name><name><surname>Frost</surname><given-names>H</given-names></name><name><surname>Gutterman</surname><given-names>JU</given-names></name><etal></etal></person-group><article-title>Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>1915</fpage><lpage>1925</lpage><pub-id pub-id-type="pmid">2479721</pub-id></element-citation></ref><ref id="R432"><label>432</label><element-citation publication-type="journal"><person-group><name><surname>Fidler</surname><given-names>IJ</given-names></name><name><surname>Fogler</surname><given-names>WE</given-names></name><name><surname>Brownbill</surname><given-names>AF</given-names></name><name><surname>Schumann</surname><given-names>G</given-names></name></person-group><article-title>Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide</article-title><source>J Immunol</source><year>1987</year><volume>138</volume><fpage>4509</fpage><lpage>4514</lpage><pub-id pub-id-type="pmid">3584979</pub-id></element-citation></ref><ref id="R433"><label>433</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Trial Watch: Experimental Toll-like receptor agonists for cancer therapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>699</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">22934262</pub-id></element-citation></ref><ref id="R434"><label>434</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>894</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">23162757</pub-id></element-citation></ref><ref id="R435"><label>435</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Eggermont</surname><given-names>A</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Trial Watch: Toll-like receptor agonists for cancer therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25238</fpage><pub-id pub-id-type="pmid">24083080</pub-id></element-citation></ref><ref id="R436"><label>436</label><element-citation publication-type="journal"><person-group><name><surname>Murad</surname><given-names>YM</given-names></name><name><surname>Clay</surname><given-names>TM</given-names></name><name><surname>Lyerly</surname><given-names>HK</given-names></name><name><surname>Morse</surname><given-names>MA</given-names></name></person-group><article-title>CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy</article-title><source>Expert Opin Biol Ther</source><year>2007</year><volume>7</volume><fpage>1257</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">17696823</pub-id></element-citation></ref><ref id="R437"><label>437</label><element-citation publication-type="journal"><person-group><name><surname>Alexopoulou</surname><given-names>L</given-names></name><name><surname>Holt</surname><given-names>AC</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><article-title>Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3</article-title><source>Nature</source><year>2001</year><volume>413</volume><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">11607032</pub-id></element-citation></ref><ref id="R438"><label>438</label><element-citation publication-type="journal"><person-group><name><surname>Levy</surname><given-names>HB</given-names></name><name><surname>Baer</surname><given-names>G</given-names></name><name><surname>Baron</surname><given-names>S</given-names></name><name><surname>Buckler</surname><given-names>CE</given-names></name><name><surname>Gibbs</surname><given-names>CJ</given-names></name><name><surname>Iadarola</surname><given-names>MJ</given-names></name><name><surname>London</surname><given-names>WT</given-names></name><name><surname>Rice</surname><given-names>J</given-names></name></person-group><article-title>A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates</article-title><source>J Infect Dis</source><year>1975</year><volume>132</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">810520</pub-id></element-citation></ref><ref id="R439"><label>439</label><element-citation publication-type="journal"><person-group><name><surname>Hagstrom</surname><given-names>J</given-names></name><name><surname>Heikkila</surname><given-names>A</given-names></name><name><surname>Siironen</surname><given-names>P</given-names></name><name><surname>Louhimo</surname><given-names>J</given-names></name><name><surname>Heiskanen</surname><given-names>I</given-names></name><name><surname>Maenpaa</surname><given-names>H</given-names></name><name><surname>Arola</surname><given-names>J</given-names></name><name><surname>Haglund</surname><given-names>C</given-names></name></person-group><article-title>TLR-4 expression and decrease in chronic inflammation: indicators of aggressive follicular thyroid carcinoma</article-title><source>J Clin Pathol</source><year>2012</year><volume>65</volume><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">22267982</pub-id></element-citation></ref><ref id="R440"><label>440</label><element-citation publication-type="journal"><person-group><name><surname>Kauppila</surname><given-names>JH</given-names></name><name><surname>Mattila</surname><given-names>AE</given-names></name><name><surname>Karttunen</surname><given-names>TJ</given-names></name><name><surname>Salo</surname><given-names>T</given-names></name></person-group><article-title>Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue</article-title><source>Br J Cancer</source><year>2013</year><volume>108</volume><fpage>638</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">23287987</pub-id></element-citation></ref><ref id="R441"><label>441</label><element-citation publication-type="journal"><person-group><name><surname>Kauppila</surname><given-names>JH</given-names></name><name><surname>Mattila</surname><given-names>AE</given-names></name><name><surname>Karttunen</surname><given-names>TJ</given-names></name><name><surname>Salo</surname><given-names>T</given-names></name></person-group><article-title>Toll-like receptor 5 and the emerging role of bacteria in carcinogenesis</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23620</fpage><pub-id pub-id-type="pmid">23734315</pub-id></element-citation></ref><ref id="R442"><label>442</label><element-citation publication-type="journal"><person-group><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Redmond</surname><given-names>HP</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name></person-group><article-title>Links between Toll-like receptor 4 and breast cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e22945</fpage><pub-id pub-id-type="pmid">23526132</pub-id></element-citation></ref><ref id="R443"><label>443</label><element-citation publication-type="journal"><person-group><name><surname>Conti</surname><given-names>L</given-names></name><name><surname>Lanzardo</surname><given-names>S</given-names></name><name><surname>Arigoni</surname><given-names>M</given-names></name><name><surname>Antonazzo</surname><given-names>R</given-names></name><name><surname>Radaelli</surname><given-names>E</given-names></name><name><surname>Cantarella</surname><given-names>D</given-names></name><name><surname>Calogero</surname><given-names>RA</given-names></name><name><surname>Cavallo</surname><given-names>F</given-names></name></person-group><article-title>The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells</article-title><source>FASEB J</source><year>2013</year><volume>27</volume><fpage>4731</fpage><lpage>4744</lpage><pub-id pub-id-type="pmid">23970797</pub-id></element-citation></ref><ref id="R444"><label>444</label><element-citation publication-type="journal"><person-group><name><surname>Tye</surname><given-names>H</given-names></name><name><surname>Kennedy</surname><given-names>CL</given-names></name><name><surname>Najdovska</surname><given-names>M</given-names></name><name><surname>McLeod</surname><given-names>L</given-names></name><name><surname>McCormack</surname><given-names>W</given-names></name><name><surname>Hughes</surname><given-names>N</given-names></name><name><surname>Dev</surname><given-names>A</given-names></name><name><surname>Sievert</surname><given-names>W</given-names></name><name><surname>Ooi</surname><given-names>CH</given-names></name><name><surname>Ishikawa</surname><given-names>TO</given-names></name><name><surname>Oshima</surname><given-names>H</given-names></name><name><surname>Bhathal</surname><given-names>PS</given-names></name><name><surname>Parker</surname><given-names>AE</given-names></name><etal></etal></person-group><article-title>STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation</article-title><source>Cancer Cell</source><year>2012</year><volume>22</volume><fpage>466</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">23079657</pub-id></element-citation></ref><ref id="R445"><label>445</label><element-citation publication-type="journal"><person-group><name><surname>Cherfils-Vicini</surname><given-names>J</given-names></name><name><surname>Platonova</surname><given-names>S</given-names></name><name><surname>Gillard</surname><given-names>M</given-names></name><name><surname>Laurans</surname><given-names>L</given-names></name><name><surname>Validire</surname><given-names>P</given-names></name><name><surname>Caliandro</surname><given-names>R</given-names></name><name><surname>Magdeleinat</surname><given-names>P</given-names></name><name><surname>Mami-Chouaib</surname><given-names>F</given-names></name><name><surname>Dieu-Nosjean</surname><given-names>MC</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Damotte</surname><given-names>D</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Cremer</surname><given-names>I</given-names></name></person-group><article-title>Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><fpage>1285</fpage><lpage>1297</lpage><pub-id pub-id-type="pmid">20237413</pub-id></element-citation></ref><ref id="R446"><label>446</label><element-citation publication-type="journal"><person-group><name><surname>Pasquier</surname><given-names>E</given-names></name><name><surname>Kavallaris</surname><given-names>M</given-names></name><name><surname>Andre</surname><given-names>N</given-names></name></person-group><article-title>Metronomic chemotherapy: new rationale for new directions</article-title><source>Nat Rev Clin Oncol</source><year>2010</year><volume>7</volume><fpage>455</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">20531380</pub-id></element-citation></ref><ref id="R447"><label>447</label><element-citation publication-type="journal"><person-group><name><surname>Sheng Sow</surname><given-names>H</given-names></name><name><surname>Mattarollo</surname><given-names>SR</given-names></name></person-group><article-title>Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e27058</fpage><pub-id pub-id-type="pmid">24498564</pub-id></element-citation></ref><ref id="R448"><label>448</label><element-citation publication-type="journal"><person-group><name><surname>Garg</surname><given-names>AD</given-names></name><name><surname>Krysko</surname><given-names>DV</given-names></name><name><surname>Verfaillie</surname><given-names>T</given-names></name><name><surname>Kaczmarek</surname><given-names>A</given-names></name><name><surname>Ferreira</surname><given-names>GB</given-names></name><name><surname>Marysael</surname><given-names>T</given-names></name><name><surname>Rubio</surname><given-names>N</given-names></name><name><surname>Firczuk</surname><given-names>M</given-names></name><name><surname>Mathieu</surname><given-names>C</given-names></name><name><surname>Roebroek</surname><given-names>AJ</given-names></name><name><surname>Annaert</surname><given-names>W</given-names></name><name><surname>Golab</surname><given-names>J</given-names></name><name><surname>de Witte</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death</article-title><source>EMBO J</source><year>2012</year><volume>31</volume><fpage>1062</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">22252128</pub-id></element-citation></ref><ref id="R449"><label>449</label><element-citation publication-type="journal"><person-group><name><surname>Panaretakis</surname><given-names>T</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Brockmeier</surname><given-names>U</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Bjorklund</surname><given-names>AC</given-names></name><name><surname>Chapman</surname><given-names>DC</given-names></name><name><surname>Durchschlag</surname><given-names>M</given-names></name><name><surname>Joza</surname><given-names>N</given-names></name><name><surname>Pierron</surname><given-names>G</given-names></name><name><surname>van Endert</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Madeo</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death</article-title><source>EMBO J</source><year>2009</year><volume>28</volume><fpage>578</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">19165151</pub-id></element-citation></ref><ref id="R450"><label>450</label><element-citation publication-type="journal"><person-group><name><surname>Cirone</surname><given-names>M</given-names></name><name><surname>Di Renzo</surname><given-names>L</given-names></name><name><surname>Lotti</surname><given-names>LV</given-names></name><name><surname>Conte</surname><given-names>V</given-names></name><name><surname>Trivedi</surname><given-names>P</given-names></name><name><surname>Santarelli</surname><given-names>R</given-names></name><name><surname>Gonnella</surname><given-names>R</given-names></name><name><surname>Frati</surname><given-names>L</given-names></name><name><surname>Faggioni</surname><given-names>A</given-names></name></person-group><article-title>Activation of dendritic cells by tumor cell death</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1218</fpage><lpage>1219</lpage><pub-id pub-id-type="pmid">23170286</pub-id></element-citation></ref><ref id="R451"><label>451</label><element-citation publication-type="journal"><person-group><name><surname>Menger</surname><given-names>L</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Sukkurwala</surname><given-names>AQ</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Mignot</surname><given-names>G</given-names></name><name><surname>Schlemmer</surname><given-names>F</given-names></name><name><surname>Sulpice</surname><given-names>E</given-names></name><name><surname>Locher</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Cardiac glycosides exert anticancer effects by inducing immunogenic cell death</article-title><source>Sci Transl Med</source><year>2012</year><volume>4</volume><fpage>143ra199</fpage></element-citation></ref><ref id="R452"><label>452</label><element-citation publication-type="journal"><person-group><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Sukkurwala</surname><given-names>AQ</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Pellegatti</surname><given-names>P</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Scoazec</surname><given-names>M</given-names></name><name><surname>Mignot</surname><given-names>G</given-names></name><name><surname>Rello-Varona</surname><given-names>S</given-names></name><name><surname>Tailler</surname><given-names>M</given-names></name><name><surname>Menger</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice</article-title><source>Science</source><year>2011</year><volume>334</volume><fpage>1573</fpage><lpage>1577</lpage><pub-id pub-id-type="pmid">22174255</pub-id></element-citation></ref><ref id="R453"><label>453</label><element-citation publication-type="journal"><person-group><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Schlemmer</surname><given-names>F</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Aymeric</surname><given-names>L</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Barault</surname><given-names>L</given-names></name><name><surname>Mendiboure</surname><given-names>J</given-names></name><name><surname>Pignon</surname><given-names>JP</given-names></name><name><surname>Jooste</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Immunogenic death of colon cancer cells treated with oxaliplatin</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>482</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">19881547</pub-id></element-citation></ref><ref id="R454"><label>454</label><element-citation publication-type="journal"><person-group><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Mattarollo</surname><given-names>SR</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Aymeric</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Portela Catani</surname><given-names>JP</given-names></name><name><surname>Hannani</surname><given-names>D</given-names></name><name><surname>Duret</surname><given-names>H</given-names></name><name><surname>Steegh</surname><given-names>K</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Schlemmer</surname><given-names>F</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells</article-title><source>Immunity</source><year>2013</year><volume>38</volume><fpage>729</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">23562161</pub-id></element-citation></ref><ref id="R455"><label>455</label><element-citation publication-type="journal"><person-group><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Vitale</surname><given-names>I</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Aranda</surname><given-names>F</given-names></name><name><surname>Barnaba</surname><given-names>V</given-names></name><name><surname>Bloy</surname><given-names>N</given-names></name><name><surname>Bracci</surname><given-names>L</given-names></name><name><surname>Breckpot</surname><given-names>K</given-names></name><name><surname>Brough</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Consensus guidelines for the detection of immunogenic cell death</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><comment>In press</comment></element-citation></ref><ref id="R456"><label>456</label><element-citation publication-type="journal"><person-group><name><surname>Bugaut</surname><given-names>H</given-names></name><name><surname>Bruchard</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>H</given-names></name><name><surname>Derangere</surname><given-names>V</given-names></name><name><surname>Odoul</surname><given-names>L</given-names></name><name><surname>Euvrard</surname><given-names>R</given-names></name><name><surname>Ladoire</surname><given-names>S</given-names></name><name><surname>Chalmin</surname><given-names>F</given-names></name><name><surname>Vegran</surname><given-names>F</given-names></name><name><surname>Rebe</surname><given-names>C</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Mignot</surname><given-names>G</given-names></name></person-group><article-title>Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e65181</fpage><pub-id pub-id-type="pmid">23762310</pub-id></element-citation></ref><ref id="R457"><label>457</label><element-citation publication-type="journal"><person-group><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Schlemmer</surname><given-names>F</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Tailler</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Menger</surname><given-names>L</given-names></name><name><surname>Gdoura</surname><given-names>A</given-names></name><name><surname>Tajeddine</surname><given-names>N</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress</article-title><source>Oncogene</source><year>2011</year><volume>30</volume><fpage>1147</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">21151176</pub-id></element-citation></ref><ref id="R458"><label>458</label><element-citation publication-type="journal"><person-group><name><surname>Schiavoni</surname><given-names>G</given-names></name><name><surname>Sistigu</surname><given-names>A</given-names></name><name><surname>Valentini</surname><given-names>M</given-names></name><name><surname>Mattei</surname><given-names>F</given-names></name><name><surname>Sestili</surname><given-names>P</given-names></name><name><surname>Spadaro</surname><given-names>F</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Lorenzi</surname><given-names>S</given-names></name><name><surname>D'Urso</surname><given-names>MT</given-names></name><name><surname>Belardelli</surname><given-names>F</given-names></name><name><surname>Gabriele</surname><given-names>L</given-names></name><name><surname>Proietti</surname><given-names>E</given-names></name><name><surname>Bracci</surname><given-names>L</given-names></name></person-group><article-title>Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>768</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">21156650</pub-id></element-citation></ref><ref id="R459"><label>459</label><element-citation publication-type="journal"><person-group><name><surname>Sistigu</surname><given-names>A</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Chaba</surname><given-names>K</given-names></name><name><surname>Enot</surname><given-names>DP</given-names></name><name><surname>Adam</surname><given-names>J</given-names></name><name><surname>Vitale</surname><given-names>I</given-names></name><name><surname>Goubar</surname><given-names>A</given-names></name><name><surname>Baracco</surname><given-names>EE</given-names></name><name><surname>Remedios</surname><given-names>C</given-names></name><name><surname>Fend</surname><given-names>L</given-names></name><name><surname>Hannani</surname><given-names>D</given-names></name><name><surname>Aymeric</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy</article-title><source>Nat Med</source><year>2014</year><volume>20</volume><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">25344738</pub-id></element-citation></ref><ref id="R460"><label>460</label><element-citation publication-type="journal"><person-group><name><surname>Guerriero</surname><given-names>JL</given-names></name><name><surname>Ditsworth</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Crawford</surname><given-names>HC</given-names></name><name><surname>Zong</surname><given-names>WX</given-names></name></person-group><article-title>Chemotherapy induces tumor clearance independent of apoptosis</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>9595</fpage><lpage>9600</lpage><pub-id pub-id-type="pmid">19047135</pub-id></element-citation></ref><ref id="R461"><label>461</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Immunogenic cell death in radiation therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26536</fpage><pub-id pub-id-type="pmid">24404424</pub-id></element-citation></ref><ref id="R462"><label>462</label><element-citation publication-type="journal"><person-group><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Mimura</surname><given-names>K</given-names></name><name><surname>Yoshimoto</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Ohkubo</surname><given-names>Y</given-names></name><name><surname>Izawa</surname><given-names>S</given-names></name><name><surname>Murata</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Kono</surname><given-names>K</given-names></name></person-group><article-title>Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>3967</fpage><lpage>3976</lpage><pub-id pub-id-type="pmid">22700877</pub-id></element-citation></ref><ref id="R463"><label>463</label><element-citation publication-type="journal"><person-group><name><surname>Ko</surname><given-names>A</given-names></name><name><surname>Kanehisa</surname><given-names>A</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Chargari</surname><given-names>C</given-names></name><name><surname>Dugue</surname><given-names>D</given-names></name><name><surname>Marino</surname><given-names>G</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Perfettini</surname><given-names>JL</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Deutsch</surname><given-names>E</given-names></name></person-group><article-title>Autophagy inhibition radiosensitizes <italic>in vitro</italic>, yet reduces radioresponses <italic>in vivo</italic> due to deficient immunogenic signalling</article-title><source>Cell Death Differ</source><year>2014</year><volume>21</volume><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">24037090</pub-id></element-citation></ref><ref id="R464"><label>464</label><element-citation publication-type="journal"><person-group><name><surname>Gameiro</surname><given-names>SR</given-names></name><name><surname>Jammeh</surname><given-names>ML</given-names></name><name><surname>Wattenberg</surname><given-names>MM</given-names></name><name><surname>Tsang</surname><given-names>KY</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name><name><surname>Hodge</surname><given-names>JW</given-names></name></person-group><article-title>Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">24480782</pub-id></element-citation></ref><ref id="R465"><label>465</label><element-citation publication-type="journal"><person-group><name><surname>Schildkopf</surname><given-names>P</given-names></name><name><surname>Frey</surname><given-names>B</given-names></name><name><surname>Ott</surname><given-names>OJ</given-names></name><name><surname>Rubner</surname><given-names>Y</given-names></name><name><surname>Multhoff</surname><given-names>G</given-names></name><name><surname>Sauer</surname><given-names>R</given-names></name><name><surname>Fietkau</surname><given-names>R</given-names></name><name><surname>Gaipl</surname><given-names>US</given-names></name></person-group><article-title>Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages</article-title><source>Radiother Oncol</source><year>2011</year><volume>101</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">21704416</pub-id></element-citation></ref><ref id="R466"><label>466</label><element-citation publication-type="journal"><person-group><name><surname>Hasumi</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>Y</given-names></name><name><surname>Wantanabe</surname><given-names>R</given-names></name><name><surname>Mann</surname><given-names>DL</given-names></name></person-group><article-title>Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26381</fpage><pub-id pub-id-type="pmid">24349874</pub-id></element-citation></ref><ref id="R467"><label>467</label><element-citation publication-type="journal"><person-group><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Enlightening the impact of immunogenic cell death in photodynamic cancer therapy</article-title><source>EMBO J</source><year>2012</year><volume>31</volume><fpage>1055</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">22252132</pub-id></element-citation></ref><ref id="R468"><label>468</label><element-citation publication-type="journal"><person-group><name><surname>Garg</surname><given-names>AD</given-names></name><name><surname>Krysko</surname><given-names>DV</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name></person-group><article-title>Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin</article-title><source>Cancer Immunol Immunother</source><year>2012</year><volume>61</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">22193987</pub-id></element-citation></ref><ref id="R469"><label>469</label><element-citation publication-type="journal"><person-group><name><surname>Spisek</surname><given-names>R</given-names></name><name><surname>Charalambous</surname><given-names>A</given-names></name><name><surname>Mazumder</surname><given-names>A</given-names></name><name><surname>Vesole</surname><given-names>DH</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Dhodapkar</surname><given-names>MV</given-names></name></person-group><article-title>Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>4839</fpage><lpage>4845</lpage><pub-id pub-id-type="pmid">17299090</pub-id></element-citation></ref><ref id="R470"><label>470</label><element-citation publication-type="journal"><person-group><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Santori</surname><given-names>FR</given-names></name><name><surname>Ng</surname><given-names>B</given-names></name><name><surname>Liebes</surname><given-names>L</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name><name><surname>Vukmanovic</surname><given-names>S</given-names></name></person-group><article-title>Select forms of tumor cell apoptosis induce dendritic cell maturation</article-title><source>J Leukoc Biol</source><year>2005</year><volume>77</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">15569694</pub-id></element-citation></ref><ref id="R471"><label>471</label><element-citation publication-type="journal"><person-group><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Rousseau</surname><given-names>V</given-names></name><name><surname>Rigoni</surname><given-names>A</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Delahaye</surname><given-names>N</given-names></name><name><surname>Schlemmer</surname><given-names>FD</given-names></name><name><surname>Menger</surname><given-names>L</given-names></name><name><surname>Sukkurwala</surname><given-names>AQ</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Michaud</surname><given-names>M</given-names></name><name><surname>Dunant</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">22737602</pub-id></element-citation></ref><ref id="R472"><label>472</label><element-citation publication-type="journal"><person-group><name><surname>Muller</surname><given-names>GW</given-names></name><name><surname>Corral</surname><given-names>LG</given-names></name><name><surname>Shire</surname><given-names>MG</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Moreira</surname><given-names>A</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name><name><surname>Stirling</surname><given-names>DI</given-names></name></person-group><article-title>Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity</article-title><source>J Med Chem</source><year>1996</year><volume>39</volume><fpage>3238</fpage><lpage>3240</lpage><pub-id pub-id-type="pmid">8765505</pub-id></element-citation></ref><ref id="R473"><label>473</label><element-citation publication-type="journal"><person-group><name><surname>Curran</surname><given-names>WJ</given-names></name></person-group><article-title>The thalidomide tragedy in Germany: the end of a historic medicolegal trial</article-title><source>N Engl J Med</source><year>1971</year><volume>284</volume><fpage>481</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">5100423</pub-id></element-citation></ref><ref id="R474"><label>474</label><element-citation publication-type="journal"><person-group><name><surname>Sarno</surname><given-names>EN</given-names></name><name><surname>Grau</surname><given-names>GE</given-names></name><name><surname>Vieira</surname><given-names>LM</given-names></name><name><surname>Nery</surname><given-names>JA</given-names></name></person-group><article-title>Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states</article-title><source>Clin Exp Immunol</source><year>1991</year><volume>84</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">2015700</pub-id></element-citation></ref><ref id="R475"><label>475</label><element-citation publication-type="journal"><person-group><name><surname>Raje</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Thalidomide--a revival story</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1606</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">10564693</pub-id></element-citation></ref><ref id="R476"><label>476</label><element-citation publication-type="journal"><person-group><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>J</given-names></name><name><surname>Desikan</surname><given-names>R</given-names></name><name><surname>Ayers</surname><given-names>D</given-names></name><name><surname>Roberson</surname><given-names>P</given-names></name><name><surname>Eddlemon</surname><given-names>P</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Anaissie</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Dhodapkar</surname><given-names>M</given-names></name><name><surname>Zeddis</surname><given-names>J</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name></person-group><article-title>Antitumor activity of thalidomide in refractory multiple myeloma</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1565</fpage><lpage>1571</lpage><pub-id pub-id-type="pmid">10564685</pub-id></element-citation></ref><ref id="R477"><label>477</label><element-citation publication-type="journal"><person-group><name><surname>Dimopoulos</surname><given-names>M</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>Attal</surname><given-names>M</given-names></name><name><surname>Prince</surname><given-names>HM</given-names></name><name><surname>Harousseau</surname><given-names>JL</given-names></name><name><surname>Dmoszynska</surname><given-names>A</given-names></name><name><surname>San Miguel</surname><given-names>J</given-names></name><name><surname>Hellmann</surname><given-names>A</given-names></name><name><surname>Facon</surname><given-names>T</given-names></name><name><surname>Foa</surname><given-names>R</given-names></name><name><surname>Corso</surname><given-names>A</given-names></name><name><surname>Masliak</surname><given-names>Z</given-names></name><name><surname>Olesnyckyj</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2123</fpage><lpage>2132</lpage><pub-id pub-id-type="pmid">18032762</pub-id></element-citation></ref><ref id="R478"><label>478</label><element-citation publication-type="journal"><person-group><name><surname>Weber</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Niesvizky</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Belch</surname><given-names>A</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Siegel</surname><given-names>D</given-names></name><name><surname>Borrello</surname><given-names>I</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Chanan-Khan</surname><given-names>AA</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Patin</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2133</fpage><lpage>2142</lpage><pub-id pub-id-type="pmid">18032763</pub-id></element-citation></ref><ref id="R479"><label>479</label><element-citation publication-type="journal"><person-group><name><surname>List</surname><given-names>A</given-names></name><name><surname>Dewald</surname><given-names>G</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name><name><surname>Giagounidis</surname><given-names>A</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Feldman</surname><given-names>E</given-names></name><name><surname>Powell</surname><given-names>B</given-names></name><name><surname>Greenberg</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Stone</surname><given-names>R</given-names></name><name><surname>Reeder</surname><given-names>C</given-names></name><name><surname>Wride</surname><given-names>K</given-names></name><name><surname>Patin</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>1456</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">17021321</pub-id></element-citation></ref><ref id="R480"><label>480</label><element-citation publication-type="journal"><person-group><name><surname>List</surname><given-names>A</given-names></name><name><surname>Kurtin</surname><given-names>S</given-names></name><name><surname>Roe</surname><given-names>DJ</given-names></name><name><surname>Buresh</surname><given-names>A</given-names></name><name><surname>Mahadevan</surname><given-names>D</given-names></name><name><surname>Fuchs</surname><given-names>D</given-names></name><name><surname>Rimsza</surname><given-names>L</given-names></name><name><surname>Heaton</surname><given-names>R</given-names></name><name><surname>Knight</surname><given-names>R</given-names></name><name><surname>Zeldis</surname><given-names>JB</given-names></name></person-group><article-title>Efficacy of lenalidomide in myelodysplastic syndromes</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">15703420</pub-id></element-citation></ref><ref id="R481"><label>481</label><element-citation publication-type="journal"><person-group><name><surname>San Miguel</surname><given-names>J</given-names></name><name><surname>Weisel</surname><given-names>K</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name><name><surname>Lacy</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Delforge</surname><given-names>M</given-names></name><name><surname>Karlin</surname><given-names>L</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><name><surname>Banos</surname><given-names>A</given-names></name><name><surname>Oriol</surname><given-names>A</given-names></name><name><surname>Alegre</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Cavo</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>1055</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">24007748</pub-id></element-citation></ref><ref id="R482"><label>482</label><element-citation publication-type="journal"><person-group><name><surname>Goy</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>ME</given-names></name><name><surname>Kalayoglu Besisik</surname><given-names>S</given-names></name><name><surname>Drach</surname><given-names>J</given-names></name><name><surname>Ramchandren</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Cicero</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>T</given-names></name><name><surname>Witzig</surname><given-names>TE</given-names></name></person-group><article-title>Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3688</fpage><lpage>3695</lpage><pub-id pub-id-type="pmid">24002500</pub-id></element-citation></ref><ref id="R483"><label>483</label><element-citation publication-type="journal"><person-group><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Fayad</surname><given-names>L</given-names></name><name><surname>Wagner-Bartak</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Hagemeister</surname><given-names>F</given-names></name><name><surname>Neelapu</surname><given-names>SS</given-names></name><name><surname>Samaniego</surname><given-names>F</given-names></name><name><surname>McLaughlin</surname><given-names>P</given-names></name><name><surname>Fanale</surname><given-names>M</given-names></name><name><surname>Younes</surname><given-names>A</given-names></name><name><surname>Cabanillas</surname><given-names>F</given-names></name><name><surname>Fowler</surname><given-names>N</given-names></name><name><surname>Newberry</surname><given-names>KJ</given-names></name><etal></etal></person-group><article-title>Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><fpage>716</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">22677155</pub-id></element-citation></ref><ref id="R484"><label>484</label><element-citation publication-type="journal"><person-group><name><surname>Bartlett</surname><given-names>JB</given-names></name><name><surname>Dredge</surname><given-names>K</given-names></name><name><surname>Dalgleish</surname><given-names>AG</given-names></name></person-group><article-title>The evolution of thalidomide and its IMiD derivatives as anticancer agents</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>314</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">15057291</pub-id></element-citation></ref><ref id="R485"><label>485</label><element-citation publication-type="journal"><person-group><name><surname>Semeraro</surname><given-names>M</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Novel insights into the mechanism of action of lenalidomide</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e28386</fpage><pub-id pub-id-type="pmid">25340011</pub-id></element-citation></ref><ref id="R486"><label>486</label><element-citation publication-type="journal"><person-group><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Middleton</surname><given-names>RE</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Naniong</surname><given-names>M</given-names></name><name><surname>Ott</surname><given-names>CJ</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names><suffix>Jr</suffix></name></person-group><article-title>The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins</article-title><source>Science</source><year>2014</year><volume>343</volume><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">24292623</pub-id></element-citation></ref><ref id="R487"><label>487</label><element-citation publication-type="journal"><person-group><name><surname>Kronke</surname><given-names>J</given-names></name><name><surname>Udeshi</surname><given-names>ND</given-names></name><name><surname>Narla</surname><given-names>A</given-names></name><name><surname>Grauman</surname><given-names>P</given-names></name><name><surname>Hurst</surname><given-names>SN</given-names></name><name><surname>McConkey</surname><given-names>M</given-names></name><name><surname>Svinkina</surname><given-names>T</given-names></name><name><surname>Heckl</surname><given-names>D</given-names></name><name><surname>Comer</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ciarlo</surname><given-names>C</given-names></name><name><surname>Hartman</surname><given-names>E</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</article-title><source>Science</source><year>2014</year><volume>343</volume><fpage>301</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">24292625</pub-id></element-citation></ref><ref id="R488"><label>488</label><element-citation publication-type="journal"><person-group><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Handa</surname><given-names>H</given-names></name></person-group><article-title>Identification of a primary target of thalidomide teratogenicity</article-title><source>Science</source><year>2010</year><volume>327</volume><fpage>1345</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">20223979</pub-id></element-citation></ref><ref id="R489"><label>489</label><element-citation publication-type="journal"><person-group><name><surname>Lopez-Girona</surname><given-names>A</given-names></name><name><surname>Mendy</surname><given-names>D</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>K</given-names></name><name><surname>Gandhi</surname><given-names>AK</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Karasawa</surname><given-names>S</given-names></name><name><surname>Carmel</surname><given-names>G</given-names></name><name><surname>Jackson</surname><given-names>P</given-names></name><name><surname>Abbasian</surname><given-names>M</given-names></name><name><surname>Mahmoudi</surname><given-names>A</given-names></name><name><surname>Cathers</surname><given-names>B</given-names></name><name><surname>Rychak</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide</article-title><source>Leukemia</source><year>2012</year><volume>26</volume><fpage>2326</fpage><lpage>2335</lpage><pub-id pub-id-type="pmid">22552008</pub-id></element-citation></ref><ref id="R490"><label>490</label><element-citation publication-type="journal"><person-group><name><surname>Loi</surname><given-names>S</given-names></name></person-group><article-title>Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24720</fpage><pub-id pub-id-type="pmid">24073365</pub-id></element-citation></ref><ref id="R491"><label>491</label><element-citation publication-type="journal"><person-group><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Aranda</surname><given-names>F</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Impact of myeloid cells on the efficacy of anticancer chemotherapy</article-title><source>Curr Opin Immunol</source><year>2014</year><volume>30C</volume><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">24950501</pub-id></element-citation></ref><ref id="R492"><label>492</label><element-citation publication-type="journal"><person-group><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><name><surname>Evdemon-Hogan</surname><given-names>M</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Burow</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">15322536</pub-id></element-citation></ref><ref id="R493"><label>493</label><element-citation publication-type="journal"><person-group><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Macrophage plasticity and polarization: <italic>in vivo</italic> veritas</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><fpage>787</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">22378047</pub-id></element-citation></ref><ref id="R494"><label>494</label><element-citation publication-type="journal"><person-group><name><surname>Kadin</surname><given-names>ME</given-names></name><name><surname>Vonderheid</surname><given-names>EC</given-names></name></person-group><article-title>Targeted therapies: Denileukin diftitox--a step towards a ‘magic bullet’ for CTCL</article-title><source>Nat Rev Clin Oncol</source><year>2010</year><volume>7</volume><fpage>430</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">20668480</pub-id></element-citation></ref><ref id="R495"><label>495</label><element-citation publication-type="journal"><person-group><name><surname>Attia</surname><given-names>P</given-names></name><name><surname>Maker</surname><given-names>AV</given-names></name><name><surname>Haworth</surname><given-names>LR</given-names></name><name><surname>Rogers-Freezer</surname><given-names>L</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma</article-title><source>J Immunother</source><year>2005</year><volume>28</volume><fpage>582</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">16224276</pub-id></element-citation></ref><ref id="R496"><label>496</label><element-citation publication-type="journal"><person-group><name><surname>Dannull</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Rizzieri</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>BK</given-names></name><name><surname>Coleman</surname><given-names>D</given-names></name><name><surname>Yancey</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Dahm</surname><given-names>P</given-names></name><name><surname>Chao</surname><given-names>N</given-names></name><name><surname>Gilboa</surname><given-names>E</given-names></name><name><surname>Vieweg</surname><given-names>J</given-names></name></person-group><article-title>Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><fpage>3623</fpage><lpage>3633</lpage><pub-id pub-id-type="pmid">16308572</pub-id></element-citation></ref><ref id="R497"><label>497</label><element-citation publication-type="journal"><person-group><name><surname>Morse</surname><given-names>MA</given-names></name><name><surname>Hobeika</surname><given-names>AC</given-names></name><name><surname>Osada</surname><given-names>T</given-names></name><name><surname>Serra</surname><given-names>D</given-names></name><name><surname>Niedzwiecki</surname><given-names>D</given-names></name><name><surname>Lyerly</surname><given-names>HK</given-names></name><name><surname>Clay</surname><given-names>TM</given-names></name></person-group><article-title>Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">18519811</pub-id></element-citation></ref><ref id="R498"><label>498</label><element-citation publication-type="journal"><person-group><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Aoyama</surname><given-names>A</given-names></name><name><surname>Tocco</surname><given-names>G</given-names></name><name><surname>Boskovic</surname><given-names>S</given-names></name><name><surname>Nadazdin</surname><given-names>O</given-names></name><name><surname>Alessandrini</surname><given-names>A</given-names></name><name><surname>Madsen</surname><given-names>JC</given-names></name><name><surname>Cosimi</surname><given-names>AB</given-names></name><name><surname>Benichou</surname><given-names>G</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name></person-group><article-title>Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates</article-title><source>J Immunol</source><year>2012</year><volume>188</volume><fpage>6063</fpage><lpage>6070</lpage><pub-id pub-id-type="pmid">22586034</pub-id></element-citation></ref><ref id="R499"><label>499</label><element-citation publication-type="journal"><person-group><name><surname>Baur</surname><given-names>AS</given-names></name><name><surname>Lutz</surname><given-names>MB</given-names></name><name><surname>Schierer</surname><given-names>S</given-names></name><name><surname>Beltrame</surname><given-names>L</given-names></name><name><surname>Theiner</surname><given-names>G</given-names></name><name><surname>Zinser</surname><given-names>E</given-names></name><name><surname>Ostalecki</surname><given-names>C</given-names></name><name><surname>Heidkamp</surname><given-names>G</given-names></name><name><surname>Haendle</surname><given-names>I</given-names></name><name><surname>Erdmann</surname><given-names>M</given-names></name><name><surname>Wiesinger</surname><given-names>M</given-names></name><name><surname>Leisgang</surname><given-names>W</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>2185</fpage><lpage>2194</lpage><pub-id pub-id-type="pmid">23958949</pub-id></element-citation></ref><ref id="R500"><label>500</label><element-citation publication-type="journal"><person-group><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Keating</surname><given-names>MJ</given-names></name><name><surname>Wierda</surname><given-names>WG</given-names></name><name><surname>Hartmann</surname><given-names>E</given-names></name><name><surname>Hoellenriegel</surname><given-names>J</given-names></name><name><surname>Rosin</surname><given-names>NY</given-names></name><name><surname>de Weerdt</surname><given-names>I</given-names></name><name><surname>Jeyakumar</surname><given-names>G</given-names></name><name><surname>Ferrajoli</surname><given-names>A</given-names></name><name><surname>Cardenas-Turanzas</surname><given-names>M</given-names></name><name><surname>Lerner</surname><given-names>S</given-names></name><name><surname>Jorgensen</surname><given-names>JL</given-names></name><name><surname>Nogueras-Gonzalez</surname><given-names>GM</given-names></name><etal></etal></person-group><article-title>Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>1090</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">25150798</pub-id></element-citation></ref><ref id="R501"><label>501</label><element-citation publication-type="journal"><person-group><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Furman</surname><given-names>RR</given-names></name><name><surname>Coutre</surname><given-names>SE</given-names></name><name><surname>Sharman</surname><given-names>JP</given-names></name><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Blum</surname><given-names>KA</given-names></name><name><surname>Grant</surname><given-names>B</given-names></name><name><surname>Richards</surname><given-names>DA</given-names></name><name><surname>Coleman</surname><given-names>M</given-names></name><name><surname>Wierda</surname><given-names>WG</given-names></name><name><surname>Jones</surname><given-names>JA</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Heerema</surname><given-names>NA</given-names></name><etal></etal></person-group><article-title>Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>48</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">24332241</pub-id></element-citation></ref><ref id="R502"><label>502</label><element-citation publication-type="journal"><person-group><name><surname>Wang</surname><given-names>ML</given-names></name><name><surname>Rule</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Goy</surname><given-names>A</given-names></name><name><surname>Auer</surname><given-names>R</given-names></name><name><surname>Kahl</surname><given-names>BS</given-names></name><name><surname>Jurczak</surname><given-names>W</given-names></name><name><surname>Advani</surname><given-names>RH</given-names></name><name><surname>Romaguera</surname><given-names>JE</given-names></name><name><surname>Williams</surname><given-names>ME</given-names></name><name><surname>Barrientos</surname><given-names>JC</given-names></name><name><surname>Chmielowska</surname><given-names>E</given-names></name><name><surname>Radford</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>507</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">23782157</pub-id></element-citation></ref><ref id="R503"><label>503</label><element-citation publication-type="journal"><person-group><name><surname>Affara</surname><given-names>NI</given-names></name><name><surname>Ruffell</surname><given-names>B</given-names></name><name><surname>Medler</surname><given-names>TR</given-names></name><name><surname>Gunderson</surname><given-names>AJ</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Bornstein</surname><given-names>S</given-names></name><name><surname>Bergsland</surname><given-names>E</given-names></name><name><surname>Steinhoff</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wiesen</surname><given-names>JF</given-names></name><name><surname>Wong</surname><given-names>MH</given-names></name><etal></etal></person-group><article-title>B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas</article-title><source>Cancer Cell</source><year>2014</year><volume>25</volume><fpage>809</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">24909985</pub-id></element-citation></ref><ref id="R504"><label>504</label><element-citation publication-type="journal"><person-group><name><surname>Dalrymple</surname><given-names>SL</given-names></name><name><surname>Becker</surname><given-names>RE</given-names></name><name><surname>Isaacs</surname><given-names>JT</given-names></name></person-group><article-title>The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts</article-title><source>Prostate</source><year>2007</year><volume>67</volume><fpage>790</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">17373719</pub-id></element-citation></ref><ref id="R505"><label>505</label><element-citation publication-type="journal"><person-group><name><surname>Murdoch</surname><given-names>C</given-names></name><name><surname>Muthana</surname><given-names>M</given-names></name><name><surname>Coffelt</surname><given-names>SB</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name></person-group><article-title>The role of myeloid cells in the promotion of tumour angiogenesis</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>618</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">18633355</pub-id></element-citation></ref><ref id="R506"><label>506</label><element-citation publication-type="journal"><person-group><name><surname>Germano</surname><given-names>G</given-names></name><name><surname>Frapolli</surname><given-names>R</given-names></name><name><surname>Belgiovine</surname><given-names>C</given-names></name><name><surname>Anselmo</surname><given-names>A</given-names></name><name><surname>Pesce</surname><given-names>S</given-names></name><name><surname>Liguori</surname><given-names>M</given-names></name><name><surname>Erba</surname><given-names>E</given-names></name><name><surname>Uboldi</surname><given-names>S</given-names></name><name><surname>Zucchetti</surname><given-names>M</given-names></name><name><surname>Pasqualini</surname><given-names>F</given-names></name><name><surname>Nebuloni</surname><given-names>M</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Mortarini</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Role of macrophage targeting in the antitumor activity of trabectedin</article-title><source>Cancer Cell</source><year>2013</year><volume>23</volume><fpage>249</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">23410977</pub-id></element-citation></ref><ref id="R507"><label>507</label><element-citation publication-type="journal"><person-group><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Germano</surname><given-names>G</given-names></name><name><surname>Belgiovine</surname><given-names>C</given-names></name><name><surname>D'Incalci</surname><given-names>M</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Trabectedin: A drug from the sea that strikes tumor-associated macrophages</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24614</fpage><pub-id pub-id-type="pmid">23894721</pub-id></element-citation></ref><ref id="R508"><label>508</label><element-citation publication-type="journal"><person-group><name><surname>Sanford</surname><given-names>DE</given-names></name><name><surname>Belt</surname><given-names>BA</given-names></name><name><surname>Panni</surname><given-names>RZ</given-names></name><name><surname>Mayer</surname><given-names>A</given-names></name><name><surname>Deshpande</surname><given-names>AD</given-names></name><name><surname>Carpenter</surname><given-names>D</given-names></name><name><surname>Mitchem</surname><given-names>JB</given-names></name><name><surname>Plambeck-Suess</surname><given-names>SM</given-names></name><name><surname>Worley</surname><given-names>LA</given-names></name><name><surname>Goetz</surname><given-names>BD</given-names></name><name><surname>Wang-Gillam</surname><given-names>A</given-names></name><name><surname>Eberlein</surname><given-names>TJ</given-names></name><name><surname>Denardo</surname><given-names>DG</given-names></name><etal></etal></person-group><article-title>Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>3404</fpage><lpage>3415</lpage><pub-id pub-id-type="pmid">23653148</pub-id></element-citation></ref><ref id="R509"><label>509</label><element-citation publication-type="journal"><person-group><name><surname>Kuhne</surname><given-names>MR</given-names></name><name><surname>Mulvey</surname><given-names>T</given-names></name><name><surname>Belanger</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Chong</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>F</given-names></name><name><surname>Niekro</surname><given-names>W</given-names></name><name><surname>Kempe</surname><given-names>T</given-names></name><name><surname>Henning</surname><given-names>KA</given-names></name><name><surname>Cohen</surname><given-names>LJ</given-names></name><name><surname>Korman</surname><given-names>AJ</given-names></name><name><surname>Cardarelli</surname><given-names>PM</given-names></name></person-group><article-title>BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis <italic>in vitro</italic> and shows antitumor activity <italic>in vivo</italic> in hematologic malignancies</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">23213054</pub-id></element-citation></ref><ref id="R510"><label>510</label><element-citation publication-type="journal"><person-group><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Escamilla</surname><given-names>J</given-names></name><name><surname>Mok</surname><given-names>S</given-names></name><name><surname>David</surname><given-names>J</given-names></name><name><surname>Priceman</surname><given-names>S</given-names></name><name><surname>West</surname><given-names>B</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>McBride</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer</article-title><source>Cancer Res</source><year>2013</year><volume>73</volume><fpage>2782</fpage><lpage>2794</lpage><pub-id pub-id-type="pmid">23418320</pub-id></element-citation></ref><ref id="R511"><label>511</label><element-citation publication-type="journal"><person-group><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Knolhoff</surname><given-names>BL</given-names></name><name><surname>Meyer</surname><given-names>MA</given-names></name><name><surname>Nywening</surname><given-names>TM</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Wang-Gillam</surname><given-names>A</given-names></name><name><surname>Goedegebuure</surname><given-names>SP</given-names></name><name><surname>Linehan</surname><given-names>DC</given-names></name><name><surname>DeNardo</surname><given-names>DG</given-names></name></person-group><article-title>CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models</article-title><source>Cancer Res</source><year>2014</year></element-citation></ref><ref id="R512"><label>512</label><element-citation publication-type="journal"><person-group><name><surname>Priceman</surname><given-names>SJ</given-names></name><name><surname>Sung</surname><given-names>JL</given-names></name><name><surname>Shaposhnik</surname><given-names>Z</given-names></name><name><surname>Burton</surname><given-names>JB</given-names></name><name><surname>Torres-Collado</surname><given-names>AX</given-names></name><name><surname>Moughon</surname><given-names>DL</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name><name><surname>Cohen</surname><given-names>DA</given-names></name><name><surname>Iruela-Arispe</surname><given-names>ML</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>1461</fpage><lpage>1471</lpage><pub-id pub-id-type="pmid">20008303</pub-id></element-citation></ref><ref id="R513"><label>513</label><element-citation publication-type="journal"><person-group><name><surname>Ghansah</surname><given-names>T</given-names></name></person-group><article-title>A novel strategy for modulation of MDSC to enhance cancer immunotherapy</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>984</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">23162780</pub-id></element-citation></ref><ref id="R514"><label>514</label><element-citation publication-type="journal"><person-group><name><surname>Iclozan</surname><given-names>C</given-names></name><name><surname>Antonia</surname><given-names>S</given-names></name><name><surname>Chiappori</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>DT</given-names></name><name><surname>Gabrilovich</surname><given-names>D</given-names></name></person-group><article-title>Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer</article-title><source>Cancer Immunol Immunother</source><year>2013</year><volume>62</volume><fpage>909</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">23589106</pub-id></element-citation></ref><ref id="R515"><label>515</label><element-citation publication-type="journal"><person-group><name><surname>Abrams</surname><given-names>SI</given-names></name><name><surname>Waight</surname><given-names>JD</given-names></name></person-group><article-title>Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>550</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">22754783</pub-id></element-citation></ref><ref id="R516"><label>516</label><element-citation publication-type="journal"><person-group><name><surname>Highfill</surname><given-names>SL</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Giles</surname><given-names>AJ</given-names></name><name><surname>Smith</surname><given-names>JP</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Morse</surname><given-names>E</given-names></name><name><surname>Kaplan</surname><given-names>RN</given-names></name><name><surname>Mackall</surname><given-names>CL</given-names></name></person-group><article-title>Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>237ra267</fpage></element-citation></ref><ref id="R517"><label>517</label><element-citation publication-type="journal"><person-group><name><surname>Weiskopf</surname><given-names>K</given-names></name><name><surname>Ring</surname><given-names>AM</given-names></name><name><surname>Schnorr</surname><given-names>PJ</given-names></name><name><surname>Volkmer</surname><given-names>JP</given-names></name><name><surname>Volkmer</surname><given-names>AK</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><article-title>Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPalpha variants</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25773</fpage><pub-id pub-id-type="pmid">24319639</pub-id></element-citation></ref><ref id="R518"><label>518</label><element-citation publication-type="journal"><person-group><name><surname>Weiskopf</surname><given-names>K</given-names></name><name><surname>Ring</surname><given-names>AM</given-names></name><name><surname>Ho</surname><given-names>CC</given-names></name><name><surname>Volkmer</surname><given-names>JP</given-names></name><name><surname>Levin</surname><given-names>AM</given-names></name><name><surname>Volkmer</surname><given-names>AK</given-names></name><name><surname>Ozkan</surname><given-names>E</given-names></name><name><surname>Fernhoff</surname><given-names>NB</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><article-title>Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">23722425</pub-id></element-citation></ref><ref id="R519"><label>519</label><element-citation publication-type="journal"><person-group><name><surname>Tseng</surname><given-names>D</given-names></name><name><surname>Volkmer</surname><given-names>JP</given-names></name><name><surname>Willingham</surname><given-names>SB</given-names></name><name><surname>Contreras-Trujillo</surname><given-names>H</given-names></name><name><surname>Fathman</surname><given-names>JW</given-names></name><name><surname>Fernhoff</surname><given-names>NB</given-names></name><name><surname>Seita</surname><given-names>J</given-names></name><name><surname>Inlay</surname><given-names>MA</given-names></name><name><surname>Weiskopf</surname><given-names>K</given-names></name><name><surname>Miyanishi</surname><given-names>M</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><article-title>Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>11103</fpage><lpage>11108</lpage><pub-id pub-id-type="pmid">23690610</pub-id></element-citation></ref><ref id="R520"><label>520</label><element-citation publication-type="journal"><person-group><name><surname>Smith</surname><given-names>BD</given-names></name><name><surname>Kasamon</surname><given-names>YL</given-names></name><name><surname>Kowalski</surname><given-names>J</given-names></name><name><surname>Gocke</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>CB</given-names></name><name><surname>Garrett-Mayer</surname><given-names>E</given-names></name><name><surname>Tsai</surname><given-names>HL</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Chia</surname><given-names>C</given-names></name><name><surname>Biedrzycki</surname><given-names>B</given-names></name><name><surname>Harding</surname><given-names>TC</given-names></name><name><surname>Tu</surname><given-names>GH</given-names></name><etal></etal></person-group><article-title>K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>338</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">20048335</pub-id></element-citation></ref><ref id="R521"><label>521</label><element-citation publication-type="journal"><person-group><name><surname>Characiejus</surname><given-names>D</given-names></name></person-group><article-title>Cancer immunotherapy: Benefit and harm?</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>232</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">22720253</pub-id></element-citation></ref><ref id="R522"><label>522</label><element-citation publication-type="journal"><person-group><name><surname>Agur</surname><given-names>Z</given-names></name><name><surname>Vuk-Pavlovic</surname><given-names>S</given-names></name></person-group><article-title>Personalizing immunotherapy: Balancing predictability and precision</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1169</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">23170268</pub-id></element-citation></ref><ref id="R523"><label>523</label><element-citation publication-type="journal"><person-group><name><surname>Dranoff</surname><given-names>G</given-names></name></person-group><article-title>Immunotherapy at large: Balancing tumor immunity and inflammatory pathology</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>1100</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">24013749</pub-id></element-citation></ref><ref id="R524"><label>524</label><element-citation publication-type="journal"><person-group><name><surname>Mittendorf</surname><given-names>EA</given-names></name><name><surname>Gurney</surname><given-names>JM</given-names></name><name><surname>Storrer</surname><given-names>CE</given-names></name><name><surname>Shriver</surname><given-names>CD</given-names></name><name><surname>Ponniah</surname><given-names>S</given-names></name><name><surname>Peoples</surname><given-names>GE</given-names></name></person-group><article-title>Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer</article-title><source>Surgery</source><year>2006</year><volume>139</volume><fpage>407</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">16546506</pub-id></element-citation></ref><ref id="R525"><label>525</label><element-citation publication-type="journal"><person-group><name><surname>Hardwick</surname><given-names>N</given-names></name><name><surname>Chain</surname><given-names>B</given-names></name></person-group><article-title>Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients</article-title><source>Immunotherapy</source><year>2011</year><volume>3</volume><fpage>731</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">21668310</pub-id></element-citation></ref><ref id="R526"><label>526</label><element-citation publication-type="journal"><person-group><name><surname>Olson</surname><given-names>BM</given-names></name><name><surname>McNeel</surname><given-names>DG</given-names></name></person-group><article-title>Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence</article-title><source>Expert Rev Vaccines</source><year>2012</year><volume>11</volume><fpage>1315</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">23249231</pub-id></element-citation></ref><ref id="R527"><label>527</label><element-citation publication-type="journal"><person-group><name><surname>Monjazeb</surname><given-names>AM</given-names></name><name><surname>Zamora</surname><given-names>AE</given-names></name><name><surname>Grossenbacher</surname><given-names>SK</given-names></name><name><surname>Mirsoian</surname><given-names>A</given-names></name><name><surname>Sckisel</surname><given-names>GD</given-names></name><name><surname>Murphy</surname><given-names>WJ</given-names></name></person-group><article-title>Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies</article-title><source>Front Oncol</source><year>2013</year><volume>3</volume><fpage>197</fpage><pub-id pub-id-type="pmid">23898464</pub-id></element-citation></ref><ref id="R528"><label>528</label><element-citation publication-type="journal"><person-group><name><surname>Maletzki</surname><given-names>C</given-names></name><name><surname>Stier</surname><given-names>S</given-names></name><name><surname>Linnebacher</surname><given-names>M</given-names></name></person-group><article-title>Microsatellite instability in hematological malignancies: Hypermutation vs</article-title><source>immune control-who is challenging who? Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e25419</fpage></element-citation></ref><ref id="R529"><label>529</label><element-citation publication-type="journal"><person-group><name><surname>Tran</surname><given-names>E</given-names></name><name><surname>Turcotte</surname><given-names>S</given-names></name><name><surname>Gros</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Lu</surname><given-names>YC</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Somerville</surname><given-names>RP</given-names></name><name><surname>Hogan</surname><given-names>K</given-names></name><name><surname>Hinrichs</surname><given-names>CS</given-names></name><name><surname>Parkhurst</surname><given-names>MR</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer</article-title><source>Science</source><year>2014</year><volume>344</volume><fpage>641</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">24812403</pub-id></element-citation></ref><ref id="R530"><label>530</label><element-citation publication-type="journal"><person-group><name><surname>Gubin</surname><given-names>MM</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Schuster</surname><given-names>H</given-names></name><name><surname>Caron</surname><given-names>E</given-names></name><name><surname>Ward</surname><given-names>JP</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Ivanova</surname><given-names>Y</given-names></name><name><surname>Hundal</surname><given-names>J</given-names></name><name><surname>Arthur</surname><given-names>CD</given-names></name><name><surname>Krebber</surname><given-names>WJ</given-names></name><name><surname>Mulder</surname><given-names>GE</given-names></name><name><surname>Toebes</surname><given-names>M</given-names></name><name><surname>Vesely</surname><given-names>MD</given-names></name><etal></etal></person-group><article-title>Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">25428507</pub-id></element-citation></ref><ref id="R531"><label>531</label><element-citation publication-type="journal"><person-group><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><article-title>Immunological effects of chemotherapy in spontaneous breast cancers</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e27158</fpage><pub-id pub-id-type="pmid">24498568</pub-id></element-citation></ref><ref id="R532"><label>532</label><element-citation publication-type="journal"><person-group><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Immune effectors required for the therapeutic activity of vorinostat</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e27157</fpage><pub-id pub-id-type="pmid">24475375</pub-id></element-citation></ref><ref id="R533"><label>533</label><element-citation publication-type="journal"><person-group><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name></person-group><article-title>The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy</article-title><source>Expert Rev Clin Immunol</source><year>2013</year></element-citation></ref><ref id="R534"><label>534</label><element-citation publication-type="journal"><person-group><name><surname>Suzuki</surname><given-names>E</given-names></name><name><surname>Kapoor</surname><given-names>V</given-names></name><name><surname>Jassar</surname><given-names>AS</given-names></name><name><surname>Kaiser</surname><given-names>LR</given-names></name><name><surname>Albelda</surname><given-names>SM</given-names></name></person-group><article-title>Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>6713</fpage><lpage>6721</lpage><pub-id pub-id-type="pmid">16166452</pub-id></element-citation></ref><ref id="R535"><label>535</label><element-citation publication-type="journal"><person-group><name><surname>Vincent</surname><given-names>J</given-names></name><name><surname>Mignot</surname><given-names>G</given-names></name><name><surname>Chalmin</surname><given-names>F</given-names></name><name><surname>Ladoire</surname><given-names>S</given-names></name><name><surname>Bruchard</surname><given-names>M</given-names></name><name><surname>Chevriaux</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>F</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Rebe</surname><given-names>C</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name></person-group><article-title>5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>3052</fpage><lpage>3061</lpage><pub-id pub-id-type="pmid">20388795</pub-id></element-citation></ref><ref id="R536"><label>536</label><element-citation publication-type="journal"><person-group><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Bruchard</surname><given-names>M</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name></person-group><article-title>Immune effects of 5-fluorouracil: Ambivalence matters</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e23139</fpage><pub-id pub-id-type="pmid">23802066</pub-id></element-citation></ref><ref id="R537"><label>537</label><element-citation publication-type="journal"><person-group><name><surname>Malvicini</surname><given-names>M</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Bayo</surname><given-names>J</given-names></name><name><surname>Fiore</surname><given-names>E</given-names></name><name><surname>Atorrasagasti</surname><given-names>C</given-names></name><name><surname>Alaniz</surname><given-names>L</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Aquino</surname><given-names>JB</given-names></name><name><surname>Gidekel</surname><given-names>M</given-names></name><name><surname>Matar</surname><given-names>P</given-names></name><name><surname>Mazzolini</surname><given-names>G</given-names></name></person-group><article-title>Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1626</fpage><lpage>1628</lpage><pub-id pub-id-type="pmid">23264916</pub-id></element-citation></ref><ref id="R538"><label>538</label><element-citation publication-type="journal"><person-group><name><surname>Foy</surname><given-names>KC</given-names></name><name><surname>Miller</surname><given-names>MJ</given-names></name><name><surname>Moldovan</surname><given-names>N</given-names></name><name><surname>Bozanovic</surname><given-names>T</given-names></name><name><surname>Carson Iii</surname><given-names>WE</given-names></name><name><surname>Kaumaya</surname><given-names>PT</given-names></name></person-group><article-title>Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer</article-title><source>Oncoimmunology</source><year>2012</year><volume>1</volume><fpage>1004</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">23170249</pub-id></element-citation></ref><ref id="R539"><label>539</label><element-citation publication-type="journal"><person-group><name><surname>Kadota</surname><given-names>K</given-names></name><name><surname>Nitadori</surname><given-names>JI</given-names></name><name><surname>Adusumilli</surname><given-names>PS</given-names></name></person-group><article-title>Prognostic value of the immune microenvironment in lung adenocarcinoma</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e24036</fpage><pub-id pub-id-type="pmid">23762792</pub-id></element-citation></ref><ref id="R540"><label>540</label><element-citation publication-type="journal"><person-group><name><surname>Escors</surname><given-names>D</given-names></name><name><surname>Liechtenstein</surname><given-names>T</given-names></name><name><surname>Perez-Janices</surname><given-names>N</given-names></name><name><surname>Schwarze</surname><given-names>J</given-names></name><name><surname>Dufait</surname><given-names>I</given-names></name><name><surname>Goyvaerts</surname><given-names>C</given-names></name><name><surname>Lanna</surname><given-names>A</given-names></name><name><surname>Arce</surname><given-names>F</given-names></name><name><surname>Blanco-Luquin</surname><given-names>I</given-names></name><name><surname>Kochan</surname><given-names>G</given-names></name><name><surname>Guerrero-Setas</surname><given-names>D</given-names></name><name><surname>Breckpot</surname><given-names>K</given-names></name></person-group><article-title>Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26148</fpage><pub-id pub-id-type="pmid">24244902</pub-id></element-citation></ref><ref id="R541"><label>541</label><element-citation publication-type="journal"><person-group><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Angell</surname><given-names>HK</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name></person-group><article-title>The immune landscape of human tumors: Implications for cancer immunotherapy</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e27456</fpage><pub-id pub-id-type="pmid">24800163</pub-id></element-citation></ref><ref id="R542"><label>542</label><element-citation publication-type="journal"><person-group><name><surname>Malyguine</surname><given-names>A</given-names></name><name><surname>Umansky</surname><given-names>V</given-names></name><name><surname>Kotlan</surname><given-names>B</given-names></name><name><surname>Aptsiauri</surname><given-names>N</given-names></name><name><surname>Shurin</surname><given-names>MR</given-names></name></person-group><article-title>Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): moving forward</article-title><source>J Immunotoxicol</source><year>2012</year><volume>9</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">22639903</pub-id></element-citation></ref><ref id="R543"><label>543</label><element-citation publication-type="journal"><person-group><name><surname>Popadic</surname><given-names>D</given-names></name><name><surname>Anegon</surname><given-names>I</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Eibel</surname><given-names>H</given-names></name><name><surname>Giese</surname><given-names>T</given-names></name><name><surname>Marits</surname><given-names>P</given-names></name><name><surname>Martinez-Caceres</surname><given-names>E</given-names></name><name><surname>Mascart</surname><given-names>F</given-names></name><name><surname>Nestle</surname><given-names>F</given-names></name><name><surname>Pujol-Borrell</surname><given-names>R</given-names></name><name><surname>Savic</surname><given-names>E</given-names></name><name><surname>Scheibenbogen</surname><given-names>C</given-names></name><name><surname>Seliger</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Predictive immunomonitoring -- the COST ENTIRE initiative</article-title><source>Clin Immunol</source><year>2013</year><volume>147</volume><fpage>23</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">23454893</pub-id></element-citation></ref><ref id="R544"><label>544</label><element-citation publication-type="journal"><person-group><name><surname>van der Burg</surname><given-names>SH</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Gouttefangeas</surname><given-names>C</given-names></name><name><surname>Janetzki</surname><given-names>S</given-names></name><name><surname>Ottensmeier</surname><given-names>C</given-names></name><name><surname>Welters</surname><given-names>MJ</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Britten</surname><given-names>CM</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name></person-group><article-title>Harmonization of immune biomarker assays for clinical studies</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><fpage>108ps144</fpage></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002F59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |